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This thesis explores helical oligomers that can be utilised to transmit information in the form 
of a chiral signal. The signal is induced at one end of the molecule, and the helical 
conformation facilitates the transfer of this chiral input to the other end. 310 helices 
constructed from the quaternary amino acid Aib have been used for this purpose, as they can 
rapidly switch between their left and right-handed screw senses and have high helical fidelity. 
 
To explore the limits of these oligomers as conformational communication systems, a family 
of molecules were synthesised that disrupted the natural N→C directionality found in 
peptides by having two opposing N-termini (Figure i.a). It was found that communication 
between the two N-termini was possible, though it was much weaker when compared against 
standard Aib oligomers.  
 
The ability of Aib oligomers to adapt to abnormal stereo-controllers was tested with the N-
terminal hydantoins (Figure i.b). These were found to be successful inducers that favour the 
opposite screw sense to their parent amino acid. The aggregation and conformation that Aib 
oligomers adopt in aqueous solution was studied with the hydrophilic Aib foldamers (Figure 
i.c). These showed that the 310 conformation can be stabilised even in fully aqueous solutions.  
 
 
Finally, the efficacy of the AibAic foldamers (Figure i.d) as a new scaffold for conformational 
communication was assessed. It was found that when these foldamers were controlled from 
the C-terminus the signal was registered at the N-terminus. However, the rate at which the 
signal decayed along the foldamer was higher than previously observed for Aib oligomers. 
  
Figure i: a) A N→N Aib Oligomer; b) A N-Terminal Hydantoin; c) A Hydrophilic Aib 
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* – Denotes 13C labelled position  
αMP – α-Methyl phenyalanine  
αMv – α-Methylvaline 
δ – Chemical shift  
ΔPhe - α,β-Didehydrophenylalanine 
λ – Wavelength  
Abu – 2-Aminoisobutyric acid 
Ac – Acetyl  
Ac6c – 1-Amino-1-cyclohexanecarboxylic acid 
Aib – α-Aminoisobutyric acid 
Aic – 4-Aminoisocaproic acid 
Ala – Alanine 
Ar – Aryl  
Asp – Aspartic acid 
Bn – Benzyl   
Boc – Tert-butyl carbamate 
Cbz – Benzyloxycarbonyl 
CD – Circular dichroism 
Conc. – Concentrated  
COSY – Correlation spectroscopy 
d – Days  
Dap – Diaminopropionic acid 
DCM – Dichloromethane 
DIPEA – N,N-Diisopropylethylamine 
DIPT – Diisoproyl tartrate 
DMF – Dimethylformamide  
DMSO – Dimethyl sulfoxide 
Dpg – Diphenyl glycine  
d.r. – Diastereomeric ratio 
EDC – N-(3-Dimethylaminopropyl)-N'-ethyl-carbodiimide  
e.e. – Enantiomeric excess 
eq. – Equivalents 
e.r. – Enantiomeric ratio 
ESI – Electrospray ionisation 
Et – Ethyl  
Fib – β,β’-difluoro-Aib  
Gly – Glycine  
GPCR – G-protein coupled receptor 
h – Hours  





h.e. – Helical Excess 
HMBC – Heteronuclear Multiple Bond Correlation  
HOBt – 1-Hydroxybenzotriazole hydrate  
HRMS – High resolution mass spectrometry 
HSQC – Heteronuclear single quantum coherence 
iPr – iso-propyl  
IR – Infra-red 
J – Coupling constant 
K – Equilibrium constant 
K-Oxyma – Ethyl-(hydroxyimino)cyanoacetate potassium salt 
LGIC – Ligand gated ion channel 
MALDI – Matrix-assisted laser desrption/ionisation 
MC – Methyl carbamate 
Me – Methyl  
m.p. – Melting point 
MTBE – Methyl tert-butyl ether 
NMR – Nuclear magnetic resonance 
NOE – Nuclear overhauser effect 
NOESY – Nuclear overhauser effect spectroscopy 
PD – 2,3-Pinanediol 
Ph - Phenyl 
Phe – Phenylalanine  
Py – Pyridine 
R – Denotes a generic substituent 
rac – Racemic 
RT – Room temperature 
Sat. – Saturated  
Ser – Serine  
Soln. – Solution  
tBu – tert-butyl 
TFA – Trifluoroacetic acid 
TFFH – Fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate  
THF – Tetrahydrofuran 
Thp – 4-aminotetrahydro-2H-pyran-4-carboxylic acid 
TLC – Thin Layer Chromatography 
TRIP – 3,3’-Bis(2,4,6-triisopropylphenyl)-1,1’-bi-2-naphthol cyclic monophosphate 
Ts – para-Toluenesulfonyl  
UV – Ultraviolet  
Val – Valine  
VT – Variable temperate 






1.1. Transmembrane Receptors – Conformation in Nature 
 
The transfer of information across the phospholipid bilayers of the cell membrane is essential 
for biological life to occur. 1 Transmembrane proteins span this impermeable barrier and 
transmit information by detecting and responding to chemical stimuli both inside and outside 
the cell. 2 Two classes of transmembrane receptors that facilitate this signal transduction by 
a conformational change within the transmembrane protein are ligand gated ion channels 
(LGICs) and G-protein coupled receptors (GPCRs).  
  
LGICs are responsible for regulating the movement of ions across the cell membrane. 4 This 
means they are key to the successful running of many bodily functions, one example being 
the nervous system. Therefore, much research has focused upon understanding these 
receptors and developing pharmaceuticals to target them. 5-7   
 
One of the best studied LGICs is the nicotinic acetylcholine receptor (Figure 1.1). 8 When the 
receptor is ‘off’ ions cannot pass through the cell membrane. When the transmembrane 
protein is activated by two molecules of acetylcholine binding to the pentameric protein 
cluster, a conformational change occurs in the protein. This opens a pore which allows ions 
to travel into and out of the cell. 3, 9 
 
Whilst an LGICs mode of action is to induce an intracellular response directly from an 
extracellular stimulus, GPCRs operate by a subtler mechanism. There are numerous known 
GPCRs, 10 which are responsible for a range of bodily functions including but not limited to: 
sight, 11 smell 12 and taste. 13 The typical GPCR is a membrane spanning protein, which is folded 
Figure 1.1: The nicotinic acetylcholine receptor, an example of an LGIC. 3 
 







into seven α-helical domains (Figure 1.2). 14 The N-terminus of this protein is extracellular and 




Upon binding at the N-terminus, a conformational change occurs at the binding site. This local 
change in conformation induces a global conformational change within the whole 
transmembrane protein, inducing the C-terminus to interact with the intracellular G-protein. 
Ultimately, this cascade of actions leads to the release of guanosine diphosphate (GDP) into 
the cell, whilst a molecule of guanosine triphosphate (GTP) takes its place within the G-
protein. This seemingly inconsequential change subsequently induces other actions within 
the cell, which are vital for life as we know it. 14, 16 – 18 As they are so prevalent and hold such 
importance in the biological world, GPCRs are common targets for many pharmaceuticals. 19 
– 22 Therefore, there has been wide interest in their structure and activity, as epitomised by 
the award of the 2012 Nobel Prize in Chemistry to Lefkowitz and Kobilka for their research 
into the mechanism of GPCR activation. 
 
Conformation is key in Nature, with the information that is encoded within DNA and proteins 
being directly related to their molecular shape. For the two receptors described above, the 
event that initiates the cascade of actions is the conformational change induced in the 
transmembrane protein when an agonist binds to it.  
 
A holy grail for synthetic chemists is to catch up with Nature and develop new artificial 
systems that can rival the gold standard of conformational signalling and control set by 
transmembrane receptors. Synthetic ion channels are well known, with many examples 
having been reported. 23 – 25 However, a true synthetic mimic of a GPCR remains more elusive, 
due to the complex structure and unique properties required. The starting point for a 
synthetic GPCR is a molecule that can change its conformation upon an external binding 
event. Whilst having a suitable reporter to register the conformational change and record the 
response over a long distance. 






















1.2. Foldamers  
Natural polypeptides that fold into an alpha helical conformation strongly favour the 
formation of a right handed (P) helix, 26, 27 this is a consequence of all the 21 proteinogenic 
amino acids (excluding glycine) having L-stereochemistry. This means that left-handed (M) 
helices are energetically unfavourable for peptides made from L-amino acids, because a left-
handed conformation would result in unfavourable steric interactions between the beta 
carbons of the amino acid’s side chain and its associated carbonyl group. 28, 29 There are 
exceptions to this rule, as shown in a study by Novotny and Kleywegt that analysed structures 
in the Protein Data Bank. 30 They discovered that left-handed helical domains do exist in some 
proteins secondary structures. These left-handed regions are usually short, at only four 
residues in length, and very rare with only 31 cases being observed in the 7284 proteins 
studied. Naturally occurring left-handed helices are mainly attributed to high amounts of 
glycine residues, due to the extra conformational flexibility imparted by glycine. 30  
 
Despite having a well-defined conformation, natural proteins are limited in their use 
regarding conformational communication through the switching of screw-sense, due to their 
predisposition to adopt a right-handed helical conformation.  
 
A solution to this issue comes from a class of synthetic oligomers known as foldamers. 31 – 33 
These molecules are synthetic mimics of biopolymers, that are designed to exhibit the well-
defined secondary structures and properties of their biological cousins. Though, as foldamers 
can be designed on a de novo basis, unique properties and structural features not found in 
biopolymers can be built in rather easily. 34 – 36 There are innumerable classes of helical 
foldamers (Figure 1.3) ranging from the protein-like quaternary α-peptides, 37 – 39 β-peptides 
40 – 42 and γ-peptides, 43 – 45 to more abstract structures like: aromatic polyureas, 46 – 48 helicenes 















Foldamers have many practical uses. One example is to gain a deeper understanding of 
structural features found in proteins, such as β and γ-turns. By creating and studying synthetic 
mimics that adopt these conformations, powerful insights can be gained into protein folding. 
54, 55 The biological activity of foldamers has also been explored, with many promising 
foldamer based pharmaceuticals having been reported. 36, 56 – 58  
 
Another key area of research looks at exploiting foldamers to develop signalling devices that 
can relay conformational and stereochemical information over long distances. An innovative 
early example of using a conformational change to transfer information, was reported by 
Koert and co-workers (Scheme 1.1). 59 The system they developed, compound 1, is built 
around a tetra-substituted perhydroanthracene which has are two bipyridines at one end of 
the molecule and two pyrenes at the other. The favoured conformation of compound 1 is to 
hold the two bipyridines in a trans-diaxial position, whilst the two pyrenes are held in a trans-
equatorial position. This causes a characteristic excimer fluorescence at 480 nm from the 
pyrene reporter. When zinc triflate is added, zinc binds between the two bipyridines inducing 
a triple ring flip in the perhydroanthracene to give complex 2. This conformational change is 
registered by the two pyrene reporters which are now forced into a trans-diaxial position, 
meaning excimer fluorescence is no longer possible. Though an elegant example of a 
conformational change being relayed from one end of a molecule to the other, this system 





Another interesting example of using conformation to communicate information was 
developed by Clayden and co-workers (Scheme 1.2). 60 Here a foldamer built around a 
repeating xanthene unit, compound 3, was synthesised. Stereochemical control was induced 
by a chiral oxazolidine and this information was then transferred along the xanthene 
backbone by a series of amides. The carbonyl groups of the amides arrange themselves in 
opposing directions to minimise unfavourable dipole-dipole interactions between them. This 
effect is enforced by capping the amides with bulky iPr groups, the high barrier of rotation 
that these groups impart upon the amides serves to enhance the transfer of information along 





the xanthene backbone by conformationally locking them in place. The transfer of 
information from the oxazolidine along the oligomer is demonstrated by the stereoselective 
attack of a Grignard reagent on an aldehyde at the uncontrolled end of the foldamer. This 
reaction gave the product, compound 4, with a d.r. of >95:5. This is a key example that showed 
how stereo control could be induced over long distances, in this example 2.5 nm. Despite 
being an effective relay of stereochemical information that more closely resembles the 
allosteric nature of transmembrane receptors, the potential for creating a reversible 



















1.3. Aib and the 310 Helix 
 
Aib is a non-proteinogenic α-quaternary amino acid. Though rare, it is found in Nature in a 
class of antibacterial agents called peptaibols that are produced by some species of fungi. 61 – 
63 Aib is a strong helical inducer, which is a result of Aib’s two methyl substituents 64 and the 
Thorpe-Ingold effect of this quaternary α-centre greatly limits the torsional angles available 
to an Aib residue in a peptide. 65 – 67 This is exemplified by the Ramachandran plot in Figure 
1.4. The shaded regions on the diagram show that there are few energetically favourable 
bond angles available to an Aib residue in a peptide. This means that there are very few 
favourable conformations for a peptide that contains many Aib residues. The ideal torsional 
angles for an Aib residue correspond to α-helical and 310 domains. 66 When only a few Aib 
monomers are present in a peptide they act as α-helix stabilisers, though when the Aib 










There are a few differences between a 310 helix (Figure 1.5a) and an α-helix (Figure 1.5b). The 
310 helix has an (i → i + 3) hydrogen bonding pattern, meaning that a ten membered ring is 
formed by each intramolecular hydrogen bond and that there are exactly 3 amino acid 
residues per turn. This means that there will be two carbonyl groups at the C-terminus and 
two N-H’s at the N-terminus that have no hydrogen bonds and will therefore be exposed to 
the solvent. Alpha helices have an (i → i + 4) hydrogen bonding pattern, which makes the α-
helix shorter yet wider than the more tightly wound 310 helix. α-Helices have 3.6 residues per 
turn with a 13 membered ring formed by each intermolecular hydrogen bond, leaving three 
carbonyl’s and three N-H’s exposed to solvent. 69 – 71 
 Figure 1.5: The structures of: a) A right handed 310 helix; b) A right handed α-helix. 




Figure 1.4: A Ramachandran plot highlighting the limited torsional angles accessible to an 
Aib residue within a peptide. 65 
Favoured dihedral 
angles correspond to 






As Aib is achiral, a 310-helix comprised of just Aib will have no screw sense preference. This 
means the populations for the right and left-handed screw senses will be equal. The 
conversion between an (M) to a (P) helix is a rapid process (Scheme 1.3) 72 that occurs by a 
‘zipper like’ mechanism where one to two hydrogen bonds break and subsequently reform at 
a time. 73 The thermodynamic stability and the potential for rapid switching between (M) and 
(P) screw senses 72 of the 310 helix makes Aib oligomers an ideal candidate to use for 

















1.4. Control of Screw Sense in Aib Oligomers 
 
A preference for one screw sense over the other can be induced by the inclusion of a single 
chiral amino acid residue in an Aib oligomer. 74, 75 The position and nature of this inducer 
within the foldamer can vary both the level of control, and the screw sense that is preferred.  
 
Early work into Aib foldamers concentrated upon control from the N terminus. 39 When a 
carbamate protected quaternary-L-amino acid (e.g. (L)-αMv) is placed at the N-terminus a 
strong preference for a right handed (P) helix is induced. 26, 27, 74 Conversely, when a carbamate 
protected α-tertiary L-amino acid is used (e.g. (L)-Val) a left handed (M) helix is favoured. This 
is because tertiary α-amino acids adopt a Type II (M) β-turn at the N-terminus (Figure 1.6.a), 
whilst quaternary α-amino acids adopt a Type III (P) β-turn (Figure 1.6.b) to accommodate the 
steric bulk of controllers two side chains. 76 The best in class for N-terminal controllers is Cbz-










Control of screw sense is also possible when the stereo inducer is placed at the C-terminus. 
74, 78 When the chiral residue is protected as an amide a right-handed screw sense is induced, 
79 and when an ester is used in place of the amide a left-handed screw sense (M) is preferred, 
though the level of screw-sense control is significantly lower. This is due to the amide 
controllers being able to hydrogen-bond back into the helix (Figure 1.7a). Whilst the ester 
forms a ‘Schellman Motif’ 80 at the C-terminus (Figure 1.7b), which excludes the chiral centre 
from the helix as the ester has no way to hydrogen bond back into it. 78 
 
Figure 1.7: Examples of screw sense control from the C-terminus with: a) XaaNHtBu; b) 
XaaOMe. 79 
 






An interesting example, showcasing just how effective Aib oligomers can be at 
communicating conformational information at a long distance, came from a study by Clayden 
and co-workers (Scheme 1.4). Here a foldamer, compound 5, was synthesised that had an 
[Aib4Ac6cAib4]3 backbone, a Cbz-(L)αMv2 screw-sense inducer and an enamide at the C-
terminus. When treated with CF3SO3H an acyliminium ion was formed at the C-terminus that 
was then trapped by the 1,3,5-trimethoxybenzene. This reaction is stereoselective as the (Re) 
face of the acyliminium ion is blocked by the foldamer, whilst the (Si) face is left open and 
hence is vulnerable to attack. This reaction gave the product, compound 6, in 78% yield and 
with a high d.r. of 88:12. This is a particularly impressive achievement when considering the 
distance between the controller and the reaction centre is 60 bonds, which is close to 4 nm. 
77 
  
Scheme 1.4: The foldamer system developed to showcase the long-range asymmetric 





1.5. Screw Sense Determination and Measuring Helical Excess  
 
As discussed in section 1.4 the screw sense preference of an Aib oligomer can be biased by 
the inclusion of a single chiral amino acid residue. 74, 75 However, being able to determine both 
the helical excess and whether an (M) or (P) helix is preferred is vital for this to be of use 
practically. 
 
Circular dichroism is a very powerful analytical technique which is well established in the 
study of secondary structure of proteins and peptides. 81, 82 CD measures the relative 
absorption of left and right handed circular polarised light and the sign, shape and position of 
peaks in the far UV region can be interpreted to reveal the handedness and type of helical 
domain present for a protein or a foldamer. The signals of interest occur due to absorption of 
the peptide bond and are found in the region of ~220-240 nm (arising from a n→π* transition) 
and from ~180-200 nm (arising from a π→π* transition). The shape of the spectra is diagnostic 
of the secondary structure of the protein or foldamer. For an (P) α-helix (Figure 1.8.a) the 
major peak between 190-200 nm is positive and the minor peak is negative with two peaks 
close in magnitude at ~210nm and ~230nm. 83 Whilst a (P) 310 helix (Figure 1.8.b) gives a 




If these bands are obscured by other chromophores then a CD probe can be used to 
compensate for this, these probes either absorb more strongly than the problematic 
chromaphores or at a different wavelength.59, 84 An example of a CD probe that can be reliably 
α-Helix 
Type I β-turn 
Anti-p. β-sheet 
Irreg. structure 





Figure 1.8: The CD spectra seen for: a) common protein secondary structures; 83 b) an 





used with Aib foldamers is the dibenzazpinyl urea reporter developed by Clayden and co-
workers. 85 Some protecting groups that are strong chromophores, such as pBr-Bz, can 
interfere with the CD spectra by reporting the local chiral environment rather than overall 
screw-sense of the oligomer. 76 This should be considered when analysing CD data for 
compounds with strong chromophore’s adjacent to a chiral residue. As such, CD can be an 
extremely powerful technique for studying a foldamers conformation in solution. 
 
NMR is an extremely powerful analytical technique that can be used to the determine helical 
excess (h.e.) of a foldamer. This is analogous to e.e. where the h.e. represents the degree that 
a helical system favours one screw sense over the other. Many NMR probes have been 
developed, some of the most commonly used include: glycine, 76, 86 mono- and di- labelled 13C 
Aib 73, 87, 88 and the Fib 89 reporter. These reporters are all achiral (or insignificantly chiral like 
Aib*) but become diastereotopic in the presence of an external chiral influence. The Aib* 
NMR probe is a special case, as it can also be used to determine the screw-sense preference 
















On the NMR timescale at room temperature, Aib oligomers are in fast exchange between 
their left and right-handed conformations. 78, 91 When a helix is racemic, rapid exchange 
between its left and right-handed states mean that at fast exchange a single signal will be 
observed (Figure 1.9.a). When the system is biased towards one screw sense over the other 
a weighted average between the two interconverting signals is seen, the splitting for which is 
Figure 1.9: A simplified view of the NMR signals observed with an NMR probe at slow 
and fast exchange with: a) a racemic helix; b) a controlled helix.   
b) 
a) 
At fast exchange this 
resolves to one peak 
At fast exchange this 
resolves into two peaks 
where Δδfast represents 
the difference in 








denoted as Δδfast (Figure 1.9.b). When at slow exchange the splitting (denoted as Δδslow) gives 
the ‘actual’ chemical shifts of these positions. The Δδslow value for a system in fast exchange 
can be extrapolated by performing VT NMR spectroscopy. 88  
This means that when Δδfast = 0, there is no screw-sense control over the helix and when Δδfast 
= Δδslow there is complete screw-sense control. Therefore, the ratio of these two values will 
equate to the h.e. of the system. As Δδfast can be interpreted as the difference in population 
between (P) and (M), whilst Δδslow gives the total population of the system. 
This can be expressed by the following equation: 








Which is analogous to the equation used to calculate e.e.: 





When studying any system, it is vitally important to appreciate and understand any limitations 
it may have. In relation to Aib oligomers, this means ascertaining the rate of degradation in 
helical fidelity with distance. There have been several studies that have sought to explore this.  
In one study, the Aib oligomer 7 was synthesised which was controlled by a Cbz(L)Phe residue 
and incorporated a series of Gly residues along the chain to act as reporters (Figure 1.10). Due 
to the high amount of glycine within the foldamer it was predisposed to faults, with the fault 
rate for a glycine residue being 17.5% whereas the chance of a fault for an Aib residue was 
only 3.5%. 75 A more in-depth study into helical decay was undertaken, was based upon 
numerous factors, including: residue, temperature and solvent. 92 Part of this study used 
compound 7, which showed a per-residue decay in h.e. of only 0.5 % in THF-d8 compared to 
6.1 % in CD3OD (see graph in Figure 1.10). This means in THF-d8 the average length of uniform 
screw sense is 200 residues but only 16 residues in CD3OD which is a result of the hydrogen 










preserved for longer 
in THF-d8 compared 
to MeOD/EtOD 
 
Figure 1.10: The Gly rich Aib foldamer, compound 7, and a graph depicting the per-





1.6. Switching Screw Sense in Aib Foldamers with Dynamic Controllers 
 
In the examples outlined in the proceeding sections the stereoinducers are all fixed. To create 
a system that can respond differently to distinct inputs, a dynamic screw sense inducer would 
be needed. There are many examples of non-covalent interactions being used to 
communicate conformational information in foldamer systems. 93, 94 – 96 However, examples 













A dynamic stereocontroller is fundamentally different to a fixed stereocontroller (Figure 
1.11.a). In the generic example presented in Figure 1.11.b the helix is racemic when 
unactivated. However, when a chiral ligand binds to the active site a screw sense preference 
is induced. As this ligand binding is reversible the system can (in theory) be turned on and off. 
It is important to note that to create a mimic of a transmembrane receptor the chiral input 
must not be able to act along the whole length of the helix, as only end-to-end communication 
is possible for receptors when they are embedded in the cell membrane. 
 
An interesting example of a dynamic screw-sense controller is the imino-boronate complex, 
compound 8, (Scheme 1.5) developed by Clayden and co-workers. 90 In this example, an Aib 
oligomer is capped at the N-terminus with an aromatic boronic ester. The nearby amino group 
of the N-terminal Aib residue can coordinate to this, forming an imino-boronate complex. 
These are known to have faster rates of transesterification compared with standard boronic 
esters, 98, 99 meaning the racemic foldamer is pre-activated to bind diols. Adding the chiral diol 
Figure 1.11: A diagram outlining the difference between the helical control exerted 
















Scheme 1.5: The imino-boronate foldamer developed as a dynamic switching system by 
Clayden and co-workers. 90 
(-)-DIPT to the foldamer forms complex 9, inducing a left-handed screw sense. The screw 
sense preference can be switched to right handed by adding in the chiral diol (+)-HB. This diol 
has a stronger affinity for the boronate, forming complex 10. The system can be turned off by 
adding the diol (-)-PD, which displaces the (+)-HB. Despite being chiral, the (-)-PD induces no 
screw sense when it forms complex 11. This is due to the amino group not being able to 
interact with the boronate, meaning the influence of the ligand is not felt by the helix. When 
the process was repeated, using various ribonucleosides, the same responses appeared 





















Though elegant, this system is still limited to a small library of diols. A step up in terms of 
complexity and scope is exemplified by the multi-component pH dependant system that was 
again developed by Clayden and co-workers (Scheme 1.6). 100 The Aib oligomer, compound 
12, with a pyridine binding site at the N-terminus and an Aib* reporter at the C-terminus is 





pyridine, which induces a right-handed screw sense. Adding the phosphoric acid 14, displaces 
compound 13 at the binding site, inducing a left-handed screw sense. The system can be 
switched back to (P) by adding NH3 (aq) as the pKa of compound 14 101 is lower than compound 
13 102 meaning the phosphoric acid will be deprotonated first. The phosphate and the 
ammonium ion form an ion pair allowing compound 13 to bind at the pyridine again. Adding 
HCl to the system protonates compound 14, allowing it to bind to compound 12 again, hence 
restoring the left-handed screw sense preference. The system can be turned off by adding 2 
eq. of NH3 (aq) and then reactivated again by adding more HCl (aq). This system can switch its 
screw-sense by selectively binding an agonist, dependant on the pH of the system and can 
also be deactivated and then subsequently reactivated, by varying pH, something previous 



























1.7. Into the Membrane with Aib Oligomers 
 
Like their biological cousins the peptaibols, Aib based foldamers have the same propensity to 
insert into membranes, where they typically span a lipid bilayer through a ‘barrel-stave’ 
mechanism. 61 – 63 How effective an Aib oligomer is at penetrating a membrane is determined 
by a few factors (Figure 1.12). Firstly, if a chiral residue is included in the oligomer then the 
membrane activity is boosted if a racemate is used rather than a chirally pure oligomer. This 
is due to the oligomers forming heterogeneous aggregates as they span the membrane, 
where the foldamer-foldamer interactions are more favourable for racemic rather than 
chirally pure oligomers. 103 Another factor is the length of the oligomer, the ideal length 
needed to span a typical membrane (20% cholesterol/EYPC – 2.8 nm in length) is ≥10 Aib 
residues in length, which corresponds to the approximate length of the membrane. 104 The 
protecting groups on the N- and C-termini were seen to have little effect on the ionophoric 











Dynamic switching systems (see Section 1.6) can be inserted into a membrane. One such 
system is the foldamer 15, which has an azobenzene capped L-Val residue at the N-terminus 
and the Fib reporter at the C-terminus (Scheme 1.7). The azobenzene can be switched 
between its preferred (E) conformation to (Z) by irradiation with UV light, and then be 
switched back with irradiation by blue light. When the azobenzene is (E) the foldamer has a 
slight preference to adopt a left-handed screw-sense. This is due to steric clashes between 
the azobenzene and the iPr group of the Val in the right-handed conformation. However, 
when the azobenzene is switched to its (Z) conformation the foldamer is no longer 
constrained by the azobenzene and instead the M/P equilibrium shifts back to a more equal 
population, as (L)-Val is a weak screws-sense controller. This foldamer readily inserts into 
membranes, and the change in screw-sense preference upon irradiation can be monitored by 
solid state 19F NMR.  The E/Z ratio is measured by the fluorine tag on the azobenzene, whilst 
the Fib controller at the C-terminus gives the helical excess of the foldamer. This system can 









Side by Side Interactions 
Membrane Membrane 
Figure 1.12: A simplified diagram showing the main factors that influence how effective an 





bond is causing a conformational change that is felt through an oligomer that is embedded 







Scheme 1.7: The photo switchable Aib foldamer 15; Note: This system was inserted into a 






2. Disrupting Directionality with N→N Aib Foldamers 
2.1. Introduction 
 
Proteins and peptidic foldamers have N→C directionality, where there is a defined N and C 
terminus because of the amide bonds that link the individual amino acids together into 
oligomers (Figure 2.1). 107 By altering this paradigm, we can push the conceptual envelope of 
how peptidic foldamers are constructed, which could have interesting implications in the 






Not all foldamers enforce this rigid sense of directionality. An interesting example of a 
foldamer with a fluid sense of directionality is the ‘meso helix’ reported by Guichard, Clayden 
and co-workers (Scheme 2.1). 110 Here a globally achiral oligourea, compound 16, was 
constructed from meso-cyclohexane-1,2-diamine. Compound 16 is symmetrical and has no 
overall screw-sense preference. When the screw sense inverts between its right and left-
handed conformations, the cyclohexane undergoes a ring flip which causes a reversal of the 
directionality of the hydrogen bonds and hence reverses the directionality of the foldamer. 
The screw-sense (and directionality) of this foldamer can be influenced by altering the 
protecting groups at each terminus or by ligands interacting with the helix. 111 
 
Figure 2.1: A diagram of a generic Aib based oligomer in a 310 conformation with the N 
and C termini highlighted. 
Scheme 2.1: A scheme illustrating the (M)/(P) interchange and the associated 





The Clayden group has sought to both disrupt and enhance the transfer of conformational 
information with Aib oligomers. In one study, various achiral amino acids were inserted 
between two Aib tetramers, to gauge the effect on both the overall conformation and the 
level of communication observed with non-Aib residues. 112 Here the N→C directionality is 
retained as the linkers are amino acids. Linkers that readily adopt a 310 conformation, like Ac6c 
or Thp, were found to slightly enhance the transfer of information (compared to Aib). While 
linkers like Dpg or GlyGly serve as insulators of screw-sense preference by disrupting the 310-




Figure 2.2: A diagram illustrating how different amino acids can support or impair the 





2.2. Project Outline 
 
Much of the work concerning conformational communication with Aib oligomers in the 
Clayden group has focused upon stereochemical induction from the N-terminus, 77 with the 
most versatile dynamic controllers being located at the N-terminus as well. 90, 106 Therefore, 
an interesting extension of the work described in figure 2.2 would be to use a diamine as a 
linker between two Aib oligomers instead of an amino acid, which would give an Aib foldamer 
with two N-termini. 
 
To explore the consequences of disrupting the natural N→C directionality, a family of Aib 
oligomers with two opposing N-termini were synthesised. These compounds were studied to 
assess whether they can adopt a conformation that facilitates N→N communication or if they 
instead disrupt the transfer of information. 
 
 
The generic structure for the family of N→N Aib oligomers is shown in Figure 2.3. There are 
two opposing Aib4 oligomers joined to each other by a selection of diamine linkers. One of 
these opposing N-terminal domains is controlled by a methyl carbamate protected (L)-αMv. 
Initially, the compounds were synthesised with a Cbz group as the reporter to preserve the 
costly Aib*, if N→N communication did not occur. The relatively uncommon methyl 
carbamate was chosen over the more usual Cbz protecting group 75 – 77 for the 
stereocontroller, so that there would be no overlap in the 1H NMR spectrum with the Cbz 
reporter. Previous work has shown that changing the carbamate protecting group of the N-
terminal chiral residue has a negligible effect on the induced screw-sense preference. 113 





Ethylenediamine and 1,2-diamino-2-methylpropane were chosen as linkers due to them 
being analogous to Gly and Aib; both of which support 310 and α-helical conformations. 
Ethylenediamine would be expected to impair N→N communication compared against 1,2-
diamino-2-methylpropane due to the comparative flexibility of the linker.  
 
1,2-Phenylene-diamine and 1,3-phenylenediamine were chosen as linkers to add more 
rigidity to the system, in the hope that this would aid with N→N communication. With 1,2-
phenylenediamine a conformation that facilitates N→N communication may be forced due 
to the rigidity of the linker and enforced proximity of the two opposing Aib oligomers. Whilst 
the two disparate Aib oligomers may be held further apart by the 1,3-phenylenediamine 








2.3. Synthesis of N to N Aib Foldamers 
2.3.1. Synthesis and Functionalisation of Aib4 
 
The key intermediate for this project was the peptide H2N-Aib4-OtBu, compound 24. This was 
synthesised following procedures previously reported by the Clayden group (Scheme 2.2). 75, 
80 Thus, coupling of the acyl chloride 18 and H2NAibOtBu gave azide 19 in 66% yield, this was 
reduced by hydrogenation to give amine 20 in 88 % yield. This process was then repeated to 









With compound 24 in hand we needed to functionalise this oligomer. For the initial studies, 
a Cbz group was chosen as the diastereotopic reporter. If N→N communication occurs, 
splitting will be observed for the benzyl CH2 signal of the Cbz group in the 1H NMR spectrum. 
Although the h.e. would not be easy to extrapolate from this, it would give an indication as to 
whether N→N communication occurs for these oligomers before any of the costly Aib* probe 
was used.   
 
Synthesis of the Cbz protected Aib tetramer 25 was not as simple as first assumed (Scheme 
2.3). Using CH2Cl2 as the solvent resulted in low yields, due to formation of an impurity 
identified as the di-peptide urea 26. When the solvent was switched to THF, a moderate 
increase in yield from 30% to 50% was observed. The yield of compound 25 could be increased 
further by tweaking experimental parameters. Following this, a TFA deprotection of the tBu 
ester of compound 25 gave the carboxylic acid 27, in quantitative yield. 













The inadvertent formation of compound 26 was fortunate as it was a key intermediate in 
another Clayden group project complementary to this one, the synthesis and categorisation 
of dual C-terminal foldamers. Up until this point, the attempted synthesis of compound 26 
using standard reactions had been unsuccessful. 114 The mechanism for the unexpected 
formation of compound 26 has not been determined, though this novel impurity is likely 
formed thanks to the 310 conformation. The carbonyl of the Cbz group is involved in the 310 
conformation. This hydrogen bond activates the carbamate to nucleophilic attack, a 
phenomenon that is widely exploited in organocatalysis 115, 116 and biological systems. 117 
 
The stereo-inducer chosen for the initial studies was alpha methyl valine (αMv), protected at 
the N-terminus as a methyl carbamate (MC). The methyl carbamate protecting group was 
chosen over the usual Cbz 75 – 77 in the interest of eliminating any clashing signals between 
two Cbz groups in the 1H NMR spectra. The controlled tetramer, compound 29, was prepared 
by an acid fluoride coupling between MC(L)αMvOH and H2NAib4OtBu,(Scheme 2.4) to give 
compound 29 in 75 % yield. This was followed by a TFA deprotection of the tert-butyl ester to 







Scheme 2.3: Synthetic scheme outlining the preparation of compounds 25 and 27 





The 13CH3 Aib monolabeled probe was synthesised following previously reported procedures 
(Scheme 2.5). 79, 87 The (L)-sodium alaninate salt was converted to the naphthamide derivative 
32. When compound 32 is treated with a strong base at low temperatures an enolate is 
formed, which holds a ‘chiral memory’ of the stereocentre, due to slow rotation of the 
naphthamide bond. Consequently, when the enolate is trapped with 13CH3I the configuration 
is retained in the product, compound 33. The free amino acid was obtained by heating this 
compound in HBr, followed by a Cbz protection to give the compound 34. This was coupled 
to H2NAib4OtBu by an acid fluoride coupling, and subsequently treated with TFA to deprotect 
the C-terminus to give compound 35 in 65 % yield. 
 






2.3.2. Synthesis of the Ethylenediamine Linked N→N Compound 
 
The synthesis of protected ethylenediamine linked compound 39 is described Scheme 2.6. 
The first step was an EDC·HCl/HOBt coupling between MCαMvAib4OH, 30, and N-Boc 
ethylenediamine, 36, which gave the coupled product, 37, in 32 % yield (For an alternate 
synthesis of compound 37 see appendix section 7.1). Initial attempts at this coupling failed, 
until it was found that DMF was needed as a co-solvent to fully dissolve compound 30. The 
Boc group of compound 37 was deprotected with HCl to give the HCl salt of compound 38 in 
quantitative yield. This was then coupled to CbzAib4OH with EDC·HCl/HOBt giving the 
compound 39 in 31 % yield. 
 
   
 
The 1H NMR spectrum of compound 39 in CDCl3 showed splitting of the benzylic CH2 protons 
into an AB system (Figure 2.4.a). To determine whether the splitting observed resulted from 
aggregation or if N→N communication was occurring a concentration dependence study was 
performed (Figure 2.4.b). This showed a relationship between the observed Δδ and 
concentration, as the solution became more dilute the magnitude of Δδ decreased. At higher 
concentrations (>18 mM) the sample aggregated into a gel in the NMR tube, a further 
indication that in CDCl3 the foldamer was simply aggregating. 1H NMR spectra were also 
recorded for compound 39 in CD3CN and CD3OD, though no splitting of the benzylic CH2 
protons was observed at any concentration in these solvents. THF d8 was also tested, though 
compound 39 was insoluble in this solvent.  
 














The initial results with compound 39 were somewhat inconclusive. As even though there was 
a clear concentration dependence to the observed Δδ values, this could not be quantified to 
a h.e. and the conformation was not determined. Therefore, it was decided to attempt to 
functionalise this compound with Aib*.  This was achieved through an azlactone coupling 
(Scheme 2.7) between compound 38 and CbzAib*Aib4OH to give the target compound, 40 in 
75% yield. 
    
Scheme 2.7: Scheme outlining the approach used to prepare the ethylene-diamine 















Figure 2.4: a) The AB system observed in the benzyl CH2 of compound 39 at 18 mM; b) Graph 
showing the concentration dependence of Δδ for compound 39 in CDCl3. 
a) b) 





2.3.3. Synthesis of the 1,2-Diamino-2-Methylpropane Linked N→N Compound  
 
The Cbz protected 1,2-diamino-2-methylpropane linked compound, 44, was synthesised 
(Scheme 2.8) starting with an azlactone coupling between MCαMvAib4OH and N-Boc-1,2-
diamino-2-methylpropane, to give compound 42 in a 15 % yield (For an alternate synthesis of 
compound 42 see appendix section 7.1). The low yield was attributed to the low solubility of 
compound 30, which inhibited the formation of the azlactone. Deprotection of the Boc group 
of compound 42 with HCl gave the HCl salt of compound 43 in 66% yield. Initial attempts at 
this deprotection used TFA, though very low yields were observed due to decomposition of 
the product. The final step was an EDC·HCl/HOBt coupling between CbzAib4OH and the HCl 




The 1H NMR spectrum of compound 44 shows some splitting of the benzylic CH2 protons in 
CDCl3 (Figure 2.5), with a weak AB system visible. Only a small amount of compound 44 was 






Scheme 2.8: Scheme outlining the synthesis of compound 44. 
Figure 2.5: Portion of the 1H NMR spectrum of compound 44 in CDCl3 





However, as diastereotopicity was observed in the Cbz reporter the 1,2-diamino-2-
methylpropane N→N Aib oligomer was functionalised with the Aib* probe (Scheme 2.9). 
Compound 45 was synthesised by an azlactone coupling between the HCl salt of compound 










2.3.4. Synthesis of the 1,2-Phenylenediamine Linked N→N Compound  
 
The initial synthetic strategy employed to access the 1,2-phenylenediamine linked N→N 
foldamer involved an EDC·HCl/HOBt coupling between MCαMvAib4OH and N-Boc-1,2-
phenylenediamine (Scheme 2.10.a), however this reaction gave no product. Clearly the 
aniline was too sterically hindered and not nucleophilic enough for this standard coupling 
reaction, meaning harsher reaction conditions or alternate coupling reactions were needed. 
 
Therefore, a different approach was taken (Scheme 2.10.b) which started with an acid 
chloride coupling between N3AibCl and N-Boc-1,2-phenylenediamine, which gave compound 





48 in 92 % yield. This azide was reduced to the amine 49 in quantitative yield. This was coupled 
with MCαMvAib3OH, compound 50, by an azlactone coupling to give compound 47 in 39 % 
yield. The Boc group of compound 47 was then deprotected with HCl to give the HCl salt of 
compound 51 in 70 % yield. The final step was an azlactone coupling between this HCl salt 
and CbzAib4OH to give compound 52 in 31 % yield. 
 
The 1H NMR spectrum of compound 52 shows that the benzylic CH2 of the Cbz is split into a 
well-defined AB system (Figure 2.6.a) in CDCl3, which was shown to be independent of 













To access the Aib* functionalised compound, the first step in the synthesis (Scheme 2.11) was 
an azlactone coupling between N3Aib4OH and N-Boc-1,2-phenylenediamine which gave 
compound 54 in 21% yield. This azide was reduced to the amine 55 in 80 % yield, which was 
subsequently coupled to MCαMvF to give compound 47 in 69% yield. This compound was 
deprotected by treating with HCl to give the HCl salt of compound 48. The final step was an 
azlactone coupling between this HCl salt and CbzAib*Aib4OH to give compound 56 in 72% 
yield. 
Figure 2.6: a) Portion of the 1H NMR spectrum of compound 52 in CDCl3 showing the AB 
system of the Cbz CH2 which is overlaid with a signal for a NH amide;  b) The concentration 


































2.3.5. Synthesis of the 1,3-Phenylenediamine Linked N→N Compound  
 
The simplest of the N→N Aib foldamers to synthesise was the 1,3-phenylenediamine linked 
molecule, compound 60 (Scheme 2.12). As N-Boc-1,3-phenylenediamine is markedly less 
hindered than N-Boc-1,2-phenylenediamine, the N→N oligomer could be assembled by a 
series of EDC·HCl/HOBt couplings. The EDC·HCl/HOBt coupling between N-Boc-1,3-
phenylenediamine and CbzAib4OH gave compound 58 in 70 % yield. The Boc group of this 
compound was deprotected with TFA to give the TFA salt of compound 59 in 27 %. The low 
yield was attributed to decomposition of the molecule in TFA. This TFA salt was then coupled 








However, in the 1H NMR spectrum of compound 60 no splitting was observed in the benzylic 
CH2 protons when either CDCl3, CD3CN or CD3OD were used as solvent. In this case, the two 
opposing Aib oligomers must be too far away from each other for N→N communication to 
occur (Figure 2.7). Here the para geometric relationship of the diamine linker makes adoption 
of the global conformation that enables N→N communication impossible. Hence the 1,3-






Scheme 2.12: Scheme outlining the synthesis of compound 60. 





2.4. Results and discussion: 
2.4.1. Helical Excess of the N→N Aib Oligomers 
 
Compounds 40, 45 and 56 were all insoluble (or sparingly soluble) in common NMR solvents 
such as: CDCl3, CD2Cl2, CD3CN or THF d8. The only suitable solvent was CD3OD/CD3OH, in which 
all compounds readily dissolved. Two conventional N→C compounds (61 and 62) were 
studied as a comparison to their N→N cousins, these compounds were synthesised by other 
members of the Clayden group. 77, 118 For each of the compounds, the helical excess was 
calculated in CD3OD/CD3OH (Table 2.1). 
 
 
Compound h.e. (P:M) 
 
3 %  
(52:49) 
 
6 %  
(54:48) 
 
58 %  
(79:21) 77 
 
22 %  
(61:39) 
 
14 % 118 





The ethylene diamine and 1,2-diamino-2-methylpropane diamine linked compounds 40 and 
45 both show negligible helical excess with a very slight preference to adopt a (P) helix that 
was independent of concentration (See appendix section 7.2). The aliphatic linkers are simply 
too flexible to force a conformation that allows N→N communication and they instead disrupt 
the transfer of screw-sense preference. Therefore,  a more rigid linker is needed to force the 
two separate Aib oligomers to interact. This result reinforces the concentration dependant 
study performed for compound 39 (Figure 2.4), which suggested the diastereotopicity seen 
in the benzylic CH2 was because of aggregation rather than N→N communication.  
 
The 1,2-phenlyene diamine linked compound 56 also shows a preference to adopt a (P) helix, 
though with a much higher h.e. of 22%, which was shown to be independent of concentration 
(Figure 2.8.b). However, this value is still low compared to compound 61, a conventional Aib 
foldamer of the same length which has a h.e. of 58%. This shows that compound 56 and by 
extension N→N Aib oligomers are worse at transmitting conformational information than 
oligomers that retain N→C directionality. The fault introduced into the helix by the 1,2-
phenylenediamine linker disrupts, but does not completely degrade, the communication 




However, when compared to the N→C analogue that contains anthranilic acid as a linker 
(compound 62), compound 56 is clearly superior with compound 62 exerting much poorer 
control at only 14%. As compound 62 is controlled by (αMv)2, a stronger screw-sense inducer 
than αMv alone, 77 it suggests that it is easier to adapt to the fault that the 1,2-phenylene 
diamine linker introduces compared to the anthranilic acid and in this case N→N 








Figure 2.8: Select  13C NMR Spectra for compound 56 in CD3OH showing: a) the Aib* probe 







Δδslow = 2464 ppb 





2.4.2. CD Spectra of the N→N Aib Oligomers 
 
The CD spectra for compounds 40 and 45 (Figure 2.9.a) both show a curve characteristic of a 
right-handed 310 helix, with a major peak at 205 nm and a minor peak at 225 nm. 77 This 
suggests that for both compounds the favoured conformation will be the two opposing Aib 
oligomers adopting separate 310 helices that do not interact with each other (Figure 2.9.b). 
This is further evidence that these linkers are too flexible to force a conformation that would 









The CD spectra for compounds 56 and 62 have some interesting features (Figure 2.10). Firstly 
there is an extra band in the region of 250-260 nm, which is due to the aromatic linker 
absorbing in this region. 119 Apart from this extra band the spectrum of 56 is reminiscent of 
the 310 helix, though slightly blue shifted. An abnormal spectrum is to be expected, as a pure 
310 conformation alone would not enable N→N communication. Compound 62 shows the 
same trends, but with the peaks closer to the expected position for a 310 helix which is 
understandable, as this compound has N→C directionality. 
Figure 2.9: a) The CD spectra from compounds 40 and 45, recorded in MeOH; b) Diagram 


































































2.4.3. Exploring the Conformation of Compound 56 
 
DMSO-d6 titrations are a powerful tool that can be used to explore the conformation that 
certain foldamers adopt in solution. As the amount of DMSO-d6 added to a sample increases, 
the chemical shift of hydrogen bond donating groups (e.g. NH peaks of amides) that are not 
hydrogen bonded will change as they interact with the DMSO-d6. When an Aib oligomer that 
adopts a 310 helix is subjected to a DMSO-d6 titration, typically only two of its NH’s will move 
to any appreciable degree – the two that are not involved in the 310 conformation. 80, 120 
 
For compound 56 (Figure 2.11) only two of the NH peaks move a large amount (Δδ = 1.06 and 
0.71 ppm), which are H1 and H4 respectively. A further two NH peaks move a smaller amount 
(Δδ = 0.32 and 0.24 ppm), which are H2 and H3 respectively. The remaining 8 NH peaks all 




This is an interesting result, because the two NH’s at both N-termini moving under DMSO-d6 
suggests that a conformation of two opposing 310 helices is present. However, as the NH’s of 
two termini move to different extents and a h.e. independent of concentration is observed, 
it indicates that at room temperature there is another favourable conformation that enables 
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The exact conformation is uncertain; however a likely structure is a combination of a 310-helix 
followed by an alpha-helical fault due to the linker, which turns over to an 11-helix (Figure 
2.12). An 11-helix is rare but has been reported in the literature, 121, 122 here it is analogous to 
a 310 helix, with C→N hydrogen bond directionality. This would leave two free NHs at the 
controlled N-terminus, which agrees with the DMSO titration. 123, 124 
  





2.5. Conclusions and Future Work 
 
A family of N→N Aib oligomers have been made, with several diamine linkers having been 
investigated. However, only compound 56 showed any appreciable degree of N→N 
communication (Figure 2.13), whilst the other diamine linkers served to disrupt the 
communication of information. For compound 56, the rigidity of the diamine linker and the 
ortho-geometry forces a conformation that favours N→N communication over two opposing 
310 helices as is seen for compounds 40, 45 and 60. Though this is still less efficient than 




However, there is still potential for inserting linkers between Aib oligomers to explore 
interesting conformations. For example, work has been started on synthesising compounds 
63 and 64 (Figure 2.14 and appendix section 7.3). Both compounds are of interest as potential 
β-sheet mimics, with compound 63 being a potential antiparallel β sheet mimic whilst 
compound 64 is a potential parallel β sheet mimic. These compounds could also provide more 
information on the foldamer-foldamer interactions that occur when Aib oligomers insert into 
a membrane. In both compounds, the two Aib oligomers would be forced to lie next to each 
other and hence interact.  
  
Figure 2.14: Two compounds that continue the research of modifying Aib oligomers by 
inserting linkers between two Aib oligomers. 





3. N-terminal Quaternary Hydantoins: Chemoselectivity from Conformation 
3.1. Introduction and Project Outline 
 
Novel stereo controllers are always of interest to the Clayden group, with many interesting 
and unique examples having been reported and investigated over the years. Some of these 
include exploring unusual chiral amino acids, 125 photo-switchable fumaramide residues 126 
and binding ligands to N-terminal ureas. 127 However, fixed stereocontrollers that are not 
amino acids are very rare. Hence, this is an area to explore further as determining what 
structures can be accommodated into a 310 conformation, whilst still facilitating 
conformational communication, can guide future research into developing new foldamer 
designs and dynamic stereo-inducers. 
 
Hydantoins are an example of a biologically and synthetically important 128 structural moiety, 
that could be exploited as a new class of stereocontroller. Here you have a structure with 
multiple opportunities to hydrogen bond into a 310 conformation (Figure 3.1). This project 
aimed to synthesise a family of N-terminal hydantoins, to explore whether this non-standard 
chiral residue can effectively facilitate conformational communication. 
  





3.2. Synthesis of and Identification of N-Terminal Quaternary Hydantoins 
3.2.1. Inadvertent Formation of an N-Terminal Hydantoin 
 
The C-terminal silyl ether 67 was synthesised from an EDC·HCl/K-Oxyma coupling between 
the carboxylic acid 65 and the amine 66 in 47 % yield (Scheme 3.1). When this compound was 
treated with TBAF, with the intention of deprotecting the C-terminal TBS group, an 

















From NMR and accurate mass data alone, the structure could not be unequivocally assigned 
(Figure 3.2), and there were two potential structures that compound 68 could be, either a N-
terminal hydantoin (compound 68a) or a macrocyclic structure (compound 68b). However, 
the IR spectra of compound 68 contains a characteristic OH stretch, meaning the likely 





Scheme 3.1: The inadvertent synthesis of the N-terminal hydantoin 68. 
16 x CH3’s 
1 x CH2 
2 x CH 
6 x NH + 1 x OH 
or 
7 x NH 
Figure 3.2: The 1H NMR spectrum of compound 68 in CDCl3 and the two possible 
structures. 
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The CD spectrum of compound 68 exhibits some interesting features (Figure 3.3). The starting 
material, compound 67, produces a CD trace characteristic of a 310 helix. 77 However, the CD 
spectrum for 68 is very different, implying that the N-terminal hydantoin may make a 310 
conformation unfavourable. Here there is no secondary band. The main band has been blue 
shifted and is of the opposite sign, indicating there has been a switch of screw sense 
preference. The unusual CD spectrum, novel structure and unexpected formation of 




































XXX cyc XXX TBS
Figure 3.3: The CD spectra of compounds 67 and 68 in MeCN. 





3.2.2. Synthesis of Achiral N-Terminal Hydantoins 
 
A satisfactory single crystal for compound 68 to use for XRD was not obtained. Therefore, a 
different approach was adopted to further explore the conformation and structure of the N-
terminal hydantoins. To do this, two achiral analogues of compound 68 were synthesised with 
the goal of being able to unequivocally assign the structure of these compounds by NMR.  
 
The first step in this synthesis (Scheme 3.2) was an azlactone coupling between N3Aib3OH and 
H2NAib3OtBu to give the Aib hexamer 69 in 75 % yield. A series of deprotections and 
reprotections followed to give compound 72 in a total yield of 86% over three steps. An 
azlactone coupling between the carboxylic acid 72 and the amine 66 gave compound 73 in 
89% yield, this was treated with TBAF in THF to give compound 74 in 54% yield. Again, the 
structure could not be unequivocally assigned through NMR data alone. However, the 





Scheme 3.2: Scheme showing the successful synthesis of two achiral N-terminal 





The carboxylic acid 72 was also coupled to amine 75 by an azlactone coupling to give 
compound 76 in 63% yield. Amine 75 was chosen as the ethyl linkage will be able to provide 
more HMBC, COSY and NOESY correlations, that will help with structural elucidation. When 
the oligomer 76 was treated with TBAF in THF, compound 77 was obtained in 75% yield. The 
COSY NMR spectrum (Figure 3.4) shows the couplings between the C-terminal hydroxyl group, 
through the ethyl linkage to the adjacent amide NH, conforming the structure present at the 
C-terminus. Additionally, the NOESY (See appendix section 7.4 for all correlations) and the 
HMBC spectra show correlations that confirm the hydantoin at the N-terminus (Figure 3.4 










Figure 3.4: A section of the COSY spectrum for compound 77 with some notable HMBC 






3.2.3. Scope and Mechanistic Insights into the Formation of N-Terminal Hydantoins  
 
A range of different Aib foldamers that were protected at the N-terminus with a Cbz group 
were subjected to the same reaction conditions, to ascertain the scope of this reaction (Table 
3.1). The synthesis of compounds 80, 82, 87 and 89 is outlined in the appendix (Section 7.5), 
whilst compounds 78, 84, 85 and 86 were synthesised by other members of the Clayden 
group. 129  
 
The only functional and protecting groups that react under the reaction conditions are the 
TBS ethers and the Cbz group. When a quaternary amino acid is used to cap the N-terminus 
of the oligomer (compounds 78, 80 and 82), N-terminal hydantoins are formed in high yields. 
The length of the oligomer does not affect the reactivity, with oligomers from four to seven 
units in length all giving respectable yields. However, when a tertiary amino acid is used as 
the N-terminal unit no reaction is seen in any of compounds 84, 85 and 86. The reaction time 
and equivalents of TBAF used were increased, though still no reaction was observed. When 
an alternative protecting group is used at the N-terminus (compounds 87 and 89) no 
formation of the N-terminal hydantoin is observed, though deprotection of the TBS group 























The origin of the different reactivities observed for oligomers, that have a tertiary or 
quaternary amino acid capping the N-terminus, can be explained by conformation (Figure 
3.5). When a tertiary amino acid is used as the N-terminal unit for an Aib oligomer a Type-II β 
turn is adopted at the N-terminus, whilst using a quaternary amino acid results in a Type-III β 
turn. 76 When a Type-II β turn is the preferred conformation at the N-terminus, the carbamate 
and the adjacent amide are kept too far apart to be able to react and form a hydantoin. Whilst 
for the Type-III β turn, the conformation forces the carbamate and the adjacent amide close 










The exact mechanism for this transformation has not been determined. However, a potential 
mechanism for this transformation is activation of the two N-terminal NH’s by the fluoride 
anion, inducing the cyclisation that forms the N-terminal hydantoin (Scheme 3.3). The two N-
terminal NH’s are not involved in the 310 helical conformation, and thus can freely hydrogen 
bond with the fluoride anion from TBAF. This is commonly seen in supramolecular fluoride 
sensors and organocatalysis, where amides and ureas are used to bind fluoride anions. 130-132 
This primes the Cbz carbamate for nucleophilic attack from the adjacent amide. 
  
Scheme 3.3: The suggested mechanism for the formation of the N-terminal hydantoins. 
Figure 3.5: The different conformations adopted at the N-terminus for: a) tertiary and b) 
quaternary amino acids.76 










3.2.4. Conformation of the N-terminal Hydantoins  
 
A 1H NMR DMSO-d6 titration was carried out on compound 68 (figure 3.6). This shows that 
only two of the NH amides are non-hydrogen bonded (NH 1 Δδ = 0.86 ppm and NH 2 Δδ = 
0.75 ppm) the two closest to the N-terminus. All other NH peaks and the OH signal only move 








This suggests that a 310-like conformation is adopted (Figure 3.6). The N-terminal hydantoin 
removes one of the amide NH’s which disrupts the standard 310 conformation. The hydrogen 
bond for NH 3 was drawn to the urea carbonyl rather than the amide, due to no correlations 
between the two αMv residues being observed in the NOESY spectrum, which would be seen 
if NH 3 was hydrogen-bonded to the carbonyl of the hydantoin amide (See appendix section 
7.4). The hydroxyl group at the C-terminus being involved in a 310 conformation has been 
































Figure 3.6: A graph showing the 1H NMR DMSO-d6 titration and the proposed hydrogen 





The CD spectra of compounds 79 and 81 exhibit some interesting features (Figure 3.7). As 
noted in section 3.2.1 the CD spectrum for 67 has a different shape and sign, when compared 
to 68. This is a consequence of the N-terminal hydantoin acting to distort the 310 helix, which 
also induces the opposite screw sense. The difference between the spectra for hydantoins 79 
and 81, and their respective starting materials 78 and 80 is less marked. Here the spectra of 
the hydantoin and starting materials are closer to mirror images of each other, implying that 
upon the change from a Cbz protected amino acid to a hydantoin, the screw-sense preference 
of the foldamer is switched. For compound 68 there is a cooperative effect between the chiral 
hydantoin and the adjacent chiral amino acid, these complementary means of inducing a 
stereochemical preference give the unexpected CD spectra. It is worth noting that compound 
79 contains an NMR reporter at its N-terminus, the helical excess was calculated as 95 % in 
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Figure 3.7: A graph collating the CD spectra for the chiral N-terminal hydantoins and 











3.3. Conclusions and Further Work 
 
A novel reaction was discovered, wherein an Aib oligomer that has a quaternary amino acid 
protected with a Cbz group at its N-terminus will undergo a reaction to form an N-terminal 
hydantoin when exposed to TBAF (Scheme 3.4). However, if a tertiary amino acid is used as 
the N-terminal capping group no reaction is observed.  
 
This chemoselectivity arises due to the different conformations induced by tertiary and 
quaternary amino acids at the N-terminus of Aib oligomers. These oligomers adopt a 310 
helical conformation, that is distorted by the N-terminal hydantoin which induces the 




Further work in this area should focus upon conclusively proving and exploring the 
mechanism of this reaction. A mechanistic experiment that could be undertaken is a React IR 
study, wherein the carbonyl of the Cbz carbamate could be monitored to determine whether 
an in-situ acid fluoride is formed from a partial deprotection of the Cbz group or whether 
fluoride anion acts only as a Lewis base. 133 From a conformational standpoint, modelling 123 
could be carried out to gain a deeper understanding. Another avenue future research could 
take would be to undertake a deeper substrate scope. For example, testing other Lewis bases 
and N-terminal protecting groups or attempting to combine this work with ‘Clayden 
rearrangement’ lithiations. 134, 135 Further effort could also be devoted to determining the 
level and effectiveness of the N-terminal hydantoins as stereo-chemical inducers. 
 
  





4. Exploring Aggregation with Hydrophilic Aib Foldamers 
4.1. Introduction 
 
The tertiary 136 and quaternary 137 structure of proteins are key features that determine their 
biological activity, the study of these helps to explain why these biological macromolecules 
function as they do. 138 – 142 Foldamers, by definition, are synthetic mimics of biomolecules. 
Therefore, the aggregation and foldamer-foldamer interactions of both esoteric and 
biologically inspired foldamers provide an interesting and vibrant area for research. 32, 143 
 
An interesting example of a foldamer that undergoes self-assembly in aqueous media was 
recently published by Guichard and co-workers. 144 In this study a series of oligoureas were 
synthesised. These fold into a fixed helical conformation that can be depicted using a helical-
wheel diagram (Figure 4.1.a), these foldamers are designed to ensure that each face of the 
helix is made up of either charged or uncharged side chains. Whether the charged faces are 
kept together or apart determines how tightly and orderly the individual oligomers pack 
together in aqueous solution (Figures 4.1.b and c), this means that different supramolecular 












Many other examples of foldamers that assemble into interesting supramolecular 
architectures have also been reported. 145 One such example are the nanotube arrays 
reported by Woolfson and co-workers, here helical bundles aggregate in a head to tail manner 
which form nanoscale tubular structures that can then be observed and analysed by TEM. 146 
Another interesting example, is where a supramolecular foldamer was assembled from 
alternating aromatic oligoureas and aromatic oligoamides. These oliogomers readily fold into 






Figure 4.1: a) The generic structure of the Guichard oligoureas and the helical-wheel 
representation; The aggregation observed in aqueous solution when the charged faces 










amino and carboxylic acid residues they can interact with each other by ion pair interactions; 
which gives an extended helical supramolecular assembly. 147 
 
Regarding Aib oligomers, it is well documented that when spanning a membrane, they 
aggregate in a side to side manner forming aggregates that are heterogenous in nature (see 
Section 1.7). In organic solvents (e.g. CDCl3) Aib oligomers will readily aggregate in a head-to-
tail manner, with longer oligomers and the presence of termini that stabilise the 310 
conformation through hydrogen bonding increasing the propensity of Aib oligomers to 
aggregate in solution. 120 However, there has been little research into creating predesigned 
Aib oligomers that would readily dissolve and aggregate in aqueous solution, making this a 







4.2. Project Overview 
 
To investigate this concept, a family of Aib foldamers that have a hydrophilic residue in every 
third position along a sizable Aib oligomer were synthesised. This will create a hydrophilic face 
on the oligomer if a 310 helical conformation is adopted (Figure 3.1.a), this can also be 
depicted as a helical-wheel (Figure 3.1.b).  If these oligomers were to aggregate, they may 




















These compounds will be synthesised in a convergent manner, which is outlined in Scheme 
4.1. First trimeric units will be constructed from Aib2 and the corresponding amino acid, these 
will then be coupled together to form the main nonomeric unit and then capped with another 











Scheme 4.1: The proposed retrosynthesis for the hydrophilic Aib foldamers. 
Figure 4.2: a) The generic structure of the hydrophilic Aib foldamers with the hydrophilic 
face highlighted; b) The helical-wheel representation of a hydrophilic Aib foldamer and a 
hypothetical aggregation pattern. 
a) 







4.3. Synthesis of the Hydrophilic Aib Foldamers 
4.3.1. Synthesis of Cbz((L)SerAib2)3(L)SerNHtBu 
 
Though neutral, serine is a strongly polar amino acid. It is known to support a 310 
conformation, 79  and therefore is an ideal candidate to construct a hydrophilic Aib foldamer 
from. 
 
Initially, the serine side chain was protected with a TBS group. Cbz(L)Ser(OTBS)OH was 
successfully coupled with H2NAib2OtBu (Scheme 4.2) by EDC·HCl/K-Oxyma to give compound 
92, in 73 % yield. The hydrogenation of the Cbz group to give the amine 93 proceeded in 
quantitative yield. However, when 92 was treated with TFA in CH2Cl2, with the aim of 
deprotecting the tert-butyl ester; inadvertent deprotection of the silyl ether instead gave 
compound 94. An EDC·HCl/K-Oxyma coupling between compounds 93 and 94 was attempted. 
However this gave no reaction, potentially due to interference of the unprotected hydroxyl 
moiety in compound 95. The hydroxyl group can be reprotected (See section 6.4.3 page 184), 




The TBDPS protecting group was chosen to replace the TBS, as it is more resistant to TFA 148 
whilst still being easy to remove with TBAF. 148 – 150 The TBDPS protected Serine monomer, 
compound 97, was synthesised (Scheme 4.3.a) from commercially available Cbz(L)Ser 
(OH)OH. This was converted to the tert-butyl amide 98, by an EDC·HCl/HOBt coupling. The 






Cbz protecting group of this compound was removed by hydrogenation to give amine 99, 
which will become the C-terminal unit of the Ser based Aib hydrophilic foldamer. Also 
compound 98 was treated with TBAF in THF giving compound 100 in 79% yield, confirming 





















The trimeric unit 101 was synthesised from an EDC·HCl/K-Oxyma coupling between 
compound 98 and H2Aib2OtBu in 64% yield (Scheme 4.3.b). The tBu ester at the C-terminus of 
this molecule was deprotected to give the carboxylic acid 102 in 94% yield, whilst 
hydrogenation deprotected the Cbz group at the N-terminus to give compound 103 in 91% 
yield. These compounds were then coupled together with EDC·HCl/K-Oxyma to give 
Scheme 4.3: a) Scheme outlining the synthesis compounds 97 and 99; b) Scheme 





compound 104 in 30% yield. The tBu ester at the C-terminus of this molecule was then 
deprotected with TFA to give the carboxylic acid 105 in 91% yield. 
 
The C-terminal residue, compound 99, was coupled to carboxylic acid 102 with EDC·HCl/K-
Oxyma (Scheme 4.4) to give compound 106 in 42% yield. This was then hydrogenated to 
remove the Cbz group at the N-terminus, giving amine 107 in 42% yield. This was coupled to 
carboxylic acid 105 with EDC·HCl/K-Oxyma to give the fully protected serine based hydrophilic 
Aib foldamer, compound 108, in 54% yield. This was then treated with TBAF to remove all the 







Scheme 4.4: Scheme detailing the final steps in the synthesis of the Serine based 





4.3.2. Synthesis of Cbz((L)AspAib2)3OtBu  
 
Aspartic acid was chosen as a hydrophilic residue as this will provide a negatively charged face 
to the oligomer when at high pH, which may encourage aggregation. The beta carboxylic acid 
of Asp was protected as a methyl ester to chemically distinguish it from the N and C termini 
during the synthesis. The trimeric unit, compound 111, was synthesised (Scheme 4.5) by an 
EDC·HCl/K-Oxyma coupling between Cbz(L)Asp(OMe)OH and H2NAib2OtBu in 71% yield. This 
was treated with TFA to deprotect the C-terminal tBu ester, giving the carboxylic acid 112 in 
95% yield. Compound 111 was also hydrogenated to deprotect the N-terminal Cbz group to 
give the amine 113 in 92% yield. These two intermediates were then coupled together by an 
EDC·HCl/K-Oxyma coupling to give compound 114 in 35% yield. This was then treated with 












The C-terminal unit, compound 116 (Scheme 4.6.a), was prepared from an EDC·HCl/HOBt 
coupling between Cbz(L)Asp(OMe)OH and tBuNH2 to give the tert-butyl amide, which was 
then hydrogenated to deprotect the N-terminal Cbz group, giving the amine 116 in 90% yield. 
This was coupled to N3Aib2OH with EDC·HCl/K-Oxyma to give compound 117 in 62% yield, 
which was hydrogenated to deprotect the azide giving amine 118 in 94% yield. This amine 
was then coupled to Cbz(L)Asp(OMe)OH with EDC∙HCl/K-Oxyma giving compound 119 in 51% 
yield. However, when this compound was hydrogenated to deprotect the N-terminal Cbz 





Rather than attempting to synthesise compound 119 again, a different approach was taken 
where an Asp containing hydrophilic Aib foldamer that did not have another Asp unit at its C-
terminus would be synthesised (Scheme 4.7). Compounds 115 and 113 were coupled 
together with EDC∙HCl/K-Oxyma to give fully protected Asp containing foldamer, compound 
120, in 59% yield. This compound was then treated with an aqueous solution of NaOH in EtOH 
to deprotect all the methyl ester protecting groups on the Asp side chains, to give compound 
121 in quantitative yield. This was then acidified with HCl (aq) to give compound 122. 












4.3.3. Synthesis of Cbz((L)AbuAib2)3OtBu 
 
2-Aminoisobutyric acid (Abu) was chosen as a hydrophobic residue that would act as a control 
to compare against the hydrophilic compounds. The Abu trimeric repeat unit, compound 124, 
was synthesised (Scheme 4.8) by an EDC·HCl/K-Oxyma coupling between Cbz(L)AbuOH, 
compound 123, and H2NAib2OtBu in 62% yield. This molecule was treated with TFA to 
deprotect the C-terminal tBu ester giving the carboxylic acid 125 in quantitative yield and 
hydrogenated to deprotect the N-terminal Cbz group to give the amine 126 in quantitative 
yield. These intermediates were then coupled with EDC·HCl/K-Oxyma to give compound 127 
in 62% yield. This was treated with TFA, to deprotect the C-terminus, which gave the 
carboxylic acid 128 in quantitative yield. This compound was then coupled with amine 126 by 











4.3.4. Synthesis of N3(Aib2(L)Lys)2OMe 
 
The final hydrophilic Aib foldamers to be synthesised was the Lys compound, lysine was 
chosen to provide a contrast to Asp containing foldamer. The synthesis (Scheme 4.9) was 
started with an EDC·HCl/K-Oxyma coupling between N3Aib2OH and H2N(L)Lys (NHBoc)OMe, 
to give compound 132 in 71 % yield. This was treated with LiOH in THF/H2O to deprotect the 
methyl ester at the C-terminus in 83 % yield and hydrogenated to deprotect the azide at the 
N-terminus. Compounds 133 and 134 were then coupled together with EDC·HCl/K-Oxyma to 
give compound 135 in 55 % yield. This was treated with HCl in dioxane to give compound 136 









4.4. Results and Discussion 
4.4.1. CD and NMR Studies with the Fully Protected Compounds 
 
The CD spectra of compounds 108 (Ser), 120 (Asp), 129 (Abu) and 135 (Lys) in MeCN show 
that all these molecules adopt a 310 conformation (Figure 4.3), shown by the major peak at 
~205 nm and a minor peak at ~225 nm. 77 Also, each compound exhibits the expected screw 
sense control from their various stereoinducers. 79, 91 In methanol the CD spectra of these 
molecules exhibit some interesting features. Compounds 120 and 129 clearly still adopt a 310 
conformation in MeOH, whilst compounds 108 and 135 appear to take on more α-helical 
character with the primary and secondary peaks becoming more equal in magnitude. This can 
be attributed to the Ser(OTBDPS) and Lys(NHBoc) being much bulkier amino acids than Abu 
or Asp(OMe), meaning the more hydrophilic and looser α-helix is more conformationally 






For compounds 120 (Figure 4.4.b) and 129 (Figure 4.4.a) concentration dependence 1H NMR 
studies were carried out. For both compounds, only two NH peaks move as the concentration 
is increased. This is further evidence that these compounds adopt a 310 conformation, and 


































Figure 4.3: The collated CD spectra for compounds 108 (Ser), 120 (Asp), 129 (Abu) and 


























































Figure 4.4: Concentration dependence 1H NMR titrations in CDCl3 focusing on the NH 





4.4.2. Water Solubility and CD Studies of the Aib Hydrophilic Oligomers 
 
To assess the solubility and to determine the conformation that these hydrophilic Aib 
foldamers adopt in aqueous solution, a series of CD spectra were recorded for each of the 




Compound 129 was synthesised with the intention of it acting as a control – against which 
the other hydrophilic Aib oligomers could be compared against. Unsurprisingly, compound 
129 was not soluble in 100% water. However, it would still readily dissolve in a 3:1 solution of 
water to methanol. The CD spectrum for compound 129 in 100% methanol gives the 
stereotypical trace for a 310 helix (Figure 4.5). As the percentage of water is increased the 
shape of the curve begins to change and take on more alpha helical character with the major 
peak at ~205nm decreasing in magnitude to become slightly smaller in size compared to the 
secondary peak at ~227nm. It is important to note that in 75% water/25% MeOH compound 
129 clearly adopts an alpha helix. This is due to the alpha helix being more conformationally 
favourable than the 310 helix in strongly polar solvents as it has more hydrogen bond donors 
































75% Water 25% MeOH
50% Water 50% MeOH
25% Water 75% MeOH
100% MeOH
Figure 4.5: The collated CD spectra for compound 129 recorded in differing solvent 





4.4.2.2. Cbz((L)Ser (OH)Aib2)3(L)Ser (OH)OtBu 
 
Compound 109 exhibits the same change in conformational preference as the percentage of 
water is increased (Figure 4.6.a). In 100% methanol a 310 helix is the preferred conformation 
(Figure 4.6.b), for the interstitial solutions all three spectra (25% MeOH and 75% H2O/50% 
MeOH and 50% H2O/75% MeOH and 25% H2O) exhibit alpha-helical characteristics. Yet none 
of these are true alpha helices, as the primary peak at ~205nm is still larger than the secondary 
peak. However, for the 100% water spectrum, a true alpha helix is adopted. Unlike for 
compound 129, the presence of the hydrophilic Ser residues stabilises the 310 helix in more 
polar solutions. Although, this effect is not strong enough to stabilise a 310 conformation as 



































75% Water 25% MeOH
50% Water 50% MeOH
































50% Water 50% MeOH
100% MeOH
Figure 4.6: a) The collated CD spectra for compound 109 recorded in differing solvent 





4.4.2.3. N3(Aib2(L)Lys (NH2))2OMe 
 
Compound 137 follows the same trend as the Ser containing molecule 109, where in 100% 
MeOH a 310 helix is preferred. As the percentage of water is increased more alpha helical 
characteristics become evident, before an alpha helix is preferentially adopted in 100% water 

































75% Water 25% MeOH
50% Water 50% MeOH
































50% Water 50% MeOH
100% MeOH
Figure 4.7: a) The collated CD spectra for compound 137 recorded in differing solvent 





4.4.2.4. N3(Aib2(L)Lys (NH3Cl))2OMe 
 
When protonated to give the double lysine hydrochloride salt (compound 136) the CD 
spectrum recorded in 100% MeOH gave a 310 helical conformation, with some alpha helical 
character still apparent (Figure 4.8.b). As the percentage of water is increased (Figure 4.8.a) 
the alpha helical character increases, though an alpha helix is still not the preferred 
conformation even in 100% water. This trend is the result of the polar side chain being further 
away from the helix itself. As though the charged side chain acts to stabilise the 310 
conformation in aqueous solution, it is simply too far away from the helix to make its 

































75% Water 25% MeOH
50% Water 50% MeOH






























50% Water 50% MeOH
100% MeOH
Figure 4.8: a) The collated CD spectra for compound 136 recorded in differing solvent 





4.4.2.5. Cbz((L)Asp (CO2H)Aib2)OtBu 
 
In methanol the CD spectrum for compound 122 shows that it adopts a 310 conformation 
(Figure 4.9.b). When run in 25% Water/75% MeOH the CD spectrum of compound 122 still 
has strong 310 character, though as the secondary peak (at ~230nm) has increased in 
magnitude there is also increased preference for an alpha helical conformation (Figure 4.9.a). 
The spectra for the remaining solvent compositions (50% Water and 50% MeOH/75% Water 
and 25% MeOH/100% Water) all exhibit the same shape; the two peaks are of equal 
magnitude meaning that there is no overall preference for an alpha helix or a 310 helix. It is 
important to note, that the more polar Asp residue must act to stabilise the 310 conformation 



























75% Water 25% MeOH
50% Water 50% MeOH






























50% Water 50% MeOH
100% MeOH
Figure 4.9: a) The collated CD spectra for compound 122 recorded in differing solvent 





4.4.2.6. Cbz((L)Asp (CO2Na)Aib2)3OtBu 
 
When deprotonated as a triple sodium aspartate salt, compound 121 adopts a 310 helical 
conformation in all the solvents tested (Figures 4.10.a and b). By making the side chain even 
more polar the trend seen for the other hydrophilic Aib foldamers is brought to its natural 


































75% Water 25% MeOH
50% Water 50% MeOH





























50% Water 50% MeOH
100% MeOH
Figure 4.10: a) The collated CD spectra for compound 121 recorded in differing 






4.4.2.7. Synopsis of Section 4.4.2. 
 
The trends observed in the CD spectra presented in section 4.4.2. can begin to be explained 
by considering aggregation. When an alpha helical conformation is adopted, the polar or 
charged face will be larger compared against a 310 helix (Figure 4.11). This means that it will 
be easier to form aggregates from hydrophilic Aib oligomers when the foldamers adopt an 
alpha helical conformation, rather than a 310 conformation. If the side chains are strongly 
polar or are charged (and bring that charge close to the helix) the 310 helix is still favourable, 
as the oligomers do not have to ‘spread’ the polar or charged side chains as the hydrophobic 
face of the 310 conformation will have a much higher charge density. Some initial NMR studies 
were performed to try and establish whether any aggregation was occurring and whether this 












Alpha Helix 310 Helix 
Polar face is larger 
Figure 4.11: Helical-wheel representations of the alpha and the 310 helical conformations 





4.5. Conclusions and Further Work 
 
A series of compounds were synthesised that can be described as hydrophilic Aib oligomers. 
When these compounds were fully protected they readily adopted a 310 conformation in non-
hydrogen bonding solvents (MeCN and CDCl3), though in hydrogen bonding solvents the 
bulkier amino acid (Ser(OTBDPS) and Lys(Boc)) containing oligomers favoured an alpha helical 
conformation.  
 
When deprotected, all the hydrophilic Aib oligomers are soluble in water. However only 
compound 121 retains its preference for a 310 conformation in 100% water, while the other 
compounds all favour an alpha helical conformation or show both 310 and alpha helical 
character. That these spectra were obtainable and that an ordered conformation is favoured 
suggests that aggregation must occur. Although, at this time the nature of this aggregation 
has not been ascertained. Further CD studies (such as studying the relationship between pH 
and conformation), computational analysis and the in-membrane activity of these 
compounds would all be interesting avenues for future research. 
  
The major challenge of this project, was the long-winded and at times inefficient synthesis of 
these molecules. Current work within the Clayden group is now focused upon using a solid-
phase peptide synthesiser to expand the family of molecules further. So far this has proved 
to be a much faster and more efficient process, with a molecule being ready in a matter of 
days rather than weeks. This means that a larger library of compounds can be built up with 





5. Exploiting a New Foldamer Scaffold – The αγ AibAic Foldamers 
5.1. Introduction 
 
Apart from Aib oligomers, there are few examples of achiral oligomers that adopt a stable 
helical conformation in solution. Some examples of these (Figure 5.1) include mixed ΔPheAib 
oligomers, 96 polyphenylenes 151 and polyisocyanates. 152 However, none of these foldamers 
would provide a superior alternative to Aib oligomers, when creating conformational 









However, a promising recent example of a stable achiral helix was reported by Gopi and co-
workers. They synthesised several foldamers constructed from a series of alternating Aib and 
Aic residues, where Aic is a γ-amino acid (Figure 5.2.a). These oligomers have been shown to 
adopt a 12-helix (which is analogous to a 310 helix) when capped with an amide at the C-
terminus (Figure 5.2.b), 153 though a 12/10 alternating helix (Figure 5.2.c) is favoured when 











Figure 5.1: Examples of achiral oligomers that form stable achiral helices in solution  





The 12-helix has a (i → i + 3) hydrogen bonding pattern, where each intramolecular hydrogen 
bond forms a 12-membered ring. The 12/10 alternating helix is a novel conformation, where 
there are two alternating and opposing series of hydrogen bonds, one with an (i → i + 3) 
hydrogen bonding pattern and the other with an (i → i – 1) hydrogen bonding pattern. 
Computational modelling has shown that the (i → i – 1) hydrogen bonds are weaker than the 
(i → i + 3) ones. 
 
AibAic oligomers have some innate advantages over pure Aib oligomers. They are easier to 
synthesise, as Aic is a less hindered amino acid than Aib, and there are potential NMR 
reporters within the molecule. Also, longer foldamers can be obtained with less synthetic 
effort and with fewer monomers. Therefore, this class of oligomers have a lot of potential as 
a new foldamer scaffold to develop further conformational communication systems. 
 
Some initial work has been done within the Clayden group in this regard, with compound 138 
(Figure 5.3.a) having been synthesised. The 1H NMR of this compound (Figure 5.3.b) shows 
that that all the methyl signals were anisochronous, showing that there is transfer of 
information from one end of the oligomer to the other. This is a promising starting point for 
exploring the behaviour of a wider family of these compounds. 155 
  
Figure 5.3: a) The AibAic foldamer 138; b) Section of the 1H NMR of compound 138 







5.2. Project Outline 
 
Aib foldamers have taken the Clayden group far, but to push the envelope even further and  
develop innovative conformational communication systems, new foldamer scaffolds need to 
be explored.  
 
To investigate the potential of the AibAic foldamers as a new scaffold for conformational 
communication, a series of oligomers were synthesised with chiral α-amino acids at the C-
terminus (Figure 5.4). This family of molecules were studied by NMR and CD to determine the 
conformation they adopt in solution, and to ascertain whether they are a suitable alternative 














5.3. Synthesis of AibAic Foldamers 
5.3.1. Synthesis of Aic  
 
Unlike with Aib, the γ-amino acid Aic is not commercially available, meaning it must be 
synthesised before use. This synthesis has been previously reported 153 and is outlined below 
in Scheme 5.1.  
 
The starting material is BocAibOH, which was converted to the Weinreb amide 139 in 80% 
yield. This was reduced to the aldehyde 140 in 85% yield, which was then coupled with 
phosphorene 141 by a Wittig reaction to give the alkene 142 in 80% yield. The alkene was 
then hydrogenated to the give Aic, compound 143, in 95% yield. Though a relatively 





The Boc group at the N-terminus of the Aic monomer was deprotected by treating with HCl 
in dioxane to give the HCl salt of compound 144 in 95% yield (Scheme 5.2). This and BocAibOH 
were coupled together with EDC·HCl/HOBt to give compound 145 in 80% yield. Treating with 
HCl in dioxane deprotected the N-terminal Boc group to give the HCl salt of compound 146, 
whilst treating with an aqueous solution of NaOH deprotects the C-terminal ethyl ester which 
gave the carboxylic acid 147 in 90% yield. These two compounds were coupled together with 
EDC·HCl/HOBt to give compound 148 in 70% yield. The ethyl ester at the C-terminus of this 
compound was deprotected by treating compound 148 with an aqueous solution of NaOH, 
giving the carboxylic acid 149 in 92% yield.  













5.3.2. Synthesis of Boc-[Aib-Aic]2-(L)Xaa-R Oligomers 
 
The (L)AlaOEt controlled AibAic oligomer, compound 150, was synthesised by an 
EDC·HCl/HOBt coupling between commercially available H2N(L)AlaOEt and the carboxylic acid 
149 (Scheme 5.3). This was deprotected at the C-terminus by hydrolysis with NaOH(aq) to give 
the carboxylic acid 151 in 90% yield. This was then converted to the N-terminal tBu amide, 
compound 152, by an EDC·HCl/HOBt coupling with tert-butyl amine. The Boc group at the N-
terminus of compound 150 was deprotected with HCl in dioxane to give the HCl salt of 









Subsequently a wide range of C-terminally controlled AibAic oligomers were synthesised 
(Table 5.1). A selection of tertiary and quaternary amino acids were chosen, that have all 
exhibited above par control of Aib oligomers. 79 All of the compounds were obtained from an 
EDC·HCl/HOBt coupling between the carboxylic acid 149 and the corresponding amine in high 
yield. The exception to this being the αMv controlled oligomer 157, whose yield was lower 








Scheme 5.3: Scheme outlining synthesis of the various (L)Ala controlled AibAic oligomers. 




















5.4. Results and Discussion 
5.4.1. NMR and CD Studies of Boc[AibAic]2XaaR 
5.4.1.1. Boc[AibAic]2(L)Ser(OtBu)NHtBu 
 
The DMSO-d6 titration of compound 154 (Figure 5.5.b) has two NH signals that move by a 
large amount (NH 1: Δδ = 0.88 ppm and NH 2: Δδ = 0.40) with the rest of the signals only 
moving a small amount (Δδ between 0.05 – 0.15 ppm). This suggests a 12-helical 



















The NOE correlations for compound 154 (Figure 5.6.a) mirror those previously reported for 
AibAic oligomers that adopt a 12-helix. 153 This further supports the result seen with the 
DMSO-d6 titration. The CD spectra for compound 154 in MeCN and MeOH (Figure 5.6.b) 




















Vol. of DMSO-d6 added / µL
NH 1 NH 2 NH 3 NH 4 NH 5 NH 6
a) 
b) 
Figure 5.5: a) Proposed hydrogen bonding pattern for compound 154; b) DMSO-d6 





helix is analogous to the 310 helix for αγ oligomers. Additionally, the (L)-amino acid is seen to 







The 1H NMR spectrum of compound 154 shows some interesting features, namely all the 
methyl signals (Figure 5.7) for the Aic and Aib residues which are diastereotopic, this indicates 
that the screw sense preference of the Ser residue at the C-terminus is felt all the way to the 
N-terminus. It is clear from the Δδ values that the signal decays as the distance from the chiral 






























Figure 5.6: a) The main NOE correlations observed in the NOESY spectrum of compound 
154, recorded in CD2Cl2; b) The CD spectra for compound 154 in MeCN and MeOH. 
a) 
b) 
Figure 5.7: A section of the 1H NMR spectrum of compound 154 in CD2Cl2 with the CH3 signals 
and the associated Δδ values labelled.  
OtBu 
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Boc-Aib [1]-Aic [1]-Aib [2]- Aic [2]-Ser(OtBu)NHtBu 
154 in MeC  





Compound 154 was cooled down to -90 0C with a 1H NMR spectrum recorded in 10 oC 
increments (Figure 5.8). The intention of this was to reach slow exchange, and hence calculate 
a h.e. for each residue in the oligomer. This did not prove to be possible, as the temperature 
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The DMSO-d6 titration of compound 155 (Figure 5.9.b) has only one NH peak that moves a 
large amount (NH 1: Δδ = 1.01 ppm), with the rest of the signals only moving a small amount 
(Δδ between 0.05 – 0.17 ppm). A similar phenomenon has been observed previously with Aib 
oligomers that adopt 310 helices, where a strong helical conformation is adopted which shields 
the second NH somewhat. 80, 120 Making this an inconclusive result, as although NH 2 does not 




















However, the CD spectra for compound 155 in MeCN and MeOH (Figure 5.10.a) exhibit the 
same shape and screw sense preference seen for compound 154, indicating that 12-helical 
conformation is indeed adopted. Also, the NOE correlations for compound 155 (Figure 5.10.b) 
mirror those previously reported for AibAic oligomers that adopt a 12-helix 153 and those seen 





















Volume of DMSO-d6 Added / µL
NH 1 NH 2 NH 3 NH 4 NH 5 NH 6
Figure 5.9: a) The proposed hydrogen bonding pattern for compound 155; b) DMSO-














The methyl signals for the Aib and Aic residues are again both diastereotopic, as can be seen 
in the 1H (Figure 5.11.a) and 13C (Figure 5.11.b) NMR spectra for compound 155. The signals 
for the Aic residues show the same trend as seen in compound 154, with the signal decaying 
in strength as the distance from the chiral residue increases. However, though the Aib signals 
are clearly diastereotopic they overlap with the Boc tBu signals in the 1H spectrum and could 



































Figure 5.10: a) The CD spectra for compound 155 in MeCN and MeOH; b) NOE 
correlations observed in the NOESY spectrum for compound 155 in CDCl3 
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Δδ = 69 
ppb 
Aic 1 
Δδ = 26 
ppb 
Boc-Aib [1]-Aic [1]-Aib [2]- Aic [2]-ValNHtBu 
Figure 5.11: a) Section of the 1H NMR spectrum in CDCl3  for compound 155 highlighting 
the CH3’s; b) section of the 13C NMR for compound 155 highlighting the CH3’s 
a) b) 
1 5 in MeCN 





VT 1H (Figure 5.12.a) and 13C (Figure 5.12.b) NMR spectra were recorded for compound 155 - 
again slow exchange was not reached and line broadening rendered the spectra increasingly 
unclear, as the temperature decreased. 
 
 



























The DMSO-d6 titration of compound 157 (Figure 5.13.b) shows that only one of the amide NH 
peaks moves a large amount (Δδ of NH 1 = 0.91), with the other signals only moving a small 
amount (Δδ = 0.20 – 0.05 ppm). Again, this DMSO-d6 titration is an inconclusive result, as here 
a strong helical conformation may serve to ‘shield’ NH 2 from the increasing volume of DMSO-









The CD spectra for compound 157 (Figure 5.14.a) gave the expected shape for a 12-helix in 
both MeOH and MeCN, and again shows a right-handed screw sense preference. It is worth 
noting that the minor peak at  ~230 nm is now positive. This is regularly seen in Aib oligomers, 
where the secondary band will mirror the sign of the major peak for tertiary amino acids but  
will be the opposite for a quaternary amino acid. 113 The NOE correlations observed in the 























Vol. of DMSO-d6 / µL
NH 1 NH 2 NH 3 NH 4 NH 5 NH 6
a) 
b) 
Figure 5.13: a) The proposed 12-helical hydrogen bonding pattern of compound 157; b) 





















































Again, all the methyl signals in the 1H NMR spectrum of compound 157 were diastereotopic 
– to a larger degree than previously seen (Figure 5.15). 1H VT NMR was carried out on 
compound 157, however as would be expected it does not reach slow exchange, and for the 
sake of brevity these spectra were not included in this section (See appendix Section 7.8). 
 
  
Figure 5.15: A portion of the 1H NMR spectrum for compound 157 in CDCl3 showing the 
diastereotopicity of the methyl signals. 
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Boc-Aib [1]-Aic [1]-Aib [2]-Aic [2]-αMv-NHtBu 
157 in eC  
157 in e  
a) 
b) 
Figure 5.14: a) CD spectra for compound 157 in MeOH and MeCN; b) The NOE 







The CD spectra for compound 156 (Figure 5.16) shares the diagnostic 12-helical shape as seen 
for compounds 154 – 155 and 157, though here the sign of the peak is positive. Whether this 
is due to PheNHtBu inducing a left-handed screw sense or the Phe residue reporting its local 
chirality rather than the overall screw sense is currently unknown. 76  
 
 
In the 1H NMR spectrum of compound 156, all the methyl signals for the Aib and Aic residues 
are diastereotopic (Figure 5.17). Again, this shows that the signal from the chiral residue 
propagates down the whole oligomer. 
 
  
Figure 5.17: A portion of the 1H NMR spectrum for compound 156 in CDCl3 showing the 
diastereotopicity of the methyl signals. 
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5.4.1.5. (L)-Ala Controlled AibAic Oligomers 
 
The CD spectrum for the (L)AlaNHtBu controlled compound 152 (Figure 5.18.a) shows the 
same shape characteristic of a 12-helix and a right handed screw sense preference. However, 
when the C-terminal protecting group is changed to an ethyl ester (compound 150) the 
conformation clearly changes along with a switch to a left handed screw sense. This is likely a 
12/10 alternating helix, which consists of two opposing arrays of 12 helical (i → i + 3) and 10 
helical (i → i – 1) hydrogen bonds (Figure 5.18.b). 154 When the N-terminus of this compound 
is deprotected to an amine (compound 153), this conformation is still adopted.However, 
when the C-terminus is deprotected to give a carboxylic acid (compound 151), this 



















The DMSO-d6 1H NMR titration of compound 150 (Figure 5.19.a) shows that only one NH 
moves a large amount (NH 1, Δδ = 0.76 ppm), with the rest of the NH’s only moving a small 
amount (Δδ = 0.20 – 0.00 ppm), which supports this molecule adopting a 12-10 alternating 
helical conformation. The NOE correlations seen in the NOESY spectrum of 150 also support 



































152 – Boc[AibAic]2(L)AlaNHtBu 
150 – Boc[AibAic]2(L)AlaOEt 
153 – H2N[AibAic]2(L)AlaOEt 
151 – Boc[AibAic]2(L)AlaOH 
Figure 5.18: a) The collated CD spectra for various Ala controlled AibAic oligomer in 
























The 1H NMR spectrum of compound 150 shows diastereotopic splitting for all the methyl 
groups in the molecule (Figure 5.20). The splitting observed for compound 150 is significantly 
higher than that seen in compound 152 (Figure 5.21), suggesting that for Ala a 12/10 






























Volume of DMSO-d6 Added / µL
NH 1 NH 2 NH 3 NH 4 NH 5
a) 
b) 
Figure 5.19: a) DMSO-d6 1H NMR titration of compound 150 in CDCl3; b) NOE correlations 
seen in the NOESY spectrum of compound 150. 
Figure 5.20: A portion of the 1H NMR spectrum for compound 150 in CDCl3 showing the 
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Figure 5.21: A portion of the 1H NMR spectrum for 152 in CDCl3 showing the 
diastereotopicity of the methyl signals. 













5.4.2. Initial Attempts at Quantifying Helical Excess 
 
Any splitting observed in the methyl signals of the 1H NMR spectra of the AibAic oligomers is 
diagnostic of conformational communication. Although this cannot be directly quantified into 
an actual helical excess, as slow exchange is not reached. The splitting can be compared 
between controllers, and the per residue decay in the signal that is observed can then be 
quantified. Compound 157 shows the greatest splitting of both Aib and Aic methyl groups 
closest to the stereo inducer (Aib [2] and Aic [2]). This indicates that αMvNHtBu is the most 
powerful screw-sense controllers of the chiral residues studied. Therefore, the Δδ values 
observed for Aic [2] and Aib [2] will be used as the benchmarks to compare the Δδ values 
observed in other oligomers. Consequently, the efficacy of the different stereo inducers can 
be compared and assessed; these values are collated in Table 5.2. 
 
 
General Structure: Boc-Aib [1]-Aic [1]-Aib [2]-Aic [2]-XaaR 
Compound 157 155 154 156 150 
(L)XaaR αMvNHtBu ValNHtBu Ser(OtBu)NHtBu PheNHtBu AlaOEt 
Aic 2 Δδ / ppm 70.1 13.6 4.7 18.5 26 
Comparison to Aic 
2 of 157 / % 
100 19 7 26 37 
Aic 1 Δδ / ppm 56.9 8.4 0 4 7.3 
Comparison to Aic 
2 of 157 / % 
81 12 / 6 10 
Decay in signal per 
Aic Residue / % 
19 7 7 21 27 
Aib 2 Δδ / ppm 28.1 Overlap 0 15.1 11 
Comparison to Aib 
2 of 157 / % 
100 N/A N/A 54 39 
Aib 1 Δδ / ppm 4 Overlap 0 8.3 ~8.5 
Comparison to Aib 
2 of 157 / %  
14 N/A N/A 30 30 
Decay in signal per 
Aib Residue / % 
86 N/A N/A 24 9 
 
The largest splitting for Aib 2 and Aic 2 are observed for compound 157. However, there is a 
decay in the strength of the signals in the Aic residues of 19%, and a much larger decay of 86% 
for the Aib signals. Compounds 154, 155 and 156 all exhibit much lower levels of control when 
compared against compound 157, with compound 154 being very poor with splitting only 
being observed in Aic [2] for this molecule. Though compound 155 is a much poorer 
controller, the decay in signal observed for the Aic residues is much lower than for compound 
157. Unfortunately, the Aib methyl signals for 155 overlapped with other signals, meaning 
Table 5.2: Table listing the splitting’s observed for the Me groups of the Aib and Aic 





though these signals were diastereotopic, accurate Δδ values were not obtained. For 
compound 156, the Aic signal decay rate is comparable to that of 157, though the Aib signal 
decay rate is much lower at only 24%.  
 
Although compound 150 shows poorer control than compound 157, it seems to be superior 
at facilitating conformational communication. The decay rate per Aic residue for compound 
150 is comparable at 27%, though the decay rate per Aib residue is significantly lower at only 
9%. This suggests that the 12-10 alternating helix is superior when compared to the 12-helix 
for conformational communication, despite previous literature evidence that the 12-10 helix 






5.5. Conclusions and Future Work 
 
A family of AibAic oligomers were synthesised with one chiral residue at the C-terminus, to 
assess the suitability of this new αγ foldamer as a scaffold for building structures that can be 
used for conformational communication. When the C-terminus was capped with an amide, a 
12-helical conformation was observed, and if an ester was used a 12/10 alternating helix was 
seen instead.  
 
All the chirally controlled AibAic oligomers displayed transfer of stereochemical information 
from the C-terminus down the oligomer to the N-terminus (Figure 5.22). Although this could 
not be quantified into a helical excess, the different compounds could be compared based 
upon the diastereotopic splitting seen in the methyl groups. The strongest inducer was 
αMvNHtBu (compound 157), though this signal also decayed at the fastest rate. The lowest 
decay in signal was seen for compound 150 (AlaOEt controlled), suggesting that the 12/10 





There is a breadth of further research that can be undertaken in this area. Initially, effort 
should concentrate upon quantifying h.e., exploring more amino acid controllers and 
determining which conformation (either 12-helical or 12/10 alternating helical) is superior for 
facilitating conformational communication. Future work can expand this area even further, 
by exploring the use of chiral γ-amino acids as stereo-controllers or developing dynamic 
screw-sense controllers.  






6.1. General Experimental Details 
 
All non-aqueous reactions were performed utilising standard anhydrous techniques, under 
an atmosphere of N2 and in flame dried glassware. Reactions run at 0 oC were cooled in an ice 
bath and reactions performed at -78 oC were cooled in an acetone/dry ice bath.  
 
Unless specified all reagents were purchased from commercially available sources and used 
with no further purification. Air/moisture sensitive solutions and reagents were added to 
reaction vessels by syringe or cannula. Unless stated, all products were concentrated first on 
a rotary evaporator, followed by drying on a high vacuum system to ensure full removal of 
solvent residues.  
 
Anhydrous CH2Cl2 was obtained by distillation over CaH2  or from a solvent purification system 
and anhydrous THF was obtained by distillation over sodium with a benzophenone indicator 
or from a solvent purification system. All other anhydrous solvents were obtained from 
commercial sources and where applicable were stored over molecular sieves. Et3N was stored 
over NaOH (s) and DIPEA was stored under an atmosphere of N2 over molecular sieves.  
 
Any water used experimentally was deionised. KHSO4 (aq) refers to a 5 % aq. solution of KHSO4. 
NaHCO3 (aq) refers to a saturated aq. solution of NaHCO3. Brine refers to a saturated aq. 
solution of sodium chloride. LiCl (aq) refers to a 5 % aq. solution of LiCl. 
 
Column chromatography was either performed on silica gel (Merck 60H, 40-60 mm, 230-300 
mesh) or by using a Biotage Isolera 4 automated purification system using commercially 
available prepacked silica columns. Analytical thin layer chromatography was performed on 
aluminium backed silica (0.2 mm, UV254) and polyester backed silica (0.2 mm, UV254). TLC 
plates were visualised using a UV lamp (λmax at 254 or 365 nm) or using vanillin, 
phosphomolybdic acid or ninhydrin dips.  
 
Compounds are either referred to by name (generated by CambridgeSoft ChemDraw 





6.2. Analytical Techniques and Instrumentation 
 
1H and 13C NMR spectra were obtained using: a 400 MHz Bruker Avance spectrometer, 500 
MHz Bruker Avance spectrometer, a 400 MHz Varian MR spectrometer, a 400 MHz Bruker 
Nano spectrometer or 500 MHz Bruker Avance III HD Cryo spectrometer. VT NMR spectra 
were obtained on a 300 MHz JEOL ECS spectrometer. 
 
Where applicable deuterated NMR solvents were dried over molecular sieves. Chemical shifts 
(δ) are reported in parts per million (ppm) and coupling constants (J) are reported to the 
nearest 0.5 Hz. Multiplicities are denoted at s – singlet, d – doublet, t – triplet, q – quartet, p 
– pentet, spt – septet, m – multiplet and br – broad or an applicable combination of these 
terms, unless specified all reported couplings are 3JH-H. 1H NMR spectra were referenced to 
the residual deuterated solvent peak (CDCl3 – 7.27 Hz, CD3OD – 3.31, DMSO-d6 – 2.50, CD3CN 
– 1.94). 13C spectra were referenced to the carbon resonance of the solvent (CDCl3 – 77.00, 
CD3OD – 49.05, DMSO-d6 – 39.52, CD3CN – 1.32). Exchangeable protons in CD3OD 1H NMR 
spectra are only reported where observed. NMR assignments were made from chemical shift, 
coupling constants, ancillary spectra (DEPT, COSY, HSQC, HMBC, TOCSY, NOESY) and 
comparison with data from related compounds. 
 
IR spectra were recorded on a Thermo Scientific iD5 ATR and a Perkin Elmer Spectrum One 
FT-IR Spectrometer with only key peaks being reported and assigned. 
 
Mass Spectrometry was performed by: 
University of Manchester staff on either a Waters Platform II (ESI) spectrometer or a Thermo 
Finnigan MAT95XP (HRMS) spectrometer. 
University of Bristol staff on a selection of spectrometers: Bruker MicrOTOF II (ESI HRMS), 
Bruker Apex IV (ESI HRMS), Bruker UltrafleXtreme (MALDI HRMS), Thermo Scientific Orbitrap 
Elite (ESI HRMS) and or a Waters Synapt G2S (ESI HRMS). 
 
[α]D values were recorded at 20 oC on an AA-100 polarimeter in a cell of 0.25 dm path length 
(l). Values were calculated according to the following formula: [α]D = 100α/lc with units of 
ocm2g-1. 
 







CD Spectra were recorded on at 20oC on a JACSO J-815 spectropolarimeter using a 1 mm cell 
with the following solvents and concentrations as listed below: 
• Compound 40 in MeOH at 0.50 mg mL-1 (Figure 2.9) 
• Compound 45 in MeOH at 0.50 mg mL-1 (Figure 2.9) 
• Compound 56 in MeOH at 0.25 mg mL-1 (Figure 2.10) 
• Compound 62 in MeOH at 0.25 mg mL-1 (Figure 2.10) 
• Compound 67 in MeCN at 0.25 mg mL-1 (Figure 3.3) 
• Compound 68 in MeCN at 0.50 mg mL-1 (Figure 3.3) 
• Compound 78 in MeCN at 0.25 mg mL-1 (Figure 3.8) 
• Compound 79 in MeCN at 0.25 mg mL-1 (Figure 3.8) 
• Compound 80 in MeCN at 0.50 mg mL-1 (Figure 3.8) 
• Compound 81 in MeCN at 0.50 mg mL-1 (Figure 3.8) 
• Compound 108 in MeCN and MeOH both at 0.125 mg mL-1 (Figure 4.3) 
• Compound 120 in MeCN and MeOH both at 0.125 mg mL-1 (Figure 4.3) 
• Compound 129 in MeCN and MeOH both at 0.25 mg mL-1 (Figure 4.3) 
• Compound 135 in MeCN and MeOH both at 0.25 mg mL-1 (Figure 4.3) 
• Compound 129 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O and 25% 
MeOH/75% H2O all at 0.25 mg mL-1 (Figure 4.5) 
• Compound 109 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O, 25% 
MeOH/75% H2O and 100% H2O all at 0.125 mg mL-1 (Figure 4.6) 
• Compound 137 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O, 25% 
MeOH/75% H2O and 100% H2O all at 0.50 mg mL-1 (Figure 4.7) 
• Compound 136 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O, 25% 
MeOH/75% H2O and 100% H2O all at 0.50 mg mL-1 (Figure 4.8) 
• Compound 122 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O, 25% 
MeOH/75% H2O and 100% H2O all at 0.25 mg mL-1 (Figure 4.9) 
• Compound 121 in 100% MeOH, 75% MeOH/25% H2O, 50% MeOH/50% H2O, 25% 
MeOH/75% H2O and 100% H2O all at 0.25 mg mL-1 (Figure 4.10) 
• Compound 154 in MeOH and MeCN both at 0.50 mg mL-1 (Figure 5.6) 
• Compound 155 in MeOH and MeCN both at 0.50 mg mL-1 (Figure 5.10) 
• Compound 157 in MeOH and MeCN both at 0.25 mg mL-1 (Figure 5.14) 
• Compound 156 in MeOH and MeCN both at 0.25 mg mL-1 (Figure 5.16) 
• Compound 152 in MeCN at 0.5 mg mL-1 (Figure 5.18) 
• Compound 150 in MeCN at 0.5 mg mL-1 (Figure 5.18) 
• Compound 153 in MeCN at 0.5 mg mL-1 (Figure 5.18) 






6.3. General Procedures 
 




Following a previously reported procedure: 75, 80  
The protected amine (1 eq.) was dissolved in EtOH (3 mL/mmol) and to this solution, Pd/C 
(10% loading, 15% g/g) was added under an atmosphere of N2. An atmosphere of H2 was 
introduced by a vacuum/H2 purge cycle (3 x) and the resulting solution was stirred at RT for 
16 h. The mixture was then filtered through a pad of Celite ® and charcoal. The filter was then 
washed repeatedly with EtOAc and the combined washings were concentrated to give the 
free amine H2N-Aibn-R. 
 
General Procedure B 
  
Following a previously reported procedure: 75, 80  
H2N-Aibn-R (1 eq.) and Et3N (1.5 eq.) were dissolved in CH2Cl2 (2 mL/mmol) and cooled to 0 
oC. To this a solution of freshly distilled N3-Aib-Cl (1.1 eq.) in CH2Cl2 (0.33 mL/mmol) was added 
and the reaction was left to warm to RT over 24 h. The reaction mixture was concentrated 
and then diluted with EtOAc (4 mL/mmol). The organic phase was washed with KHSO4 (aq) (2 x 
1.3 mL/mmol), NaHCO3 (aq) (2 x 1.3 mL/mmol) and Brine (1.3 mL/mmol). The organic phase 














The protected amine/carboxylic acid was dissolved in CH2Cl2 (20 mL/mmol) and trifluoroacetic 
acid (7 mL/mmol). The resulting solution was stirred for 3 h, after which time the reaction 
mixture was concentrated. To the resulting residue Et2O was added and the resulting 
suspension was concentrated to ensure full removal of the trifluoroacetic acid and to give the 
product. 
 
General Procedure D 
 
The carboxylic acid was dissolved in DMF (7 mL/mmol), to this K-Oxyma (1.1 eq.) was added 
and the resulting solution was cooled to 0 oC. Once at temperature, EDC∙HCl (1.3 eq.) and 
DIPEA (1.3 eq.) were added and the solution was warmed to RT. Once a homogeneous 
solution had formed the amine (molar equivalents dependant on reactants) and DIPEA (3 eq. 
if free amine, 4 eq. if ammonium salt) were added and the resulting solution was left to stir 
for 3 d. After this time the reaction mixture was diluted with an excess of MTBE and washed 
with water. The aqueous layer was washed once with MTBE. The organic phases were 
combined and sequentially washed with KHSO4 (aq), NaHCO3 (aq), LiCl (aq) and brine. The organic 
phase was dried over Na2SO4, filtered and concentrated and the crude product was then 











General Procedure E 
 
 
The carboxylic acid was dissolved in DMF (5 mL/mmol), to this HOBt (1.1 eq.) was added and 
the resulting solution was cooled to 0 oC. Once at temperature, EDC∙HCl (1.3 eq.) and DIPEA 
(1.3 eq.) were added and the solution was warmed to RT. Once a homogeneous solution had 
formed the amine (2 eq.) and DIPEA (3 eq. if free amine, 4 eq. if ammonium salt) were added 
and the resulting solution was left to stir for 3 d. After this time the reaction was diluted with 
an excess of MTBE and washed with water. The aqueous layer was washed once with MTBE. 
The organic phases were combined and sequentially washed with KHSO4 (aq), NaHCO3 (aq), LiCl 
(aq) and brine. The organic phase was dried over Na2SO4, filtered and concentrated. The crude 








6.4. Experimental Details 
6.4.1. Experimental Details for Section 2 
 
Synthesis of 18 – N3-Aib-Cl 
Previously synthesised and published 75 
Synthesis of N3AibOH 
 
Br-Aib-OH (20.5 g, 123 mmol) was dissolved in DMF (65 mL), to this NaN3 (12.0 g, 184 mmol) 
was added and the resulting solution was left to stir at RT for 3 d. After this time, the reaction 
mixture was diluted with H2O (40 mL) and then acidified to pH = 2 with 1 M HCl (aq). This was 
washed twice with MTBE, the organic washes were combined and washed three times with 1 
M HCl (aq). The organic phase was dried (MgSO4), filtered and concentrated to give N3AibOH 
(12.8 g, 99 mmol, 81 %) as a colourless oil which was used with no further purification. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 1.52 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 172.4 (CO), 58.2 (αC), 25.3 (CH3) 
 All spectra consistent with previously reported data. 75 
Synthesis of N3AibCl 
 
N3-Aib-OH (10.1 g, 78.0 mmol) was dissolved in CH2Cl2 (35 mL). Thionyl chloride (11.3 mL, 156 
mmol) was added and the resulting mixture was heated to reflux for 3 h. The reaction mixture 
was concentrated, and the resulting mixture was distilled under vacuum to give compound 














Synthesis of 19 – N3-Aib2-OtBu  
Previously synthesised and published 75 
Synthesis of N3AibOtBu 
 
Br-Aib-OtBu (11.7 g, 53 mmol) was dissolved in DMF (95 mL), to this NaN3 (5.12 g, 83 mmol) 
was added. The resulting solution was left to stir at RT for 3 d. After this, the reaction mixture 
was diluted with H2O (30 mL) and then acidified to pH = 2 with 1 M HCl (aq). This was washed 
twice with MTBE, the organic washes were combined and washed three times with 1 M HCl 
(aq). The organic phase was dried (MgSO4), filtered and concentrated to give N3AibOH (7.4 g, 
40 mmol, 75 %) as a colourless oil which was used with no further purification. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 1.52 (6 H, s, 2 x CH3), 1.39 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 171.7 (CO), 81.2 (C(CH3)3), 58.2 (αC), 24.9 (CH3), 23.7 (CH3). 
 All spectra consistent with previously reported data. 75 
Synthesis of NH2AibOtBu 
 
NH2-Aib-OtBu was prepared following general procedure A on a 40.0 mmol scale. NH2-Aib-
OtBu (5.41 g, 34.0 mmol, 85 %) was isolated as a white solid with no further purification 
required.  
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 1.48 (6 H, s, 2 x CH3), 1.38 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.7 (CO), 80.2 (C(CH3)3), 56.2 (αC), 26.9 (CH3), 24.7 (CH3). 
 All spectra consistent with previously reported data. 75 






N3-Aib2-OtBu was prepared from H2N-Aib-OtBu following general procedure B on a 26.0 mmol 
scale. Compound 19 (4.64 g, 66 %, 17.2 mmol) was isolated as a white solid with no further 
purification required. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 7.11 (1 H, br s, NH), 1.54 (6 H, s, 2 x CH3), 1.53 (6H, s, 2 x CH3), 
1.47 (9 H, s, 3 x CH3)  
13C NMR (100 MHz, CDCl3) 173.5 (CO), 171.1 (CO), 81.6 (C(CH3)3), 64.3 (αC), 56.7 (αC), 27.8 
(CH3), 24.3 (CH3).  
All spectra consistent with previously reported data. 75 
 
Synthesis of 20 – NH2-Aib2-OtBu  
Previously synthesised and published 75 
 
NH2-Aib2-OtBu was prepared following general procedure A on a 17.0 mmol scale. Compound 
20 (3.65 g, 88 %, 15.0 mmol) was isolated as a white solid with no further purification 
required.  
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 8.07 (1 H, s, NH), 1.49 (6 H, s, 2 x CH3), 1.43 (9 H, s, 3 x CH3), 1.32 
(6 H, s, 2 x CH3) 
13C NMR (100 MHz in CDCl3): δC 176.4 (CO), 173.9 (CO), 81.1 (C(CH3)3), 56.1 (αC), 54.7 (αC), 
29.0 (CH3), 27.8 (CH3), 24.5 (CH3).  
All spectra consistent with previously reported data. 75 
 
Synthesis of 21 – N3-Aib3-OtBu  






N3-Aib3-OtBu was prepared following general procedure B on an 18.0 mmol scale. Compound 
21 (6.43 g, 95 %, 17.1 mmol) was isolated as a white solid with no further purification 
required. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 7.24 (1 H, s, NH), 7.01 (1 H, s, NH), 1.58 (6 H, s, 2 x CH3), 1.55 (6 
H, s, 2 x CH3), 1.54 (6 H, s, 2 x CH3), 1.47 (9 H, s, 3 x CH3) 
13C NMR (100 MHz in CDCl3) δC 174.1 (CO), 172.9 (CO), 171.8 (CO), 81.8 (C(CH3)3), 64.4 (αC), 
57.1 (αC), 57.0 (αC), 27.8 (CH3), 24.9 (CH3), 24.3 (CH3), 24.0 (CH3) 
All spectra consistent with previously reported data. 75 
 
Synthesis of 22 – NH2-Aib3-OtBu 
Previously synthesised and published 75 
 
NH2-Aib3-OtBu was prepared following general procedure A on an 18.0 mmol scale. 
Compound 22 (6.43 g, 89 %, 16.0 mmol) was isolated as a white solid with no further 
purification required. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 8.18 ( 1 H, s, NH), 7.48 (1 H, s, NH), 1.55 (6 H, s, 2 x CH3), 1.52 (6 
H, s, 2 x CH3), 1.46 (9 H, s, 3 x CH3), 1.37 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 177.7 (CO), 174.1 (CO), 173.4 (CO), 81.3 (C(CH3)3), 56.9 (αC), 
56.6 (αC), 55.0 (αC), 29.0 (CH3), 27.8 (CH3), 25.2 (CH3), 24.3 (CH3).  
All spectra consistent with previously reported data. 75 
 
Synthesis of 23 – N3-Aib4-OtBu  






N3-Aib4-OtBu was prepared following general procedure B on a 16.0 mmol scale. Compound 
23 (5.28 g, 75 %, 12.0 mmol) was isolated as a white solid with no further purification 
required.  
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 7.03 (1 H, s, NH), 6.99 (1 H, s, NH), 6.50 (1 H, s, NH), 1.55 (6 H, s, 
2 x CH3), 1.53 (6 H, s, 2 x CH3), 1.52 (6 H, s, 2 x CH3), 1.50 (6 H, s, 2 x CH3), 1.46 (9 H, s, 3 x CH3) 
13C NMR (100 MHz in CDCl3) δC 173.8 (CO), 173.0 (CO), 172.4 (CO), 172.3 (CO), 80.9 (C(CH3)3), 
64.2 (αC), 57.1 (αC), 56.8 (αC), 56.6 (αC), 27.8 (CH3), 25.1 (CH3), 25.0 (CH3), 24.4 (CH3), 24.3 
(CH)3.  
All spectra consistent with previously reported data. 75 
 
Synthesis of 24 – NH2-Aib4-OtBu  
Previously synthesised and published 75 
 
NH2-Aib4-OtBu was prepared following general procedure A on a 1.40 mmol scale. Compound 
24 (550 mg, 97 %, 1.36 mmol) was isolated as a white solid with no further purification 
required. 
Analytical Data: 
1H NMR (400 MHz, CDCl3) δH 8.14 (1 H, s, NH), 7.28 (1 H, s, NH), 6.64 (1 H, s, NH), 1.51 (6 H, s, 
2 x CH3), 1.50 (12 H, s, 4 x CH3), 1.45 (9 H, s, 3 x CH3), 1.38 (6 H, s, 2 x CH3)  
13C NMR (100 MHz, CDCl3) δC 178.1 (CO), 173.9 (CO), 173.0 (CO), 172.8 (CO), 80.5 (C(CH3)3), 
56.7 (αC), 56.6 (αC), 56.4 (αC), 54.8 (αC), 29.0 (CH3), 27.9 (CH3), 25.4 (CH3), 25.1 (CH3), 24.5 
(CH3)  
All spectra consistent with previously reported data. 75 
 
Synthesis of 25 – Cbz-Aib4-OtBu 






Benzyl chloroformate (0.35 mL, 2.48 mmol) and N-N-Diisopropylethylamine (0.61 mL, 3.47 
mmol) were dissolved in THF (4 mL) and cooled to 0 oC. A solution of H2N-Aib4-OtBu (410 mg, 
0.99 mmol) in THF (12 mL) was added to this mixture over 3 h, after which time the reaction 
was warmed to RT and left stirring for a further 6 h. The reaction mixture was concentrated, 
dissolved in EtOAc (30 mL) and washed with KHSO4 (aq) (2 x 10 mL), NaHCO3 (aq) (2 x 10 mL) and 
brine (10 mL). The organic phase was dried (MgSO4), filtered and concentrated. The crude 
product was then purified by column chromatography (SiO2, 5% MeOH in CH2Cl2), to give 
compound 25 (405 mg, 75 %, 0.74 mmol) as a pale-yellow solid.  
Analytical Data: 
Rf (SiO2, 5% MeOH in DCM) = 0.27 
1H NMR (400 MHz, CDCl3) δH 7.38 (5 H, m, ArCH), 7.24 (1 H, br s, NH), 7.13 (1 H, br s, NH), 6.35 
(1 H, br s, NH), 5.42 (1 H, br s, NH), 5.12 (2 H, s, CH2), 1.50 (6 H, s, 2 x CH3), 1.48 (12 H, s, 4 x 
CH3), 1.45 (9 H, s, 3 x CH3), 1.35 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δc 174.8 (CO), 174.0(CO), 173.5 (CO), 172.4 (CO), 155.6 (CO), 136.0 
(ArC), 128.7 (ArCH), 128.6 (ArCH), 128.3 (ArCH), 79.9 (C(CH3)3), 67.4 (CH2), 57.3 (αC), 57.0 (αC), 
56.7 (αC), 56.0 (αC), 27.9 (CH3), 25.4 (CH3), 25.2 (CH3), 25.2 (CH3), 24.8 (CH3).  
MS ESI+ (CH2Cl2): 549.5 (M+H)+.  
All spectra consistent with previously reported data. 156, 157 
Note compound 26 can be formed as a by-product of this reaction, for full data and an 
optimised synthesis of this impurity refer to K. Gratzner’s work. 114 
 
Synthesis of 27 – Cbz-Aib4-OH  
 
Cbz-Aib4-OH was prepared following general procedure C on a 0.31 mmol scale. Compound 
27 (152 mg, 99%, 0.31 mmol) was isolated as an off-white solid.  
Analytical Data: 
Rf (SiO2, 5% MeOH in DCM) = 0.05 
1H NMR (400 MHz, CD3OD) δH 7.44 – 7.29 (5 H, m, ArCH), 5.14 (2 H, s, CH2), 1.51 (6 H, s, 2 x 
CH3), 1.42 (6 H, s, 2 x CH3), 1.39 (6 H, s, 2 x CH3), 1.33 (6 H, s, 2 x CH3)  
13C NMR (100 MHz, CD3OD) δC 176.9 (CO), 175.8 (CO), 175.3 (CO), 175.0(CO), 156.4 (CO), 
137.3 (ArC), 128.2 (ArCH), 127.6 (ArC), 127.2 (ArCH), 66.2 (CH2), 56.4 (αC), 56.3 (αC), 56.2 (αC), 





HRMS (ESI+, MeCN) calc. for C24H37N4O7 = 493.5732; observed = 493.2665 (M+H)+.  
IR (neat) νmax/cm-1 = 3292 (OH br), 3010 (CH), 2998 (CH), 1725 (CO), 1704 (CO), 1652 (CO), 
1513 (OBn) 
Mp (Et2O): 228-230 oC. 
 
Synthesis of 28 – MC-(L)αMv-OH  
 
H2N-(L)αMv-OH (1.00 g, 7.50 mmol) was dissolved in acetone (7.5 mL) and NaOH (aq) (2 M, 7.5 
mL). The resulting solution was cooled to 0 oC and methyl chloroformate (0.89 mL, 11.0 mmol) 
was added in a drop wise manner. After addition was complete, the pH was adjusted to pH 
>13 with NaOH (aq) (2 M). The mixture was stirred for 8 h and allowed to warm to RT. The 
reaction mixture was concentrated, dissolved in NaOH (aq) (2 M, 20 mL) and then washed with 
Et2O (2 x 20 mL). The aqueous phase was acidified to pH = 1 with conc. HCl (aq) and washed 
with EtOAc (3 x 30 mL). The organic phase was dried (Na2SO4), filtered and concentrated to 
give compound 28 (0.92 g, 93%, 7.00 mmol) as a white solid. 
Analytical Data: 
Rf (SiO2, 10% MeOH in DCM) = 0.15 
1H NMR (400 MHz, CDCl3) δH 5.29 (1 H, br s, NH), 2.25 (1 H, m, CH), 1.57 (3 H, s, CH3), 1.01 (3 
H, d, J = 7.0 Hz, CH3), 0.98 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 178.9 (CO), 156.1 (CO), 62.8 (αC), 52.2 (OCH3), 37.4 (CH), 18.8 
(CH3), 17.3 (CH3), 17.1 (CH3).  
[α]D (c = 1.0, MeOH) = +18.9.  
HRMS (ESI+, MeOH) calc. for C8H16O4N = 190.2169; observed = 190.1073 (M+H)+.  
IR (neat) νmax/cm-1 = 3274 (br OH), 2970 (CH), 1709 (CO), 1652 (CO), 1461 (OMe) 










Synthesis of 29 – MC-(L)αMv-Aib4-OtBu  
 
Preparation of the acid fluoride: 
Mc-(L)αMv-OH (172 mg, 0.91 mmol) and pyridine (74 μL, 0.91 mmol) were dissolved in CH2Cl2 
(7.2 mL). Fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate (359 mg, 1.36 
mmol) was added and the reaction mixture was stirred for 3 h. The mixture was diluted with 
CH2Cl2 (17 mL) and washed with ice cold water (3 x 24 mL), dried (Na2SO4), filtered and 
concentrated to give the crude acid fluoride which was used immediately with no further 
purification.  
Preparation of compound 29 
NH2-Aib4-OtBu (300 mg, 0.72 mmol) and N-N-Diisopropylethylamine (0.15 mL, 0.86 mmol) 
were dissolved in CH2Cl2 (16 mL) and cooled to 0 oC. The crude acid fluoride was dissolved in 
CH2Cl2 (4 mL) and added drop wise to the reaction mixture. It was then left to warm to room 
temperature. After 5 d the reaction was diluted with EtOAc (100 mL), washed with KHSO4 (2 
x 20 mL), NaHCO3 (2 x 20 mL) and brine (20 mL), dried (MgSO4), filtered and concentrated to 
give the crude product which was purified by column chromatography (SiO2, 5 % MeOH in 
CH2Cl2) to give compound 29 (257 mg, 61%, 0.83 mmol) as a white solid. 
Analytical Data: 
Rf (SiO2, 10 % MeOH in CH2Cl2) = 0.23 
1H NMR (400 MHz, CDCl3) δH 7.53 (1 H, br s, NH), 7.34 (1 H, br s, NH), 7.31 (1 H, br s, NH), 6.40 
(1 H, br s, NH), 5.18 (1 H, br s, NH), 3.72 (3 H, s, OCH3), 1.97 (1 H, spt, J = 6.5 Hz, CH), 1.56 (3 
H, s, CH3), 1.52 (3 H, s, CH3), 1.52 (3 H, s, CH3), 1.50 (6 H, br s, 2 x CH3), 1.48 (3 H, s, CH3), 1.45 
(12 H, s, 4 x CH3), 1.43 (6 H, s, 2 x CH3), 1.00 (3 H, d, J = 6.5 Hz, CH3), 0.97 (3 H, d, J = 6.5 Hz, 
CH3) 
13C NMR (100 MHz, CDCl3) δC 174.1 (CO), 173.9 (CO), 173.8 (CO), 173.7 (CO), 172.5 (CO), 156.2 
(CO), 79.7 (C(CH3)3), 62.9 (αC), 57.0 (αC), 56.9 (αC), 56.7 (αC), 56.0 (αC), 52.7 (OCH3), 35.7 
(CH), 27.9 (CH3), 27.1 (CH3), 26.9 (CH3), 26.7 (CH3), 25.5 (CH3), 24.2 (CH3), 23.9 (CH3), 23.7 
(CH3), 17.7 (CH3), 17.3 (CH3), 17.1 (CH3). 
[α]D (c = 1.0, MeOH) =  +34.3.  
HRMS (ESI+, DCM) calc. for C24H44N5O8: 530.318990; observed: 530.319012 (M+H)+  
IR (neat) νmax/cm-1 = 3316 (NH), 3093 (CH), 2953 (CH), 2938 (CH), 1715 (CO), 1653 (CO), 1579 
(OR), 1546 (OR), 1490 (CH)  





Synthesis of 30 – MC-(L)αMv-Aib4-OH  
 
MC-(L)αMv-Aib4-OH was prepared following general procedure C on a 0.44 mmol scale. 
Compound 30 (230 mg, 99%, 0.43 mmol) was isolated as a white solid. 
Analytical Data: 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.05 
1H NMR (400 MHz, CD3OD) δH 3.70 (3 H, s, OCH3), 2.01 (1 H, spt, J = 7.0 Hz, CH), 1.53 (6 H, s, 2 
x CH3), 1.50 (3 H, s, CH3), 1.49 (3 H, s, CH3), 1.48 (3H, s, CH3), 1.47 (3 H, s, CH3), 1.45 (3H, s, 
CH3), 1.40 (6 H, s, 2 x CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.98 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CD3OD) δC 176.9 (CO), 175.7 (CO), 175.5 (CO), 175.4 (CO), 174.2 (CO), 
157.4 (CO), 62.4 (αC), 56.6 (αC), 56.5 (αC), 56.4 (αC), 55.6 (αC), 51.2 (OCH3), 34.9 (CH), 25.5 
(CH3), 25.3 (CH3), 25.2 (CH3), 25.2 (CH3), 24.5 (CH3), 23.3 (CH3), 23.0 (CH3), 22.7 (CH3), 17.3 
(CH3), 16.5 (CH3), 16.3 (CH3) 
[α]D (c = 1.0, MeOH) = +36.9 
HRMS (ESI+, MeOH) calc. for C24H43N5NaO8 = 552.6167; observed = 552.3005 (M+Na)+  
IR (neat) νmax/cm-1 = 3285 (br OH), 2984 (CH), 2904 (CH), 1699 (CO), 1651 (CO), 1529 (OMe), 
1462 (CH) 
Mp (Et2O): 212-214 oC. 
 
Synthesis of 36 – N-Boc-ethylenediamine  
Previously synthesised and published 158 
 
Ethylenediamine (3.34 mL, 50.0 mmol) was dissolved in CH2Cl2 (15 mL) and cooled to 0 oC. To 
this, a solution of di-tert-butyl-carbonate (1.09 g, 5.00 mmol) in CH2Cl2 (50 mL) was added 
over 2 h, after which time the resulting mixture warmed to RT and stirred for a further 24 h. 
The solution was then concentrated, dissolved in Na2CO3 (aq) (2 M, 15 mL) and washed with 
CH2Cl2 (3 x 20 mL). The combined organic washes were dried (Na2SO4), filtered and 






1H NMR (400 MHz, CDCl3) δH 5.06 (1 H, br s, NH), 3.14 (2 H, q, J = 6.0 Hz, CH2), 2.76 (2 H, t, J = 
6.0 Hz, CH2), 1.41 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δc 156.2 (CO), 79.1 (C(CH3)3), 43.4 (CH2), 41.9 (CH2), 28.4 (CH3)  
MS ESI+ (CH2Cl2): 161.3 (M+H)+  
All spectral data consistent with previously reported data. 158 
 
Synthesis of 37 – MC-(L)αMv-Aib4-NH(CH2)2-NHBoc  
 
MC-(L)αMv-Aib4-OH (75 mg, 0.14 mmol) and 1-hydroxybenzotriazole hydrate (24 mg, 0.18 
mmol) were dissolved in CH2Cl2 (8.5 mL) and DMF (1.5 mL) and then cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (30 mg, 0.15 mmol) was added 
and the resulting solution was warmed to RT. N-Boc-ethylenediamine (56 mg, 0.35 mmol) and 
Et3N (60 μL, 0.42 mmol) were added, and the resulting solution was left for 4 d. The reaction 
mixture was concentrated, dissolved in EtOAc (40 mL), washed with KHSO4 (aq) (2 x 10 mL), 
NaHCO3 (aq) (2 x 10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated. This was 
purified by column chromatography (SiO2, 7:3 EtOAc/Petroleum ether → 10% MeOH in 
CH2Cl2) giving compound 32 (30 mg, 32%, 0.04 mmol) as a white solid.  
Analytical Data: 
Rf (SiO2 7:3 EtOAc:Petroleum Ether) = 0.2 
1H NMR (400 MHz, CDCl3) δH 7.77 (1 H, s, NH), 7.64 (1 H, s, NH), 7.49 (1 H, t, J = 5.5 Hz, NH), 
7.41 (1 H, s, NH), 6.65 (1 H, s, NH), 6.16 (1 H, t, J = 6.0 Hz, NH), 5.50 (1 H, s, NH), 3.71 (3 H, s, 
OCH3), 3.52-3.16 (4 H, m, 2 x CH2), 2.01 (1 H, sept, J = 7.0 Hz, CH), 1.57 (3 H, s, CH3), 1.51 (6 H, 
s, 2 x CH3), 1.50 (6 H, s, 2 x CH3), 1.49 (3 H, s, CH3), 1.45 (6 H, s, 2 x CH3), 1.42 (9 H, s, CH3), 1.41 
(3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.97 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δc 175.8 (CO), 175.6 (CO), 174.6 (CO), 174.1 (CO), 173.1 (CO), 157.0 
(CO), 156.5 (CO), 78.4 (C(CH3)3), 62.9 (αC), 57.1 (αC), 57.0 (αC), 56.8 (αC), 56.8 (αC), 52.6 
(OCH3), 40.5 (CH2), 40.0 (CH2), 35.5 (CH), 28.5 (CH3), 27.3 (CH3), 26.8 (CH3), 26.6 (CH3), 26.4 
(CH3), 24.1 (CH3), 23.6 (CH3), 23.5 (CH3), 17.6 (CH3), 17.3 (CH3), 17.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +39.1 
HRMS (ESI+, CH2Cl2) calc. for C31H58N7O9: 672.4271; observed: 672.4391 (M+H)+ 
IR (neat) νmax/cm-1 = 3310 (NH2), 2989 (CH), 2978 (CH), 1725 (CO), 1701 (CO), 1545 (OR), 1532 
(OR), 1474 (CH), 1456 (CH) 





Synthesis of 38 – MC-(L)αMv-Aib4-NH(CH2)2-NH2∙HCl  
 
MC-(L)αMv-Aib4-NH(CH2)2-NHBoc (150 mg, 0.25 mmol) was dissolved in a 1.25 M solution of 
HCl in MeOH (4 mL) and stirred for 12 h, after which time the reaction mixture was 
concentrated  to give the HCl salt of compound 38 (137 mg, 95 %, 0.24 mmol) as a white solid.  
Analytical Data: 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.10 
1H NMR (400 MHz, CD3OD) δH 3.72-3.64 (4 H, m, OCH3 and part of AB system CH2), 3.38 (1 H, 
dt, J = 14.5, 5.0 Hz, part of AB system CH2), 3.20-3.09 (2 H, m, the other AB CH2 system), 1.99 
(1 H, sept, J = 7.0 Hz, CH), 1.47 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.46 (3 H, s, CH3), 1.44 (3 H, s, 
CH3), 1.43 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.37 (3 H, s, CH3), 1.36 (3 H, s, 
CH3), 0.97 (3 H, d, J = 7.0 Hz, CH3), 0.92 (3 H, d, J = 7.0 Hz) 
13C NMR (100 MHz, CD3OD) δc 177.1 (CO), 177.1 (CO), 176.9 (CO), 176.1 (CO), 174.7 (CO), 
157.5 (CO), 62.5 (αC), 56.9 (αC), 56.7 (αC), 56.6 (αC), 56.5 (αC), 51.4 (OCH3), 39.5 (CH2), 36.6 
(CH2), 34.9 (CH), 25.3 (CH3), 25.2 (CH3), 25.1 (CH3), 25.0 (CH3), 23.3 (CH3), 22.8 (CH3), 22.7 
(CH3), 22.7 (CH3), 17.1 (CH3), 16.6 (CH3), 16.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +34.7 
HRMS (ESI+, MeOH) calc. for C26H50N7O7: 572.3768, observed: 572.3766 (M+H)+ 
IR (neat) νmax/cm-1 = 3318 (NH2), 3280 (NH), 3096 (CH), 2948 (CH), 1710 (CO), 1673 (CO), 1581 
(OR), 1466 (CH)  
Mp (MeOH): 238-240 oC 
  
Synthesis of 39 – MC-(L)αMv-Aib4-NH(CH2)2NH-Aib4-Cbz  
 
Cbz-Aib4-OH (38 mg, 0.07 mmol) and 1-hydroxybenzotriazole hydrate (12 mg, 0.09 mmol) 
were dissolved in CH2Cl2 (5 mL) and DMF (1 mL) and then cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (15 mg, 0.07 mmol) was then 
added and the resulting solution was warmed to RT. MC-(L)αMv-Aib4-NH(CH2)2NH2 (24 mg, 





d. The reaction mixture was concentrated, dissolved in EtOAc (30 mL), washed with KHSO4 (2 
x 7 mL), NaHCO3 (2 x 7 mL) and brine (7 mL), dried (MgSO4), filtered and concentrated. The 
crude product was purified by column chromatography (SiO2, 5% → 30% MeOH in CH2Cl2) 
giving compound 39 (30 mg, 32%, 0.04 mmol) as a white solid.  
Analytical Data: 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.15 
1H NMR (400 MHz, CD3OD) δH 7.29 (2 H, dd, J = 8.5 Hz, 1.5 Hz, ArCH), 7.25 (2 H, m, ArCH), 7.20 
(1 H, m, ArCH), 5.03 (2 H, br s, CH2 of Cbz), 3.58 (3 H, s, OCH3), 3.26 (2 H, m, CH2 of ethylene 
diamine linker), 3.21 (2 H, m, CH2 of ethylene diamine linker), 1.90 (1 H, spt, J = 7.0 Hz, CH), 
1.41 (3 H, s, CH3), 1.39 (3 H, s, CH3), 1.39 (3 H, s, CH3), 1.38 (3 H, s, CH3), 1.37 (6 H, s, 2 x CH3), 
1.35 (3 H, s, CH3), 1.34 (6 H, s, 2 x CH3), 1.30 (6 H, s, 2 x CH3), 1.29 (3 H, s, CH3), 1.28 (3 H, s, 
CH3), 1.25 (6 H, s, 2 x CH3), 1.23 (3 H, s, CH3), 1.22 (3 H, s, CH3), 0.89 (3 H, d, J = 6.5 Hz, CH3), 
0.85 (3 H, d, J = 6.5 Hz, CH3). 
13C NMR (100 MHz, CD3OD) δc 176.4 (CO), 176.4 (CO), 176.3 (CO), 176.2 (CO), 175.7 (CO), 
175.6 (CO), 175.6 (CO), 174.5 (CO), 174.4 (CO), 157.5 (CO), 156.5 (CO), 137.3 (ArC), 128.2 
(ArCH), 127.6 (ArC), 127.2 (ArCH), 66.2 (CH2 of Cbz), 62.5 (OCH3), 62.4 (αC), 56.8 (αC), 56.8 
(αC), 56.7 (αC), 56.6 (αC), 56.5 (αC), 56.2 (αC), 56.2 (αC), 38.7 (CH2 of ethylenediamine linker), 
38.6 (CH2 of ethylenediamine linker), 34.9 (CH), 25.5 (CH3), 25.2 (CH3), 24.5 (CH3), 24.2 (CH3), 
24.0 (CH3), 23.9 (CH3), 23.8 (CH3), 23.7 (CH3), 23.6 (CH3), 23.1 (CH3), 22.8 (CH3), 22.7 (CH3), 
17.2 (CH3), 16.5 (CH3), 16.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +36.2 
HRMS (ESI+, MeOH) calc for C50H84N11O13: 1046.625008; observed: 1046.625231 (M+H)+ 
IR (neat) νmax/cm-1 = 3319 (NH), 2982 (CH), 2978 (CH), 1756 (CO), 1720 (CO), 1690 (CO), 1475 
(OR), 1443 (OR), 1397 (CH), 1384 (CH) 
Mp (CH2Cl2): >300 oC. 
 
Synthesis of 34 – Cbz-Aib*-OH  
  
CbzAib*OH was prepared by following two previously reported procedures: 79, 87 







L-Alanine (6.65 g, 74.6 mmol) was dissolved in NaOH (aq) (1 M, 75 mL, 74.6 mmol), 
concentrated and dried for 9 d in a vacuum oven. After which time a portion (4.37 g, 39 mmol) 
was transferred to a flame dried flask under argon. Acetone (dry, 40 mL) and powdered mol. 
sieves (~33 g) were added and cooled to 0 oC. AlMe3 in toluene (2 M, 19.5 mL, 39 mmol) was 
added in a drop wise manner. After addition was complete the reaction mixture was warmed 
to RT and left stirring for 9 h. The reaction mixture was then cooled to 0 oC and 1-naphthoyl 
chloride (5.88 mL, 39 mmol) was added drop wise. After addition was complete, the reaction 
mixture was warmed to RT and left stirring for 3 h, then filtered through a pad of Celite®, 
washed repeatedly with Et2O and concentrated. The crude product was purified by column 
chromatography (SiO2 – 2:8 EtOAc:Petroleum Ether) to give (S)-2,2-Dimethyl-4-methyl-3-(1-
naphthoyl)-oxazolidin-5-one (1.5 g, 14 %, 5.3 mmol) as a white solid.  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.89 (1 H, dd, J = 7.5 Hz, 1.5 Hz, ArCH), 7.33 (1 H, dd, J = 7.0 Hz, 
2.0 Hz, ArCH), 7.75 (1 H, br s, ArCH), 7.50 (2 H, m, 2 x ArCH), 7.41 (2 H, m, 2 x ArCH), 2.02 (3 
H, br s, CH3) 1.98 (3 H, br s, CH3), 0.91 (3 H, br s, CH3).  
13C NMR (100 MHz, CDCl3) δC 171.5 (CO), 167.6 (CO), 133.6 (ArC), 133.5 (ArC), 130.4 (ArCH), 
128.8 (ArC), 127.9 (ArCH), 126.8 (ArCH), 125.0 (ArC), 98.4 (CH), 53.9 (αC), 27.5 (CH3), 26.1 
(CH3), 20.1 (CH3).  
All spectral data consistent with previously reported data. 87 
Synthesis of compound 34  
(S)-2,2-Dimethyl-4-methyl-3-(1-naphthoyl)-oxazolidin-5-one (1.50 g, 5.30 mmol) was 
dissolved in THF (37 mL) and cooled to -78 oC. To this a 0.3 M solution of potassium 
hexamethyl disilazide (36.13 mL, 11.13 mmol) at -78 oC was swiftly added (5 x 7.4 mL, every 
40 s). The resulting mixture was stirred for 4 min, after which time 13CH3I (1.65 mL, 26.5 mmol) 
was added in one portion. The mixture was then stirred at -78 oC for 30 min, after which time 
it was diluted with HCl (aq) (1 M, 20 mL) and allowed to warm to RT. The reaction mixture was 
diluted with EtOAc (100 mL) and H2O (30 mL). The organic phase was then concentrated, 
dissolved in HBr (conc., 40 mL) and heated to reflux overnight.  After this time the mixture 
was cooled to RT, diluted with water (20 mL) and washed with CH2Cl2 (2 x 40 mL) and Et2O 
(40 mL). The aq. phase was concentrated to give BrH3NAib*OH (964 mg, 99 %, 5.27 mmol), 
which was dissolved in acetone (6 mL) and NaOH (aq) (6 mL) and cooled to 0 oC. Benzyl 
chloroformate (0.9 mL, 6.34 mmol) was added in a drop wise manner and then the pH was 
adjusted to pH>13 with NaOH (aq) (2M). The reaction mixture was left stirring overnight, after 
which the reaction mixture was concentrated. This was dissolved in NaOH (aq) (20 mL) and 





washed with EtOAc (3 x 30 mL). The combined organic phases were dried (Na2SO4), filtered 
and concentrated to give compound 34 (690 mg, 2.91 mmol, 55%) as an off-white solid.  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.37-7.28 (5 H, m, 5 x ArH), 5.43 (1 H, br s, NH), 5.09 (2 H, s, CH2), 
1.57 (3 H, d, 1JCH = 130 Hz, CH3), 1.57 (3 H, d, 3JCH = 4.0 Hz, CH3).  
13C NMR (100 MHz, CDCl3) δC 179.8 (CO), 154.9 (CO), 136.1 (ArC), 128.5 (ArCH), 128.2 (ArCH), 
128.1 (ArCH), 66.8 (CH2), 56.3 (d, J = 36.5 Hz, αC-*CH3), 25.0 (*CH3).  
All spectral data consistent with previously reported data. 79 
 
Synthesis of 35 – CbzAib*Aib4OtBu 
Previously synthesised and published 79 
 
Preparation of the acid fluoride: 
Cbz-Aib*-OH (202 mg, 0.91 mmol) and pyridine (74 μL, 0.91 mmol) were dissolved in CH2Cl2 
(7.2 mL). Fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate (359 mg, 1.36 
mmol) was added and the reaction mixture was stirred for 3 h. The mixture was diluted with 
CH2Cl2 (20 mL) and washed with ice cold water (3 x 20 mL), dried over Na2SO4, filtered and 
concentrated to give the crude acid fluoride, which was used immediately with no further 
purification.  
Preparation of compound 35 
NH2-Aib4-OtBu (331 mg, 0.80 mmol) and N-N-Diisopropylethylamine (0.13 mL, 0.80 mmol) 
were dissolved in CH2Cl2 (20 mL) and cooled to 0 oC. The crude acid fluoride was dissolved in 
CH2Cl2 (5 mL) and added drop wise to the reaction mixture, which was then left to warm to 
room temperature. After 5 d the reaction was diluted with EtOAc (100 mL), washed with 
KHSO4 (aq) (2 x 20 mL), NaHCO3 (aq) (2 x 20 mL) and brine (20 mL), dried (MgSO4), filtered and 
concentrated to give the crude product which was then purified by column chromatography 
(SiO2, 5 % MeOH in CH2Cl2) to give compound 35 (321 mg, 65%, 0.52 mmol) as a white solid. 
Analytical Data: 
1H NMR (400 MHz, CD3OD) δH 7.39-7.31 (5H, m, 2 x ArH), 5.16 (2H, s, CH2 of Cbz), 1.53 (6H, s, 
2 x CH3), 1.48 (6H, s, 2 x CH3), 1.47 (3H, d, J = 129.0 Hz, *CH3), 1.46 (3H, d, J = 4.5 Hz, *CH3-C-
CH3), 1.43 (6H, s, 2 x CH3), 1.42 (9H, s, 3 x CH3), 1.35 (6H, s, 2 x CH3).  
13C-NMR (75 MHz, CD3OD) δC 174.0 (CO), 173.9 (CO), 173.6 (CO), 173.6 (CO), 173.5 (CO), 156.2 





58.7 (αC), 57.3 (αC), 56.8 (αC), 56.5 (αC), 56.1 (d, J = 40.0 Hz, αC-*CH3), 27.3(CH3), 25.4 (CH3), 
25.2 (CH3), 24.7 (*CH3), 24.6 (CH3) 
All spectral data consistent with previously reported data. 79 
 
Synthesis of 53 – N3-Aib4-OH  
Previously synthesised and published 75 
  
N3Aib4OH was synthesised following general procedure C on a 1.70 mmol scale. Compound 
53 was synthesised as a white solid (576 mg, 88 %, 1.50 mmol). 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 1.53 (6 H, s, 2 x CH3), 1.51 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 
1.42 (6 H, s, 6 x CH3) 
13C NMR (100 MHz, CD3OD) δC 176.8 (CO), 174.8 (CO), 174.2 (CO), 173.2 (CO), 63.4 (αC), 56.6 
(αC), 56.3 (αC), 55.7 (αC), 24.0 (CH3), 23.8 (CH3), 23.6 (CH3), 23.2 (CH3).  
All spectra consistent with previously reported data. 75 
 
Synthesis of 158 – N3-Aib4-NH(CH2)2NHBoc  
 
N3Aib4OH (190 mg, 0.19 mmol) and 1-hydroxybenzotriazole hydrate (86 mg, 0.64 mmol) were 
dissolved in CH2Cl2 (8 mL) and cooled to 0 oC. N-(3-Dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (103 mg, 0.54 mmol) was added and the resulting solution 
was warmed to RT. N-Boc-ethylenediamine (117 mg, 0.74 mmol) and N-N-diisopropylethyl 
amine (0.26 mL, 1.47 mmol) were added and the resulting solution was left stirring for 5 d. 
The reaction mixture was then concentrated, dissolved in EtOAc (25 mL), washed with KHSO4 
(2 x 10 mL), NaHCO3 (2 x 10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated. 
The crude product was purified by column chromatography (SiO2, 4:6 CH2Cl2, EtOAc → 100 % 






Rf (SiO2, 100 % EtOAc) = 0.28 
1H NMR (400 MHz, CDCl3) δH 7.26 (1 H, br s, NH), 7.19 (1 H, br s, NH), 6.99 (1 H, br s, NH), 6.20 
(1 H, br s, NH), 5.87 (1 H, br m, NH), 3.32 (4 H, m, 2 x CH2), 1.54 (6 H, s, 2 x CH3), 1.52 (6 H, s, 
2 x CH3), 1.51 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.42 (9 H, s, 3 x CH3) 
13C (100 MHz, CDCl3) δC 175.2 (CO), 173.4 (CO), 173.0 (CO), 173.0 (CO), 156.3 (CO), 78.5 
(C(CH3)3), 64.0 (αC), 57.3 (αC), 57.3 (αC), 57.0 (αC), 56.8 (αC), 40.1 (CH2), 39.8 (CH2), 28.5 (CH3), 
25.6 (CH3), 25.4 (CH3), 24.9 (CH3), 24.3 (CH3).  
HRMS (ESI+, CH2Cl2) calc. for C23H42N8O6Na = 549.6194; observed = 549.3122 (M+Na)+   
IR (neat) νmax/cm-1 = 3330 (NH), 2950 (CH), 2910 (CH), 2250 (N3), 1667 (CO), 1515 (OR) 
Mp (EtOAc) 144-146 oC 
 
Synthesis of 160 – NH2-Aib4-NH(CH2)2NHBoc  
  
NH2-Aib4-NH(CH2)2NHBoc was synthesised following general procedure A on a 0.3 mmol 
scale. NH2-Aib4-NH(CH2)2NHBoc (105 mg, 0.21 mmol, 70 %) was synthesised as a white solid.  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.08 
1H NMR (400 MHz, CDCl3) δH 8.18 (1 H, br s, NH), 7.45 (1 H, br s, NH), 7.30 (1 H, br s, NH), 6.52 
(1 H, br s, NH), 5.96 (1 H, br s, NH), 3.25 (4 H, m, 2 x CH2), 1.44 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 
x CH3), 1.36 (6 H, s, 2 x CH3), 1.34 (9 H, s, 3 x CH3), 1.28 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 178.5 (CO), 175.6 (CO), 174.5 (CO), 173.6 (CO), 156.4 (CO), 78.5 
(C(CH3)3), 57.1 (αC), 56.8 (αC), 56.1 (αC), 54.7 (αC), 40.5 (CH2), 39.8 (CH2), 28.8 (CH3), 28.5 
(CH3), 25.6 (CH3), 25.3 (CH3), 24.8 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C23H44N6NaO6: 523.3215, observed: 523.3214 (M+Na)+ 
IR (neat) νmax/cm-1 = 3304(NH/NH2), 2951 (CH), 2892 (CH), 1641 (CO), 1519 (OR), 1475 (CH)  








Synthesis of 40 – MC-(L)αMv-Aib4-NH(CH2)2NH-Aib4-Aib*-Cbz  
 
Formation of the azlactone 
Cbz-Aib*Aib4-OH (150 mg, 0.26 mmol) was dissolved in CH2Cl2 (5 mL) and was cooled to 0 oC. 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (65 mg, 0.34 mmol) and 
N,N-diisopropylethylamine (0.07 mL, 0.34 mmol) were added and the resulting solution was 
stirred at RT for 4 h. The reaction mixture was then concentrated, dissolved in EtOAc and 
washed with KHSO4 (aq), NaHCO3 (aq) and brine. The organic phase was dried over MgSO4, 
filtered and concentrated to give the crude azlactone that was used with no further 
purification. 
Synthesis of compound 40 
The crude azlactone and MC(L)αMvAib4-NH(CH2)2NH2∙HCl (121 mg, 0.20 mmol) were 
dissolved in MeCN (15 mL) and heated at reflux for 5 d. After which time the solution was 
cooled to RT, concentrated, dissolved in EtOAc and then washed with KHSO4 (aq), NaHCO3 (aq) 
and brine. The organic phase was then dried over MgSO4, filtered and concentrated. The 
crude product was then purified by column chromatography (SNAP Ultra 10g, 2% → 10%) to 
give compound 40 as a white solid (220 mg, 0.20 mmol, 75 %). 
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.13 
1H NMR (500 MHz, CD3OD) δH 7.42 (2 H, d, J = 7.0 Hz, 2 x ArH), 7.37 (2 H, t, J = 7.0 Hz, 2 x ArH), 
7.32 (1 H, t, J = 7.0 Hz, ArH), 5.15 (2 H, s, CH2Ph), 3.70 (3 H, s, OCH3), 3.40-3.36 (4 H, m, 2 x 
CH2), 2.02 (1 H, hept, J = 7.0 Hz, CH), 1.53 (3 H, s, CH3), 1.51 (6 H, s, 2 x CH3), 1.50 (3 H, s, CH3), 
1.49 (3 H, s, CH3), 1.49 (3 H, d, 1JCH = 65 Hz, 13CH3), 1.47 (3 H, s, CH3), 1.46 (6 H, s, 2 x CH3), 1.46 
(6 H, s, 2 x CH3), 1.40 (3 H, s, CH3), 1.40 (3 H, s, CH3), 1.39 (6 H, s, 2 x CH3), 1.36 (3 H, d, 1JCH = 
65 Hz, 13CH3), 1.34 (3 H, s, CH3), 1.33 (6 H, s, 2 x CH3), 1.31 (3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, 
CH3), 0.97 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (125 MHz, CD3OD) δH 176.4 (CO), 176.3 (CO), 176.2 (CO), 176.1 (CO), 175.7 (CO), 
175.6 (CO), 175.6 (CO), 175.5 (CO), 175.4 (CO), 174.4 (CO), 157.4 (CO), 156.5 (CO), 137.3 (ArC), 
128.2 (ArH), 127.6 (ArH), 127.2 (ArH), 62.9 (CH2 of Cbz), 58.9 (αC), 58.7 (αC), 58.7 (αC), 58.5 
(αC), 58.4 (αC), 58.1 (αC), 57.8 (αC), 57.5 (αC*CH3), 57.3 (αC), 57.0 (αC), 51.2 (OCH3), 38.6 
(CH2), 37.4 (CH2), 34.9 (CH), 25.4 (CH3), 25.3 (CH3), 25.1 (CH3), 24.5 (CH3), 23.9 (13CH3 major), 
23.8 (13CH3 minor), 23.6 (CH3), 23.1 (CH3), 23.0 (CH3), 22.8 (CH3), 22.7 (CH3), 22.3 (CH3), 17.2 
(CH3), 16.5 (CH3), 16.3 (CH3) 





HRMS (MALDI, CH3OH) calc. for C5313CH90N12O14: 1154.6620 observed: 1154.6625 (M+H)+ 
IR (neat) νmax/cm-1 = 3299 (NH), 2983 (CH), 2935 (CH), 1706 (CO), 1654 (CO), 1528 (Ar), 1261 
(OBn/OMe), 1106 (OBn/OMe). 
Mp >300 oC (CH2Cl2) 
 
Synthesis of 41 – H2N-C(CH3)2CH2-NHBoc  
Previously synthesised and published 159 
  
1,2-diamino-2-methylpropane (2.3 mL, 22.9 mmol) was dissolved in CH2Cl2 (17 mL) and cooled 
to 0 oC. To this, a solution of di-tert-butyl-carbonate (1.00 g, 4.60 mmol) in CH2Cl2 (80 mL) was 
added over 5 h; after which time the solution was warmed to room temperature and stirred 
for a further 8 h. The reaction mixture was concentrated, dissolved in Na2CO3 (aq) (2M, 50 mL) 
and washed with CH2Cl2 (3 x 55 mL). The combined organic phases were dried (Na2SO4), 
filtered and concentrated to give compound 41 (748 mg, 4.0 mmol, 87 %) as a colourless solid. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 5.04 (1 H, br s, NH), 3.00 (2 H, d, J = 6.0 Hz, CH2), 1.44 (9 H, s, 3 x 
CH3), 1.08 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 156.5 (CO), 79.1 (C(CH3)3), 52.1 (C(CH3)2), 50.1 (CH2), 28.4 (CH3), 
28.3 (CH3) 
All spectral data consistent with previously reported data. 159 
 
Synthesis of 41 – MC-(L)αMv-Aib4-HN-C(CH3)2CH2NH-Boc  
  
Formation of the azlactone 
MC-(L)αMvAib4-OH (50 mg, 0.094 mmol) was dissolved in CH2Cl2 (6 mL) and DMF (1 mL) and 
cooled to 0 oC. N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (27.2 mg, 
0.14 mmol) was added, and the resulting solution was stirred at RT for 4 h. The reaction 
mixture was then concentrated, dissolved in EtOAc (25 mL) and washed with KHSO4 (aq) (2 x 8 
mL), NaHCO3 (aq) (2 x 8 mL) and brine (8 mL). The organic phase was dried (MgSO4), filtered 





Synthesis of compound 42 
The crude azlactone and N-Boc-1,2-diamino-2-methylpropane (27 mg, 0.14 mmol) were 
dissolved in MeCN (8 mL) and heated at reflux for 5 d. After which time the solution was 
cooled to RT, concentrated and dissolved in EtOAc (10 mL) and then washed with HCl (aq) (1 
M, 2 x 2.5 mL) and brine (2.5 mL). The organic phase was then dried (MgSO4), filtered and 
concentrated. The crude product was then purified by column chromatography (SiO2: 5% 
MeOH in CH2Cl2 → 10 % MeOH in CH2Cl2) to give compound 42 as a white solid (9.8 mg, 0.014 
mmol, 15 %).  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.30 
1H NMR (400 MHz, CDCl3) δH 7.64 (1 H, s, NH), 7.62 (1 H, s, NH), 7.53 (1 H, s, NH), 6.82 (1 H, s, 
NH), 6.71 (1 H, s, NH), 6.07 (1 H, dd, J = 8.0, 4.5 Hz, NH), 5.74 (1 H, s, NH), 3.66 (1 H, s, OCH3), 
3.53 (1 H, dd, J = 13.5, 4.5 Hz, part of AB system CH2), 3.31 (1 H, dd, J = 13.5, 8.0 Hz, part of 
AB system CH2), 2.00 (1 H, hept, J = 6.5 Hz, CH), 1.49 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.44 (3 H, 
s, CH3), 1.43 (9 H, s, 3 x CH3), 1.40 (3 H, s, CH3), 1.37 (15 H, br s, 5 x CH3), 1.33 (3 H, s, CH3), 
1.26 (3 H, s, CH3), 0.96 (3 H, d, J = 6.5 Hz, CH3), 0.92 (3 H, d, J = 6.5 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 175.1 (CO), 175.0 (CO), 174.9 (CO), 174.4 (CO), 173.3 (CO), 157.0 
(CO), 78.1 (C(CH3)3), 62.9 (αC), 56.9 (αC), 56.7 (αC), 54.2 (αC), 52.4 (αC), 46.8 (CH2), 35.3 (CH), 
28.4 (CH3), 26.9 (CH3), 26.7 (CH3), 26.5 (CH3), 26.3 (CH3), 24.9 (CH3), 24.5 (CH3), 23.9 (CH3), 
23.7 (CH3), 23.4 (CH3), 17.6 (CH3), 17.3 (CH3), 17.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +35.6 
HRMS (ESI+, CH2Cl2) calc. for C33H61N7NaO9: 722.4423, observed: 722.4420 (M+Na)+    
IR (neat) νmax/cm-1 = 3300 (NH), 2971 (CH), 1731 (CO), 1675 (CO), 1550 (OR), 1541 (OR) 
Mp (CH2Cl2): 169-172 oC  
 
Synthesis of 43 – MC-(L)αMv-Aib4-HN-C(CH3)2CH2NH2∙HCl  
 
MC-(L)αMv-Aib4-HN-C(CH3)2CH2NHBoc was dissolved in a solution of HCl in MeOH (0.75 M, 
0.2 mL) and stirred for 3 h. The reaction mixture was concentrated to give the HCl salt of 
compound 43 as a white solid (5.9 mg, 0.009 mmol, 66 %). 
Analytical Data 





1H NMR (400 MHz, CDCl3) δH 7.84 (1 H, br s, NH), 7.82 (1 H, s, NH), 7.72 (1 H, s, NH), 7.62 (1 H, 
br s, NH), 7.41 (1 H, br s, NH), 6.93 (1 H, s, NH), 3.65 (3 H, s, OCH3), 3.14-3.04 (1 H, m, part of 
the CH2 AB system), 2.16-2.06 (1 H, m, part of the CH2 AB system), 1.48 (3 H, s, CH3), 1.43 (6 
H, s, 2 x CH3), 1.41 (3 H, s, CH3), 1.40 (6 H, s, 2 x CH3), 1.37 (12 H, s, 4 x CH3), 1.31 (3 H, s, CH3), 
1.26-1.16 (1 H, m, CH), 0.97-0.92 (3 H, m, CH3), 0.90-0.85 (3 H, m, CH3) 
13C NMR (100 MHz, CDCl3) δH 177.0 (CO), 176.4 (CO), 176.1 (CO), 175.3 (CO), 174.4 (CO), 157.2 
(CO), 62.8 (αC), 57.0 (αC), 56.7 (αC), 56.5 (αC), 56.4 (αC), 52.4 (αC), 52.2 (OCH3), 46.7 (CH2), 34.9 
(CH3), 34.4 (CH), 26.8 (CH3), 26.5 (CH3), 26.3 (CH3), 25.8 (CH3), 24.9 (CH3), 23.4 (CH3), 23.2 
(CH3), 23.1 (CH3), 17.3 (CH3), 17.2 (CH3), 16.9 (CH3) 
[α]D (c = 1.0, CH2Cl2) =  +42.3 
HRMS (ESI+, MeOH) calc. for C28H54N7O7: 600.4070, observed: 600.4079 (M+H)+ 
IR (neat) νmax/cm-1 = 3301 (NH2/NH), 2998 (CH), 2953 (CH), 1726 (CO), 1704 (CO), 1667 (CO), 
1581 (OR) 
Mp (MeOH): 216-219 oC 
 
Synthesis of 44 – MC-(L)αMv-Aib4-HN-C(CH3)2CH2NH-Aib4-Cbz 
 
Cbz-Aib4-OH (0.019 mmol, 9.17 mg) and 1-hydroxybenzotriazole hydrate (3.4 mg, 0.025 
mmol) were dissolved in CH2Cl2 (1.5 mL) and DMF (0.5 mL) and then cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (4 mg, 0.021 mmol) was added 
and the resulting solution was warmed to RT. MC-(L)αMv-Aib4-HN-C(CH3)2CH2NH3Cl (5.9 mg, 
9.3 μmol) and Et3N (8 μL) were added and the reaction was stirred for 5 d. The resulting 
solution was then concentrated, dissolved in EtOAc (6 mL) and washed with KHSO4 (aq) (2 x 1 
mL), NaHCO3 (aq) (2 x 1 mL) and brine (1 mL), dried (MgSO4), filtered and concentrated. The 
crude product was purified by column chromatography (SiO2: 10 % MeOH in CH2Cl2) to give 
compound 44 as a white solid (7 mg, 6.5 μmol, 70 %). 
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.24 
 1H NMR (400 MHz, CD3Cl) δH 7.61 (1 H, br s, NH), 7.57 (1 H, br s, NH), 7.52 (1 H, br s, NH), 7.43 
(1 H, br s, NH), 7.41 (1 H, br s, NH), 7.39 (5 H, m, 5 x ArCH), 7.34 (1 H, br s, NH), 7.32 (1 H, br 
s, NH), 6.44 (1 H, br s, NH), 6.33 (1 H, br s, NH), 6.25 (1 H, br s, NH), 6.11 (1 H, br m, NH), 5.14 
(1 H, br s, NH), 5.13 (2 H, d, J = 1.5 Hz, CH2 of Cbz), 3.74 (3 H, s, OCH3), 3.71 (2  H, br s, CH2 of 





(3 H, s, CH3), 1.53 (3 H, s, CH3), 1.52 (3 H, s, CH3), 1.50 (6 H, s, 2  x CH3), 1.49 (3 H, s, CH3), 1.48 
(6 H, s, 2 x CH3), 1.47 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.44 (3 H, s, CH3), 1.43 (12 H, s, 4 x CH3), 
1.41 (3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.98 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δc 176.6 (CO), 176.5 (CO), 176.4 (CO), 176.4 (CO), 175.8 (CO), 175.6 
(CO), 175.5 (CO), 174.5 (CO), 174.3 (CO), 156.1 (CO), 155.9 (CO), 137.8 (ArC), 128.9 (ArCH), 
127.6 (ArC), 127.1 (ArCH), 66.1 (CH2 of Cbz), 63.5 (OCH3), 61.2 (αC), 57.8 (αC), 56.9 (αC), 56.7 
(αC), 56.4 (αC), 56.3 (αC), 56.2 (αC), 56.1 (αC), 53.3 (C(CH3)2), 38.9 (CH2 of linker), 35.4 (CH), 
25.6 (CH3), 25.3 (CH3), 24.5 (CH3), 24.3 (CH3), 24.1 (CH3), 23.8 (CH3), 23.7 (CH3), 23.7 (CH3), 
23.6 (CH3), 23.3 (CH3), 22.9 (CH3), 22.7 (CH3), 17.0 (CH3), 16.5 (CH3), 16.4 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +32.5 
HRMS (ESI+, MeCN) calc. for C52H87N11O13: 1074.656309; observed: 1074.656407 (M+H)+ 
IR (neat) νmax/cm-1 = 3304 (NH), 2924 (CH), 2827 (CH), 1715 (CO), 1702 (CO), 1679 (CO), 1505 
(OR) 
Mp (CH2Cl2): > 300 oC 
 
Synthesis of 159 – N3-Aib4-HN-C(CH3)2CH2NHBoc  
 
N3Aib4OH (190 mg, 0.49 mmol) and 1-Hydroxy-7-azabenzotriazole hydrate (87 mg, 0.64 
mmol) were dissolved in CH2Cl2 and cooled to 0 oC. N-(3-Dimethylaminopropyl)-N'-ethyl-
carbodiimide (103 mg, 0.54 mmol) was added and the resulting solution warmed to RT. N-
Boc-1,2-diamino-2-methylpropane (138 mg, 0.74 mmol) and N,N-diiso-propylethylamine 
(0.26 mL, 1.47 mmol) were added and the mixture was stirred for 4 d. After this time the 
reaction mixture was concentrated, dissolved in EtOAc (25 mL), washed with KHSO4 (5% aq. 
soln., 2 x 10 mL), NaHCO3 (sat. aq. sol., 2 x 10 mL) and brine (10 mL), dried (MgSO4), filtered 
and concentrated. The crude product was purified by column chromatography (SiO2: 4:6 
EtOAc:CH2Cl → 6:4 EtOAc:CH2Cl2) to give N3-Aib4-HN-C(CH3)2CH2NHBoc as a white solid (132 
mg, 0.24 mmol, 48 %).  
Analytical Data 
Rf (SiO2 6:4 EtOAc:CH2Cl2) = 0.3 
1H NMR (400 MHz, CDCl3) δH 7.35 (1 H, br s, NH), 6.89 (1 H, br s, NH), 6.66 (1 H, br s, NH), 6.06 
(1 H, br s, NH), 5.93 (1 H, t, J = 6.5 Hz, NH), 3.48 (2 H, d, J = 6.5 Hz, CH2), 1.55 (6 H, s, 2 x CH3), 
1.50 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.41 (9 H, s, 3 x CH3), 1.31 (6 





13C NMR (100 MHz, CDCl3) δC 174.3 (CO), 173.2 (CO), 172.9 (CO), 172.5 (CO), 157.0 (CO), 78.1 
(C(CH3)3), 64.0 (αC), 57.1 (αC), 56.9 (αC), 56.8 (αC), 54.4 (αC), 46.4 (CH2), 28.5 (CH3), 25.4 (CH3), 
24.9 (CH3), 24.8 (CH3), 24.3 (CH3) 
HRMS (ESI+, CH2Cl2) calc for C25H47N8O6: 555.361857; 555.362652 (M+H)+  
IR (neat) νmax/cm-1 = 3333 (NH), 2980 (CH), 2251 (N3), 1745 (CO), 1664 (CO), 1524 (OR) 
Mp (EtOAc): 197-200 oC.  
 
Synthesis of 161 – NH2-Aib4-HN-C(CH3)2CH2NHBoc  
 
NH2-Aib4-HN-C(CH3)2CH2NHBoc was synthesised following general procedure A on a 0.24 
mmol scale. NH2-Aib4-HN-C(CH3)2CH2NHBoc was synthesised as a white solid (105 mg, 0.24 
mmol, 83 %).  
Analytical Data 
Rf (SiO2 6:4 EtOAc:CH2Cl2) = 0.14 
1H NMR (400 MHz, CDCl3) δH 8.24 (1 H, br s, NH), 7.65 (1 H, br s, NH), 6.73 (1 H, br s, NH), 6.37 
(1 H, br s, NH), 5.96 (1 H, t, J = 6.5 Hz, NH), 3.44 (2 H, d, J = 6.5 Hz, CH2), 1.45 (6 H, s, 2 x CH3), 
1.42 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x CH3), 1.38 (9 H, s, 3 x CH3), 1.35 (6 H, s, 2 x CH3), 1.28 (6 
H, s, 2 x CH3). 
13C NMR (100 MHz, CDCl3) δC 178.2 (CO), 174.7 (CO), 173.8 (CO), 173.5 (CO), 157.0 (CO), 78.1 
(C(CH3)3), 57.0 (αC), 56.6 (αC), 56.3 (αC), 54.8 (C), 54.3 (αC), 46.4 (CH2), 28.6 (CH3), 28.5 (CH3), 
25.4 (CH3), 24.8 (CH3), 24.7 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C25H49N6O6: 529.3708, observed: 529.3708 (M+H)+ 
IR (neat) νmax/cm-1 = 3321 (NH2/NH), 2977 (CH), 2934 (CH), 1731 (CO), 1657 (CO), 1525 (OR) 
Mp (EtOAc): 210-213 oC.  
 






Formation of the azlactone 
Cbz-Aib*Aib4-OH (175 mg, 0.30 mmol) was dissolved in CH2Cl2 (5 mL) and was cooled to 0 oC. 
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (75 mg, 0.39 mmol) and 
N,N-diisopropylethylamine (0.07 mL, 0.39 mmol) were added and the resulting solution was 
stirred at RT for 4 h. The reaction mixture was then concentrated, dissolved in EtOAc and 
washed with NaHCO3 (aq) and brine. The organic phase was dried (MgSO4), filtered and 
concentrated to give the crude azlactone that was used with no further purification. 
Synthesis of 45 
The crude azlactone and MC(L)αMvAib4-NH(C(CH3)2CH2NH2∙HCl (196 mg, 0.31 mmol) were 
dissolved in MeCN (15 mL) and heated at reflux for 5 d. After which time the solution was 
cooled to RT, concentrated, dissolved in EtOAc and then washed with KHSO4 (aq), NaHCO3 (aq) 
and brine. The organic phase was then dried over MgSO4, filtered and concentrated, the crude 
product was then purified by column chromatography (SNAP Ultra 25g, 5% → 10% MeOH in 
CH2Cl2) to give compound 45 as a white solid (302 mg, 0.26 mmol, 85 %).  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.17 
1H NMR (500 MHz, CD3OD) δH 7.42 (2 H, d, J = 7.0 Hz, 2 x ArH), 7.37 (2 H, t, J = 7.0 Hz, 2 x ArH), 
7.32 (1 H, t, J = 7.0 Hz, ArH), 5.15 (2 H, s, CH2 of Cbz), 3.70 (3 H, s, OCH3), 3.62 (1 H, d, J = 13.5 
Hz, part of the CH2 AB system in the diamine linker), 3.50 (1 H, d, J = 13.5 Hz, part of CH2 AB 
system in the diamine linker), 2.03 (1 H, hept, J = 7.0 Hz, CH), 1.52 (3 H, s, CH3), 1.51 (3 H, s, 
CH3), 1.49 (3 H, s, CH3), 1.48 (3 H, d, 1JCH = 64.5 Hz, CH3) 1.47 (9 H, s, 3 x CH3), 1.47 (3 H, s, CH3), 
1.46 (6 H, s, 2 x CH3), 1.45 (3 H, s, CH3), 1.41 (3 H, s, CH3), 1.40 (3 H, s, CH3), 1.39 (3 H, s, CH3), 
1.39 (3 H, s, CH3), 1.37 (6 H, s, 2 x CH3), 1.36 (3 H, d, 1JCH = 65.0 Hz, CH3), 1.34 (3 H, s, CH3), 1.33 
(3 H, s, CH3), 1.30 (3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.97 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (125 MHz, CD3OD) δH 176.4 (CO), 176.0 (CO), 175.8 (CO), 175.7 (CO), 175.7 (CO), 
175.6 (CO), 175.5 (CO), 175.4 (CO), 175.2 (CO), 174.4 (CO), 157.4 (CO), 156.5 (CO), 137.4 (ArC), 
128.2 (ArH), 127.6 (ArH), 127.2 (ArH), 66.2 (CH2 of Cbz), 62.4 (αC), 56.8 (αC), 56.7 (αC), 56.5 
(αC), 56.4 (αC), 56.4 (αC), 56.4 (αC), 56.3 (αC), 56.1 (αC), 56.1 (αC), 54.7 (CH2 of the diamine 
linker), 51.2 (OCH3), 34.8 (CH), 25.5 (CH3), 25.4 (CH3), 25.2 (CH3), 24.8 (CH3), 24.4 (CH3), 24.3 
(CH3), 23.9 (13CH3 major), 23.8 (13CH3 minor), 23.6 (CH3), 23.1 (CH3), 22.9 (CH3), 22.7 (CH3), 
17.1 (CH3), 16.5 (CH3), 16.3 (CH3) 
[α]D (c = 0.75, MeOH) = +37.2 
HRMS (MALDI, CH3OH) calc. for C5513CH94N12NaO14: 1182.6938; observed: 1182.6933 (M+Na)+ 
IR (neat) νmax/cm-1 = 3303 (NH), 2980 (CH), 2935 (CH), 1705 (CO), 1657 (CO), 1529 (Ar), 1267 
(OMe/OBn), 1225 (OMe/OBn) 






Synthesis of 48 – N3Aib-NH-(1,2-Ph)-NHBoc 
 
N-Boc-1,2-phenylenediamine (249 mg, 1.2 mmol) and pyridine (0.29  mL, 3.6 mmol) were 
dissolved in THF (8 mL). To this mixture a solution of freshly distilled N3AibCl (195 mg, 1.32 
mmol) in THF (4 mL) was added in a drop wise manner and left stirring for 8 h. The resulting 
mixture was diluted with THF (20 mL) and CH2Cl2 (15 mL), filtered then concentrated and 
dissolved in EtOAc (40 mL). The organic phase was then washed with KHSO4 (aq) (2 x 10 mL), 
NaHCO3 (aq) (2 x 10 mL) and brine (10 mL), dried (MgSO4), filtered and concentrated to give 
compound 48 as pale green solid (351 mg, 1.08 mmol, 92%). 
Analytical Data 
Rf (SiO2 7:3 Petroleum ether:EtOAc) = 0.5 
1H NMR (400 MHz, CD3OD) δH 7.66 (1 H, m, ArCH), 7.28 – 7.21 (3 H, m, 3 x ArCH), 1.63 (6 H, s, 
2 x CH3), 1.56 (9 H, s, 3 x CH3). 
13C NMR (100 MHz, CD3OD) δC 171.8 (CO), 155.1 (CO), 130.6 (ArC), 125.9 (ArCH), 125.4 (ArCH), 
125.0 (ArCH), 124.7 (ArC), 80.3 (C(CH3)3), 64.2 (αC), 27.2 (CH3), 23.4 (CH3).  
HRMS (ESI+, CH2Cl2) calc. for C15H22N5O3: 320.1722; observed: 320.1762 (M+H)+ 
IR (neat) νmax/cm-1 = 3270 (NH), 2981 (CH), 2114 (N3), 1721 (CO), 1455 (OR) 
Mp (EtOAc): 121-123 oC  
 
Synthesis of 49 – NH2Aib-NH-(1,2-Ph)-NHBoc  
 
NH2Aib-NH-(1,2-Ph)-NHBoc was synthesised by following general procedure A on a 1.08 
mmol scale. Compound 49 was synthesised as a pale green solid (315 mg, 1.07 mmol, 99 %). 
Analytical Data 





1H NMR (400 MHz, CD3OD) δH 7.76 (1 H, dd, J = 7.5 Hz, 1.5 Hz, ArCH), 7.34 (1 H, dd, J = 7.5 Hz, 
1.5 Hz, ArCH), 7.19 (2 H, m, 2 x ArCH), 1.54 (9 H, s, 3 x CH3), 1.44 (6 H, s, 2 x CH3).  
13C NMR (100 MHZ, CD3OD) δC 177.5 (CO), 154.9 (CO), 131.5 (ArC), 130.1 (ArCH), 125.5 (ArCH), 
125.2 (ArCH), 123.8 (ArC), 80.1 (C(CH3)3), 55.0 (αC), 27.4 (CH3), 27.3 (CH3).  
HRMS (ESI+, MeOH) calculated for C15H24N3O3: 294.18176; observed 294.18245 (M+H)+  
IR (neat) νmax/cm-1 = 3150 (NH2/NH), 2981 (CH), 1701 (CO), 1684 (CO), 1546 (OR)  
Mp (EtOAc): 137-139 oC. 
 
Synthesis of Cbz-(L)αMv-Aib3-OH  
 
Cbz(L)αMvAib3OH was synthesised following general procedure C on a 0.51 mmol scale. This 
gave the title product (254 mg, 0.49 mmol, 97 %) as a white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.43 – 7.29 (5 H, m , 5 x ArH), 5.20 (1 H, d, J = 12.5 Hz, part of 
the AB system of the CH2), 5.08 (1 H, d, J = 12.5 Hz, part of the AB system of the Cbz CH2), 2.03 
(1 H, sept, J = 7.0 Hz, CH), 1.52 (6 H, s , 2 x CH3), 1.42 (6 H, s, 2 x CH3), 1.40 (3 H, s, CH3), 1.39 
(3 H, s, CH3), 1.29 (3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.95 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CD3OD) δC 176.8 (CO), 175.3 (CO), 174.8 (CO), 174.3 (CO), 156.6 (CO), 
137.2 (ArC), 128.2 (ArH), 127.7 (ArH), 127.6 (ArH), 66.3 (Cbz CH2), 62.6 (αC), 56.4 (αC), 56.4 
(αC), 55.6 (αC), 34.6 (CH), 25.7 (CH3), 25.4 (CH3), 24.5 (CH3), 23.4 (CH3), 22.8 (CH3), 22.7 (CH3), 
16.7 (CH3), 16.6 (CH3), 16.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +35.2 
HRMS (ESI+, CH3OH) calc. for C26H39N4O7: 519.2824; observed: 519.2831 (M+H)+ 
IR (neat) νmax/cm-1: 3300 (OH), 2985 (CH), 2970 (CH), 1675 (CO), 1545 (NH), 1280 (OBn/OtBu), 
1123 (OBn/OtBu) 









Synthesis of 47 – MC-(L)αMv-Aib3-NH-(1,2-Ph)-NHBoc  
 
Formation of the azlactone. 
MC-(L)αMvAib3-OH (42 mg, 0.095 mmol) was dissolved in CH2Cl2 (6 mL) and was then cooled 
to 0 oC. N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (27 mg, 0.14 mmol) 
was added and the resulting solution was stirred at RT for 4 h. The reaction mixture was 
concentrated, dissolved in EtOAc (20 mL) and washed with KHSO4 (aq) (2 x 7 mL), NaHCO3 (aq) 
(2 x 7 mL) and brine (7 mL). The organic phase was dried over MgSO4, filtered and 
concentrated to give the crude azlactone that was used with no further purification. 
Synthesis of 47 
The crude azlactone and NH2Aib-NH-(1,2-Ph)-NHBoc (27 mg, 0.14 mmol) were dissolved in 
MeCN (6 mL) and heated at reflux for 5 d. After which time the solution was cooled to RT, 
concentrated, dissolved in EtOAc (15 mL) and then washed with HCl (aq) (1 M, 2 x 3 mL) and 
brine (3 mL). The organic phase was dried over MgSO4, filtered and concentrated to give 
compound 47 as a pale green solid (26 mg, 0.037 mmol, 39 %).  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.33 
1H NMR (400 MHz, CDCl3) δH 8.66 (1 H, br s, NH), 7.92 (1 H, d, J = 8.0 Hz, ArCH), 7.74 (1 H, br 
s, NH), 7.66 (1 H, br s, NH), 7.59 (1 H, br s, NH), 7.53 (1 H, br s, NH), 7.43 (1 H, br s, NH), 7.17 
(1 H, d, J = 8.0 Hz, ArCH), 7.10 (1 H, t, J = 8.0 Hz, ArCH), 7.02 (1 H, br s, NH), 6.92 (1 H, t, J = 7.0 
Hz, ArCH), 3.63 (3 H, s, OCH3), 1.88 (1 H, m, CH), 1.60 (3 H, s, CH3), 1.56 (6 H, s, 2 x CH3), 1.48 
(3 H, s, CH3), 1.44 (3 H, s, CH3), 1.41 (15 H, s, 5 x CH3), 1.34 (3 H, s, CH3), 1.33 (3 H, s, CH3), 0.90 
(3 H, br s, CH3), 0.84 (3 H, br s, CH3). 
13C NMR (100 MHz, CDCl3) δC 175.8 (CO), 175.7 (CO), 174.9 (CO), 174.4 (CO), 173.3 (CO), 170.6 
(CO), 153.8 (CO), 134.5 (ArCH), 127.4 (ArCH), 127.2 (ArC), 126.8 (ArC), 122.9 (ArCH), 79.5 
(C(CH3)3), 77.3 (αC), 57.2 (αC), 56.9 (αC), 56.8 (αC), 56.7 (αC), 52.8 (OCH3), 28.4 (CH3), 28.4 
(CH3), 28.3 (CH), 27.1 (CH3), 24.1 (CH3), 17.5 (CH3), 17.4 (CH3), 17.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +29.1 





IR (neat) νmax/cm-1 = 3330 (NH), 2972 (CH), 2963 (CH), 1701 (CO), 1687 (CO), 1513 (OR), 1451 
(OR) 
Mp (EtOAc): 223-226 oC 
 
Synthesis of 51 – MC-(L)αMv-Aib4-NH-(1,2-Ph)-NH2·HCl  
  
MC-(L)αMv-Aib4-NH-(1,2-Ph)-NHBoc (26 mg, 0.037 mmol) was dissolved in a mixture of MeOH 
(0.5 mL) and a solution of HCl in MeOH (0.5 mL, 1.25 M) and stirred for 12 h. The mixture was 
concentrated, washed with Et2O and concentrated again to ensure the full removal of the 
excess HCl. This gave the HCl salt of compound 51 (23 mg, 95 %, 0.035 mmol) as a pale green 
solid.  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.19 
1H NMR (400 MHz, CD3OD) δH 7.57-7.44 (4 H, m, 4 x ArH), 3.71 (3 H, s, OMe), 2.04 (1 H, sept, 
J = 7.0 Hz, CH), 1.67 (3 H, s, CH3), 1.64 (3 H, s, CH3), 1.55 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.51 
(3 H, s, CH3), 1.46 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.41 (3 H, s, CH3), 1.02 (3 
H, d, J = 7.0 Hz, CH3), 0.98 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CD3OD) δC 171.9 (CO), 176.5 (CO), 176.0 (CO), 176.0 (CO), 174.6 (CO), 
157.5 (CO), 131.8 (ArC), 129.5 (ArH), 127.5 (ArH), 126.8 (ArH), 125.8 (ArC), 123.8 (ArH), 62.5 
(αC), 57.1 (αC), 56.6 (αC), 56.5 (αC), 56.4 (αC), 51.3 (OCH3), 34.8 (CH), 25.2 (CH3), 25.1 (CH3), 
25.0 (CH3), 23.2 (CH3), 22.9 (CH3), 22.7 (CH3), 22.6 (CH3), 17.1 (CH3), 16.5 (CH3), 16.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +31.4 
HRMS (ESI+, CH2Cl2) calc. for C30H50N7O7: 620.377173; observed: 620.377301 (M+H)+ 
IR (neat) νmax/cm-1 = 3340 (NH2/NH), 2965 (CH), 1726 (CO), 1685 (CO), 1534 (OR) 








Synthesis of 52 – MC-(L)αMv-Aib4-NH-(1,2-Ph)-NH-Aib4-Cbz  
 
Formation of the azlactone. 
CbzAib4-OH (28 mg, 0.052 mmol) was dissolved in CH2Cl2 (3 mL) and DMF (0.5 mL) and then 
cooled to 0 oC. N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (15 mg, 0.072 
mmol) was added and the resulting solution was stirred at RT for 4 h. The reaction mixture 
was concentrated, dissolved in EtOAc (12 mL) and washed with KHSO4 (aq) (2 x 4 mL), NaHCO3 
(aq) (2 x 4 mL) and brine (4 mL). The organic phase was dried (Na2SO4), filtered and 
concentrated. Giving the crude azlactone, that was used with no further purification. 
Synthesis of 52 
The crude azlactone and MC-(L)αMv-Aib3-NH-(1,2-Ph)-NH2∙HCl (16 mg, 0.026 mmol) were 
dissolved in MeCN (2 mL) and heated at reflux for 5 d. After which time the solution was 
cooled to RT and concentrated. The crude product was purified with column chromatography 
(SiO2: 5% MeOH in CH2Cl2 → 10% MeOH in CH2Cl2) to give compound 52 as a pale green solid 
(10 mg, 8 μmol, 31 %).  
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.17 
1H NMR (400 MHz, CD3Cl) δH 8.84 (1 H, br s, NH), 8.82 (1 H, br s, NH), 8.75 (1 H, br s, NH), 7.60 
(1 H, br s, NH), 7.53 (1 H, br s, NH), 7.30 (4 H, m, 4 x ArCH), 7.26 (1 H, br s, NH), 7.07 (5 H, m, 
5 x ArCH), 7.02 (1 H, br s, NH), 6.74 (1 H, br s, NH), 6.23 (1 H, br s, NH), 5.89 (1 H, br s, NH), 
5.05 (1 H, d, J = 13.0 Hz, CH2 AB system), 5.03 (1 H, s, NH), 5.03 (1 H, d, J = 13.0 Hz, CH2 AB 
system), 3.57 (3 H, s, OCH3), 1.95 (1 H, sept, J = 7.0 Hz, CH), 1.67 (6 H, s, 2 x CH3), 1.65 (3 H, s, 
CH3), 1.60 (3 H, s, CH3), 1.53 (12 H, s, 4 x CH3), 1.51 (3 H, s, CH3), 1.46 (6 H, s, 2 x CH3), 1.45 (3 
H, s, CH3), 1.41 (9 H, s, 3 x CH3), 1.40 (3 H, s, CH3), 1.01 (3 H, d, J = 7.0 Hz, CH3), 0.96 (3 H, d, J 
= 7.0 Hz, CH3) 
[α]D (c = 1.0, CH2Cl2) = +37.9 





IR (neat) νmax/cm-1 = 3250, 2922, 2852, 1739, 1711, 1669, 1525, 1456, 1377 
Mp (CH2Cl2): > 300 oC 
 
Synthesis of 54 – N3-Aib4-NH-(1,2-Ph)-NHBoc  
 
Formation of the azlactone. 
N3-Aib4-OH (161 mg, 0.42 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (157 mg, 0.82 mmol) was added 
and the resulting solution stirred at RT for 6 h. The reaction mixture was diluted with CH2Cl2 
(18 mL) and washed with H2O (8 mL), NaHCO3 (aq) (2 x 8 mL), dried over Na2SO4, filtered and 
concentrated, to give the crude azlactone that was then used with no further purification. 
Synthesis of 54 
The crude azlactone and N-Boc-1,2-phenylenediamine (130 mg, 0.63 mmol) were dissolved in 
MeCN (5 mL) and Et3N (0.087 mL, 0.63 mmol) and then heated at reflux for 3 d. After which 
time the solution was cooled to RT and concentrated, dissolved in EtOAc (20 mL) and washed 
with KHSO4 (aq) (2 x 7 mL), NaHCO3 (aq) (2 x 7 mL) and brine (7 mL), dried  over MgSO4, filtered 
and concentrated. The crude product was purified with column chromatography (SiO2, 8:2 
CH2Cl2:EtOAc → 100% CH2Cl2) to give compound 54 as a pale green solid (53 mg, 0.087 mmol, 
31 %).  
Analytical Data 
Rf (SiO2 100% CH2Cl2) = 0.29 
1H NMR (400 MHz, CDCl3) δH 8.73 (1 H, s, NH), 7.95 (1 H, d, J = 8.5 Hz, ArH), 7.58 (1 H, s, NH), 
7.39 (1 H, s, NH), 7.17-7.12 (2 H, m, 2 x ArH), 6.98-6.93 (2 H, m, 1 x ArH and 1 x NH), 6.41 (1 
H, s, NH), 1.58 (6 H, s, 2 x CH3), 1.46 (9 H, s, 3 x CH3), 1.43 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x 
CH3), 1.34 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.2 (CO), 173.8 (CO), 173.6 (CO), 173.0 (CO), 153.6 (CO), 134.5 
(ArC), 127.3 (ArH), 127.0 (ArC), 126.8 (ArH), 128.9 (ArH), 121.5 (ArH), 79.6 (C(CH3)3), 63.8 (αC), 
57.2 (αC), 56.9 (αC), 56.8 (αC), 28.37 (CH3), 25.5 (CH3), 25.2 (CH3), 24.6 (CH3), 24.2 (CH3).  
HRMS (ESI+, CH2Cl2) calc. for C27H42N8NaO6: 575.3120; observed: 597.3114 (M+Na)+ 





Mp (CH2Cl2): 160-162 oC 
 
Synthesis of 55 – NH2-Aib4-NH-(1,2-Ph)-NHBoc  
 
NH2-Aib4-NH-(1,2-Ph)-NHBoc was synthesised by following general procedure A on a 0.087 
mmol scale. Compound 55 was synthesised as a pale green solid (49 mg, 80 %, 0.070 mmol). 
Analytical Data 
Rf (SiO2, 100% CH2Cl2) = 0.05 
1H NMR (400 MHz, CDCl3) δH 8.79 (1 H, br s, NH), 8.17 (1 H, br s, NH), 7.98 (1 H, d, J = 6.5 Hz, 
ArCH), 7.74 (1 H, br s, NH), 7.64 (1 H, br s, NH), 7.18 (2 H, m, 2 x ArCH), 6.99 (1 H, t, J = 7.5 Hz, 
ArCH), 6.49 (1 H, br s, NH), 1.61 (6 H, s, 2 x CH3), 1.49 (9 H, s, 3 x CH3), 1.46 (6 H, s, 2 x CH3), 
1.38 (6 H, s, 2 x CH3), 1.29 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 178.5 (CO), 175.4 (CO), 174.4 (CO), 173.7 (CO), 153.7 (CO), 134.6 
(ArC), 127.4 (ArCH), 127.1 (ArC), 126.8 (ArCH), 122.9 (ArCH), 79.6 (C(CH3)3), 57.3 (αC), 56.7 
(αC), 56.1 (αC), 54.6 (αC), 28.7 (CH3), 28.4 (CH3), 25.5 (CH3), 25.4 (CH3), 24.8 (CH3) 
MS ESI+ (CH2Cl2) calculated for C27H44N6NaO6: 571.322004; observed: 571.322732 (M+Na)+  
IR (neat) νmax/cm-1 = 3286 (NH), 2983 (CH), 2936 (CH), 1704 (CO), 1644 (CO), 1520 (OR) 














Synthesis of 56 – MC-(L)αMv-Aib3-NH-(1,2-Ph)-NH-Aib4-Aib*-Cbz  
 
Formation of the azlactone. 
CbzAib*Aib4-OH (63 mg, 0.11 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (27 mg, 0.14 mmol) and DIPEA 
(24 μl, 0.14 mmol) were added and the resulting solution was stirred at RT for 4 h. The 
reaction mixture was concentrated, dissolved in EtOAc (12 mL) and washed with KHSO4 (aq), 
NaHCO3 (aq) and brine. The organic phase was dried over Na2SO4, filtered and concentrated. 
To give the crude azlactone that was used with no further purification. 
Synthesis of 56 
The crude azlactone and MC-(L)αMv-Aib3-NH-(1,2-Ph)-NH2∙HCl (24 mg, 0.036 mmol) were 
dissolved in MeCN (10 mL) and DIPEA (20 μL, 0.11 mmol) and heated at reflux for 10 d. After 
which time the solution was cooled to RT and concentrated. The crude product was purified 
by column chromatography (ZIP Sphere 5g, 5% → 10% MeOH in CH2Cl2) to give 56 as a 
colourless solid (30 mg, 0.026 mmol, 72 %).  
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.21 
1H NMR (500 MHz, CDCl3) δH 9.05 (1 H, s, NH), 9.03 (1 H, s, NH), 7.62-7.60 (1 H, m, ArH), 7.58-
7.55 (2 H, m, ArH), 7.49 (1 H, s, NH), 7.46-7.44 (2 H, br s, 2 x NH), 7.43 (1 H, s, NH), 7.40 (1 H, 
s, NH), 7.39 (1 H, s, NH), 7.38-7.35 (5 H, m, 5 x ArH), 7.13-7.10 (2 H, m, 2 x ArH), 6.53 (1 H, s, 
NH), 6.49 (1 H, s, NH), 5.57 (1 H, s, NH), 5.25 (1 H, s, NH), 5.14 (1 H, d, J = 12.5 Hz, part of the 
Cbz CH2 AB system), 5.10 (1 H, d, J = 12.5 Hz, part of the Cbz CH2 AB system), 3.71 (3 H, s, 
OCH3), 1.97 (1 H, sept, J = 7.0 Hz, CH of αMv), 1.64 (3 H, s, CH3), 1.63 (15 H, s, 5 x CH3), 1.61 (3 
H, s, CH3), 1.55 (3 H, s, CH3), 1.54 (3 H, s, CH3), 1.53 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.47 (3 H, 
s, CH3), 1.46 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.41 (3 H, s, 
CH3), 1.35 (3 H, s, CH3), 1.28 (3 H, s, CH3), 0.98 (3 H, d, J = 7.0 Hz, CH3), 0.95 (3 H, d, J = 7.0 Hz, 
CH3) 
13C NMR (125 MHz, CDCl3) δC 174.8 (CO), 174.7 (CO), 174.7 (CO), 174.6 (CO), 174.6 (CO), 174.5 





(ArC), 131.4 (ArC), 128.7 (ArH), 128.6 (ArH), 128.1 (ArH), 125.6 (ArH), 125.6 (ArH), 125.3 (ArH), 
125.2 (ArH), 67.3 (CH2 of Cbz), 65.4 (αC), 62.9 (αC), 57.3 (αC), 57.1 (αC), 57.0 (αC), 56.9 (αC), 56.8 
(αC), 56.8 (αC), 56.5 (αC), 52.6 (OCH3), 35.5 (CH), 29.7 (CH3), 26.8 (CH3), 26.4 (CH3), 26.4 (CH3), 
25.8 (CH3), 25.5 (CH3), 25.4 (13CH3 major peak, Δδ = 803 ppb), 25.2 (CH3), 25.1 (CH3), 25.0 
(CH3), 24.9 (CH3), 24.6 (13CH3 minor peak), 24.1 (CH3), 23.8 (CH3), 17.6 (CH3), 17.3 (CH3), 17.1 
(CH3) 
[α]D (c = 1.0, CH2Cl2) = +33.7 
HRMS (MALDI, CH2Cl2), calc. for C5713CH90N12NaO14: 1202.6625, observed: 1202.6610 (M+Na)+ 
IR (neat) νmax/cm-1 = 3250 (NH), 2922 (Ar), 2852 (Ar), 1739 (CO), 1711 (CO), 1669 (CO), 1525 
(Ar), 1456 (OMe/OBn), 1377 (OMe/OBn) 
Mp (CH2Cl2): > 300 oC 
 
Synthesis of 57 – N-Boc-1,3-Phenylenediamine  
Previously synthesised and reported 160 
 
1,3-Phenylenediamine (1 g, 9.25 mmol) was dissolved in CH2Cl2 (3 mL) and cooled to 0 oC. To 
this, a solution of di-tert-butyl-carbonate (336 mg, 1.54 mmol) in CH2Cl2 (16 mL) was added 
drop wise. After which time the solution was warmed to room temperature and  stirred for a 
further 18 h. The reaction mixture was concentrated, dissolved in Na2CO3 (aq) (2M, 10 mL) and 
washed with EtOAc (3 x 15 mL). The combined organic washes were dried (Na2SO4), filtered 
and concentrated. The crude product was purified by column chromatography (SiO2: 5 % 
MeOH in CH2Cl2) to give compound 57 as a beige solid (191 mg, 60%, 0.92 mmol). 
Analytical Data 
Rf (SiO2 5 % MeOH in CH2Cl2) = 0.32 
1H NMR (400 MHz, CDCl3) δH 7.03 (1 H, t, J = 8.0 Hz, ArCH), 6.93 (1 H, br s, NH), 6.78 (1 H, s, 
ArCH), 6.59 (1 H, dd, J = 8.0 Hz, 1.5 Hz, ArCH), 6.36 (1 H, dd, J = 8.0 Hz, 1.5 Hz, ArCH), 1.51 (9 
H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 152.9 (CO), 147.2 (ArC), 139.4 (ArC), 129.7 (ArCH), 110.0 (ArCH), 
108.7 (ArCH), 105.3 (ArCH), 80.36 (C(CH3)3), 28.36 (CH3).  







Synthesis of N3Aib4NH-(1,3-Ph)-NHBoc 
 
N3Aib4NH-(1,3-Ph)-NHBoc was synthesised by following general procedure E on a 0.65 mmol. 
The product was purified by column chromatography (SNAP 10g, 2% MeOH in CH2Cl2 →7% 
MeOH in CH2Cl2) to give the product (264 mg, 0.46 mmol, 70 %) as a white solid. 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.27 
1H NMR (400 MHz, CDCl3) δH 8.98 (1 H, s, NH), 7.88-7.86 (1 H, m, ArH), 7.49 (1 H, dt, J = 6.5, 
2.0 Hz, ArH), 7.27 (1 H, s, NH), 7.21-7.18 (2 H, m, 2 x ArH), 7.07 (1 H, s, NH), 1.60 (6 H, s, 2 x 
CH3), 1.53 (6 H, s, 2 x CH3), 1.51 (9 H, s, 3 x CH3), 1.47 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3)  
13C NMR (100 MHz, CDCl3) δC 173.7 (CO), 173.6 (CO), 173.1 (CO), 172.7 (CO), 152.7 (CO), 140.0 
(ArC), 138.5 (ArC), 129.0 (ArH), 114.7 (ArH), 113.6 (ArH), 113.6 (ArH), 110.1 (ArH), 80.1 
(C(CH3)3), 63.9 (αC), 57.7 (αC), 57.0 (αC), 56.8 (αC), 28.3 (CH3), 25.7 (CH3), 25.3 (CH3), 24.8 
(CH3), 24.3 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C27H42N8NaO8: 597.311952; observed: 597.310135 (M+Na)+ 
IR (neat) νmax/cm-1: 3321 (NH), 2981 (CH), 2933 (CH), 2113 (N3), 1667 (CO), 1517 (NH), 1161 
(OtBu) 
Mp (CH2Cl2): 153-154 oC. 
 
Synthesis of H2NAib4-(1,3-Ph)-NHBoc 
 
H2NAib4-(1,3-Ph)-NHBoc was synthesised following general procedure A on a 0.25 mmol 
scale, giving the product (131 mg, 0.24 mmol, 95 %) as an off-white solid. 
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.05 
1H NMR (400 MHz, CD3OD) δH 7.92-7.89 (1 H, m, ArH), 7.40 (1 H, dt, J = 7.5, 2.0 Hz, ArH), 7.19-
7.11 (2 H, m, 2 x ArH), 1.59 (6 H, s, 2 x CH3), 1.55 (6 H, s, 2 x CH3), 1.52 (6 H, s, 2 x CH3), 1.50 (9 





13C NMR (100 MHz, CD3OD) δC 175.0 (CO), 174.8 (CO), 174.7 (CO), 173.9 (CO), 153.8 (CO), 
139.4 (ArC), 139.2 (ArC), 128.2 (ArH), 114.7 (ArH), 114.3 (ArH), 111.1 (ArH), 79.3 (C(CH3)3), 
57.3 (αC), 56.9 (αC), 56.6 (αC), 56.2 (αC), 27.3 (CH3), 24.2 (CH3), 23.9 (CH3), 23.6 (CH3) 
HRMS (ESI+, MeOH) calc. for C27H45N6O6: 549.339510; observed: 549.338583 (M+H)+ 
IR (neat) νmax/cm-1: 3289 (NH2/NH), 2981 (CH), 2936 (CH), 1660 (CO), 1524 (NH), 1159 (OtBu) 
Mp (CH2Cl2): 172-174 oC 
 
Synthesis of 58 – Cbz-Aib4-NH-(1,3-Ph)-NHBoc  
 
Cbz-Aib4-OH (83 mg, 0.17 mmol) and 1-hydroxybenzotriazole hydrate (49 mg, 0.36 mmol) 
were dissolved in CH2Cl2 (7 mL) and DMF (1.5 mL) and cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (59 mg, 0.31 mmol) was added 
and the resulting solution was then warmed to RT. N-Boc-1,3-Phenylenediamine (58 mg, 0.28 
mmol) and Et3N (0.046 mL, 0.33 mmol) were added and the reaction was stirred for 5 d. The 
resulting solution was then concentrated, dissolved in EtOAc (45 mL), washed with KHSO4 (aq) 
(2 x 15 mL), NaHCO3 (aq) (2 x 15 mL) and brine (15 mL), dried (MgSO4), filtered and 
concentrated. The crude product was purified by column chromatography (SiO2: 5 % MeOH 
in CH2Cl2) to give compound 58 as a beige solid (84 mg, 0.12 mmol, 70 %).  
Analytical Data 
Rf (SiO2: 10% MeOH in CH2Cl2) = 0.6 
1H NMR (400 MHz, CDCl3) 9.10 (1 H, br s, NH), 8.07 (1 H, d, J = 8.5 Hz, ArCH), 8.03 (1 H, s, NH), 
8.00 (1 H, s, NH), 7.90 (1 H, d, J = 8.5 Hz, NH), 7.80 (1 H, s, ArCH), 7.34 (5 H, m, 5 x ArCH), 7.16 
(1 H, t, J = 8.0 Hz, ArCH), 6.67 (1 H, br s, NH), 6.56 (1 H, s, NH), 6.31 (1 H, br s, NH), 5.09 (2 H, 
s, CH2), 1.59 (6 H, s, 2 x CH3), 1.48 (9 H, s, 3 x CH3), 1.43 (6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x CH3), 
1.35 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.6 (CO), 174.3 (CO), 174.2 (CO), 174.2 (CO), 160.0 (CO), 153.5 
(CO), 140.0 (ArC), 138.5 (ArC), 128.8 (ArCH), 128.7 (ArCH), 128.0 (ArCH), 125.1 (ArCH), 109.4 
(ArCH), 105.0 (ArCH), 85.2 (C(CH3)3), 67.2 (CH2), 57.5 (αC), 57.1 (αC), 56.9 (αC), 56.5 (αC), 28.3 
(CH3), 25.0 (CH3), 24.9 (CH3), 24.9 (CH3), 24.7 (CH3). 
HRMS (ESI+, CH3OH) calc. for C35H51N6O8: 683.37, observed: 683.5329 (M+H)+ 
IR (neat) νmax/cm-1 = 2893 (CH), 1704 (CO), 1657 (CO), 1644 (NH), 1578 (NH), 1520 (OR), 1453 
(OR), 1435 (CH) 





Synthesis of 66 – Cbz-Aib4-NH-(1,3-Ph)-NH2∙TFA  
 
Cbz-Aib4-NH-(1,3-Ph)-NHBoc (84 mg, 0.12 mmol) was prepared by following general 
procedure C on a (0.12 mmol scale). The crude product was purified by column 
chromatography (SiO2: 1% MeOH in CH2Cl2 → 10 % MeOH in CH2Cl2) to give compound 59 as 
a beige solid (18.6 mg, 27 % yield, 0.032 mmol).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.35 
1H NMR (400 MHz, CDCl3) 8.97 (1 H, br s, NH), 7.9 (1 H, br s, NH), 7.71 (1 H, br s, NH), 7.57 (1 
H, s, ArCH), 7.44 (1 H, d, J = 7.5 Hz, ArCH), 7.37 (5 H, m, 5 x ArCH), 7.19 (1 H, d, J = 7.5 Hz, 
ArCH), 7.05 (1, H, t, J = 8.0 Hz, ArCH), 6.50 (1 H, br s, NH), 5.75 (1 H, br s, NH), 5.13 (2 H, s, 
CH2), 1.61 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.44 (6 H, s, 2 x CH3), 1.36 (6 H, s, 2 x CH3). 
13C NMR (100 MHz, CDCl3) δC 174.9 (CO), 174.5 (CO), 174.5 (CO), 174.4 (CO), 157.3 (CO), 141.0 
(ArC), 138.1 (ArC), 129.3 (ArCH), 128.9 (ArCH), 127.4 (ArCH), 125.1 (ArCH), 115.0 (ArCH), 65.3 
(CH2), 57.7 (αC), 57.4 (αC), 56.8 (αC), 56.5 (αC), 28.1 (CH3), 25.8 (CH3), 24.7 (CH3), 24.7 (CH3). 
HRMS (ESI+, CH2Cl2) calc. for C30H42N6NaO6: 605.306354; observed: 605.306501 (M+Na)+ 
IR (neat) νmax/cm-1 = 3256 (NH/NH2), 2904 (CH), 1714 (CO), 1689 (CO), 1581 (NH), 1453 (CH) 
Mp (MeOH): 183-186 oC. 
 
Synthesis of 60 – MC-(L)αMv-Aib4-NH-(1,3-Ph)-NH-Aib4-Cbz  
 
MC-(L)αMvAib4OH (11.3 mg, 0.021 mmol) and 1-hydroxybenzotriazole hydrate (4 mg, 0.032 
mmol) were dissolved in CH2Cl2 (1.2 mL) and DMF (0.3 mL) and cooled to 0 oC. N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (4 mg, 0.023 mmol) was added 
and the resulting solution was warmed to RT. Cbz-Aib4-NH-(1,3-Ph)-NH2 (19 mg, 0.032 mmol) 
and Et3N (0.09 mL, 0.63 mL) were added and the reaction was stirred for 4 d. The resulting 
solution was then concentrated, dissolved in EtOAc (13 mL) and washed with KHSO4 (aq) (2 x 3 





crude product was purified by column chromatography (SiO2, 10 % MeOH in CH2Cl2) to give 
compound 60 as a beige solid (11 mg, 0.01 mmol, 50 %).  
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.20 
1H NMR (400 MHz, CDCl3) δH 9.03 (1 H, br s, NH), 9.00 (1 H, br s, NH), 8.38 (1 H, t, J = 2.0 Hz, 
ArCH), 7.84 (1 H, br s, NH), 7.71 (1 H, br s, NH), 7.59 (1 H, br s, NH), 7.54 (1 H, br s, NH), 7.52 
(1 H, br s, NH), 7.43-7.38 (5 H, m, 5 x ArCH), 7.35 (1 H, m, ArCH), 7.22 (1 H, d, J = 8.0 Hz, NH), 
7.19 (1 H, d, J = 7.5 Hz, ArCH), 7.18 (1 H, br s, NH), 6.36 (1 H, br s, NH), 6.00 (1 H, br s, NH), 
5.15 (2 H, s, CH2), 3.69 (3 H, s, OCH3) 2.02 (1 H, m, CH), 1.54 (3 H, s, CH3), 1.53 (3 H, s, CH3), 
1.52 (6 H, s, 2 x CH3), 1.50 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.46 (3 H, s, CH3), 1.46 (3 H, s, CH3), 
1.44 (3 H, s, CH3), 1.42 (6 H, s, 2 x CH3), 1.41 (3 H, s, CH3), 1.39 (3 H, s, CH3), 1.38 (6 H, s, 2 x 
CH3), 1.37 (6 H, s, 2 x CH3), 0.99 (3 H, d, J = 7.0 Hz, CH3), 0.95 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 175.2 (CO), 174.9 (CO), 174.7 (CO), 174.7 (CO), 174.5 (CO), 174.2 
(CO), 173.9 (CO), 173.7 (CO), 173.2 (CO), 156.8 (CO), 155.1 (CO), 136.1 (ArC), 133.9 (ArC), 
130.2 (ArC), 128.9 (ArH), 128.9 (ArH), 127.3 (ArH), 125.8 (ArH), 125.4 (ArH), 125.4 (ArH), 128.9 
(ArH), 68.9 (CH2 of Cbz), 66.4 (αC), 63.3 (αC), 58.0 (αC), 57.6 (αC), 57.3 (αC), 56.9 (αC), 56.6 (αC), 
56.6 (αC), 54.1 (αC), 52.1 (OCH3), 34.5 (CH), 27.4 (CH3), 26.5 (CH3), 26.4 (CH3), 25.8 (CH3), 25.5 
(CH3), 25.3 (CH3), 25.1 (CH3), 24.9 (CH3), 24.6 (CH3), 17.5 (CH3), 17.2 (CH3), 17.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +29.9 
HRMS (ESI+, CH3CN) calculated for C54H83N11NaO13: 1116.6070; observed: 116.6081 (M+Na)+  
IR (neat) νmax/cm-1 = 3300 (NH), 2970 (CH), 2890 (CH), 1750 (CO), 1725 (CO), 1659 (CO), 1525 
(NH)  
Mp (EtOAc) > 300 oC 
 
Synthesis of 167 – 1,8-Bis-(toluene-4-sulfonylamino)-anthraquinone  
Previously synthesised and reported 161 
 
4-Tolunenesulfonamide (3.17 g, 19 mmol), 1,8-dichloranthraquinone (1.71 g, 62 mmol) and 
sodium acetate (1.52 g, 19 mmol) were dissolved in 1-pentanol (60 mL). Copper (ii) acetate 





reaction mixture was cooled to 0 oC and filtered to give the crude product, which was then 
dissolved in CH2Cl (150 mL), washed with NaHCO3 (aq) (2 x 35 mL), dried (MgSO4), filtered and 
concentrated. The crude product was then purified by column chromatography (SiO2: 1:1 
Petroleum Ether:EtOAc → 1:1 Petroleum Ether:CH2Cl2 → 100 % CH2Cl2) to give 1,8-Bis-
(toluene-4-sulfonylamino)-anthraquinone as a bright orange solid (2.0 g, 3.7 mmol, 60 %).  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 11.81 (2 H, s, 2 x NH), 8.04 (2 H, dd, J = 8.5 Hz, 1.0 Hz, 2 x ArCH), 
7.94 (2 H, dd, J = 7.5 Hz, 1.0 Hz, 2 X ArCH), 7.88 (4 H, d, J = 8.0 Hz, 4 x ArCH), 7.68 (2 H, t, J = 
8.0 Hz, 2 x ArCH), 7.32 (4 H, d, J = 8.0 Hz, 4 x ArCH), 2.41 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 190.64 (CO), 181.57 (CO), 144.67 (ArC), 141.54 (ArC), 136.25 
(ArC), 135.97 (ArCH), 133.66 (ArC), 130.04 (ArCH), 127.37 (ArCH), 123.86 (ArCH), 122.35 
(ArCH), 118.00 (ArC), 21.62 (CH3) 
Analytical data consistent with previously reported information 161 
 
Synthesis of 168 – 1,8-Diamino-anthraquinone  
Previously reported and synthesised 161 
  
1,8-Bis-(toluene-4-sulfonylamino)-anthraquinone (608 mg, 1.11 mmol) was added in ~50 mg 
portions to a stirred solution of conc. H2SO4 (5 mL). Upon addition of a portion of 1,8-Bis-
(toluene-4-sulfonylamino)-anthraquinone a thick black suspension forms which rapidly turns 
over to a clear yellow solution. Once the solution becomes clear, another portion of the 1,8-
Bis-(toluene-4-sulfonylamino)-anthraquinone can be added. The resulting solution was 
stirred at RT for a further 3 h after which time it was cooled to 0 oC and diluted with H2O (35 
mL) and NaHCO3 (aq) (50 mL). The aqueous phase was repeatedly washed with EtOAc (50 mL) 
until it becomes colourless. The combined organic washes were dried (Na2SO4), filtered and 
concentrated to give 1,8-diamino-anthraquinone (186 mg, 70 %, 0.78 mmol) as a bright red 
solid.  
Analytical Data 
1H NMR (400 MHz, DMSO-d6) δH 7.45 (2 H, dd, J = 8.5 Hz, 7.5 Hz, 2 x ArCH), 7.35 (2 H, dd, J = 
7.0 Hz, 1.0 Hz, 2 x ArCH), 7.16 (2 H, dd, J = 8.5 Hz, 1.0 Hz, 2 x ArCH).  
13C NMR (100 MHz, DMSO-d6) δC 188.2 (CO), 183.9 (CO), 152.0 (ArC), 134.2 (ArCH), 134.0 





Spectral data consistent with previously reported data. 161 
 
Synthesis of 169 – 1,8-Diaminoanthracene  
Previously synthesised and reported 162 
 
1,8-Diamino-anthraquinone (183 mg, 0.77 mmol) and NaOH (6mg, 0.15 mmol) were dissolved 
in 2-propanol (7 mL) and the resulting solution was purged under Argon. NaBH4 (291 mg, 7.7 
mmol) was added to the mixture in ~50 mg portions and the mixture was then refluxed for 8 
h. After which time the reaction was cooled to RT and poured over a mixture of ice and water. 
This was filtered to give 1,8-diaminoanthracene as a dark red solid (120 mg, 0.58 mmol, 75 
%). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 8.29 (1 H, s, ArCH), 8.26 (1 H, s, ArCH), 7.41 (2 H, d, J = 8.5 Hz, 
ArCH), 7.21 (2 H, dd, J = 8.5 Hz, 7.5 Hz, ArCH), 6.09 (2 H, d, J = 7.0 Hz, ArCH) 
13C (100 MHz, CDCl3) δC 142.0 (ArC), 132.5 (ArC), 132.2 (ArC), 127.2 (ArCH), 126.0 (ArCH), 123.1 
(ArCH), 119.3 (ArCH), 108.0 (ArCH).  
Spectral data consistent with previously reported data. 162 
 
Synthesis of 163 – tert-butyl-1-(2-iodophenyl)-3,3,6,6,9,9,12,12-octamethyl-1,4,7,10-tetra-
oxo-2,5,8,11-tetraazatridecan-13-oate  
 
2-Iodobenzoyl chloride (267 mg, 1.0 mmol, 1 eq) and pyridine (0.24 mL, 3.0 mmol, 3 eq) were 
dissolved in CH2Cl2 (5 mL), to this a solution of H2NAib4OtBu (500 mg, 1.2 mmol, 1.2 eq) in 
CH2Cl2 (5 mL) was added in a dropwise manner. The resulting solution was left to stir at RT for 
48 h, after which it was diluted with CH2Cl2 (~30 mL) and washed with KHSO4 (aq), NaHCO3 (aq) 
and brine. The organic phase was then dried over Na2SO4, filtered and concentrated to give 






Rf (SiO2 5% MeOH in CH2Cl2) = 0.23 
1H NMR (400 MHz, CD3OD) δH 7.96 (1 H, dt, J = 8.0, 1.0 Hz, ArH), 7.51-7.48 (2 H, m, 2 x ArH), 
7.22 (1 H, ddd, J = 8.0, 6.0, 3.5 Hz, ArH), 1.56 (6 H, s, 2 x CH3), 1.53 (6 H, s, 2 x CH3), 1.49 (6 H, 
s, 2 x CH3), 1.48 (6 H, s, 2 x CH3), 1.45 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CD3OD) δC 175.1 (CO), 174.8 (CO), 174.7 (CO), 174.2 (CO), 170.4 (CO), 
141.2 (ArC), 139.7 (ArH), 131.1 (ArH), 128.3 (ArH), 127.9 (ArH), 92.2 (ArI), 80.2 (C(CH3)3), 57.0 
(αC), 56.7 (αC), 56.6 (αC), 56.1 (αC), 26.8 (CH3), 24.5 (CH3), 24.1 (CH3), 23.8 (CH3), 23.6(CH3) 
HRMS ESI+ (CH3OH) calc. for C27H42IN4NaO6: 654.214360 observed: 645.212916 (M+Na)+ 
IR (neat) νmax/cm-1 = 3227 (NH), 2978 (CH), 2983 (CH), 1723 (CO), 1659 (CO), 1537 (Ar), 1142 
(OtBu), 541 (ArI) 
Mp (CH2Cl2): 176-179 oC 
 




tetraazatridecan-13-oate (250 mg, 0.39 mmol) was dissolved in Et3N (5 mL) and DMF (2 mL). 
This solution was then bubbled through with N2. After ~10 min CuI (11.2 mg, 0.02 mmol) and 
PdCl2(PPh3)2 (14 mg, 0.02 mmol) were added. Following this 2-ethynylaniline (0.09 mL, 0.78 
mmol) was added in a dropwise manner, after which the reaction was heated at 80oC 
overnight. Following this the crude reaction mixture was poured into water and extracted 
with EtOAc (3 x 20 mL). The organic phases were combined, dried over Na2SO4, filtered and 
concentrated. The crude residue was then dissolved in a minimum amount of EtOAc and 
filtered through Celite®. The filtrate was concentrated, and then purified by column 
chromatography (10g SNAP Ultra, 1:1 EtOAc/Petrol with 1% Et3N → 9:1 EtOAc/Petrol with 1% 
Et3N) giving the title compound as a white solid (85 mg, 0.13 mmol, 34 %). 
Analytical Data  





 1H NMR (400 MHz, CD3OD) δH 7.83 (1 H, dt, J = 8.0, 1.0 Hz, ArH), 7.57-7.51 (2 H, m, 2 x ArH), 
7.48-7.42 (2 H, m, 2 x ArH), 7.37 (2 H, d, J = 4.5 Hz, 2 x ArH), 7.09 (1 H, dt, J = 8.0, 4.5 Hz, ArH), 
1.44 (6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x CH3), 1.37 (6 H, s, 2 x CH3), 1.36 (6 H, s, 2 x CH3), 1.32 (9 
H, s, 3 x CH3) 
13C NMR (100 MHz, CD3OD) δC 175.1 (CO), 174.7 (CO), 174.7 (CO), 174.1 (CO), 170.4 (CO), 
141.1 (ArC), 139.7 (ArH), 132.4 (ArC), 132.4 (ArC), 131.7 (ArH), 131.6 (ArH), 131.1 (ArH), 128.7 
(ArH), 128.5 (ArH), 128.4 (ArH), 127.9 (ArH), 92.3 (CΞC), 80.1 (C(CH3)3), 57.0 (αC), 57.0 (αC), 
56.8 (αC), 56.7 (αC), 24.6 (CH3), 24.2 (CH3), 24.1 (CH3), 23.8 (CH3), 23.7 (CH3) 








6.4.2. Experimental Details for Section 3 
 
Synthesis of 66 – H2NAibCH2OTBS  
Previously synthesised and reported 163 
 
H2AibCH2OH (0.95 mL, 10 mmol) and Et3N (3.74 mL, 25 mmol) were dissolved in CH2Cl2 (20 
mL) and DMF (10 mL). To this TBSCl (2.26 g, 15 mmol) was added and the resulting mixture 
was left to stir overnight. After this time the reaction mixture was diluted with CH2Cl2 (100 
mL) and washed with NaHCO3 (aq) (50 mL), the organic phase was dried over Na2SO4, filtered 
and concentrated to give compound 143 as a clear oil.  
Analytical data 
1H NMR (400 MHz, CDCl3) δH 3.31 (2 H, s, CH2), 2.09 (2 H, br s, NH2), 1.07 (6 H, s, 2 x CH3), 0.90 
(9 H, s, 3 x CH3), 0.05 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 72.8 (CH2), 51.0 (C(CH3)2), 26.4 (CH3), 25.9 (CH3), 18.3 (C(CH3)3), 
-5.5 (CH3) 
Spectral data consistent with previously reported data. 163 
 
Synthesis of N3Aib4AibCH2OTBS  
 
N3Aib4AibCH2OTBS was synthesised by following general procedure D on a 0.49 mmol. This 
was purified by column chromatography (SNAP Ultra 10 g, 1% → 10% MeOH in CH2Cl2) to give 
N3Aib4AibCH2OTBS as a white solid (153 mg, 0.27 mmol, 55%) 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.28 
1H NMR (400 MHz, CDCl3) δH 7.11 (1 H, s, NH), 6.89 (1 H, s, NH), 6.52 (1 H, s, NH), 6.20 (1 H, s, 
NH), 3.65 (2 H, s, CH2), 1.52 (6 H, s, 2 x CH3), 1.48 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.42 
(6 H, s, 2 x CH3), 1.30 (6 H, s, 2 x CH3), 0.86 (9 H, s, 3 x CH3), 0.01 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.2 (CO), 172.6 (CO), 172.4 (CO), 172.4 (CO), 68.3 (CH2), 64.1 
(C(CH3)3), 57.2 (αC), 57.0 (αC), 56.8 (αC), 54.6 (αC), 25.9 (CH3), 25.4 (CH3), 25.3 (CH3), 24.9 





HRMS (ESI+, CH2Cl2/CDCl3) calc. for C26H52N7O5Si: 570.3794; observed: 570.3790 (M+H)+  
IR (neat) νmax/cm-1 = 3297 (NH), 2953 (CH), 2854 (CH), 2114 (N3), 1736 (CO), 1670 (CO), 1515 
(CH), 1360 (SiO), 1217 (SiC) 
Mp (CH2Cl2): 175-177 oC  
 
Synthesis of 65 – Cbz-(L)αMv2-Aib4OH  
Previously synthesised and reported 77 
 
Cbz(L)αMv2Aib4OH was synthesised by following general procedure C on a 0.65 mmol scale. 
This gave compound 65 (435 mg, 0.62 mmol, 95 %) as a white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.28-7.21 (5 H, m, 5 x ArH), 5.23 (1 H, d, J = 10.0 Hz, part of the 
AB system of the Cbz CH2), 5.14 (1 H, d, J = 10.0 Hz, part of the AB system of the Cbz CH2), 
2.21-2.03 (2 H, m, 2 x CH), 1.49 (3 H, s, CH3), 1.49 (3 H, s, CH3), 1.46 (6 H, s, 2 x CH3), 1.45 (9 H, 
s, 3 x CH3), 1.44 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.38 (3 H, s, 2 x CH3), 1.03-0.97 (6 H, m, 2 x 
CH3), 0.95 (3 H, d, J = 7.0 Hz, CH3), 0.92 (3 H, d, J = 7.0 Hz, CH3)  
Spectral data consistent with previously reported information 77 
 
Synthesis of 67 – Cbz-(L)αMv2-Aib4-AibCH2OTBS 
 
Cbz(L)αMv2Aib4AibCH2OTBS was synthesised following general procedure D on a 0.19 mmol 
scale. This was purified by column chromatography (SNAP Ultra 10g, 1% → 10% MeOH in 
CH2Cl2) to give compound 67 as a white solid (70 mg, 0.089 mmol, 47 %).  
Analytical Data 





1H NMR (400 MHz, CDCl3) δH 7.69 (1 H, s, NH), 7.58 (1 H, s, NH), 7.55 (1 H, s, NH), 7.37-7.30 (6 
H, m, 5 x ArH and 1 x NH), 6.76 (1 H, s, NH), 6.35 (1 H, s, NH), 5.54 (1 H, s, NH), 5.17 (1 H, d, J 
= 12.0 Hz, part of the AB system of the Cbz CH2), 5.00 (1 H, d, J = 12.0 Hz, part of the AB system 
of the Cbz CH2), 3.85 (1 H, d, J = 9.5 Hz, part of AB system CH2OTBS), 3.61 (1 H, d, J = 9.5 Hz, 
part of AB system CH2OTBS), 1.86 (1 H, hept, J = 7.5 Hz, CH(CH3)2), 1.73-1.63 (1 H, m, CH(CH3)2), 
1.50 (3 H, s, CH3), 1.49 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.45 
(3 H, s, CH3), 1.43 (6 H, s, 2 x CH3), 1.42 (6 H, s, 2 x CH3), 1.38 (3 H, s, CH3), 1.34 (3 H, s, CH3), 
1.32 (3 H, s, CH3), 0.97 (3 H, d, J = 7.0 Hz, CH3), 0.95 (3 H, d, J = 7.0 Hz, CH3), 0.86 (9 H, s, 3 x 
CH3), 0.76 (6 H, 2 x d, J = 6.5 Hz, 2 x CH3), 0.01 (6 H, s, 2 x CH3). 
13C NMR (100 MHz, CDCl3) δC 175.1 (CO), 175.0 (CO), 175.0 (CO), 174.3 (CO), 172.5 (CO), 172.4 
(CO), 156.4 (CO), 135.9 (ArC), 128.6 (ArH), 128.5 (ArH), 128.5 (ArH), 68.0 (CH2OTBS), 67.4 (CH2 
of Cbz), 63.4 (αC), 62.3 (αC), 57.1 (αC), 56.8 (αC), 56.7 (αC), 56.6 (αC), 54.6 (αC), 35.8 (CH), 
35.6 (CH), 27.9 (CH3), 27.4 (CH3), 27.1 (CH3), 25.9 (CH3), 24.0 (CH3), 23.5 (CH3), 23.4 (CH3), 22.9 
(CH3), 22.8 (CH3), 22.7 (CH3), 18.1 (C(CH3)3), 18.0 (CH3), 17.4 (CH3), 17.2 (CH3), 17.0 (CH3), 16.9 
(CH3), -5.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +44.2 
HRMS (MALDI, CH2Cl2) calc. for C46H82N7O9Si: 904.594438; observed: 904.594546 (M+H)+ 
IR (neat) νmax/cm-1: 3309 (NH), 2980 (Ar), 2938 (Ar), 1651 (CO), 1525 (Ar), 1336 (SiO), 1259 
(SiC/OBn), 1228 (SiC/OBn) 
Mp (CH2Cl2) 156-158 oC 
 
Synthesis of 68 – Hyd[(L)αMv]-(L)αMv-Aib4-AibCH2OH  
 
Cbz(L)αMv2Aib4AibCH2OTBS (214 mg, 0.24 mmol) was dissolved in tetrahydrofuran (2 mL), to 
this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (1 mL, 0.72 mmol, 
3 eq) was added. The resulting solution was left to stir overnight, after which time the reaction 
mixture was concentrated and dissolved in EtOAc. This was then washed with water, NaHCO3, 
1 M HCl (aq) and brine, dried over Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography (SNAP Ultra 10g, 2% MeOH → 10% MeOH in CH2Cl2) to 
give compound 68 (80 mg, 0.13 mmol, 54 %) as a white solid.  
Analytical Data 





1H NMR (500 MHz, CDCl3) δH 7.72 (1 H, s, NH), 7.57 (1 H, s, NH), 7.45 (1 H, s, NH), 6.96 (1 H, s, 
NH), 5.76 (1 H, s, NH), 5.56 (1 H, s, NH), 4.56 (1 H, t, J = 7.0 Hz, OH), 3.78-3.70 (1 H, m, part of 
ABX system CH2OH), 3.59-3.50 (1 H, m, part of ABX system CH2OH), 3.08 (1 H, sept, J = 7.0 Hz, 
CH of hydantoin αMv), 2.09 (1 H, sept, J = 7.0 Hz, CH of αMv), 1.71 (3 H, s, CH3), 1.51 (6 H, s, 
2 x CH3), 1.49 (9 H, s, 3 x CH3), 1.47 (3 H, s, CH3), 1.45 (6 H, s, 2 x CH3), 1.43 (3 H, s, CH3), 1.38 
(3 H, s, CH3), 1.37 (3 H, s, CH3), 1.09 (3 H, d, J = 7.0 Hz, CH3 of iPr), 1.04 (3 H, d, J = 7.0 Hz, CH3 
of iPr), 1.01 (3 H, d, J = 7.0 Hz, CH3 of iPr), 0.99 (3 H, d, J = 7.0 Hz, CH3 of iPr) 
13C NMR (125 MHz, CDCl3) δC 177.7 (CO), 175.5 (CO), 175.1 (CO), 174.9 (CO), 173.6 (CO), 170.4 
(CO), 157.1 (CO), 68.9 (Hydantoin αC), 67.7 (CH2), 64.4 (αMv αC), 57.3 (αC), 57.1 (αC), 57.0 
(αC), 56.8 (αC), 55.4 (C(CH3)2), 34.5 (CH Hydantoin), 32.5 (CH), 26.2 (CH3), 25.6 (CH3), 24.9 
(CH3), 24.7 (CH3), 24.2 (CH3), 23.6 (CH3), 22.5 (CH3), 20.4 (CH3), 19.0 (CH3), 18.3 (CH3), 17.2 
(CH3), 16.6 (CH3) 
[α]D (c = 0.5, MeOH) = +34.5 
HRMS (ESI+, MeOH) calc. for C33H59N7NaO8:  704.431733; observed: 704.431324 (M+Na)+ 
IR (neat) νmax/cm-1: 3304 (br, OH), 2971 (CH), 2937 (CH), 1709 (CO), 1657 (CO), 1530 (CH), 
1383 (OH) 
Mp (CH2Cl2): 200-203 oC. 
 
Synthesis of HCl∙H2NAibMe  
Synthesis of BocAibMe  
 
BocNHAibN(OMe)Me (257 mg, 1.05 mmol, 1 eq.) was dissolved in tetrahydrofuran (2 mL) and 
cooled to 0 oC. To this a solution of MeMgBr in Et2O (3 M, 2.61 mmol, 1.15 mL) was added in 
a dropwise manner. The resulting solution was warmed to RT and stirred for a further 4 h. 
After this time a saturated solution of NH4Cl (aq) (10 mL) and water (10 mL) was added and the 
resulting solution was washed with Et2O (3 x 25 mL). The organic phases were combined and 
washed with brine (10 mL), then dried with Na2SO4, filtered and concentrated to give 
BocAibMe (197 mg, 0.98 mmol, 93 %) as a yellow oil which was used without further 
purification. 






Crude BocNHAibCH3 (196 mg, 0.98 mmol) was dissolved in a solution of dioxane in HCl (4 M, 
3 mL) and left to stir overnight. After this time the reaction mixture was concentrated, and 
the crude solid was triturated with Et2O to give HCl∙H2NAibMe as a yellow solid (94 mg, 0.68 
mmol, 70%). 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 2.29 (3 H, s, CH3), 1.57 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 205.5 (CO), 100.0 (αC), 61.6 (COCH3), 21.57 (CH3).  
Spectra consistent with previously reported data. 164 
 
Synthesis of Cbz-(L)αMv2-Aib4-AibMe  
 
CbzαMv2Aib4AibCH3 was synthesised by following general procedure D on a 0.21 mmol scale. 
CbzαMv2Aib4AibCH3 was purified by column chromatography (SNAP Ultra 10 g, 1% → 10 % 
MeOH in CH2Cl2) as an off-white solid (104 mg, 0.13 mmol, 62 %). 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.38 
1H NMR (400 MHz, CDCl3) δH 7.72 (1 H, s, NH), 7.66 (1 H, s, NH), 7.55 (1 H, s, NH), 7.46 (1 H, s, 
NH), 7.40 (1 H, s, NH), 7.37-7.33 (5 H, m, 5 x ArH), 6.35 (1 H, s, NH), 6.31 (1 H, s, NH), 5.18 (1 
H, dd, J = 16.0 Hz, 6.0 Hz, part of the AB system of the CH2 Cbz, 5.01 (1 H, dd, J = 12.0 Hz, 6.0 
Hz, part of the AB system of the CH2 Cbz), 2.17 (3 H, s, CH3), 1.85 (1 H, sept, J = 7.0 Hz, CH), 
1.61 (3 H, m, CH3), 1.55 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.49 (3 H, s, CH3), 1.48 (3 H, s, CH3), 
1.47 (3 H, m, CH3), 1.45 (6 H, s, 2 x CH3), 1.44 (3 H, s, CH3), 1.41 (3 H, s, CH3), 1.39 (6 H, s, 2 x 
CH3), 1.37 (3 H, s, CH3), 0.98 (3 H, m, CH3), 0.95 (3 H, m, CH3), 0.78 (3 H, m, CH3), 0.76 (3 H, m, 
CH3) 
HRMS (ESI+, CH2Cl2) calc. for C41H67N7NaO9: 824.489247; observed: 824.489849 (M+Na)+ 
IR (neat) νmax/cm-1 = 3303 (NH), 2980 (CH), 2970 (CH), 1674 (CO), 1656 (CO), 1525 (NH) 








Synthesis of N3Aib3OH  
Previously synthesised and reported 90 
 
N3Aib3OH was synthesised following general procedure C on a 2.82 mmol scale. N3Aib3OH 
was obtained as a white solid (844 mg, 2.80 mmol, 99%). 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 1.58 (6 H, s, 2 x CH3), 1.57 (6 H, s, 1 x CH3), 1.50 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CD3OD) δC 177.5 (CO), 173.2 (CO), 172.9 (CO), 64.9 (αC), 58.2 (αC), 56.1 
(αC), 24.9 (CH3), 24.7 (CH3), 24.1 (CH3) 
Spectral data consistent with previously reported data 90 
 
Synthesis of 69 – N3Aib6OtBu  
Previously synthesised and reported 105 
 
Formation of the Azlactone: 
N3AibOH (500 mg, 1.67 mmol) was dissolved in CH2Cl2 and the resulting solution was cooled 
to 0oC. EDC∙HCl (414 mg, 2.17 mmol, 1.3 eq.) and DIPEA (0.38 mL, 2.17 mmol, 1.3 eq.) were 
added. The resultant solution was left to warm to RT overnight. The reaction mixture was 
concentrated and then diluted with EtOAc and washed twice with NaHCO3 (aq) and once with 
brine. The organic phase was dried over Na2SO4, filtered and concentrated to give the crude 
azlactone which was used without further purification. 
Formation of 69: 
The crude azlactone, H2NAib3OtBu (500 mg, 1.51 mmol) and DIPEA (0.20 mL, 1.17 mmol) were 
dissolved in MeCN and heated to reflux for 3 d. The reaction mixture was then concentrated 
and diluted with EtOAc and washed with KHSO4 (aq), NaHCO3 (aq) and brine. The organic phase 
was then dried over Na2SO4, filtered and concentrated to give the crude product which was 
purified by column chromatography (SNAP ULTRA 10g 1% MeOH in CH2Cl2 → 7% MeOH in 






1H NMR (400 MHz, CDCl3) δH 7.40 (1 H, s, NH), 7.31 (1 H, s, NH), 7.23 (1 H, s, NH), 6.97 (1 H, s, 
NH), 6.18 (1 H, s, NH), 1.55 (6 H, s, 2 x CH3), 1.50 (6 H, s, 2 x CH3), 1.49 (6 H, s, 2 x CH3), 1.47 (6 
H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.43 (15 H, s, 5 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.0 (CO), 173.8 (CO), 173.7 (CO), 173.6 (CO), 173.0 (CO), 
172.9 (CO), 79.7 (C(CH3)3), 63.9 (αC), 57.0 (αC), 56.9 (αC), 56.7 (αC), 56.6 (αC), 55.6 (αC), 
27.9 (CH3), 25.5 (CH3), 25.2 (CH3), 24.8 (CH3), 24.3 (CH3)  
HRMS (CH2Cl2 ESI+) calc. for C28H51N8O7: 611.3870; observed: 611.3870 (M+H)+ 
Spectral data consistent with previously reported data 105 
 
Synthesis of 70 – H2NAib6OtBu  
Previously synthesised and reported 165 
 
H2NAib6OtBu was prepared by following general procedure C on a 190 mg scale to give 
compound 70 (169 mg, 0.29 mmol, 95 %) as an off-white solid.  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 8.21 (1 H, s, NH), 7.68 (1 H, s, NH), 7.28 (1 H, s, NH), 7.23 (1 H, s, 
NH), 6.28 (1 H, s, NH), 1.43 (6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x CH3), 1.40 (12 H, s, 4 x CH3), 1.36 
(9 H, s, 3 x CH3), 1.35 (6 H, s, 2 x CH3), 1.30 (6 H, s, 2 x CH3) 
13C (100 MHz, CDCl3) δC 178.7 (CO), 174.1 (CO), 174.1 (CO), 174.0 (CO), 173.9 (CO), 173.7 (CO), 
79.7 (C(CH3)3), 56.9 (αC), 56.6 (αC), 56.5 (αC), 56.2 (αC), 56.0 (αC), 54.7 (αC), 28.8 (CH3), 27.9 
(CH3), 25.5 (CH3), 25.2 (CH3), 25.1 (CH3), 24.8 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C28H52N6NaO7: 607.3790; observed: 607.3796 (M+Na)+ 











Synthesis of 71 – CbzHNAib6OtBu  
Previously synthesised and reported 166 
 
A solution of H2NAib6OtBu (194 mg, 0.33 mmol) in THF (10 mL) was added dropwise to a 
stirred solution of benzyl chloroformate (0.06 mL, 0.40 mmol) and DIPEA (0.23 mL, 1.32 mmol) 
in THF (2 mL) at 0 oC. The resulting solution was left to warm to room temperature and left 
stirring overnight. The reaction mixture was concentrated, diluted with EtOAc then washed 
with KHSO4 (aq), NaHCO3 (aq) and brine. The organic phase was dried over Na2SO4, filtered and 
concentrated. The crude product was purified by column chromatography (SNAP Ultra 10g, 
2%→8% MeOH in CH2Cl2) to give compound 71 (220 mg, 0.31 mmol, 93 %) as an off-white 
solid.  
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.16 
1H NMR (400 MHz, CDCl3) δH 7.48 (1 H, s, NH), 7.39 (1 H, s, NH), 7.32 (1 H, s, NH), 7.30-7.23 (6 
H, m, 5 x ArH and 1 x NH), 6.39 (1 H, s, NH), 6.17 (1 H, s, NH), 5.03 (2 H, s, CH2), 1.44 (6 H, s, 2 
x CH3), 1.41 (6 H, s, 2 x CH3), 1.40 (12 H, s, 4 x CH3), 1.36 (15 H, s, 5 x CH3), 1.24 (6 H, s, 2 x CH3) 
13C (100 MHz, CDCl3) δC 175.1 (CO), 174.4 (CO), 174.1 (CO), 174.1 (CO), 173.9 (CO), 156.1 (CO), 
136.3 (ArC), 128.6 (ArH), 128.5 (ArH), 128.1 (ArH), 79.7 (C(CH3)3), 67.2 (CH2), 57.2 (αC), 56.8 
(αC), 56.7 (αC), 56.6 (αC), 56.4 (αC), 56.0 (αC), 27.9 (CH3), 25.5 (CH3), 25.2 (CH3), 25.0 (CH3), 
24.9 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C36H59N6O9: 719.433804, observed: 719.434211 (M+H)+ 
Analytical data consistent with previously reported data 166 
 
Synthesis of 72 – CbzHNAib6OH 
Previously synthesised and reported 167 
 
CbzAib6OH was prepared by following general procedure C on a 190 mg scale to give 






1H NMR (400 MHz, CD3OD) δH 7.33-7.19 (5 H, m, ArH), 5.04 (2 H, s, CH2), 1.42 (6 H, s, 2 x CH3), 
1.38 (6 H, s, 2 x CH3), 1.36 (6 H, s, 2 x CH3), 1.33 (6 H, s, 2 x CH3), 1.29 (6 H, s, 2 x CH3), 1.24 (6 
H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.8 (CO), 176.0 (CO), 175.7 (CO), 175.5 (CO), 175.4 (CO), 174.3 
(CO), 156.5 (CO), 137.3 (ArC), 128.2 (ArH), 127.7 (ArH), 127.2 (ArH), 66.3 (CH2), 56.4 (αC), 56.4 
(αC), 56.4 (αC), 56.2 (αC), 56.2 (αC), 55.6 (αC), 24.3 (CH3), 24.1 (CH3), 24.0 (CH3), 23.8 (CH3), 
23.7 (CH3) 
HRMS (ESI+ MeOH) calc. for C32H50N6NaO9: 685.353148; observed: 685.355824 (M+Na)+ 
Data consistent with previously reported data 167 
 
Synthesis of CbzHNAib3OtBu  
Previously synthesised and reported 168 
 
A solution of H2NAib3OtBu (660 mg, 2.0 mmol, 1 eq.) in THF (15 mL) was added in a dropwise 
manner to a stirred solution of benzyl chloroformate (0.63 mL, 4.4 mmol, 1.2 eq) and DIPEA 
(1.04 mL, 6.0 mmol, 3 eq.) in THF (10 mL) at 0 oC. The resulting solution was left to warm to 
RT overnight after which time the reaction mixture was concentrated and then dissolved in 
EtOAc. The reaction mixture was washed with KHSO4 (aq), NaHCO3 (aq), and brine; then dried 
over MgSO4, filtered and concentrated. This was purified by column chromatography (SNAP 
Ultra 25g, 2→10 % MeOH in CH2Cl2) to give CbzAib3OtBu as a white solid (787 mg, 1.7 mmol, 
85 %) 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.36-7.03 (5 H, m, 5 x ArH), 7.16 (1 H, s, NH), 6.43 (1 H, s, NH), 
5.77 (1 H, s, NH), 5.08 (2 H, s, CH2), 1.46 (6 H, s, 2 x CH3), 1.44 (6 H, s, 2 x CH3), 1.43 (9 H, s, 3 x 
CH3), 1.41 (6 H, s, 2 x CH3) 
13C (100 MHz, CDCl3) δC 173.7 (CO), 173.0 (CO), 172.9 (CO), 155.6 (CO), 136.2 (ArC), 128.6 
(ArH), 128.3 (ArH), 128.1 (ArH), 80.4 (C(CH3)3), 66.8 (CH2), 57.2 (αC), 56.6 (αC), 56.3 (αC), 27.9 
(CH3), 25.3 (CH3), 25.2 (CH3), 24.5 (CH3) 








Synthesis of CbzHNAib3OH  
Previously synthesised and reported 169 
 
CbzHNAib3OH was prepared by following general procedure C on a 787 mg scale to give 
CbzAib3OH (659 mg, 1.62 mmol, 95 %) as a white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.42-7.28 (5 H, m, 5 x ArH), 5.14 (2 H, s, CH2), 1.47 (6 H, s, 2 x 
CH3), 1.41 (6 H, s, 2 x CH3), 1.38 (6 H, s, 2 x CH3) 
13C (100 MHz, CD3OD) δC 176.8 (CO), 175.0 (CO), 174.8 (CO), 156.4 (CO), 137.0 (ArC), 128.2 
(ArH), 127.8 (ArH), 127.5 (ArH), 66.1 (CH2), 56.4 (αC), 56.2 (αC), 55.7 (αC), 24.0 (CH3), 23.9 
(CH3), 23.8 (CH3) 
Spectral data consistent with previously reported data 169 
 
Synthesis of 73 – CbzHNAib6AibCH2OTBS  
 
Formation of the azlactone: 
A solution of CbzAib6OH (520 mg, 0.79 mmol, 1 eq.) in CH2Cl2 (35 mL) was cooled to 0oC, to 
this EDC∙HCl (243 mg, 1.27 mmol, 1.3 eq.) and DIPEA (0.4 mL, 2.29 mmol, 3 eq.) were added 
and the resulting solution was warmed to RT overnight. After this the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried over Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of 73: 
The crude azlactone, H2NAibCH2OTBS (202 mg, 1.0 mmol, 1.25 eq.) and DIPEA (0.21 mL, 1.2 
mmol, 1.5 eq.) were dissolved in MeCN (20 mL) and heated at reflux for 5 d. After this time 
the reaction mixture was concentrated and dissolved in EtOAc. This was washed with KHSO4 
(aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. This was then 
purified by column chromatography (SNAP Ultra 25g, 2→8% MeOH in CH2Cl2) to give 






Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.34 
1H NMR (400 MHz, CDCl3) δH 7.60 (1 H, s, NH), 7.52 (1 H, s, NH), 7.50 (1 H, s, NH), 7.42 (1 H, s, 
NH), 7.34-7.28 (5 H, m, 5 x ArH), 6.76 (1 H, s, NH), 6.69 (1 H, s, NH), 6.66 (1 H, s, NH), 5.08 (2 
H, s CH2 of Cbz), 3.70 (2 H, s, CH2OTBS), 1.47 (6 H, s, 2 x CH3), 1.46-1.43 (18 H, m, 6 x CH3), 1.39 
(6 H, s, 2 x CH3), 1.32 (6 H, s, 2 x CH3), 1.29 (6 H, s, 2 x CH3), 0.85 (9 H, s, SiC(CH3)3), 0.00 (6 H, 
s, Si(CH3)2) 
13C (100 MHz, CDCl3) δC 175.2 (CO), 175.1 (CO), 175.1 (CO), 174.9 (CO), 174.5 (CO), 156.3 (CO), 
136.5 (ArC), 128.6 (ArH), 128.3 (ArH), 128.0 (ArH), 68.1 (CH2 of Cbz), 67.0 (CH2OTBS), 57.1 
(αC), 56.7 (αC), 56.6 (αC), 56.6 (αC), 56.4 (αC), 54.6 (C(CH3)2 on AibCH2), 25.9 (CH3), 25.2 (CH3), 
24.9 (CH3), 24.7 (CH3), 23.8 (CH3), 18.4 (SiC), 18.2 (SiC(CH3)3), -5.4 (SiCH3) 
HRMS (ESI+, CH2Cl2) calc. for C42H73N7O9Si: 848.5312; observed: 848.5314 (M+H)+ 
IR (neat) νmax/cm-1: 3301 (NH), 2985 (CH), 2939 (CH), 1737 (CO), 1658 (CO), 1530 (Ar), 1214 
(OMe/OtBu/OBn), 1168 (OMe/OtBu/OBn), 1146 (OMe/OtBu/OBn) 
Mp (CH2Cl2): 199-201 oC. 
 
Synthesis of 74 – Hyd[Aib]Aib5AibCH2OH  
 
CbzAib6AibCH2OTBS (200 mg, 0.24 mmol, 1 eq.) was dissolved in tetrahydrofuran (2 mL), to 
this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (1 mL, 1 mmol, 4.2 
eq.) was added. The resulting solution was left to stir overnight after which time the reaction 
mixture was concentrated and dissolved in EtOAc which was then washed with water, 
NaHCO3, 1 M HCl (aq) and brine, dried over Na2SO4, filtered and concentrated. This was purified 
by column chromatography (SNAP Ultra 10g 2% → 10%) to give compound 74 (80 mg, 0.13 
mmol, 54 %) as a white solid 
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.15 
1H NMR (500 MHz, CDCl3) δH 7.62 (1 H, s, NH), 7.49 (1 H, s, NH), 7.44 (1 H, s, NH), 6.94 (1 H, s, 
NH), 6.84 (1 H, s, NH), 6.03 (1 H, s, NH), 4.61 (1 H, t, J = 7.0 Hz, OH), 3.66-3.61 (2 H, m, CH2OH), 
1.77 (6 H, s, 2 x CH3), 1.50 (6 H, s, 2 x CH3), 1.48 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.45 (6 





13C NMR (125 MHz, CDCl3) δc 177.9 (CO), 175.5 (CO), 175.0 (CO), 174.9 (CO), 173.6 (CO), 172.9 
(CO), 155.9 (CO), 68.7 (CH2), 60.8 (αC), 58.6 (αC), 57.1 (αC), 57.0 (αC), 56.9 (αC), 55.4 (C(CH3)2), 
25.6 (CH3), 25.2 (CH3), 25.1 (CH3), 25.0 (CH3), 24.9 (CH3), 24.0 (CH3) 
HRMS (ESI+, CH2Cl2/CDCl3) calc. for C29H51N7NaO8: 648.3691; observed: 648.3687 (M+Na)+ 
IR (neat) νmax/cm-1 = 3312 (br, OH), 2991 (CH), 2956 (CH), 1714 (CO), 1685 (CO), 1532 (CH), 
1367 (OH) 
Mp (CH2Cl2): 189-192 oC 
 
Synthesis of 75 – H2N(CH2)2OTBS  
Previously synthesised and reported 170 
 
Ethanolamine (0.6 mL, 10.0 mmol) and tert-butyldimethylsilyl chloride (1.35 g, 9.0 mmol, 0.9 
eq.) were dissolved in CH2Cl2 (30 mL) and left to stir overnight. After this time the reaction 
mixture was diluted with CH2Cl2 (~35mL) and washed twice with water and then brine. The 
organic phase was dried over Na2SO4, filtered and concentrated to give compound 75 (1.34 g, 
7.7 mmol, 85%) as a colourless oil which required no further purification. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 3.56 (2 H, t, J = 5.5 Hz, CH2), 2.70 (2 H, t, J = 5.5 Hz, CH2), 0.84 (9 
H, s, C(CH3)3), 0.00 (3 H, s, 2 x CH3).  
Data consistent with previously reported information. 170 
 
Synthesis of 76 – CbzHNAib6(CH2)2OTBS  
 
Formation of the azlactone: 
A solution of CbzAib6OH (123 mg, 0.19 mmol, 1 eq.) in CH2Cl2 (7 mL) was cooled to 0oC, to this 
EDC∙HCl (48 mg, 0.25 mmol, 1.3 eq.) and DIPEA (0.07 mL, 0.38 mmol, 2 eq.) were added and 
the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 





The crude azlactone, H2N(CH2)2OTBS (100 mg, 0.57 mmol, 3 eq.) and DIPEA (0.04 mL, 0.25 
mmol, 1.3 eq.) were dissolved in MeCN (10 mL) and heated at reflux for 5 d. After this time 
the reaction mixture was concentrated and dissolved in EtOAc. This was washed with KHSO4 
(aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. The crude 
product was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in 
CH2Cl2) to give compound 76 as a white solid (101 mg, 0.12 mmol, 63 %). 
Analytical Data 
Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.17 
1H NMR (500 MHz, CDCl3) δH 7.68 (1 H, s, NH), 7.65 (1 H, s, NH), 7.54 (1 H, s, NH), 7.48 (1 H, t, 
J = 6.0 Hz, NH), 7.44 (1 H, s, NH), 7.38-7.32 (5 H, m, 5 x ArH), 6.89 (1 H, s, NH), 6.60 (1 H, s, 
NH), 5.12 (2 H, s, CH2Ph), 3.69 (2 H, t, J = 7.0 Hz, CH2OTBS), 3.41-3.36 (2 H, m, NHCH2), 1.55 (6 
H, s, 2 x CH3), 1.48 (18 H, s, 6 x CH3), 1.41 (6 H, s, 2 x CH3), 1.35 (6 H, s, 2 x CH3), 0.88 (9 H, s, 
C(CH3)3), 0.05 (6 H, s, 2 x CH3) 
13C NMR (125 MHz, CDCl3) δC 176.1 (CO), 175.9 (CO), 175.3 (CO), 175.0 (CO), 174.7 (CO), 174.6 
(CO), 156.2 (CO), 136.5 (ArC), 128.6 (ArH), 128.3 (ArH), 127.9 (ArH), 67.0 (CH2Ph), 61.6 (CH2-
OTBS), 57.1 (αC), 57.0 (αC), 56.8 (αC), 56.6 (αC), 56.6 (αC), 56.5 (αC), 41.9 (NHCH2), 25.9 (CH3 
of TBS), 25.3-24.6 (m, Aib CH3, not resolved), 18.3 (Si-C), -5.3 (Si-CH3) 
HRMS (ESI+, MeOH) calc. for C40H69N7NaO9Si: 842.4818; observed: 842.4842 (M+Na)+ 
IR (neat) νmax/cm-1 = 3286 (NH), 2985 (CH), 2935 (CH), 1709 (CO), 1651 (CO), 1530 (CH), 1384 
(SiO), 1268 (SiC/OBn), 1227 (SiC/OBn) 
Mp (CH2Cl2): 205-207 oC. 
 
Synthesis of 77 – Hyd[Aib]Aib5(CH2)2OH  
 
CbzAib6(CH2)2OTBS (20 mg, 0.024 mmol, 1 eq.) was dissolved in tetrahydrofuran (0.24 mL), to 
this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (75 μL, 75 μmol, 3 
eq.) was added. The resulting solution was left to stir for 2 h after which time the reaction 
mixture was concentrated and dissolved in EtOAc which was then washed with water, KHSO4 
(aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The crude product 
was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give compound 77 (11 
mg, 0.018 mmol, 75 %) as a white solid 
Analytical Data 





1H NMR (500 MHz, CDCl3) δH 7.68 (1 H, s, NH), 7.43 (1 H, t, J = 5.5 Hz, NH), 7.36 (1 H, s, NH), 
7.35 (1 H, s, NH), 5.91 (1 H, s, NH), 5.55 (1 H, s, NH), 4.06 (1 H, t, J = 7.0 Hz, OH), 3.76 (2 H, m, 
CH2OH),  3.46-3.42 (2 H, m, NHCH2), 1.78 (6 H, s, 2 x CH3), 1.56 (6 H, s, 2 x CH3), 1.49 (6 H, s, 2 
x CH3), 1.49 (6 H, s, 2 x CH3), 1.48 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3) 
13C NMR (125 MHz, CDCl3) δc 177.4 (CO), 175.7 (CO), 175.6 (CO), 174.6 (CO), 173.4 (CO), 172.7 
(CO), 155.7 (CO), 61.7 (CH2OH), 61.0 (αC hydantoin), 58.6 (αC), 57.3 (αC), 57.2 (αC), 57.0 (αC), 
57.0 (αC), 43.1 (NHCH2), 25.7 (CH3), 25.2 (CH3), 25.1 (CH3), 24.8 (CH3), 23.9 (CH3) 
HRMS (ESI+, MeOH) calc. for C27H47N7NaO8: 620.3378; observed: 620.3379 (M+Na)+ 
IR (neat) νmax/cm-1 = 3301 (br, OH), 2982 (CH), 2930 (CH), 1710 (CO), 1655 (CO), 1528 (CH), 
1365 (OH) 
Mp (CH2Cl2): 186-188 oC 
 
Synthesis of 170 – NH2Aib5OtBu  
Previously synthesised and reported 171 
 
NH2Aib5OtBu was synthesised by following general procedure A on a 2.60 mmol scale. 
NH2Aib5OtBu (1.2 g, 2.29 mmol, 88%) was obtained as a white solid.  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 8.15 (1 H, s, NH), 7.32 (1 H, s, NH), 7.20 (1 H, s, NH), 6.28 (1 H, s, 
NH), 1.50 (6 H, s, 2 x CH3), 1.47 (6 H, s, 2 x CH3), 1.47 (6 H, s, 2 x CH3), 1.43 (9 H, s, C(CH3)3), 
1.42 (6 H, s, 2 x CH3), 1.37 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.0 (CO), 173.6 (CO), 173.4 (CO), 172.6 (CO), 79.9 (C(CH3)3), 
56.8 (αC), 56.1 (αC), 56.4 (αC), 56.1 (αC), 54.9 (αC), 28.9 (CH3), 27.8 (CH3), 25.5 (CH3), 25.4 
(CH3), 25.0 (CH3), 24.8 (CH3) 
Data consistent with previously reported information. 171 
 
Synthesis of 171 – CbzHNAib5OtBu  






A solution of H2NAib5OtBu (582 mg, 1.16 mmol, 1 eq.) in THF (35 mL) was added in a dropwise 
manner to a stirred solution of benzyl chloroformate (0.20 mL, 1.39 mmol, 1.2 eq) and DIPEA 
(0.81 mL, 4.64 mmol, 4 eq.) in THF (7 mL) at 0oC. The resulting solution was left to warm to 
RT overnight, after which time the reaction mixture was concentrated and dissolved in EtOAc. 
The reaction mixture was washed with KHSO4 (aq), NaHCO3 (aq), and brine; then dried over 
MgSO4, filtered and concentrated. The crude product was purified by column 
chromatography (SNAP Ultra 25g, 2→10 % MeOH in CH2Cl2) to give CbzAib5OtBu as a white 
solid (624 mg, 0.97 mmol, 85 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.44 (1 H, s, NH), 7.36 (1 H, s, NH), 7.32-7.26 (5 H, m, 5 x ArH), 
7.24 (1 H, s, NH), 6.38 (1 H, s, NH), 5.73 (1 H, s, NH), 5.04 (2 H, s, CH2Ph), 1.44 (6 H, s, 2 x CH3), 
1.41 (6 H, s, 2 x CH3), 1.40 (12 H, s, 4 x CH3), 1.36 (15 H, s, 5 x CH3), 1.24 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.2 (CO), 174.1 (CO), 173.9 (CO), 172.1 (CO), 156.3 (CO), 136.4 
(ArC), 128.9 (ArH), 127.1 (ArH), 126.9 (ArH), 82.3 (C(CH3)3), 62.3 (CH2), 56.9 (αC), 56.4 (αC), 
56.2 (αC), 56.1 (αC), 55.3 (αC), 28.4 (CH3), 28.1 (CH3), 27.6 (CH3), 27.5 (CH3), 27.1 (CH3) 
Data consistent with previously reported information. 171 
 
Synthesis of 172 – CbzHNAib5OH  
Previously synthesised and reported 172 
 
CbzHNAib3OH was prepared by following general procedure C on a 0.20 mmol scale to give 
the CbzAib5OH (114 mg, 0.20 mmol, 99 %) as a white solid.  
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.97 (1 H, s, NH), 7.73 (1 H, s, NH), 7.70 (1 H, s, NH), 7.41-7.32 
(5 H, m, 5 x ArH), 5.12 (2 H, s, CH2Ph), 1.49 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.40 (6 H, s, 
2 x CH3), 1.35 (6 H, s, 2 x CH3), 1.32 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CD3OD) δC 178.2 (CO), 174.5 (CO), 173.9 (CO), 172.6 (CO), 172.5 (CO), 
157.2 (CO), 136.2 (ArC), 131.2 (ArH), 129.1 (ArH), 128.5 (ArH), 66.2 (CH2), 57.1 (αC), 56.8 (αC), 
56.7 (αC), 56.5 (αC), 56.1 (αC), 28.1 (CH3), 27.6 (CH3), 27.5 (CH3), 27.1 (CH3), 26.8 (CH3) 







Synthesis of CbzHNAib5AibCH2OTBS  
 
Formation of the azlactone: 
A solution of CbzAib5OH (211 mg, 0.37 mmol, 1 eq.) in CH2Cl2 (15 mL) was cooled to 0oC, to 
this EDC∙HCl (78 mg, 0.41 mmol, 1.3 eq.) and DIPEA (0.13 mL, 0.74 mmol, 2 eq.) were added 
and the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of CbzAib5AibCH2OTBS: 
The crude azlactone (75 mg), H2NAibCH2OTBS (67 mg, 0.33 mmol, 2.5 eq.) and DIPEA (0.03 
mL, 0.17 mmol, 1.3 eq.) were dissolved in MeCN (15 mL) and heated at reflux for 5 d. After 
this time the reaction mixture was concentrated and dissolved in EtOAc. This was washed 
with KHSO4 (aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. The 
crude product was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH 
in CH2Cl2) to give CbzAib5AibCH2OTBS as a white solid (71 mg, 0.097 mmol, 75 %).  
Analytical Data 
Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.21 
1H NMR (400 MHz, CDCl3) δH 7.46 (1 H, s, NH), 7.44 (1 H, s, NH), 7.35-7.30 (6 H, m, 1 x NH and 
5 x ArH), 6.74 (1 H, s, NH), 6.54 (1 H, s, NH), 6.34 (1 H, s, NH), 5.08 (2 H, s, CH2Ph), 3.70 (2 H, 
s, CH2OTBS), 1.46 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.44 (6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x 
CH3), 1.32 (6 H, s, 2 x CH3), 1.28 (6 H, s, 2 x CH3), 0.86 (9 H, s, C(CH3)3), 0.01 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.0 (CO), 174.6 (CO), 174.5 (CO), 174.2 (CO), 174.0 (CO), 156.1 
(CO), 136.3 (ArC), 128.6 (ArH), 128.4 (ArH), 128.0 (ArH), 68.1 (CH2OTBS), 67.1 (CH2Ph), 57.1 
(αC), 57.1 (αC), 56.7 (αC), 56.6 (αC), 56.4 (αC), 54.6 (C(CH3)2), 25.9 (C(CH3)3), 25.6 (CH3), 25.2 
(CH3), 24.9 (CH3), 23.8 (CH3), 18.2 (SiC), -5.4 (SiCH3) 
HRMS (ESI+, MeOH) calc. for C38H67N6O8Si: 763.4784; observed: 763.4804 (M+H)+ 
IR (neat) νmax/cm-1 = 3272 (NH), 2991 (CH), 2941 (CH), 1721 (CO), 1664 (CO), 1511 (CH), 1379 
(SiO), 1271 (SiC/OBn), 1241 (SiC/OBn) 








Synthesis of 82 – CbzHNAib5(CH2)2OTBS  
 
Formation of the azlactone: 
A solution of CbzAib5OH (211 mg, 0.37 mmol, 1 eq.) in CH2Cl2 (15 mL) was cooled to 0oC, to 
this EDC∙HCl (78 mg, 0.41 mmol, 1.3 eq.) and DIPEA (0.13 mL, 0.74 mmol, 2 eq.) were added 
and the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc, then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of 82: 
The crude azlactone (75 mg), H2N(CH2)2OTBS (57 mg, 0.33 mmol, 2.5 eq.) and DIPEA (0.03 mL, 
0.17 mmol, 1.3 eq.) were dissolved in MeCN (15 mL) and heated at reflux for 5 d. After this 
time the reaction mixture was concentrated and dissolved in EtOAc. This was washed with 
KHSO4 (aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. This was 
then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in CH2Cl2) to give 
compound 82 as a white solid (74 mg, 0.10 mmol, 77 %) 
Analytical Data 
Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.25 
1H NMR (400 MHz, CDCl3) δH 7.58 (1 H, s, NH), 7.44 (1 H, s, NH), 7.39 (1 H, t, J = 6.0 Hz, NH), 
7.33-7.27 (6 H, m, 1 x NH and 5 x ArH), 6.78 (1 H, s, NH), 6.44 (1 H, s, NH), 5.07 (2 H, s CH2Ph), 
3.63 (2 H, t, J = 7.0 Hz, CH2OTBS), 3.36-3.29 (2 H, m, NHCH2), 1.48 (6 H, s, 2 x CH3), 1.42 (12 H, 
s, 4 x CH3), 1.36 (6 H, s, 2 x CH3), 1.28 (6 H, s, 2 x CH3), 0.83 (9 H, s, C(CH3)3), 0.00 (6 H, s, 2 x 
CH3) 
13C NMR (100 MHz, CDCl3) δc 176.0 (CO), 175.5 (CO), 174.8 (CO), 174.5 (CO), 174.3 (CO), 156.2 
(CO), 136.5 (ArC), 128.6 (ArH), 128.3 (ArH), 127.9 (ArH), 67.0 (CH2Ph), 61.2 (CH2OTBS), 57.1 
(αC), 57.0 (αC), 56.8 (αC), 56.6 (αC), 56.5 (αC), 41.9 (NHCH2), 25.9 (C(CH3)3), 25.8 (CH3), 25.2 
(CH3), 24.9 (CH3), 18.3 (SiC), -5.3 (SiCH3) 
HRMS (ESI+, MeOH) calc. for C36H63N6O8Si: 735.4471; observed: 735.4496 (M+H)+ 
IR (neat) νmax/cm-1 = 3261 (NH), 2995 (CH), 2952 (CH), 1702 (CO), 1661 (CO), 1541 (CH), 1392 
(SiO), 1273 (SiC/OBn), 1234 (SiC/OBn) 








Synthesis of 83 – Hyd[Aib]Aib4(CH2)2OH   
 
CbzAib5(CH2)2OTBS (95 mg, 0.13 mmol, 1 eq.) was dissolved in tetrahydrofuran (2 mL), to this 
a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (0.52 mL, 0.52 mmol, 
4.2 eq.) was added. The resulting solution was left to stir for 3 h, after which time the reaction 
mixture was concentrated then dissolved in EtOAc, which was then washed with water, 
NaHCO3 (aq), 1 M HCl (aq) and brine, dried over Na2SO4, filtered and concentrated. This was 
purified by column chromatography (SNAP Ultra 10g 2% → 10%) to give compound 83 (50 
mg, 0.10 mmol, 78 %) as a white solid. 
Analytical Data 
Rf (SiO2, 10% MeOH in CH2Cl2) = 0.15 
1H NMR (500 MHz, CDCl3) δH 7.49 (1 H, s, NH), 7.46 (1 H, s, NH), 7.32 (1 H, t, J = 5.0 Hz, NH), 
6.21 (1 H, s, NH), 6.09 (1 H, s, NH), 3.88-3.84 (1 H, br s, OH), 3.74 (2 H, t, J = 5.0 Hz, CH2OH), 
3.43 (2 H, q, J = 5.0 Hz, NHCH2), 1.76 (6 H, s, 2 x CH3), 1.51 (6 H, s, 2 x CH3), 1.48 (6 H, s, 2 x 
CH3), 1.48 (6 H, s, 2 x CH3), 1.47 (6 H, s, 2 x CH3) 
13C NMR (125 MHz, CDCl3) δc 177.9 (CO), 175.7 (CO), 174.7 (CO), 174.2 (CO), 172.7 (CO), 155.8 
(CO), 61.6 (CH2OH), 61.0 (αC), 58.5 (αC), 57.3 (αC), 57.2 (αC), 57.1 (αC), 43.0 (NHCH2), 25.6 
(CH3), 25.1 (CH3), 25.0 (CH3), 24.0 (CH3) 
HRMS (ESI+, CH2Cl2/CDCl3) calc. for C23H40N6NaO7: 535.285068; observed: 535.284150 
(M+Na)+ 
IR (neat) νmax/cm-1 = 3310 (br, OH), 2983 (CH), 2926 (CH), 1706 (CO), 1650 (CO), 1529 (CH), 
1384 (OH) 
Mp (CH2Cl2): 161-164 oC 
 






Cbz(L)αMPheAib4GlyNH2 (17 mg, 0.020 mmol, 1 eq.) was dissolved in tetrahydrofuran (0.2 
mL), to this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (60 μL, 
0.060 mmol, 3 eq.) was added. The resulting solution was left to stir overnight after which 
time the reaction mixture was concentrated and dissolved in EtOAc which was then washed 
with water, KHSO4 (aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. 
The crude product was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give 
compound 79 (10 mg, 0.017 mmol, 85 %) as a white solid.  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.18 
1H NMR (400 MHz, CDCl3) δH 9.50 (1 H, s, NH), 7.85 (1 H, dd, J = 7.0, 5.5 Hz, NH), 7.64 (1 H, s, 
NH), 7.54 (2 H, d, J = 8.5 Hz, 2 x ArH), 7.26 (1 H, d, J = 7.0 Hz, ArH), 7.22-7.18 (2 H, m, 2 x ArH), 
6.39 (1 H, s, NH), 4.75 (1 H, s, NH), 4.07 (1 H, dd, J = 17.5, 7.0 Hz, part of Gly CH2 ABX system), 
3.57 (1 H, dd, J = 17.5, 5.5 Hz, part of Gly CH2 ABX system), 3.06 (1 H, d, J = 13.5 Hz, part of 
hyd[αMP] CH2 AB system), 2.84 (1 H, d, J = 13.5 Hz, part of hyd[αMP] CH2 AB system), 1.47 (3 
H, s, CH3), 1.41 (6 H, s, 2 x CH3), 1.38 (3 H, s, CH3), 1.36 (3 H, s, CH3), 1.28 (3 H, s, CH3), 1.26 (3 
H, s, CH3), 1.23 (3 H, s, CH3), 1.05 (3 H, s, CH3) 
13C NMR (100 MHz, CDCl3) δc 177.3 (CO), 176.1 (CO), 175.7 (CO), 175.0 (CO), 174.7 (CO), 172.6 
(CO), 157.3 (CO), 135.2 (ArC), 130.6 (ArH), 128.4 (ArH), 127.6 (ArH), 63.0 (αC Hyd[αMPhe]), 
60.8 (αC), 57.0 (αC), 56.9 (αC), 56.8 (αC), 43.8 (CH2 Hyd[αMPhe]), 43.2 (CH2 Gly), 26.5 (CH3), 
24.7 (CH3), 24.3 (CH3), 23.8 (CH3), 23.7 (CH3), 23.3 (CH3) 
[α]D (c = 1.0, CH2Cl2) =  +40.1 
HRMS (ESI+, MeOH) calc. for C29H43N7NaO7: 624.3116; observed: 624.3120 (M+Na)+ 
IR (neat) νmax/cm-1: 3300 (NH2/NH), 2990 (CH), 2925 (CH), 2856 (CH), 1705 (CO), 1651 (CO), 
1531 (NH) 
Mp (CH2Cl2): 171-173 oC 
 
Synthesis of N3Aib4Aib*OEt  
Previously synthesised and reported 77 
 
Formation of the azlactone: 
A solution of N3Aib4OH (356 mg, 0.92 mmol, 1 eq.) in CH2Cl2 (10 mL) was cooled to 0 oC, to 
this EDC∙HCl (230 mg, 1.2 mmol, 1.3 eq.) and DIPEA (0.21 mL, 1.2 mmol, 1.3 eq.) were added 





concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of N3Aib4Aib*OEt: 
The crude azlactone (323 mg), HCl∙Aib*OEt (100 mg, 0.59 mmol, 1 eq.) and DIPEA (0.17 mL, 
1.0 mmol, 1.3 eq.) were dissolved in MeCN (10 mL) and heated at reflux for 5 d. After this 
time the reaction mixture was concentrated and dissolved in EtOAc. This was washed with 
KHSO4 (aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. The crude 
product was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in 
CH2Cl2) to give N3Aib4Aib*OEt as a white solid (249 mg, 0.50 mmol, 88 %).  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.29 (1 H, s, NH), 7.10 (1 H, s, NH), 6.98 (1 H, s, NH), 6.21 (1 H, s, 
NH), 4.07 (2 H, J = 7.0 Hz, CH2), 1.49 (6 H, s, 2 x CH3), 1.45 (3 H, d, 1JC-H = 129.0 Hz, 13CH3), 1.46-
1.43 (9 H, m, CH3 of *Aib and 2 x CH3), 1.43 (6 H, s, 2 x CH3), 1.37 (6 H, s, 2 x CH3), 1.17 (3 H, t, 
J = 7.0 Hz, CH3 of OEt) 
13C NMR (100 MHz, CDCl3) δC 174.9 (CO), 174.1 (d, J = 1.5 Hz, CO of *Aib), 173.1 (CO), 172.8 
(CO), 172.5 (CO), 63.9 (CH2), 56.9 (αC), 56.8 (αC), 56.7 (αC), 55.6 (d, J = 37.0 Hz, αC of *Aib), 
25.2 (CH3), 24.8 (13CH3), 24.3 (CH3), 14.1 (CH3 of OEt) 
HRMS (ESI+, CH2Cl2) calc. for C2113CH40N7O6: 499.306813; observed: 499.305754 (M+H)+ 
Data consistent with previously reported information 77 
 
 
Synthesis of NH2Aib4Aib*OEt 
Previously synthesised and reported 77 
 
NH2Aib4Aib*OEt was synthesised by following general procedure A on a 0.31 mmol scale, 
giving NH2Aib4Aib*OEt as a white solid (141, 0.30 mmol, 98 %).  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 8.19 (1 H, s, NH), 7.39 (1 H, s, NH), 7.31 (1 H, s, NH), 6.28 (1 H, s, 
NH), 4.10 (2 H, q, J = 7.0 Hz, CH2), 1.47 (3 H, d, 1JC-H = 129 Hz, 13CH3), 1.48-1.45 (3 H, m, CH3 on 
Aib*), 1.47 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.39 (6 H, s, 2 x CH3), 1.34 (6 H, s, 2 x CH3), 





13C NMR (100 MHz, CDCl3) δc 178.5 (CO), 174.9 (CO), 174.2 (d, J = 1.5 Hz, CO of Aib*), 173.7 
(CO), 172.7 (CO), 60.5 (CH2), 56.6 (αC), 56.5 (d, J = 44.0 Hz, αC of Aib*), 55.8 (αC), 55.4 (αC), 
54.7 (αC), 28.9 (CH3), 25.4 (CH3), 25.3 (CH3), 24.8 (13CH3), 14.1 (CH3 of Et). 
HRMS (ESI+, MeOH) calc. for C2113CH41N5NaO6: 495.2983; observed: 495.2965 (M+Na)+ 
Data consistent with previously reported data 77 
 
Synthesis of Cbz-(L)αMv-Aib4-Aib*OEt  
 
Preparation of the Acid Fluoride: 
Cbz(L)αMvOH (56 mg, 0.21 mmol, 1 eq) and pyridine (0.25 mL, 0.32 mmol, 1.5 eq) were 
dissolved in CH2Cl2 (5 mL). Fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate 
(66 mg, 0.25 mmol, 1.2 eq) was added to this and the resulting solution was left to stir 
overnight. After this time the reaction mixture was diluted with CH2Cl2 (10 mL) and washed 
with ice cold water (3 x ~3 mL), dried over Na2SO4, filtered and concentrated to give the crude 
acid fluoride that was used with no further purification. 
Acid fluoride coupling: 
H2NAib4Aib*OEt (44 mg, 0.09 mmol, 0.8 eq), CbzαMvF (31 mg, 0.12 mmol, 1 eq) and DIPEA 
(20 μL, 0.12 mmol, 1 eq) were dissolved in CH2Cl2 (5 mL) and the resulting solution was left to 
stir at RT for 5 d. After this time the reaction mixture was concentrated and dissolved in 
EtOAc. The organic phase was washed sequentially with KHSO4 (aq), NaHCO3 (aq) and brine, then 
dried over Na2SO4, filtered and concentrated. The crude peptide was purified by column 
chromatography (5 g ZIP Sphere, 2% → 10% MeOH in CH2Cl2) to give Cbz-(L)αMv-Aib4-Aib*OEt 
(41 mg, 0.057 mmol, 63%) as a colourless solid.  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.23 
1H NMR (500 MHz, CDCl3) δH 7.60 (1 H, s, NH), 7.49 (1 H, s, NH), 7.45 (1 H, s, NH), 7.43-7.38 (5 
H, m, 5 x ArH), 7.30 (1 H, s, NH), 6.29 (1 H, s, NH), 5.23 (1 H, s, NH), 5.21 (1 H, d, J = 11.0 Hz, 
part of the AB system of the Cbz CH2), 5.06 (1 H, d, J = 11.0 Hz, part of the AB system of the 
Cbz CH2), 4.20-4.13 (2 H, m, CH2 of OEt), 1.95 (1 H, hept, J = 7.0 Hz, αMv CH), 1.57 (3 H, d, J = 
4.5 Hz, CH3 of Aib*), 1.56 (3 H, s, CH3), 1.53 (3 H, d, J = 129.0 Hz, 13CH3), 1.52 (3 H, s, CH3), 1.51 
(3 H, s, CH3), 1.49 (3 H, s, CH3), 1.47 (6 H, s, 2 x CH3), 1.45 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.27-






13C NMR (125 MHz, CDCl3) δC 175.1 (CO), 174.9 (CO), 174.5 (CO of Aib*, d, J = 2.0 Hz), 173.9 
(CO), 173.6 (CO), 172.4 (CO), 156.0 (CO), 135.8 (ArC), 128.8 (ArH), 128.3 (ArH), 67.6 (CH2 Cbz), 
63.1 (αMv αC), 60.5 (CH2 of OEt), 56.8 (αC), 56.8 (αC), 56.7 (αC), 56.6 (αC), 55.6 (αC of *Aib, 
d, J = 36.0 Hz), 35.7 (CH of αMv), 29.7 (CH3), 27.3 (CH3), 26.8 (CH3), 26.7 (CH3), 25.6 (*CH3 
major), 24.8 (CH3), 24.3 (*CH3 minor), 23.6 (CH3), 23.5 (CH3), 23.3 (CH3), 22.7 (CH3), 17.1 (CH3 
of OEt) 
HRMS (MeOH, ESI+) calc. for C3513CH59N6O9: 720.4372; observed: 720.4369 (M+H)+ 
IR (neat) νmax/cm-1 = 3324 (NH), 3045 (CH), 2969 (CH), 2930 (CH), 1710 (CO), 1665 (CO), 1561 
(NH), 1390 (OBn/OEt), 1354 (OBn/OEt) 
Mp (CH2Cl2): 200-203 oC 
 
Synthesis of 80 - Cbz-(L)αMv-Aib3-OtBu 
 
Preparation of the acid fluoride  
Cbz-(L)αMv-OH (150 mg, 0.79 mmol) and pyridine (60 μL, 0.79 mmol) were dissolved in CH2Cl2 
(8 mL). Fluoro-N,N,N′,N′-tetramethylformamidinium hexafluorophosphate (314 mg, 1.19 
mmol) was added and the reaction stirred for 3 h. The mixture was diluted with CH2Cl2 (18 
mL) and washed with ice cold water (4 x 25 mL), dried (Na2SO4), filtered and concentrated to 
give the crude acid fluoride, which was used immediately with no further purification.  
 
Preparation of 80 
NH2-Aib3-OtBu (234 mg, 0.71 mmol) and N-N-Diisopropylethylamine (0.21 mL, 0.71 mmol) 
were dissolved in CH2Cl2 (15 mL) and cooled to 0 oC. The crude acid fluoride was dissolved in 
CH2Cl2 (5 mL) and added to the reaction in a drop wise manner. The resulting mixture was left 
to warm to RT. After 5 d the reaction was diluted with EtOAc, washed with KHSO4 (aq), NaHCO3 
(aq) and brine, dried (MgSO4), filtered and concentrated to give compound 80 as a white solid 
(252 mg, 64 %, 0.45 mmol).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.29 
1H NMR (400 MHz, CDCl3) δH 7.38 (1 H, s, NH), 7.36-7.29 (5 H, m, 5 x ArH), 7.21 (1 H, s, NH), 
6.39 (1 H, s, NH), 5.72 (1 H, s, NH), 5.15 (1 H, d, J = 12.0 Hz, part of the AB system of the Cbz 





Hz, CH), 1.49 (3 H, s, CH3), 1.46 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.42 (3 H, s, 
CH3), 1.41 (12 H, s, 4 x CH3), 1.21 (3 H, s, CH3), 0.96 (3 H, d, J = 6.5 Hz, CH3), 0.93 (3 H, d, J = 6.5 
Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 174.0 (CO), 173.7 (CO), 172.7 (CO), 156.1 (CO), 136.2 (ArC), 128.6 
(ArH), 128.5 (ArH), 128.3 (ArH), 79.8 (C(CH3), 67.2 (Cbz CH2), 63.0 (αC), 56.8 (αC), 56.6 (αC), 
56.0 (αC), 35.3 (CH), 27.8 (CH3), 27.0 (CH3), 26.8 (CH3), 25.4 (CH3), 24.0 (CH3), 23.8 (CH3), 23.6 
(CH3), 17.8 (CH3), 17.3 (CH3), 17.2 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +37.3 
HRMS (ESI+, CH2Cl2) calc. for C30H48N4NaO7: 599.341521; observed: 599.341274 (M+Na)+ 
IR (neat) νmax/cm-1: 3251 (NH), 2987 (CH), 2940 (CH), 1733 (CO), 1656 (CO), 1532 (NH), 1257 
(OBn/OtBu), 1147 (OBn/OtBu) 
Mp (CH2Cl2): 145-147 oC. 
 
Synthesis of 81 – Hyd[(L)αMv]-Aib3-OtBu 
 
Cbz(L)αMvAib3OtBu (18 mg, 0.030 mmol, 1 eq.) was dissolved in tetrahydrofuran (0.4 mL), to 
this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (90 μL, 0.090 mmol, 
3 eq.) was added. The resulting solution was left to stir overnight, after which time the 
reaction mixture was concentrated and dissolved in EtOAc, which was then washed with 
water, KHSO4 (aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The 
crude product was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give 
compound 81 (12 mg, 0.026 mmol, 87 %) as a white solid.  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.26 
1H NMR (500 MHz, CDCl3) δH 7.01 (1 H, s, NH), 6.14 (1 H, s, NH), 5.48 (1 H, s, NH), 2.04 (1 H, 
hept, J = 7.0 Hz, CH), 1.75 (6 H, s, 2 x CH3), 1.55 (6 H, s, 2 x CH3), 1.49 (6 H, s, 2 x CH3), 1.46 (9 
H, s, 3 x CH3), 1.41 (3 H, s, CH3), 0.99 (3 H, d, J = 7.0 Hz, CH3), 0.94 (3 H, d, J = 7.0 Hz, CH3) 
13C NMR (125 MHz, CDCl3) δC 177.4 (CO), 173.7 (CO), 172.8 (CO), 171.3 (CO), 156.6 (CO), 80.8 
(C(CH3)3), 63.9 (αC), 61.4 (αC), 57.1 (αC), 56.6 (αC), 34.4 (CH), 27.9 (CH3), 25.1 (CH3), 25.0 





[α]D (c = 0.75, CH2Cl2) = +34.2 
HRMS (ESI+, CH2Cl2) calc. for C23H40N4NaO6: 491.284006; observed: 491.284651 (M+Na)+  
IR (neat) νmax/cm-1: 3295 (NH), 2980 (CH), 2940 (CH), 1701 (CO), 1511 (NH), 1141 (OtBu) 
Mp (CH2Cl2): 152-154 oC. 
 
Attempted synthesis of Hyd[(L)Phe]-Aib4-Aib**OMe from 84 
 
CbzPhe(L)-Aib4-Aib**OMe (80 mg, 0.10 mmol, 1 eq.) was dissolved in tetrahydrofuran (1.5 
mL), to this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (1 mL, 1 
mmol) was added. The resulting solution was left to stir overnight, after which time the 
reaction mixture was concentrated and dissolved in EtOAc, which was then washed with 
water, KHSO4 (aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The 
crude product was purified by column chromatography (SNAP 10g, 2% → 8% in MeOH in 
CH2Cl2) to give the starting material, compound 84 (65 mg, 0.081 mmol) as a white solid.  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.27 
1H NMR (500 MHz, CDCl3) δH 7.55 (1 H, s, NH), 7.50 (1 H, s, NH), 7.37 (1 H, s, NH), 7.34-7.25 
(8 H, m, 8 x ArH), 7.21-7.18 (2 H, m, 2 x ArH), 7.16 (1 H, s, NH), 6.76 (1 H, s, NH), 6.03 (1 H, d, 
J = 5.0 Hz, NH), 5.07 (2 H, s, CH2 of Cbz), 4.10 (1 H, dt, J = 10.0 Hz, 5.0 Hz, αCH), 3.62 (3 H, s, 
OCH3), 3.19 (1 H, J = 14.0 Hz, 5.0 Hz, part of the Phe CH2 AB system), 3.01 (1 H, J = 14.0 Hz, 
9.0 Hz, part of the Phe CH2 AB system), 1.68-1.64 (3 H, m, 1 x 13CH3 of Aib**), 1.47 (3 H, s, 
CH3), 1.46 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.44 (3 H, s, CH3), 1.40 (3 H, s, CH3), 1.39 (3 H, s, 
CH3), 1.36-1.32 (9 H, m, 2 x CH3 and 1 x 13CH3 of Aib**), 1.30 (3 H, s, CH3) 
HRMS (ESI+, CH2Cl2) calculated for C3613C2H55N6O9: 741.4098; observed: 741.4103 (M+H)+ 
Spectral data consistent with previously reported data 91, 129 
 
Attempted synthesis of Hyd[(L)Ala]-Aib4-tBu from compound 85 
 
CbzAla(L)-Aib4OtBu (30 mg, 0.048 mmol, 1 eq.) was dissolved in tetrahydrofuran (1 mL), to 
this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (0.5 mL, 0.5 mmol) 
was added. The resulting solution was left to stir overnight, after which time the reaction 
mixture was concentrated and dissolved in EtOAc, which was then washed with water, KHSO4 
(aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The crude product 
was purified by column chromatography (ZIP Sphere 5g, 2% → 8% MeOH in CH2Cl2) to give 






Rf (SiO2 5% MeOH in CH2Cl2) = 0.29 
1H NMR (400 MHz, CDCl3) δH 7.37-7.32 (5 H, m, 5 x ArH), 7.30 (1 H, s, NH), 7.15 (1 H, s, NH), 
6.99 (1 H, s, NH), 6.50 (1 H, s, NH), 5.73 (1 H, d, J = 4.5 Hz, NH), 5.09 (2 H, s, CH2 of Cbz), 3.98-
3.91 (1 H, m, αCH), 1.48 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.44 (3 H, s, CH3), 
1.43-1.37 (21 H, m, 7 x CH3), 1.34 (3 H, s, CH3) 
HRMS (ESI+, CH2Cl2) calc. for C31H50N5O8: 620.3659; observed: 620.3661 (M+H)+ 
Spectral data consistent with previously reported data 113, 129 
 
Attempted synthesis of Hyd[(L)Ser(OtBu)]-Aib4-tBu from 86 
 
CbzSer(L)(OtBu)-Aib4-GlyNH2 (20 mg, 0.036 mmol, 1 eq.) was dissolved in tetrahydrofuran 
(0.36 mL), to this a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (0.11 
mL, 0.11 mmol) was added. The resulting solution was left to stir overnight, after which time 
the reaction mixture was concentrated and dissolved in EtOAc, which was then washed with 
water, KHSO4 (aq), NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The 
crude product was purified by column chromatography (SiO2, 5% MeOH in CH2Cl2) to give the 
starting material, compound 86, (15 mg, 0.027 mmol) as a white solid.  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.18 
1H NMR (400 MHz, CDCl3) δH 7.93 (1 H, t, J = 6.5 Hz, NH), 7.64 (1 H, s, NH), 7.58 (1 H, s, NH), 
7.50 (1 H, s, NH), 7.42-7.38 (5 H, m, 5 x ArH), 7.03 (1 H, s, NH), 6.56 (1 H, s, NH), 5.65 (1 H, d, 
J = 5.0 Hz, NH), 5.22 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB system), 5.38-5.32 (1 H, m, 
αCH), 5.12 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB system), 4.18-4.08 (2 H, m, part of βCH2 
and Gly CH2), 3.58-3.38 (2 H, m part of βCH2 and Gly CH2), 1.62 (3 H, s, CH3), 1.58 (3 H, s, CH3), 
1.54 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.44 (6 H, s, 2 x CH3), 
1.34 (3 H, s, CH3), 1.23 (9 H, s, 3 x CH3). 
HRMS (ESI+, CH2Cl2) calc. for C33H53N7NaO9: 714.3802; observed: 714.3773 
Spectral data consistent with previously reported data 113, 129 
 






Formation of the azlactone: 
A solution of N3Aib4OH (170 mg, 0.44 mmol, 1 eq.) in CH2Cl2 (10 mL) was cooled to 0oC, to this 
EDC∙HCl (109 mg, 0.57 mmol, 1.3 eq.) and DIPEA (0.15 mL, 0.88 mmol, 2 eq.) were added and 
the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of N3Aib7OtBu: 
The crude azlactone (150 mg), H2NAib3OtBu (217 mg, 0.66 mmol, 1.5 eq.) and DIPEA (0.15 mL, 
0.88 mmol, 2 eq.) were dissolved in MeCN (10 mL) and heated at reflux for 5 d. After this time 
the reaction mixture was concentrated and dissolved in EtOAc. This was washed with KHSO4 
(aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. The crude 
product was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in 
CH2Cl2) to give N3Aib7OtBu (236 mg, 0.34 mmol, 77 %) as a white solid. 
Tert-butyl ester deprotection to give N3Aib7OH: 
N3Aib7OH was prepared by following general procedure C on a 0.25 mmol scale to give 
N3Aib7OH ( 170 mg, 0.25 mmol, 98 %) as a white solid 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.05 
1H NMR (400 MHz, CDCl3) δH 7.73 (1 H, s, NH), 7.58 (2 H, s, 2 x NH), 7.51 (1 H, s, NH), 6.96 (1 
H, s, NH), 6.24 (1 H, s, NH), 1.60 (6 H, s, 2 x CH3), 1.55 (6 H, s, 2 x CH3), 1.50 (6 H, s, 2 x CH3), 
1.49 (6 H, s, 2 x CH3), 1.46 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.42 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 178.0 (CO), 176.8 (CO), 176.6 (CO), 176.5 (CO), 176.3 (CO), 176.0 
(CO), 174.2 (CO), 66.4 (αC), 59.2 (αC), 58.9 (αC), 58.7 (αC), 58.5 (αC), 58.2 (αC), 57.8 (αC), 25.6 
(CH3), 24.9 (CH3), 24.7 (CH3), 24.5 (CH3), 24.2 (CH3), 24.0 (CH3) 
HRMS (ESI+, MeOH) calc. for C28H49N9NaO8: 662.3601; overserved: 662.3609 (M+Na)+ 
IR (neat) νmax/cm-1: 3350 (br OH), 2987 (CH), 2939 (CH), 2114 (N3), 1701 (CO), 1629 (CO), 1508 
(NH) 
Mp (MeOH): 187-188 oC 
 
Synthesis of 89 – N3Aib7AibCH2OTBS  
 





A solution of N3Aib7OH (170 mg, 0.27 mmol, 1 eq.) in CH2Cl2 (10 mL) was cooled to 0oC, to this 
EDC∙HCl (67 mg, 0.35 mmol, 1.3 eq.) and DIPEA (0.12 mL, 0.68 mmol, 2.5 eq.) were added and 
the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried of Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of 89: 
The crude azlactone (82 mg), H2NAibCH2OTBS (79 mg, 0.39 mmol, 3 eq.) and DIPEA (0.03 mL, 
0.17 mmol, 1.3 eq.) were dissolved in MeCN (15 mL) and heated at reflux for 5 d. After this 
time the reaction mixture was concentrated and then dissolved in EtOAc. This was washed 
with KHSO4 (aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. This 
was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in CH2Cl2) to 
give compound 89 as a white solid (74 mg, 0.09 mmol, 69 %) 
Analytical Data 
Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.32 
1H NMR (400 MHz, CDCl3) δH 7.52 (1 H, s, NH), 7.47 (1 H, s, NH), 7.45 (1 H, s, NH), 7.34 (1 H, s, 
NH), 7.02 (1 H, s, NH), 6.75 (1 H, s, NH), 6.27 (1 H, s, NH), 3.72 (2 H, s, CH2), 1.54 (6 H, s, 2 x 
CH3), 1.48 (12 H, s, 4 x CH3), 1.46 (6 H, s, 2 x CH3), 1.44 (12 H, s, 4 x CH3), 1.41 (6 H, s, 2 x CH3), 
1.33 (6 H, s, 2 x CH3), 0.86 (9 H, s, C(CH3)3), 0.01 (6 H, s, 2 x SiCH3) 
13C NMR (100 MHz, CDCl3) δc 175.0 (CO), 174.9 (CO), 174.8 (CO), 174.0 (CO), 173.9 (CO), 173.2 
(CO), 173.2 (CO), 68.0 (CH2), 63.9 (αC on N3), 57.1 (αC), 56.9 (αC), 56.8 (αC), 56.7 (αC), 56.6 
(αC), 56.6 (αC), 54.6 (C(CH3)2), 25.9 (CH3), 25.6 (CH3), 25.2 (CH3), 25.1 (CH3), 25.0 (CH3), 24.9 
(CH3), 24.8 (CH3), 24.3 (CH3), 23.8 (CH3), 18.2 (SiC), -5.4 (SiCH3) 
HRMS (ESI+, MeOH) calc. for C38H73N10O8Si: 825.537662; observed: 825.538236 (M+H)+ 
IR (neat) νmax/cm-1: 3302 (NH), 2987 (CH), 2935 (CH), 2859 (CH), 2113 (N3), 1654 (CO), 1527 
(NH), 1363 (SiO), 1226 (SiC) 
Mp (CH2Cl2): 218-219 oC 
 
Synthesis of 90 – N3Aib7AibCH2OH  
 
N3Aib7AibCH2OTBS (53 mg, 0.064 mmol, 1 eq.) was dissolved in tetrahydrofuran (1 mL), to this 
a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (0.26 mL, 0.26 mmol, 
4.2 eq.) was added. The resulting solution was left to stir for 3 h, after which time the reaction 
mixture was concentrated then dissolved in EtOAc. It was then washed with water, NaHCO3 





column chromatography (SNAP Ultra 10g 2% → 10%) to give compound 90 (36 mg, 0.051 
mmol, 80 %) as a white solid. 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.18 
1H NMR (400 MHz, CDCl3) δH 7.67 (1 H, s, NH), 7.60 (1 H, s, NH), 7.54 (1 H, s, NH), 7.52 (1 H, s, 
NH), 7.22 (1 H, s, NH), 7.01 (1 H, s, NH), 6.84 (1 H, s, NH), 3.59 (2 H, s, CH2), 1.55 (6 H, s, 2 x 
CH3), 1.48 (12 H, s, 4 x CH3), 1.45 (12 H, s, 4 x CH3), 1.44 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x CH3), 
1.34 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.0 (CO), 175.6 (CO), 175.5 (CO), 174.9 (CO), 174.6 (CO), 173.8 
(CO), 173.2 (CO), 69.5 (CH2), 63.8 (αC), 57.0 (αC), 56.9 (αC), 56.8 (αC), 56.8 (αC), 56.7 (αC), 
56.6 (αC), 55.6 (αC), 24.9 (CH3), 24.7 (CH3), 24.3 (CH3), 24.0 (CH3), 23.9 (CH3) 
HRMS (ESI+, CH2Cl2) calc. for C32H58N10NaO8: 733.433130; observed: 733.434753 (M+Na)+ 
IR (neat) νmax/cm-1: 3299 (OH sharp), 2983 (CH), 2934 (CH), 2879 (CH), 2113 (N3), 1657 (CO), 
1529 (NH) 
Mp (CH2Cl2): 195-197 oC 
 
Synthesis of 87 – N3Aib7(CH2)2OTBS  
 
Formation of the azlactone: 
A solution of N3Aib7OH (170 mg, 0.27 mmol, 1 eq.) in CH2Cl2 (10 mL) was cooled to 0 oC, to 
this EDC∙HCl (67 mg, 0.35 mmol, 1.3 eq.) and DIPEA (0.12 mL, 0.68 mmol, 2.5 eq.) were added 
and the resulting solution was warmed to RT overnight. After this time the reaction was 
concentrated and dissolved in EtOAc then washed with KHSO4 (aq), NaHCO3 (aq) and brine. The 
organic layer was dried over Na2SO4, filtered and concentrated to give the crude azlactone. 
Formation of 87: 
The crude azlactone (82 mg), H2N(CH2)2OTBS (68 mg, 0.39 mmol, 3 eq.) and DIPEA (0.03 mL, 
0.17 mmol, 1.3 eq.) were dissolved in MeCN (15 mL) and heated at reflux for 5 d. After this 
time the reaction mixture was concentrated and dissolved in EtOAc. This was washed with 
KHSO4 (aq), NaHCO3 (aq) and brine, then dried over Na2SO4, filtered and concentrated. The crude 
product was then purified by column chromatography (SNAP Ultra 10g, 2→8% MeOH in 






Rf (SiO2, 5 % MeOH in CH2Cl2) = 0.34 
1H NMR (400 MHz, CDCl3) δH 7.62 (1 H, s, NH), 7.60 (1 H, s, NH), 7.51 (1 H, s, NH), 7.43 (1 H, t, 
J = 6.0 Hz, NH), 7.35 (1 H, s, NH), 7.22 (1 H, s, NH), 6.58 (1 H, s, NH), 3.67 (2 H, t, J = 7.5 Hz, 
CH2OTBS), 3.34 (2 H, q, J = 7.0 Hz, NHCH2), 1.53 (12 H, s, 4 x CH3), 1.48 (6 H, s, 2 x CH3), 1.46 
(6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.44 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x CH3), 0.85 (9 H, s, 
C(CH3)3), 0.02 (6 H, s, 2 x SiCH3) 
13C NMR (100 MHz, CDCl3) δc 175.8 (CO), 175.7 (CO), 175.2 (CO), 174.6 (CO), 174.4 (CO), 173.7 
(CO), 173.2 (CO), 63.8 (αC on N3), 61.5 (CH2OTBS), 57.1 (αC), 56.9 (αC), 56.8 (αC), 56.7 (αC), 
56.6 (αC), 56.6 (αC), 41.8 (NHCH2), 25.9 (CH3), 25.2 (CH3), 24.9 (CH3), 24.7 (CH3), 24.3 (CH3), 
18.2 (SiC), -5.3 (SiCH3) 
HRMS (ESI+, MeOH) calc. for C36H69N10O8Si: 797.5064; observed: 797.5064 (M+H)+ 
IR (neat) νmax/cm-1: 3309 (NH), 2990 (CH), 2936 (CH), 2856 (CH), 2113 (N3), 1651 (CO), 1524 
(NH), 1362 (SiO), 1226 (SiC) 
Mp (CH2Cl2): 211-212 oC 
 
Synthesis of 88 – N3Aib7(CH2)2OH  
 
N3Aib7(CH2)2OTBS (82 mg, 0.10 mmol, 1 eq.) was dissolved in tetrahydrofuran (2 mL), to this 
a 1 M solution of tetra-N-butylammonium fluoride in tetrahydrofuran (0.40 mL, 0.40 mmol, 4 
eq.) was added. The resulting solution was left to stir for 3 h, after which time the reaction 
mixture was concentrated then dissolved in EtOAc, which was then washed with water, 
NaHCO3 (aq), 1 M HCl (aq) and brine, dried over Na2SO4, filtered and concentrated. This was 
purified by column chromatography (SNAP Ultra 10g 2% → 10%) to give compound 88 (58 
mg, 0.085 mmol, 85 %) as a white solid. 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.21 
1H NMR (400 MHz, CDCl3) δH 7.76 (1 H, s, NH), 7.74 (1 H, s, NH), 7.55 (1 H, s, NH), 7.53 (1 H, s, 
NH), 7.42 (1 H, t, J = 5.5 Hz, NH), 7.36 (1 H, s, NH), 7.14 (1 H, s, NH), 3.72 (2 H, t, J = 5.5 Hz, 
NHCH2), 3.43-3.35 (2 H, m, CH2OH), 1.55 (6 H, s, 2 x CH3), 1.52 (6 H, s, 2 x CH3), 1.49 (6 H, s, 2 
x CH3), 1.46 (6 H, s, 2 x CH3), 1.45 (6 H, s, 2 x CH3), 1.44 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x CH3). 
OH not observed in 1H NMR spectrum. 
13C NMR (100 MHz, CDCl3) δC 176.5 (CO), 176.2 (CO), 175.6 (CO), 175.3 (CO), 174.9 (CO), 174.2 
(CO), 173.3 (CO), 63.8 (αC), 61.7 (NHCH2), 58.7 (CH2OH), 57.1 (αC), 56.9 (αC), 56.9 (αC), 56.7 





HRMS (ESI+, CH2Cl2) calc. for C30H54N10NaO8: 705.401829; observed: 705.399004 (M+Na)+ 
IR (neat) νmax/cm-1: 3279 (OH sharp), 2966 (CH), 2934 (CH), 2873 (CH), 2113 (N3), 1651 (CO), 
1537 (NH) 






6.4.3. Experimental Details for Section 4 
   
Synthesis of 91 – Cbz-(L)Ser(OTBS)-OH  
Previously synthesised and reported 173 
 
Cbz(L)SerOH (879 mg, 3.0 mmol) and imidazole (595 mg, 9 mmol) were dissolved in CH2Cl2 
(30 mL) and cooled to 0 oC. Once at temperature TBSCl (0.78 mL, 4.5 mmol) was added in a 
portion wise manner. The resulting solution was warmed to RT and left to stir overnight. After 
this the reaction mixture was diluted with HCl (aq) (1 M) and the layers were separated. The 
organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to give 
compound 91 (741 mg, 2.1 mmol, 70 %) as a clear oil. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.38-7.31 (5 H, m, 5 x ArH), 5.60 (1 H, d, J = 8.0 Hz, NH), 5.15 (1 
H, d, J = 11.0 Hz, part of the Cbz CH2 AB system), 5.12 (1 H, d, J = 11.0 Hz, part of Cbz CH2 AB 
system), 4.45 (1 H, m, αCH), 4.11 (1 H, m, part of AB system βCH2), 3.85 (1 H, m, part of AB 
system βCH2), 0.86 (9 H, s, 3 x CH3), 0.04 (6 H, br s, 2 x CH3). 
13C NMR (100 MHz, CDCl3) δC 175.4 (CO), 156.2 (CO), 136.2 (ArC), 128.6 (ArCH), 128.3 (ArCH), 
128.3 (ArCH), 67.3 (CH2 of Cbz), 63.4 (βCH2), 55.7 (αCH), 25.8 (CH3), 18.3 (C(CH3)3), -3.6 (CH3), 
-5.5 (CH3).  
Spectral data consistent with previously reported data. 173 
 
Synthesis of H2NAib2OtBu  
Previously reported and synthesised 174 
 
H2NAib2OtBu was synthesised by following general procedure A on a 0.30 mmol scale to give 
the product as an off-white solid (70 mg, 0.29 mmol, 95 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.89 (1 H, s, NH), 1.54 (6 H, s, 2 x CH3), 1.48 (9 H, s, 3 x CH3), 1.46 





13C NMR (100 MHz, CDCl3) δC 174.8 (CO), 173.9 (CO), 81.4 (C(CH3)3), 56.5 (αC), 55.6 (αC), 27.9 
(CH3), 27.8 (CH3), 24.5 (CH3). 
Spectral data consistent with previously reported data 174  
 
Synthesis of 92 – Cbz-(L)Ser(OTBS)-Aib2OtBu  
 
Cbz(L)Ser(OTBS)Aib2OtBu was synthesised following general procedure D on a 0.96 mmol 
scale. Compound 92 was purified by column chromatography (SNAP Ultra 10g, 0.5% → 6% 
MeOH in CH2Cl2) to give an off-white solid (406 mg, 0.70 mmol, 73 %).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.46 
1H NMR (400 MHz, CDCl3) δH 7.34-7.26 (5 H, m, 5 x ArH), 6.96 (1 H, s, NH), 6.95 (1 H, s, NH), 
5.67 (1 H, d, J = 6.0 Hz, NH), 5.12 (1 H, d, J = 12.5 Hz, part of the Cbz CH2 AB system), 5.07 (1 
H, d, J = 12.5 Hz, part of the Cbz CH2 AB system), 4.10 (1 H, td, J = 7.0, 4.0 Hz, αCH), 3.98 (1 H, 
dd, J = 10.0, 4.0 Hz, part of AB system βCH2), 3.67 (1 H, dd, J = 10.0, 7.0 Hz, part of AB system 
βCH2), 1.52 (3 H, s, CH3), 1.47 (6 H, s, 2 x CH3), 1.47 (3 H, s,  CH3), 1.42 (9 H, s, 3 x CH3), 0.87 (9 
H, s, 3 x CH3), 0.06 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 173.8 (CO), 172.7 (CO), 169.4 (CO), 156.1 (CO), 136.1 (ArC), 128.5 
(ArCH), 128.2 (ArCH), 128.1 (ArCH), 81.3 (C(CH3)3), 67.1 (CH2 of Cbz), 63.0 (αCH), 57.3 (βCH2), 
56.7 (αC), 56.5 (αC), 27.8 (CH3), 25.8 (CH3), 25.6 (CH3), 24.6 (CH3), 24.3 (CH3), 24.1 (CH3), 18.2 
(C(CH3)3), -5.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +29.1 
HRMS (ESI+, CH2Cl2) calc. for C29H49N3NaO7Si: 602.323750; observed: 602.323901 (M+Na)+ 
IR (neat) νmax/cm-1 = 3325 (NH), 2931 (CH), 2857 (CH), 1702 (CO), 1683 (CO), 1503 (NH), 1249 
(SiO), 1150 (SiC/OBn/OtBu) 










Synthesis of 93 – H2N-(L)Ser(OTBS)-Aib2OtBu  
 
H2N(L)Ser(OTBS)Aib2OtBu was synthesised following general procedure A on a 0.35 mmol 
scale. Compound 93 was synthesised as an off-white solid (148 mg, 0.33 mmol, 95 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.87 (1 H, s, NH), 7.36 (1 H, s, NH), 3.79 (1 H, dd, J = 10.0, 6.0 Hz, 
part of AB system βCH2), 3.74 (1 H, dd, J = 10.0, 5.0 Hz, part of AB system βCH2), 3.37 (1 H, dd, 
J = 6.0, 5.0 Hz, αCH), 1.84 (2 H, br s, NH2), 1.51 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.46 (6 H, s, 2 x 
CH3), 1.41 (9 H, s, 3 x CH3), 0.85 (9 H, s, 3 x CH3), 0.03 (3 H, s, CH3), 0.03 (3 H, s, CH3) 
13C NMR (100 MHz, CDCl3) δC 173.9 (CO), 173.1 (CO), 173.0 (CO), 81.0 (C(CH3)3), 65.0 (βCH2), 
57.1 (αC), 56.8 (αCH), 56.6 (αC), 27.8 (CH3), 25.8 (CH3), 25.4 (CH3), 25.0 (CH3), 18.2 (C(CH3)3), 
-5.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +27.4 
HRMS (ESI+, CH2Cl2) calc. for C21H44N3O5Si: 446.305025; observed: 446.305123 (M+H)+ 
IR (neat) νmax/cm-1 = 3393 (NH2), 2941 (CH), 2897 (CH), 1693 (CO), 1521 (NH), 1249 (SiO), 1121 
(SiC/OtBu) 
Mp (CH2Cl2): 162-164 oC 
 
Synthesis of 94 – Cbz-(L)Ser(OH)-Aib2OH  
 
Cbz(L)Ser(OH)Aib2OH was synthesised following general procedure C on a 0.62 mmol scale. 
Compound 94 was synthesised as an off-white solid (229 mg, 0.56 mmol, 91 %). 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.35-7.24 (5 H, m, 5 x ArH), 5.09 (2 H, br s, CH2 of Cbz), 4.09 (1 
H, m, αCH), 3.78 (1 H, d, J = 11.5, 6.0 Hz, part of AB system βCH2), 3.70 (1 H, d, J = 11.5, 6.0 
Hz, part of AB system βCH2), 1.42 (3 H, s, CH3), 1.41 (3 H, s, CH3), 1.39 (3 H, s, CH3), 1.38 (3 H, 





13C NMR (100 MHz, CDCl3) δC 176.7 (CO), 174.6 (CO), 171.3 (CO), 157.1 (CO), 136.8 (ArC), 128.2 
(ArCH), 127.7 (ArCH), 127.5 (ArCH), 66.5 (CH2 of Cbz), 61.7 (βCH2), 57.3 (αCH), 56.7 (αC), 55.7 
(αC), 24.2 (CH3), 24.0 (CH3), 23.8 (CH3), 23.8 (CH3) 
[α]D (c = 0.5, MeOH) = +24.0 
HRMS (ESI+, MeOH) calc. for C19H27N3NaO7: 432.1741; observed for: 432.1757 (M+Na)+ 
IR (neat) νmax/cm-1 = 3411 (OH sharp), 3296 (OH broad), 2989 (CH), 2882 (CH), 1721 (CO), 1659 
(CO), 1425 (NH), 1161 (OBn) 
Mp (EtOAc): 183-185 oC 
 
Synthesis of Cbz-(L)Ser(OTBS)-Aib2OH  
 
Cbz(L)Ser(OH)Aib2OH (251 mg, 0.48 mmol) and imidazole (80 mg, 1.20 mmol) were dissolved 
in CH2Cl2 (10 mL) and cooled to 0 oC. Once at temperature TBSCl (145 mg, 0.96 mmol) was 
added in a portion wise manner and the resulting solution was warmed to RT and left to stir 
overnight. After this the reaction mixture was diluted with HCl (aq) (1 M) and the layers  
separated. The organic phase was washed with brine, dried over Na2SO4, filtered and 
concentrated to give compound Cbz-(L)Ser(OTBS)-Aib2OH (197 mg, 0.31 mmol, 65 %) as a 
white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.39-7.31 (5 H, m, 5 x ArH), 5.13 (2 H, br s, CH2 of Cbz), 4.12-
4.09 (1 H, m, αCH), 3.78-3.70 (2 H, m, βCH2), 1.44 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.38 (6 H, s, 
2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.7 (CO), 174.6 (CO), 171.3 (CO), 157.1 (CO), 136.8 (ArC), 128.2 
(ArCH), 127.7 (ArCH), 127.5 (ArCH), 66.5 (CH2 of Cbz), 61.7 (βCH2), 57.3 (αCH), 56.7 (αC), 55.7 
(αC), 24.2 (CH3), 24.0 (CH3), 23.8 (CH3), 23.8 (CH3), 18.7 (C(CH3)3), -3.9 (CH3) 
[α]D (c = 0.5, MeOH) = +28.7 
HRMS (ESI+, MeOH) calc. for C25H41N3NaO7Si: 546.261150; observed: 546.261025 (M+H)+ 
IR (neat) νmax/cm-1: 3328 (OH, broad), 3276 (NH), 2939 (CH), 2933 (CH), 1723 (CO), 1659 (CO), 
1439 (SiO), 1351 (SiC), 1152 (OBn) 






Synthesis of 97 – Cbz-(L)Ser(OTBDPS)OH  
Previously synthesised and reported 175 
 
Cbz(L)Ser(OH)OH (4 g, 16.7 mmol) and imidazole (2.95 g, 43.4 mmol) were dissolved in DMF 
(8 mL) and the resulting solution was cooled to 0 oC. Once at temperature tBuPh2SiCl (4.79 
mL, 18.4 mmol) was slowly added, followed by DMAP (5 mol %) and the reaction was left to 
warm to room temperature overnight. The reaction mixture was diluted with MTBE (100 mL) 
and washed with H2O (100 mL). The aqueous phase was washed with MTBE (3 x 60 mL), the 
organic washes were combined, dried over Na2SO4, filtered and concentrated. The crude 
product was purified by column chromatography (Snap Ultra 100 g, 5:95 EtOAc:Petroleum 
ether + 0.2% TFA → 75:25 EtOAc:Petroleum ether +0.2 % TFA) to give compound 97 (6.79 g, 
14.2 mmol, 85%) as a clear viscous oil. NOTE: This compound is not stable at room 
temperature and should be used within a week of synthesising and then stored in a freezer. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH .7.61 (4 H, d, J = 7.0 Hz, ArH), 7.45 – 7.29 (11 H, m, ArCH), 5.73 
(1 H, d, J = 9.0 Hz, NH) 5.14 (2 H, br s, ArCH2), 4.51 (1 H, dt, J = 9.0, 3.0 Hz, αCH), 4.16 (1 H, dd, 
J = 10.0, 3.0 Hz, part of AB system βCH2) 3.94 (1 H, dd, J = 10.0, 3.0 Hz, part of AB system 
βCH2), 1.03 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.1 (CO), 156.3 (CO), 135.9 (ArC), 135.5 (ArCH), 135.5 (ArCH), 
132.6 (ArC), 132.4 (ArCH), 130.0 (ArCH), 128.6 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.8 
(ArCH), 127.8 (ArCH), 67.4 (CH2 of Cbz), 64.1 (βCH2), 55.8 (αCH), 26.7 (CH3), 19.3 (C(CH3)3 of 
TBDPS) 
HRMS (ESI+, CH2Cl2) calc. for C27H31NNaO5Si: 500.1864; observed: 500.1849 (M+Na)+ 
Spectral data consistent with previously reported data. 175 
 
Synthesis of 98 – Cbz-(L)Ser(OTBDPS)-NHtBu  
 





scale. Compound 98 was purified by column chromatography (ZIP Sphere 30g, 5% → 40% 
EtOAc in Petroleum Ether) as a clear viscous oil (664 mg, 1.25 mmol, 62 %). 
Analytical Data 
Rf (SiO2 8:2 Petroleum ether:EtOAc) = 0.42 
1H NMR (400 MHz, CDCl3) δH 7.68-7.59 (4 H, m, 4 x ArCH), 7.45-7.28 (11 H, m, 11 x ArCH), 6.30 
(1 H, s, NH), 5.70 (1.H, d, J = 5.0 Hz), 5.08 (2 H, br s, ArCH2), 4.19 (1 H, m, αCH), 3.99 (1 H, dd, 
J = 10.0, 4.0 Hz, part of AB system βCH2), 3.72 (1 H, dd, J = 10.0, 7.0 Hz, part of AB system 
βCH2), 1.34 (9 H, s, 3 x CH3), 1.06 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 169.1 (CO), 156.0 (CO), 136.2 (ArC), 135.5 (ArCH), 135.4 (ArCH), 
132.4 (ArC), 130.0 (ArCH), 128.5 (ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 67.0 
(C(CH3)3), 64.3 (CH2), 56.4 (αCH), 50.5 (βCH2), 26.9 (CH3), 26.8 (CH3), 19.2 (C(CH3)3 of TBDPS) 
[α]D (c = 1.0, CH2Cl2) = +30.2 
HRMS (ESI+, CH2Cl2) calc. for C31H40N2NaO4Si: 555.2649; observed: 555.2650 (M+Na)+ 
IR (neat) νmax/cm-1: 3346 (NH amide), 3070 (Ar), 2961 (Ar), 1660 (CO amide), 1528 (Ar), 1224 
(SiC), 1111 (CO ether) 
 
Synthesis of 100 – CbzHN-(L)Ser(OH)-NHtBu 
Previously synthesised and reported 176 
 
Cbz(L)Ser(OTBDPS)NHtBu (50 mg, 0.093 mmol) was dissolved in THF (0.5 mL), to this a solution 
of TBAF in THF (1M, 0.24 mmol) was added and the resulting solution was left to stir for 3 h. 
The reaction mixture was concentrated, dissolved in EtOAc and washed with KHSO4 (aq), 
NaHCO3 (aq) and brine. The organic phase was dried over Na2SO4, filtered and concentrated to 
give compound 100 (22 mg, 0.074 mmol, 79 %) as a viscous colourless oil. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.32-7.22 (5 H, m, 5 x ArH), 6.37 (1 H, s, NH), 5.82 (1 H, d, J = 7.5 
Hz, NH), 5.08 (1 H, d, J = 12.0 Hz, part of the AB system of CH2Ph), 5.02 (1 H, d, J = 12.0 Hz, 
part of the AB system of CH2Ph), 4.05-3.97 (2 H, m, αCH and part of the AB system of βCH2), 
3.56 (1H, dd, J = 11.0, 5.0 Hz, part of the AB system of βCH2), 1.24 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 170.1 (CO), 156.8 (CO), 136.1 (ArC), 128.6 (ArH), 128.3 (ArH), 
128.0 (ArH), 67.3 (CH2 of Cbz), 63.0 (βCH2), 55.5 (αCH), 51.5 (C(CH3)3), 28.6 (CH3). 





Synthesis of 99 – H2N-(L)Ser(OTBDPS)-NHtBu  
 
H2N(L)Ser(OTBDPS)NHtBu was synthesised by following general procedure A on a 1.25 mmol 
scale. Compound 99 was synthesised as a clear viscous oil (482 mg, 1.21 mmol, 96 %). 
Analytical Data 
Rf (SiO2 8:2 Petroleum ether:EtOAc) = 0.12 
1H NMR (400 MHz, CDCl3) δH 7.65 (4 H, dq, J = 6.5, 2.0 Hz, 4 x ArH), 7.45-7.35 (6 H, m, 6 x ArH), 
7.23 (1 H, br s, NH), 3.92 (1 H, dd, J = 10.0, 6.0 Hz, part of AB system βCH2), 3.82 (1 H, dd, J = 
10.0, 4.5 Hz, part of AB system βCH2), 3.35 (1 H, dd, J = 6.0, 4.5 Hz, αCH), 1.64 (2 H, br s, NH2), 
1.35 (9 H, s, 3 x CH3), 1.06 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 171.8 (CO), 135.6 (ArCH), 135.5 (ArCH), 133.3 (ArC), 133.0 (ArC), 
129.8 (ArCH), 127.7 (ArCH), 66.3 (C(CH3)3), 57.0 (αCH), 50.5 (βCH2), 28.8 (CH3), 26.9 (CH3), 19.3 
(C(CH3)3 of TBDPS) 
[α]D (c = 1.0, CH2Cl2) =  +29.7 
HRMS (ESI+, CH2Cl2) calc. for C23H35N2O2Si: 399.246491; observed: 399.246231 (M+H)+ 
IR (neat) νmax/cm-1 = 3319 (NH2), 2960 (CH), 2857 (CH), 1653 (CO), 1517 (NH), 1362 (SiC), 1110 
(SiO) 
 
Synthesis of 101 – Cbz-(L)Ser(OTBDPS)-Aib2OtBu  
 
Cbz(L)Ser(OTBDPS)Aib2OtBu was synthesised by following general procedure D on a 7.05 
mmol scale. Compound 101 was purified by column chromatography (ZIP Sphere 120g, 1% → 
10%) as an off-white solid (3.18 g, 4.5 mmol, 64 %). 
Analytical Data 
Rf (SiO2 7:3 Petroleum Ether: EtOAc) = 0.22 
1H NMR (400 MHz, CDCl3) δH 7.63 (4 H, ddt, J = 6.5, 5.5, 1.5 Hz, 4 x ArH), 7.46-7.31 (11 H, m, 





(1 H, q, J = 5.5 Hz, αCH), 4.05 (1 H, dd, J = 10.0, 4.0 Hz, part of AB system βCH2), 3.79 (1 H, dd, 
J = 10.0, 6.0 Hz, part of AB system βCH2), 1.56 (3 H, s, CH3), 1.52 (3 H, s, CH3), 1.50 (3 H, s, CH3), 
1.50 (3 H, s, CH3), 1.44 (9 H, s, 3 x CH3), 1.05 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 172.8 (CO), 169.2 (CO), 136.1 (ArC), 135.5 (ArCH), 135.4 (ArCH), 
132.3 (ArC), 130.0 (ArCH), 128.5 (ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 77.2 (αC), 
67.1 (ArCH2), 57.4 (αCH), 56.9 (βCH2), 56.8 (αC), 27.8 (CH3), 26.9 (CH3), 24.7 (CH3), 24.2 (CH3), 
19.2 (C(CH3)3) 
[α]D (c = 1.0, CH2Cl2) =  +30.8 
IR (neat) νmax/cm-1 = 3340 (NH), 2931 (CH), 2857 (CH), 1702 (CO), 1683 (CO), 1503 (OR) 
HRMS (ESI+, MeOH) calc. for C39H53N3NaO7Si: 726.3545; observed: 726.3524 (M+Na)+ 
Mp (CH2Cl2): 140-142 oC. 
 
Synthesis of 102 – Cbz-(L)Ser(OTBDPS)-Aib2OH  
 
Cbz(L)Ser(OTBDPS)Aib2OtBu was synthesised by following general procedure C on a 3.37 
mmol scale. Compound 102 was synthesised as an off-white solid (2.05 g, 3.17 mmol, 94 %). 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 7.66 (4 H, ddt, J = 8.0, 7.0, 2.0 Hz, 4 x ArH), 7.45-7.25 (11 H, m, 
11 x ArCH), 5.10 (2 H, br s, CH2 of Cbz), 4.21 (1 H, t, J = 6.0 Hz, αCH), 3.93-3.82 (2 H, m, 2 x 
βCH2), 1.47 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.39 (3 H, s, CH3), 1.04 (9 H, s, 3 
x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.6 (CO), 174.4 (CO), 171.0 (CO), 157.0 (CO), 135.3 (ArCH), 
135.2 (ArCH), 134.5 (ArC), 132.7 (ArC), 132.6 (ArC), 129.7 (ArCH), 129.6 (ArCH), 128.1 (ArCH), 
127.5 (ArCH), 127.5 (ArCH), 66.3 (ArCH2), 65.5 (αC), 63.3 (βCH2), 57.2 (αCH), 56.7 (αC), 25.9 
(CH3), 25.7 (CH3), 25.0 (CH3), 24.1 (CH3), 23.3 (CH3), 18.7 (CH3), 14.0 (C(CH3)3) 
[α]D (c = 1.0, MeOH) =  +32.2 
IR (neat) νmax/cm-1 = 3326 (OH br), 2940 (CO), 1740 (CO), 1687 (CO), 1519 (OR) 
HRMS (ESI+, MeOH) calc. for C35H45N3NaO7Si: 670.291898; observed: 670.291290 (M+Na)+ 







Synthesis of 103 – H2N-(L)Ser(OTBDPS)-Aib2OtBu 
 
H2N(L)Ser(OTBDPS)Aib2OtBu was synthesised by following general procedure A on a 1.42 
mmol scale. Compound 103 was synthesised as an off-white solid (736 mg, 1.29 mmol, 91 %).  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 8.12 (1 H, s, NH), 7.64-7.59 (4 H, m, 4 x ArH), 7.44-7.32 (6 H, m, 
6 x ArCH), 7.24 (1 H, s, NH), 4.28-4.15 (1 H, br s, αCH), 4.09 (1 H, dd, J = 10.0, 3.5 Hz, part of 
AB system βCH2), 4.00 (1 H, dd, J = 10.0, 3.5 Hz, part of AB system βCH2), 1.51 (3 H, s, CH3), 
1.46 (3 H, s, CH3), 1.44 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.41 (9 H, s, 3 x CH3), 1.03 (9 H, s, 3 x 
CH3) 
13C NMR (100 MHz, CDCl3) δC 174.2 (CO), 173.2 (CO), 135.6 (ArCH), 135.5 (ArCH), 132.3 (ArC), 
130.0 (ArCH), 129.9 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 81.4 (C(CH3)3), 57.4 (αC), 57.0 (βCH2), 
50.8 (αCH), 27.8 (CH3), 26.8 (CH3), 24.3 (CH3), 24.3 (CH3), 19.3 (C(CH3)3) 
[α]D (c = 1.0, CH2Cl2) =  +37.1 
HRMS (ESI+, CH2Cl2) calc. for C31H47N3NaO5Si: 592.3177; observed: 592.3177 (M+Na)+ 
IR (neat) νmax/cm-1 = 3289 (NH2/NH), 2954 (CH), 1701 (CO), 1673 (CO), 1510 (NH) 
Mp (MeOH): 156-158 oC 
 
Synthesis of 104 – Cbz-[(L)Ser(OTBDPS)-Aib2]2-OtBu 
 
Cbz[(L)Ser(OTBDPS)Aib2]2OtBu was synthesised by following general procedure D on a 1.10 
mmol scale. Compound 104 was purified by column chromatography (SNAP Ultra 50g, 1% → 
10% MeOH in CH2Cl2) as an off-white solid (400 mg, 0.33 mmol, 30 %) 
Analytical Data 





1H NMR (400 MHz, CDCl3) δH 7.64-7.59 (6 H, m, 6 x ArH), 7.58-7.53 (3 H, m, 3 x ArH), 7.45 (2 
H, m, 2 x ArH), 7.41-7.35 (12 H, m, 10 x ArH, 2 x NH), 7.26 (1 H, br s, NH), 7.25 (1 H, br s, NH), 
7.23-7.16 (4 H, m, 4 x ArH), 6.31 (1 H, br s, NH), 5.25 (1 H, d, J = 3.5 Hz, NH), 5.18 (1 H, d, J = 
12.0 Hz, part of the Cbz CH2 AB system), 5.08 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB 
system), 4.31 (1 H, J = 8.0, 5.5 Hz, αCH), 4.14-4.04 (2 H, m, two parts of AB system βCH2), 3.84 
(1 H, dd, J = 11.0, 4.0 Hz, part of AB system βCH2), 3.70 (1 H, m, αCH), 3.62 (1 H, dd, J = 11.0, 
4.0 Hz, part of AB system βCH2), 1.56 (3 H, s, CH3), 1.53 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.50 (3 
H, s, CH3), 1.48 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.44 (3 H, s, CH3), 1.42 (9 H, s, 4 x CH3), 1.06 (9 
H, s, 3 x CH3), 0.96 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.6 (CO), 173.8 (CO), 173.5 (CO), 173.4 (CO), 170.1 (CO), 169.1 
(CO), 156.8 (CO), 135.9 (ArC), 135.5 (ArCH), 135.4 (ArCH), 135.4 (ArCH), 135.4 (ArCH), 133.2 
(ArC), 133.2 (ArC), 132.1 (ArC), 131.8 (ArC), 130.5 (ArCH), 130.4 (ArCH), 129.6 (ArCH), 129.5 
(ArCH), 128.7 (ArCH), 128.7 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.6 (ArCH), 
127.5 (ArCH), 79.9 (C(CH3)3 of OtBu), 67.7 (CH2 of Cbz), 63.2 (βCH2), 62.6 (βCH2), 58.6 (αCH), 
58.4 (αCH), 57.1 (αC), 56.7 (αC), 56.7 (αC), 56.1 (αC), 27.9 (CH3), 27.8 (CH3), 27.1 (CH3), 27.1 
(CH3), 26.9 (CH3), 26.8 (CH3), 25.5 (CH3), 24.1 (CH3), 24.0 (CH3), 23.5 (CH3), 23.2 (CH3), 19.3 
(C(CH3)), 19.2 (C(CH3)3) 
[α]D (c = 1.0, CH2Cl2) = +61.2 
HRMS (MALDI+, CH2Cl2) calc. for C66H90N6NaO11Si2: 1221.6091; observed 1221.6091 (M+Na)+ 
IR (neat) νmax/cm-1 = 3325 (NH), 2934 (CH), 2890 (CH), 1704 (CO), 1663 (CO), 1519 (NH) 
Mp (MeOH): 215-218 oC 
 
Synthesis of 105 – Cbz-[(L)Ser(OTBDPS)-Aib2]2OH 
 
Cbz[(L)Ser(OTBDPS)Aib2]OH was synthesised by following general procedure C on a 0.20 
mmol scale. Compound 105 was synthesised as a white solid (205 mg, 0.18 mmol, 91 %). 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.03 
1H NMR (400 MHz, CDCl3) δH 7.86 (1 H, br s, NH), 7.79 (1 H, d, J = 5.0 Hz, NH), 7.63-7.53 (10 H, 
m, 10 x ArCH), 7.41-7.33 (15 H, m, 15 x ArCH), 7.24 (1 H, br s, NH), 7.22 (1 H, br s, NH), 6.49 (1 
H, br s, NH), 5.32 (1 H, d, J = 5.5 Hz, NH), 5.16 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB 
system), 5.08 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB system), 4.27 (1 H, dt, J = 7.0, 5.0, 





part of AB system βCH2), 3.82 (1 H, dd, J = 10.5, 4.0 Hz, part of AB system βCH2), 3.73 (1 H, m, 
αCH), 3.66 (1 H, dd, J = 10.5, 4.0 Hz, part of AB system βCH2), 1.55 (3 H, s, CH3), 1.52 (3 H, s, 
CH3), 1.51 (3 H, s, CH3), 1.50 (3 H, s, CH3), 1.47 (12 H, br s, 4 x CH3), 1.06 (9 H, s, 3 x CH3), 0.97 
(9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 187.7 (CO), 178.1 (CO), 177.6 (CO), 176.0 (CO), 174.0 (CO), 171.5 
(CO), 157.1 (CO), 135.8 (ArC), 135.5 (ArCH), 135.4 (ArCH), 134.8 (ArC), 132.6 (ArC), 131.8 (ArC), 
128.7 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 68.1 (CH2 of Cbz), 62.6 (βCH2), 62.5 (βCH2), 58.6 (αCH), 58.4 (αCH), 57.5 
(αC), 57.0 (αC), 56.7 (αC), 56.7 (αC), 26.9 (CH3), 26.8 (CH3), 26.5 (CH3), 24.8 (CH3), 24.3 (CH3), 
23.5 (CH3), 23.2 (CH3), 19.3 (C(CH3)3), 19.22 (C(CH3)3) 
[α]D (c = 1.0, MeOH) = +54.7 
HRMS (MALDI+, MeOH) calc. for C62H82N6O11Si2Na: 1165.5472; observed: 1165.5462 (M+Na)+ 
IR (neat) νmax/cm-1 = 3600 (br OH), 3306 (NH), 2956 (CH), 2938 (CH), 1702 (CO), 1656 (CO), 
1524 (NH) 
Mp (MeOH): 212-214 oC 
 
Synthesis of 106 – Cbz-(L)Ser(OTBDPS)-Aib2-(L)Ser(OTBDPS)-NHtBu 
 
Cbz(L)Ser(OTBDPS)Aib2(L)Ser(OTBDPS)NHtBu was synthesised by following general 
procedure D on a 0.5 mmol scale. Compound 106 was purified by column chromatography 
(SNAP Ultra 25g, 0.2% → 1.5%) as an off-white solid (220 mg, 0.21 mmol, 42 %). 
Analytical Data 
Rf (SiO2 1% MeOH in CH2Cl2) = 0.22 
1H NMR (400 MHz, CDCl3) δH 7.67-7.54 (12 H, m, 12 x ArH), 7.42-7.35 (13 H, m, 13 x ArH), 7.04 
(1 H, br s, NH), 6.88 (1 H, br s, NH), 6.32 (1 H, br s, NH), 5.32 (1 H, d, J = 4.5 Hz, NH), 5.17 (1 H, 
d, J = 12.0 Hz, part of the Cbz CH2 AB system), 5.09 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB 
system), 4.55 (1 H, td, J = 7.5, 4.5 Hz, αCH), 4.12 (1 H, m, αCH), 3.88 (1 H, dd, J = 10.5, 3.5 Hz, 
part of AB system βCH2), 3.81 (1 H, dd, J = 10.5, 4.5, part of AB system βCH2), 3.61 (1 H, dd, J 
= 10.5, 4.5 Hz, part of AB βCH2), 3.35 (1 H, m, part of AB system βCH2), 1.56 (3 H, s, CH3), 1.48 






13C NMR (100 MHz, CDCl3) δC 174.4 (CO), 173.3 (CO), 171.8 (CO), 169.1 (CO), 156.6 (CO), 135.9 
(ArC), 135.6 (ArCH), 135.5 (ArCH), 135.5 (ArCH), 135.4 (ArCH), 135.4 (ArCH) 133.5 (ArC), 133.3 
(ArC), 133.2 (ArC), 131.9 (ArC), 130.4 (ArCH), 130.3 (ArCH), 129.8 (ArCH), 128.7 (ArCH), 128.6 
(ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 67.6 (CH2 of 
Cbz), 66.3 (βCH2), 64.0 (βCH2), 57.0 (αCH), 57.0 (αCH), 51.3 (αC), 50.5 (αC), 49.7 (C(CH3)3), 28.8 
(CH3), 28.7 (CH3), 26.9 (CH3), 23.7 (CH3), 23.4 (CH3), 19.2 (C(CH3)3), 19.23 (C(CH3)3) 
[α]D (c = 1.0, CH2Cl2) =  +42.3 
HRMS (MALDI+, CH2Cl2) calc. for C58H77N5NaO8Si2: 1050.5203; observed: 1050.5209 (M+Na)+ 
IR (neat) νmax/cm-1 = 3336 (NH), 2965 (CH), 2934 (CH), 1732 (CO), 1664 (CO), 1525 (NH) 
Mp (CH2Cl2): 146-148 oC 
 
Synthesis of 107 – H2N-(L)Ser(OTBDPS)-Aib2-(L)Ser(OTBDPS)-NHtBu 
 
H2N(L)Ser(OTBDPS)Aib2(L)Ser(OTBDPS)NHtBu was synthesised by following general 
procedure A on a 0.19 mmol scale. Compound 107 was purified by column chromatography 
(SNAP Ultra 10 g, 20% → 100% EtOAc in n-hexane) as a white solid (69 mg, 0.077 mmol, 42 
%). 
Analytical Data 
Rf (SiO2 8:2 EtOAc:Petroleum Ether + 1% Et3N) = 0.25 
1H NMR (400 MHz, CDCl3) δH 7.94 (1 H, br s, NH), 7.65-7.56 (8 H, m, 8 x ArH), 7.44-7.31 (8 H, 
m, 7 x ArH and 1 NH), 7.30-7.26 (3 H, m, 3 x ArH), 7.23-7.18 (2 H, m, 2 x ArH), 6.90 (1 H, br s, 
NH), 6.84 (1 H, br s, NH), 4.53 (1 H, td, J = 7.5, 4.5 Hz, αCH), 4.17 (1 H, dd, J = 10.0, 7.5 Hz, part 
of AB system βCH2), 4.05 (2 H, td, J = 10.0, 4.0 Hz, AB system of βCH2), 3.57 (1 H, dd, J = 10.0, 
4.0 Hz, part of AB system βCH2), 3.21 (1 H, t, J = 4.0 Hz, αCH), 1.55 (3 H, s, CH3), 1.48 (3 H, s, 
CH3), 1.47 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.38 (9 H, s, 3 x CH3), 1.03 (9 H, s, 3 x CH3), 0.98 (9 
H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.1 (CO), 173.8 (CO), 173.7 (CO), 169.0 (CO), 135.5 (ArCH), 
135.4 (ArCH), 135.4 (ArCH), 135.4 (ArCH), 133.3 (ArC), 133.3 (ArC), 132.9 (ArC), 132.4 (ArC), 
130.0 (ArCH), 130.0 (ArCH), 129.7 (ArCH), 129.6 (ArCH), 127.9 (ArCH), 127.7 (ArCH), 127.6 
(ArCH), 65.5 (βCH2), 64.0 (βCH2), 57.1 (αC), 56.9 (αC), 56.2 (αCH), 56.1 (αCH), 51.21 (C(CH3)3), 






[α]D (c = 1.0, CH2Cl2) =  +45.7 
HRMS (MALDI+, CH2Cl2) calc. for C34H55N5NaO6Si2: 708.358861; observed: 708.358902 
(M+Na)+ 
IR (neat) νmax/cm-1 = 3451 (NH2), 2965 (CH), 2934 (CH), 2904 (CH), 1664 (CO), 1525 (NH), 1243 
(SiC), 1150 (SiO) 
Mp (CH2Cl2): 162-165 oC. 
 
Synthesis of 108 – Cbz-[(L)Ser(OTBDPS)-Aib2]3-(L)Ser(OTBDPS)-NtBu  
 
Cbz[(L)Ser(OTBDPS)Aib2]3(L)Ser(OTBDPS)NHtBu was synthesised by following general 
procedure D on a 0.077 mmol scale. Compound 108 was purified by column chromatography 
(SNAP Ultra 25g, 1% → 10% MeOH in CH2Cl2) as a white solid (82 mg, 0.041 mmol, 54%). 
Analytical Data 
Rf (SiO2 10% MeOH in CH2Cl2) = 0.19 
1H NMR (400 MHz, CDCl3) δH 8.00 (1 H, s, NH), 7.79 (1 H, s, NH), 7.75 (1 H, s, NH), 7.74 (1 H, 
m, NH), 7.71 (1 H, s, NH), 7.68 (1 H, s, NH), 7.65-7.51 (20 H, m, 18 x ArH and 2 x NH), 7.49-7.27 
(26 H, m, 25 x ArH and 1 x NH), 7.24-7.08 (12 H, m, 12 x ArH), 6.39 (1 H, s, NH), 5.32 (1 H, d, J 
= 3.0 Hz, NH), 5.19 (1 H, d, J = 12.5 Hz, part of the Cbz CH2 AB system), 5.09 (1 H, d, J = 12.5 
Hz, part of the Cbz CH2 AB system), 4.60 (1 H, td, J = 9.0 Hz, 3.5 Hz, αCH), 4.07-3.63 (11 H, m, 
8 x βCH2 and 3 x αCH), 1.59 (3 H, s, CH3), 1.59 (3 H, s, CH3), 1.55 (6 H, s, 2 x CH3), 1.51 (6 H, s, 
2 x CH3), 1.49 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.38 (3 H, s, CH3), 1.37 (3 H, s, CH3), 1.36 (9 H, s, 
3 x CH3), 1.07 (9 H, s, 3 x CH3), 0.95 (9 H, s, 3 x CH3), 0.95 (9 H, s, 3 x CH3), 0.87 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.4 (CO), 175.8 (CO), 175.5 (CO), 175.3 (CO), 173.9 (CO), 171.6 
(CO), 171.2 (CO), 171.1 (CO), 169.8 (CO), 169.7 (CO), 155.3 (CO), 135.6 (ArCH), 135.5 (ArCH), 
135.5 (ArCH), 135.5 (ArCH), 135.4 (ArCH), 135.4 (ArCH), 131.9 (ArC), 130.5 (ArC), 129.7 (ArC), 
129.4 (ArC), 129.2 (ArC), 128.7 (ArC), 128.2 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.7 (ArCH), 
127.6 (ArCH), 127.5 (ArCH), 127.5 (ArCH), 127.4 (ArCH), 67.0 (CH2 of Cbz), 62.8 (αCH), 60.4 
(αCH), 57.0 (αC), 57.0 (αC), 56.9 (αC), 56.7 (αC), 56.6 (αC), 56.4 (αC), 51.4 (αCH), 28.7 (βCH2), 
26.9 (βCH2), 26.8 (βCH2), 26.8 (βCH2), 26.7 (CH3), 23.4 (CH3), 23.3 (CH3), 23.3 (CH3), 23.1 (CH3), 
19.3 (CH3), 19.3 (CH3), 19.2 (CH3), 14.2 (CH3), 14.0 (CH3) 





HRMS (MALDI, MeOH) calc. for C112H151N11NaO16Si4: 2041.0310; observed: 2041.0328 
(M+Na)+ 
IR (neat) νmax/cm-1: 3317 (NH), 2931 (Ar), 2857 (ArC), 1659 (CO), 1531 (Ar), 1226 (SiC) 
Mp (MeOH): >300 oC 
 
Synthesis of 109 – Cbz-[(L)Ser(OH)-Aib2]3-(L)Ser(OH)-NtBu  
 
Cbz[(L)Ser(OTBDPS)Aib2]3(L)Ser(OTBDPS)NHtBu (30 mg, 0.015 mmol) was dissolved in THF 
(0.5 mL) and to this a solution of TBAF in THF (0.15 mmol, 1 M) was added. The resulting 
solution was left to stir over night. The reaction mixture was then concentrated, dissolved in 
EtOAc, washed with 1 M HCl (aq), 1 M NaOH (aq) and brine, then dried (Na2SO4), filtered and 
concentrated to give compound 109 as a white solid (17 mg, 0.013 mmol, 85%). 
Analytical Data 
Rf (SiO2 10% MeOH in CH2Cl2) = 0.00 
1H NMR (400 MHz, CD3OD) δH 7.24-7.17 (5 H, m, 5 x ArH), 5.19-5.14 (2 H, m, Cbz CH2), 4.60-
4.56 (1 H, m, αCH), 4.12-3.64 (11 H, m, 4 x βCH2 and 3 x αCH), 1.60 (3 H, s, CH3), 1.58 (3 H, s, 
CH3), 1.53 (6 H, s, 2 x CH3), 1.50 (9 H, s, 3 x CH3), 1.45 (6 H, s, CH3), 1.36 (12 H, s, 4 x CH3). 
13C NMR (100 MHz, CD3OD) δC 175.4 (CO), 174.8 (CO), 174.5 (CO), 173.3 (CO), 172.5 (CO), 
171.7 (CO), 171.2 (CO), 170.9 (CO), 170.8 (CO), 169.9 (CO), 155.3 (CO), 136.1 (ArCH), 132.6 
(ArC), 131.2 (ArCH), 130.1 (ArC), 65.2 (CH2 of Cbz), 61.5 (αCH), 60.8 (αCH), 58.7 (αC), 58.6 (αC), 
57.9 (αC), 57.5 (αC), 57.0 (αC), 56.8 (αC), 53.4 (αCH), 27.4 (βCH2), 26.6 (βCH2), 26.1 (βCH2), 
26.1 (βCH2), 25.7 (CH3), 25.4 (CH3), 25.3 (CH3), 24.8 (CH3), 23.5 (CH3), 23.3 (CH3), 23.1 (CH3) 
[α]D (c = 0.5, CH2Cl2) = +49.8 
HRMS (MALDI, MeOH) calc. for C48H79N11NaO16: 1088.5598; observed: 1088.5587 (M+Na)+ 
IR (neat) νmax/cm-1: 3317 (OH), 2931 (CH), 2857 (ArC), 1734 (CO), 1659 (CO), 1531 (NH)  









Synthesis of Cbz(L)Asp(OMe)NHtBu  
 
Cbz(L)Asp(OMe)NHtBu was synthesised by following general procedure E on a 3.44 mmol 
scale. Cbz(L)Asp(OMe)NHtBu was synthesised as a pale-yellow solid (875 mg, 2.60 mmol, 76 
%). 
Analytical Data 
Rf (SiO2, 2% MeOH in CH2Cl2) = 0.48 
1H NMR (400 MHz, CDCl3) δH 7.36-7.30 (5 H, m, 5 x ArH), 6.26 (1 H, br s, NH), 5.91 (1 H, d, J = 
8.5 Hz, NH), 5.14 (1 H, d, J = 12.0 Hz, part of the Cbz CH2 AB system), 5.09 (1 H, d, J = 12.0 Hz, 
part of Cbz CH2 AB system), 4.43 (1 H, ddd, J = 8.5, 6.5, 4.5 Hz, αCH), 3.68 (3 H, s, OCH3), 2.96 
(1 H, dd, J = 17.0, 4.5 Hz, part of AB system βCH2), 2.63 (1 H, dd, J = 17.0, 6.5 Hz, part of AB 
system βCH2), 1.30 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 172.4 (CO), 169.2 (CO), 156.0 (CO), 136.1 (ArC), 128.6 (ArCH), 
128.3 (ArCH), 128.1 (ArCH), 67.2 (CH2 of Cbz), 52.0 (OCH3), 51.4 (αCH), 51.4 (C(CH3)3), 36.1 
(βCH2), 28.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) =  +28.4 
IR (neat) νmax/cm-1 = 3337 (NH), 2981 (CH), 2965 (CH), 1727 (CO), 1667 (CO), 1513 (NH) 
HRMS (ESI+, CH2Cl2/CDCl3) calc. for C17H24N2NaO5: 359.157743; observed: 359.157812 
(M+Na)+ 
Mp (MeOH): 79-82 oC 
 
Synthesis of 116 – H2N(L)Asp(OMe)NtBu  
 
H2N(L)Asp(OMe)NHtBu was synthesised by following general procedure A on a 2.38 mmol 






Rf (SiO2, 5% MeOH in CH2Cl2) = 0.13 
1H NMR (400 MHz, CDCl3) δH 7.16 (1 H, br s, NH), 3.69 (3 H, s, OCH3), 3.60 (1 H, dd, J = 6.5, 
4.5 Hz, αCH), 2.88 (1 H, dd, J = 17.0, 6.5 Hz, part of AB system βCH2), 2.79 (1 H, dd, J = 17.0, 
4.0 Hz, part of AB system βCH2), 1.45 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.2 (CO), 170.3 (CO), 54.2 (OCH3), 51.7 (αCH), 49.3 (C(CH3)3), 
37.1 (βCH2), 26.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) = + 27.6 
HRMS (ESI+, CH2Cl2) calc. for C9H18N2NaO3: 225.121513; observed: 225.121482 (M+Na)+ 
IR (neat) νmax/cm-1 = 3374 (NH2), 3223 (NH), 2979 (CH), 1726 (CO), 1665 (CO), 1511 (NH)  
 
Synthesis of 117 – N3-Aib2-(L)Asp(OMe)NHtBu 
 
N3Aib2(L)Asp(OMe)NHtBu was synthesised by following general procedure D on a 2.03 mmol 
scale. Compound 117 was purified by column chromatography (SNAP Ultra 10g, 0.5% → 4% 
MeOH in CH2Cl2) as a white solid (500 mg, 1.25 mmol, 62 %). 
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.23 
1H NMR (400 MHz, CDCl3) δH 7.32 (1 H, d, J = 9.0 Hz, NH), 6.84 (1 H, br s, NH), 6.69 (1 H, br s, 
NH), 4.62 (1 H, ddd, J = 9.0, 5.0, 4.0 Hz, αCH), 3.63 (3 H, s, OCH3), 3.12 (1 H, dd, J = 17.0, 4.0 
Hz, part of AB system βCH2), 2.42 (1 H, dd, J = 17.0, 5.0 Hz, part of AB system βCH2), 1.53 (3 
H, s, CH3), 1.49 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.29 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 173.3 (CO), 173.0 (CO), 172.3 (CO), 169.1 (CO), 64.2 (αC), 56.8 
(αC), 51.9 (OCH3), 51.4 (C(CH3)3), 49.6 (αCH), 34.9 (βCH2), 28.5 (CH3), 26.0 (CH3), 24.4 (CH3), 
24.3 (CH3), 24.2 (CH3) 
[α]D (c = 1.0, CH2Cl2) =  +34.6 






IR (neat) νmax/cm-1 = 3314 (NH), 2980 (CH), 2106 (N3), 1737 (CO), 1650 (CO), 1535 (NH), 1514 
(OR) 
Mp (EtOAc): 121-125 oC. 
 
Synthesis of 118 – H2N-Aib2-(L)Asp(OMe)-NHtBu 
 
H2NAib2(L)Asp(OMe)NHtBu was synthesised by following general procedure A on a 1.10 mmol 
scale. Compound 118 was synthesised as an off-white solid (383 mg, 1.03 mmol, 94 %). 
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.09 
1H NMR (400 MHz, CDCl3) δH 8.06 (1 H, br s, NH), 7.36 (1 H, d, J = 9.0 Hz, NH), 6.81 (1 H, br s, 
NH), 4.59 (1 H, dt, J = 9.0, 5.0 Hz, αCH), 3.57 (3 H, s, CH3), 3.08 (1 H, dd, J = 17.0, 5.0 Hz, part 
of AB system βCH2), 2.42 (1 H, dd, J = 17.0, 5.0 Hz, part of AB system βCH2), 1.44 (3 H, s, CH3), 
1.37 (3 H, s, CH3), 1.34 (3 H, s, CH3), 1.27 (3 H, s, CH3), 1.25 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 177.7 (CO), 173.8 (CO), 173.1 (CO), 169.4 (CO), 56.4 (αC), 55.1 
(αC), 51.9 (αCH), 51.4 (OCH3), 49.6 (C(CH3)3), 35.1 (βCH2), 28.8 (CH3), 28.5 (CH3), 26.4 (CH3), 
24.0 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +32.8 
IR (neat) νmax/cm-1 = 3316 (NH), 2979 (CH), 1737 (CO), 1675 (CO), 1520 (NH) 
HRMS (ESI+, CH2Cl2) calc. for C17H32N4NaO5: 395.226491; observed: 395.227631 (M+Na)+ 
Mp (MeOH): 139-142 oC 
 






Cbz(L)Asp(OMe)Aib2OtBu was synthesised by following general procedure D on a 3.76 mmol 
scale. Compound 111 was purified by column chromatography (SNAP Ultra 50g, 10% → 80% 
EtOAc in Petroleum Ether) as a white solid (1.36 g, 2.68 mmol, 71 %). 
Analytical Data 
Rf (SiO2, 40% EtOAc in Petroleum Ether) = 0.19 
1H NMR (400 MHz, CDCl3) δH 7.37-7.31 (5 H, m, 5 x ArH), 6.87 (1 H, s, NH), 6.82 (1 H, s, NH), 
5.82 (1 H, d, J = 8.5 Hz, NH), 5.14 (2 H, br s, CH2 of Cbz), 4.50 (1 H, ddd, J = 8.5, 6.0, 4.5 Hz, 
αCH), 3.68 (3 H, s, OCH3), 3.04 (1 H, dd, J = 17.5, 4.5 Hz, part of AB system βCH2), 2.71 (1 H, 
dd, J = 17.5, 6.0 Hz, part of AB system βCH2), 1.51 (3 H, s, CH3), 1.48 (3 H, s, CH3), 1.47 (6 H, s, 
2 x CH3), 1.44 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 173.7 (CO), 172.5 (CO), 172.3 (CO), 169.5 (CO), 156.1 (CO), 135.9 
(ArC), 128.6 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 81.2 (C(CH3)3), 67.4 (CH2 of Cbz), 57.3 (αC), 
56.6 (αC), 52.1 (OCH3), 51.5 (αCH), 35.8 (βCH2), 27.8 (CH3), 25.4 (CH3), 24.7 (CH3), 24.4 (CH3), 
24.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +29.3 
HRMS (ESI+, CH2Cl2) calc. for C25H37N3NaO8: 530.247837; observed: 530.247812 (M+Na)+ 
IR (neat) νmax/cm-1: 3299 (NH), 2983 (CH), 2943 (CH), 1717 (CO), 1660 (CO), 1518 (NH), 1231 
(OMe/OtBu/OBn), 1158 (OMe/OtBu/OBn) 
Mp (CH2Cl2): 130-132 oC 
 
Synthesis of 112 – Cbz-(L)Asp(OMe)-Aib2OH  
 
Cbz(L)Asp(OMe)Aib2OH was synthesised by following general procedure C on a 1.61 mmol 
scale. Compound 112 was synthesised as white solid (690 mg, 1.53 mmol, 95 %).  
Analytical Data 
Rf (SiO2, 40% EtOAc in Petroleum Ether) = 0.03 
1H NMR (400 MHz, CD3OD) δH 7.37-7.26 (5 H, m, 5 x ArH), 5.11 (2 H, br s, CH2 of Cbz), 4.38 (1 
H, t, J = 7.0 Hz, αCH), 3.67 (3 H, s, OCH3), 2.83 (1 H, dd, J = 16.5, 7.0 Hz, part of AB system 
βCH2), 2.71 (1 H, dd, J = 16.5, 7.0 Hz, part of AB system βCH2), 1.43 (3 H, s, CH3), 1.43 (3 H, s, 





13C NMR (100 MHz, CD3OD) δC 176.6 (CO), 174.4 (CO), 171.3 (CO), 171.0 (CO), 156.9 (CO), 
136.7 (ArC), 128.1 (ArCH), 127.6 (ArCH), 127.4 (ArCH), 66.4 (CH2 of Cbz), 56.5 (αC), 55.7 (αC), 
51.8 (αCH), 51.0 (OCH3), 35.2 (βCH2), 24.2 (CH3), 23.8 (CH3), 23.5 (CH3) 
[α]D (c = 1.0, MeOH) = +27.9 
HRMS (MALDI+, MeOH) calc. for C21H29N3O8Na: 474.1847; observed: 474.1840 (M+Na)+ 
IR (neat) νmax/cm-1 = 3350 (NH), 2966 (CH), 2940 (CH), 1723 (CO), 1655 (CO), 1521 (NH) 
Mp (MeOH): 146-149 oC. 
 
Synthesis of 113 – H2N-(L)Asp(OMe)-Aib2OtBu 
 
H2N(L)Asp(OMe)Aib2OtBu was synthesised by following general procedure A on a 0.98 mmol 
scale. Compound 113 was synthesised as a white solid (336 mg, 0.90 mmol, 92 %). 
Analytical Data 
Rf (SiO2, 40% EtOAc in Petroleum Ether) = 0.06 
1H NMR (400 MHz, CDCl3) δH 7.88 (1 H, s, NH), 7.14 (1 H, s, NH), 3.67 (3 H, s, OCH3), 3.57 (1 H, 
dd, J = 6.5, 4.0 Hz, αCH), 2.87 (1 H, dd, J = 17.0, 6.5 Hz, part of AB system βCH2), 2.75 (1 H, dd, 
J = 17.0, 4.0 Hz, part of AB system βCH2), 1.96 (2 H, br s, NH2), 1.53 (3 H, s, CH3), 1.49 (3 H, s, 
CH3), 1.45 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.42 (9 H, s, 3 x CH3). 
13C NMR (100 MHz, CDCl3) δC 173.8 (CO), 173.0 (CO), 172.9 (CO), 172.5 (CO), 81.0 (C(CH3)3), 
56.9 (αC), 56.5 (αC), 51.9 (OCH3), 51.8 (αCH), 38.8 (βCH2), 27.8 (CH3), 26.0 (CH3), 24.5 (CH3), 
24.5 (CH3), 24.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +34.1 
HRMS (ESI+, CH2Cl2) calc. for C17H31N3NaO6: 396.210506; observed: 396.210544 (M+Na)+ 
IR (neat) νmax/cm-1 = 3532 (NH2), 3347 (CH), 2984 (CH), 2926 (CH), 1720 (CO), 1668 (CO), 1510 
(NH), 1143 (OtBu)  







Synthesis of 114 – Cbz-[(L)Asp(OMe)-Aib2]2OtBu  
 
Cbz[(L)Asp(OMe)Aib2]2OtBu was synthesised by following general procedure D on a 1.17 
mmol scale. Compound 114 was purified by column chromatography (SNAP Ultra 50g, 1% → 
10%) as an off-white solid (330 mg, 0.41 mmol, 35 %).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.21 
1H NMR (400 MHz, CDCl3) δH 7.76 (1 H, d, J = 7.0 Hz, NH), 7.40 (1 H, s, NH), 7.33-7.27 (5 H, m, 
5 x ArH), 7.04 (1 H, s, NH), 7.00 (1 H, s, NH), 6.45 (1 H, d, J = 7.0 Hz, NH), 5.14-5.02 (2 H, m, the 
Cbz CH2 AB system), 4.50-4.34 (2 H, m, 2 x αCH), 3.64 (3 H, s, CH3), 3.55 (3 H, s, CH3), 2.98-2.83 
(4 H, m, 2 x βCH2), 1.48 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.40 (3 H, s, CH3), 
1.39 (6 H, s, 2 x CH3), 1.38 (12 H, s, 4 x CH3) 
13C NMR (100 MHz, CDCl3) δC 173.7 (CO), 173.6 (CO), 173.5 (CO), 172.5 (CO), 172.3 (CO), 171.1 
(CO), 169.7 (CO), 169.2 (CO), 156.6 (CO), 135.7 (ArC), 129.4 (ArC), 128.7 (ArCH), 128.2 (ArCH), 
81.2 (C(CH3)3), 66.3 (CH2 of Cbz), 57.5 (αC), 57.3 (αC), 56.9 (αC), 56.5 (αC), 52.3 (OCH3), 52.0 
(OCH3), 51.1 (αCH), 35.8 (βCH2), 34.4 (βCH2), 28.3 (CH3), 27.9 (CH3), 27.8 (CH3), 26.4 (CH3), 
25.4 (CH3), 24.7 (CH3), 24.4 (CH3), 24.1 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +31.5 
HRMS (ESI+, CH2Cl2) calc. for C38H58N6NaO13: 829.395407; observed: 829.392902 (M+Na)+ 
IR (neat) νmax/cm-1 = 3290 (NH), 3020 (CH), 2950 (CH), 1720 (CO), 1654 (CO), 1534 (NH), 1250 
(OMe/OBn/OtBu), 1140 (OMe/OBn/OtBu) 
Mp (MeOH): 202-205 oC. 
 






Cbz[(L)Asp(OMe)Aib2]2OH was synthesised by following general procedure C on a 0.59 mmol 
scale. Compound 115 was obtained as white solid (375 mg, 0.50 mmol, 85 %).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.07 
 1H NMR (400 MHz, CD3OD) δH 7.36-7.28 (5 H, m, 5 x ArH), 5.12 (1 H, d, J = 11.5 Hz, part of the 
Cbz CH2 AB system), 5.09 (1 H, d, J = 11.5 Hz, part of the Cbz CH2 AB system), 4.45-4.34 (2 H, 
m, 2 x αCH), 3.67 (3 H, s, OCH3), 3.62 (3 H, s, OCH3), 2.97-2.86 (3 H, m, one and a half of the 
AB systems of βCH2), 2.79 (1H, dd, J = 16.5, 6.0 Hz, part of one of the AB systems βCH2),  1.49 
(3 H, s, CH3), 1.47 (6 H, s, 2 x CH3), 1.46 (3 H, s, CH3), 1.45 (3 H, s, CH3), 1.40 (3 H, s, CH3), 1.38 
(3 H, s, CH3), 1.36 (3 H, s, CH3) 
13C NMR (100 MHz, CD3OD) δC 176.6 (CO), 176.6 (CO), 175.2 (CO), 174.7 (CO), 174.7 (CO), 
172.1 (CO), 171.5 (CO), 171.4 (CO), 156.9 (CO), 136.4 (ArC), 128.1 (ArCH), 127.7 (ArCH), 127.5 
(ArCH), 66.5 (CH2 of Cbz), 56.8 (αC), 56.7 (αC), 56.6 (αC), 56.6 (αC), 51.6 (OCH3), 51.5 (OCH3), 
51.2 (αCH), 51.1 (αCH), 35.2 (βCH2), 34.6 (βCH2), 24.9 (CH3), 24.8 (CH3), 24.5 (CH3), 24.2 (CH3), 
23.9 (CH3), 23.8 (CH3), 23.2 (CH3), 22.9 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +47.2 
HRMS (ESI+, CH2Cl2) calc. for C34H50N6NaO13: 773.332806; observed: 773.333125 (M+Na)+ 
IR (neat) νmax/cm-1 = 3542 (OH), 3328 (NH amide), 3288 (NH amide), 2989 (Ar), 2949 (Ar), 1720 
(CO), 1658 (CO), 1524 (Ar), 1212 (OMe/OBn), 1168 (OMe/OBn) 
Mp (MeOH): 202-205 oC 
 
Synthesis of 119 – Cbz-(L)Asp(OMe)-Aib2-(L)Asp(OMe)-NHtBu   
 
Cbz(L)Asp(OMe)Aib2(L)Asp(OMe)NHtBu was synthesised by following general procedure D on 
a  0.86 mmol scale. Compound 119 was purified by column chromatography (SNAP Ultra 10g, 
0.5% → 4% MeOH in CH2Cl2) to give a white solid (279 mg, 0.44 mmol, 51 %).  
Analytical Data 





1H NMR (400 MHz, CDCl3) δH 7.56 (1 H, d, J = 8.0 Hz, NH), 7.36-7.29 (5 H, m, ArH), 7.14 (1 H, s, 
NH), 6.90 (1 H, s, NH), 6.82 (1 H, s, NH), 6.17 (1 H, d, J = 8.0 Hz, NH), 5.16-5.04 (2 H, m, AB 
system of the Cbz CH2), 4.65 (1 H, td, J = 9.0, 4.0 Hz, αCH), 4.41 (1 H, dt, J = 8.0, 6.0 Hz, αCH), 
3.65 (3 H, s, OCH3), 3.55 (3 H, s, OCH3), 3.10-2.65 (4 H, m, 2 x AB systems of βCH2), 1.49 (3 H, 
s, CH3), 1.40 (6 H, s, CH3), 1.33 (12 H, 4 x CH3).  
13C NMR (100 MHz, CDCl3) δC 174.5 (CO), 173.5 (CO), 172.1 (CO), 172.0 (CO), 171.1 (CO), 169.8 
(CO), 156.3 (CO), 135.9 (ArC), 128.6 (ArCH), 128.4 (ArCH), 128.0 (ArCH), 67.3 (CH2 of Cbz), 58.3 
(αCH), 57.3 (αCH), 57.1 (αCH), 57.0 (OCH3), 56.9 (αC), 51.6 (OCH3), 51.0 (αCH), 36.0 (βCH2), 
35.5 (βCH2), 28.5 (CH3), 26.7 (CH3), 26.1 (CH3), 24.0 (CH3), 23.5 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +45.2 
IR (neat) νmax/cm-1 = 3313 (NH), 2971 (CH), 1725 (CO), 1658 (CO), 1522 (NH) 
HRMS (ESI+, CH2Cl2) calc. for C30H45N5NaO10: 658.305863; observed: 658.305380 (M+Na)+ 
Mp (CH2Cl2): 159-161 oC 
 
Synthesis of 120 – Cbz-[(L)Asp(OMe)-Aib2]3-OtBu  
 
Cbz[(L)Asp(OMe)Aib2]3OtBu was synthesised by following general procedure D on a  0.50 
mmol scale. Compound 120 was purified by column chromatography (SNAP Ultra 25, 1% → 
10% MeOH in CH2Cl2) as a white solid (336 mg, 0.30 mmol, 59 %).  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.19  
1H NMR (400 MHz, CD3OD) δH 7.29-7.22 (5 H, m, 5 x ArH), 5.12-5.07 (2 H, m, Cbz CH2), 4.39-
4.24 (3 H, m, 3 x αCH), 3.74 (3 H, s, OCH3), 3.69 (3 H, s, OCH3), 3.58 (3 H, s, OCH3), 3.02-2.88 
(6 H, m, 3 x βCH2), 1.49 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.44 (6 H, s, 2 x CH3), 1.41 (6 H, s, 2 x 
CH3), 1.38 (6 H, s, 2 x CH3), 1.36 (12 H, s, 4 x CH3) 
13C NMR (100 MHz, CD3OD) δC 173.8 (CO), 173.5 (CO), 173.5 (CO), 173.2 (CO), 172.8 (CO), 
172.9 (CO), 172.6 (CO), 171.8 (CO), 169.9 (CO), 169.7 (CO), 168.9 (CO), 156.6 (CO), 135.9 (ArC), 
129.8 (ArCH), 128.7 (ArC), 128.0 (ArCH), 79.8 (C(CH3)3), 67.9 (CH2 of Cbz), 57.5 (αC), 57.3 (αC), 
56.9 (αC), 56.5 (αC), 55.5 (αC), 55.0 (αC), 53.6 (OCH3), 53.0 (OCH3), 52.7 (OCH3), 51.1 (αCH), 
50.7 (αCH), 50.7 (αCH), 35.9 (βCH2), 34.2 (βCH2), 34.0 (βCH2), 28.5 (CH3), 27.8 (CH3), 27.3 (CH3), 





[α]D (c = 1.0, MeOH) = +58.2 
HRMS (MALDI, MeOH) calc. for C51H79N9O18K: 1144.5175; observed: 1144.5188 (M+K)+ 
IR (neat) νmax/cm-1 = 3301 (NH), 2985 (CH), 2939 (CH), 1729 (CO), 1658 (CO), 1530 (CH), 1214 
(OMe/OtBu/OBn), 1168 (OMe/OtBu/OBn), 1146 (OMe/OtBu/OBn) 
Mp (EtOAc): 220-223 oC. 
 
Synthesis of 121 (Cbz-[(L)Asp(O∙Na)-Aib2]3-OtBu) and 122 (Cbz-[(L)Asp(OH)-Aib2]3-OtBu) 
 
Cbz[(L)Asp(OMe)Aib2]3OtBu (60 mg, 0.050 mmol) was dissolved in EtOH (0.75 mL) and NaOH 
(aq) (2 M, 0.75 mL) and left to stir for 5 h. The reaction mixture was concentrated to give 
compound 121. This was then acidified to pH = 2 with 1 M HCl (aq) and repeatedly extracted 
with EtOAc. The organic washes were combined then dried over Na2SO4, filtered and 
concentrated to give compound 122 (45 mg, 0.043 mmol, 85 %) as a white solid. 
Analytical Data for 122 
Rf (SiO2 10% MeOH in CH2Cl2) = 0.00  
1H NMR (400 MHz, CD3OD) δH 7.27-7.21 (5 H, m, 5 x ArH), 5.11-5.06 (2 H, m, Cbz CH2), 4.33-
4.22 (3 H, m, 3 x αCH), 2.97-2.81 (6 H, m, 3 x βCH2), 1.48 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.42 
(6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x CH3), 1.37 (6 H, s, 2 x CH3), 1.35 (12 H, s, 4 x CH3) 
13C NMR (100 MHz, CD3OD) δC 173.7 (CO), 173.6 (CO), 173.5 (CO), 173.2 (3O), 172.3 (CO), 
172.2 (CO), 172.0 (CO), 171.9 (CO), 171.6 (CO), 171.4 (CO), 153.6 (CO), 136.0 (ArC), 130.2 
(ArCH), 129.3 (ArC), 129.1 (ArCH), 77.3 (C(CH3)3), 68.3 (CH2 of Cbz), 57.8 (αC), 57.5 (αC), 56.9 
(αC), 56.7 (αC), 55.4 (αC), 55.1 (αC), 51.5 (αCH), 50.9 (αCH), 50.4 (αCH), 35.8 (βCH2), 34.6 
(βCH2), 28.5 (CH3), 27.7 (CH3), 27.5 (CH3), 26.8 (CH3), 26.3 (CH3), 25.7 (CH3), 25.1 (CH3), 24.6 
(CH3), 24.1 (CH3)  
[α]D (c = 1.0, MeOH) = +51.7 
HRMS (MALDI, MeOH) calc. for C48H73N9NaO18: 1086.4966; observed: 1086.4959 (M+Na)+ 
IR (neat) νmax/cm-1 = 3508 (OH broad), 2985 (CH), 1732 (CO), 1701 (CO), 1538 (NH), 1212 
(OtBu/OBn), 1182 (OtBu/OBn) 






Synthesis of 124 – Cbz-(L)Abu-Aib2-OtBu  
 
Cbz(L)AbuAib2OtBu was synthesised by following general procedure D on a 0.42 mmol scale. 
Compound 124 was purified by column chromatography (SNAP Ultra 25g, 0.5% → 4% MeOH 
in CH2Cl2) to give as a colourless solid (120 mg, 0.26 mmol, 62 %). 
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.17 
1H NMR (400 MHz, CDCl3) δH 7.36 (5 H, m, 5 x ArH), 6.89 (1 H, s, NH), 6.54 (1 H, s, NH), 5.25 (1 
H, br s, NH), 5.11 (2 H, br s, CH2 of Cbz), 3.99 (1 H, q, J = 7.0 Hz, αCH), 1.86 (1 H, dt, J = 14.0, 
7.0 Hz, part of AB system βCH2), 1.63 (1 H, dt, J = 14.0, 7.0 Hz, part of AB system βCH2), 1.54 
(3 H, s, CH3), 1.53 (3 H, s, CH3), 1.50 (3 H, s, CH3), 1.50 (3 H, s, CH3), 1.45 (9 H, s, 3 x CH3), 0.94 
(3 H, t, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 173.6 (CO), 173.2 (CO), 171.9 (CO), 156.6 (CO), 136.2 (ArC), 128.3 
(ArCH), 127.9 (ArCH), 127.6 (ArCH), 80.7 (C(CH3)3), 66.6 (CH2 of Cbz), 56.9 (αC), 56.8 (αCH), 
56.3 (αC), 27.6 (CH3), 25.3 (CH3), 25.0 (βCH2), 24.5 (CH3), 24.4 (CH3), 24.1 (CH3), 14.0 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +35.6 
HRMS (ESI+, CH2Cl2) calc. for C24H37N3NaO6: 486.257457; observed: 486.255889 (M+Na)+ 
IR (neat) νmax/cm-1: 3303 (NH amide), 2971 (Ar), 1729 (CO), 1660 (CO), 1521 (Ar), 1144 (OtBu) 
Mp (CH2Cl2): 114-116 oC 
 
Synthesis of 125 – Cbz-(L)Abu-Aib2-OH  
 
Cbz(L)AbuAib2OH was synthesised following general procedure C on a 1.56 mmol scale. 
Compound 125 was synthesised a white solid (614 mg, 1.51 mmol, 97 %).  
Analytical Data 





1H NMR (400 MHz, CD3OD) δH 7.34-7.24 (5 H, m, 5 x ArH), 5.12 (1 H, d, J = 12.5 Hz, part of AB 
system of the Cbz CH2), 5.07 (1 H, d, J = 12.5 Hz, part of AB system of the Cbz CH2), 3.86 (1 H, 
t, J = 7.0 Hz, αCH), 1.74 (1 H, h, J = 7.5 Hz, part of AB system CH2CH3), 1.65 (1 H, h, J = 7.5 Hz, 
part of AB system CH2CH3), 1.44 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.39 (3 H, s, 
CH3), 0.96 (3 H, t, J = 7.5 Hz, CH2CH3) 
13C NMR (100 MHz, CD3OD) δC 176.6 (CO), 174.5 (CO), 173.3 (CO), 157.2 (CO), 136.8 (ArC), 
128.1 (ArCH), 127.6 (ArCH), 127.2 (ArCH), 66.2 (CH2 of Cbz), 57.1 (αCH), 56.5 (αC), 55.7 (αC), 
24.9 (CH3), 24.4 (βCH2), 24.1 (CH3), 23.3 (CH3), 23.2 (CH3), 9.3 (CH2CH3) 
[α]D (c = 1.0, CH2Cl2) = +33.4 
HRMS (ESI+, CH2Cl2) calc. for C20H29N3NaO6: 430.194856; observed: 430.195540 (M+Na)+ 
IR (neat) νmax/cm-1: 3301 (br, OH), 2980 (Ar), 2938 (Ar), 1726 (CO), 1657 (CO), 1529 (Ar), 1160 
(OBn) 
Mp (CHCl3): 139-140 oC 
 
Synthesis of 126 – H2N-(L)Abu-Aib2-OtBu  
 
H2N(L)AbuAib2OtBu was synthesised following general procedure A on a 2.58 mmol scale. 
Compound 126 was synthesised a white solid (789 mg, 2.40 mmol, 93 %). 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.05 
1H NMR (400 MHz, CDCl3) δH 7.74 (1 H, s, NH), 7.47 (1 H, s, NH), 3.22 (1 H, dd, J = 7.5, 4.5 Hz, 
αCH), 1.79-1.70 (1 H, m, part of AB system βCH2), 1.54 (1 H, dq, J = 14.0, 7.5 Hz, part of AB 
system βCH2), 1.47 (3 H, s, CH3), 1.46 (3 H, s, CH3), 1.43 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.37 (9 
H, s, 3 x CH3), 0.89 (3 H, t, J = 7.5 Hz, CH2CH3) 
13C NMR (400 MHz, CDCl3) δC 175.1 (CO), 173.9 (CO), 173.3 (CO), 81.2 (C(CH3)3), 57.0 (αC), 56.6 
(αC), 56.4 (αCH), 27.9 (βCH2), 27.4 (CH3), 25.2 (CH3), 25.0 (CH3), 24.2 (CH3), 9.8 (CH2CH3) 
[α]D (c = 1.0, CH2Cl2) = +21.7 
HRMS (ESI+, CH2Cl2) calc. for C16H31N3NaO4: 352.2207; observed: 352.2220 (M+Na)+ 
IR (neat) νmax/cm-1: 3477 (NH2), 3309 (NH), 1724 (CO), 1658 (CO), 1146 (OtBu) 





Synthesis of 127 – Cbz-[(L)Abu-Aib2]2-OtBu 
 
Cbz[(L)AbuAib2]2OtBu was synthesised by following general procedure D on a 0.61 mmol 
scale. This was purified by column chromatography (SNAP Ultra 25g, 0.5% → 4% MeOH in 
CH2Cl2) to give compound 127 (273 mg, 0.38 mmol, 62 %) a white solid.  
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.15 
1H NMR (400 MHz, CDCl3) δH 7.63 (1 H, d, J = 6.0 Hz, NH), 7.38-7.28 (6 H, m, 5 x ArH and 1 x 
NH), 7.06 (1 H, s, NH), 7.05 (1 H, s, NH), 6.92 (1 H, s, NH), 6.64 (1 H, d, J = 4.0 Hz, NH), 5.16 (1 
H, d, J = 12.5 Hz, part of the AB system of the Cbz CH2), 5.03 (1 H, d, J = 12.5 Hz, part of the AB 
system of the Cbz CH2), 3.89 (1 H, ddd, J = 10.0, 6.0, 4.5 Hz, αCH), 3.76 (1 H, td, J = 7.5, 4.0 Hz, 
αCH), 1.97-1.70 (4 H, m, 2 x βCH2), 1.52 (3 H, s, CH3), 1.46 (6 H, s, 2 x CH3), 1.43 (9 H, s, 3 x 
CH3), 1.39 (9 H, s, 3 x CH3), 1.38 (3 H, s, CH3), 1.24 (3 H, s, CH3), 0.97 (6 H, q, J = 7.5 Hz, 2 x 
CH2CH3) 
13C NMR (100 MHz, CDCl3) δC 176.1 (CO), 174.2 (CO), 174.0 (CO), 173.9 (CO), 173.3 (CO), 172.3 
(CO), 157.3 (CO), 136.4 (ArC), 128.5 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 80.1 (C(CH3)3), 67.1 
(CH2 of Cbz), 58.8 (αCH), 57.5 (αCH), 56.8 (αC), 56.7 (αC), 56.5 (αC), 56.0 (αC), 27.8 (CH3), 27.1 
(CH3), 26.7 (CH3), 26.7 (CH3), 25.4 (CH3), 24.2 (CH3), 24.1 (CH3), 24.1 (CH2), 24.0 (CH2), 23.2 
(CH3), 23.1 (CH3), 10.8 (CH2CH3), 10.5 (CH2CH3) 
[α]D (c = 1.0, CH2Cl2) = +49.2 
HRMS (ESI+, CH2Cl2) calc. for C36H58N6NaO9: 741.415748; observed: 741.418537 (M+Na)+ 
IR (neat) νmax/cm-1: 3331 (NH), 3296 (NH), 2987 (Ar), 2942 (Ar), 1667 (CO), 1644 (CO), 1524 
(Ar), 1229 (OtBu/OBn), 1142 (OtBu/OBn) 
Mp (CH2Cl2): 176-178 oC 
 






Cbz[(L)AbuAib2]2OH was synthesised by following general procedure C on a 0.47 mmol scale 
to give compound 128 (305 mg, 0.46 mmol, 98 %) as a colourless solid. 
Analytical Data 
Rf (SiO2 2% MeOH in CH2Cl2) = 0.02 
1H NMR (400 MHz, CD3OD) δH 7.39-7.26 (5 H, m, 5 x ArH), 5.15 (1 H, d, J = 12.5 Hz, part of the 
AB system of Cbz CH2), 5.08 (1 H, d, J = 12.5 Hz, part of the AB system of the Cbz CH2), 3.86-
3.79 (2 H, m, 2 x αCH), 1.87 (2 H, p, J = 7.0 Hz, βCH2), 1.78 (1 H, p, J = 7.0 Hz, part of AB system 
βCH2), 1.71 (1 H, p, J = 7.0 Hz, part of AB system βCH2), 1.48 (3 H, s, CH3), 1.47 (6 H, s, 2 x CH3), 
1.47 (3 H, s, CH3), 1.44 (3 H, s, CH3), 1.41 (3 H, s, CH3), 1.37 (3 H, s, CH3), 1.36 (3 H, s, CH3), 0.99 
(6 H, two overlapping q where J = 7.0 Hz and J = 7.5 Hz, 2 x CH2CH3) 
13C NMR (100 MHz, CD3OD) δC 176.8 (CO), 176.7 (CO), 175.1 (CO), 174.9 (CO), 174.0 (CO), 
173.2 (CO), 157.4 (CO), 136.9 (ArC), 128.2 (ArH), 127.7 (ArH), 127.3 (CO), 66.4 (CH2 Cbz), 57.7 
(αCH), 57.3 (αCH), 56.5 (αC), 56.4 (αC), 56.3 (αC), 55.6 (αC), 25.4 (CH3), 25.1 (CH3), 24.6 (CH3), 
24.3 (CH3), 24.1 (βCH2), 23.5 (βCH2), 23.5 (CH3), 23.2 (CH3), 22.9 (CH3), 10.0 (CH2CH3), 9.4 
(CH2CH3) 
[α]D (c = 1.0, MeOH) = +46.8 
HRMS (ESI+, MeOH) calc. for C32H50N6NaO9: 685.353699; observed: 685.353804 (M+Na)+ 
IR (neat) νmax/cm-1: 3345 (OH broad), 3297 (NH), 2991 (CH), 2896 (CH), 1702 (CO), 1674 (CO), 
1524 (NH), 1180 (OBn) 
Mp (CH2Cl2): 196-199 oC 
 
Synthesis of 129 – Cbz-[(L)Abu-Aib2]3OtBu  
 
Cbz[(L)AbuAib2]3OtBu was synthesised by following general procedure E on a 0.49 mmol 
scale. Compound 129 was purified by column chromatography (SNAP Ultra 10g, 2% → 10% 
MeOH in CH2Cl2) to give (311 mg, 0.32 mmol, 65 %) a white solid.  
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.16 
1H NMR (500 MHz, CDCl3) δH 7.75 (1 H, s, NH), 7.71 (1 H, d, J = 5.0 Hz, NH), 7.68 (1 H, d, J = 5.0 
Hz, NH), 7.51 (1 H, s, NH), 7.40-7.30 (6 H, m, 5 x ArH and 1 x NH), 7.17 (1 H, s, NH), 7.08 (1 H, 





system of the Cbz CH2), 5.06 (1 H, d, J = 12.5 Hz, part of the AB system of the Cbz CH2), 3.99 
(1 H, ddd, J = 10.5, 6.0, 4.5 Hz, αCH), 3.81-3.76 (2 H, m, 2 x αCH), 2.02-1.76 (6 H, m, 3 x βCH2), 
1.56 (3 H, s, CH3), 1.56 (3 H, s, CH3), 1.54 (3 H, s, CH3), 1.53 (3 H, s, CH3), 1.50 (3 H, s, CH3), 1.49 
(3 H, s, CH3), 1.47 (3 H, s, CH3), 1.47 (6 H, s, 2 x CH3), 1.45 (3 H, s, CH3), 1.42 (9 H, s, 3 x CH3), 
1.40 (3 H, s, CH3), 1.27 (3 H, s, CH3), 1.04 (9 H, q, J = 7.5 Hz, 3 x CH2CH3) 
13C NMR (125 MHz, CD3OD) δC 176.6 (CO), 176.5 (CO), 175.6 (CO), 174.7 (CO), 174.1 (CO), 
174.0 (CO), 173.5 (CO), 173.5 (CO), 172.5 (CO), 157.5 (CO), 136.5 (ArC), 128.6 (ArH), 128.3 
(ArH), 127.9 (ArH), 80.1 (C(CH3)3), 67.2 (CH2 Cbz), 59.1 (αCH), 58.4 (αCH), 57.4 (αCH), 56.8 (αC), 
56.7 (αC), 56.7 (αC), 56.6 (αC), 56.5 (αC), 56.1 (αC), 27.9 (CH3), 27.6 (CH3), 27.3 (CH3), 27.0 
(CH3), 27.0 (CH3), 26.5 (CH3), 25.3 (CH3), 24.4 (CH3), 24.3 (βCH2), 24.2 (βCH2), 23.9 (βCH2), 23.1 
(CH3), 22.9 (CH3), 22.8 (CH3), 22.7 (CH3), 10.9 (γCH3), 10.8 (γCH3), 10.6 (γCH3) 
[α]D (c = 1.0, CH2Cl2) = +55.4  
HRMS (MALDI, CH2Cl2) calc. for C48H79N9NaO12: 996.5740; observed: 996.5754 (M+Na)+ 
IR (neat) νmax/cm-1: 3300 (NH), 2979 (Ar), 2936 (Ar), 1659 (CO), 1524 (Ar), 1228 (OtBu/OBn), 
1146 (OtBu/OBn) 
Mp (CH2Cl2): 214-216 oC 
 
Synthesis of 132 – N3-Aib2-(L)Lys(NHBoc)OMe  
 
N3Aib2(L)Lys(NHBoc)OMe was synthesised by following general procedure D on a 2.94 mmol 
scale. Compound 132 was purified by column chromatography (SNAP Ultra 25g, 0.5% MeOH 
→ 7% MeOH in CH2Cl2) to give 132 (949 mg, 2.08 mmol, 71 %) as white solid.  
Analytical Data 
Rf (SiO2, 2% MeOH in CH2Cl2) = 0.16 
1H NMR (400 MHz, CDCl3) δH 6.97 (1 H, br s, NH), 6.84 (1 H, d, J = 8.0 Hz, NH), 4.88 (1 H, br s, 
NH), 4.56 (1 H, td, J = 7.5, 5.0 Hz, αCH), 3.73 (3 H, s, OCH3), 3.16-3.12 (2 H, m, εCH2), 1.96-1.84 
(1 H, m, part of AB system βCH2), 1.74-1.66 (1 H, m, part of AB system βCH2), 1.57 (3 H, s, CH3), 
1.56 (3 H, s, CH3), 1.54 (6 H, s, 2 x CH3), 1.54-1.48 (2 H, m, CH2), 1.43 (9 H, s, 3 x CH3), 1.39-
1.22 (2 H, m, CH2) 
13C NMR (100 MHz, CDCl3) δC 173.6 (CO), 172.9 (CO), 172.3 (CO), 156.2 (CO), 77.1 (C(CH3)3), 
64.4 (αC), 57.2 (αC), 52.5 (αCH), 52.2 (OCH3), 40.2 (εCH2), 31.8 (βCH2), 29.3 (δCH2), 28.5 (CH3), 
25.2 (CH3), 24.9 (CH3), 24.4 (CH3), 24.3 (CH3), 22.0 (γCH2) 





HRMS (ESI+, CH2Cl2) calc. for C20H36N6NaO6: 479.2589; observed: 479.2589 (M+Na)+ 
IR (neat) νmax/cm-1 = 3346 (NH), 2972 (CH), 2935 (CH), 2111 (N3), 1674 (CO), 1249 (OtBu/OMe), 
1168 (OtBu/OMe) 
Mp (CH2Cl2): 151-154 oC 
 
Synthesis of 133 – N3-Aib2-(L)Lys(NHBoc)OH  
 
N3Aib2(L)Lys(NHBoc)OMe (300 mg, 0.66 mmol) was dissolved in a mixture of EtOH (3 mL), THF 
(3 mL) and 2 M LiOH(aq) (8 mL) and then left to stir overnight. After this time 2 M HCl (aq) was 
added to the mixture until pH < 2 was reached. The resulting solution was repeatedly washed 
with CH2Cl2, the combined organic washes were dried over Na2SO4, filtered and concentrated 
to give to give compound 133 (242 mg, 0.55 mmol, 83 %) a colourless solid. 
Analytical Data 
Rf (SiO2, 2% MeOH in CH2Cl2) = 0.00 
1H NMR (400 MHz, CD3OD) δH 7.80 (1 H, br s, NH), 7.59 (1 H, d, J = 8.0 Hz, NH), 4.38 (1 H, dtd, 
J = 8.0, 4.0, 2.5 Hz, αCH), 3.02 (2 H, t, J = 7.0 Hz, εCH2), 1.93-1.83 (1 H, m, part of AB system 
βCH2), 1.75-1.64 (1 H, m, part of AB system βCH2), 1.51 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.49 (3 
H, s, CH3), 1.49 (3 H, s, CH3), 1.42 (9 H, s, 3 x CH3), 1.48-1.30 (4 H, m, δCH2 and γCH2) 
13C NMR (100 MHz, CD3OD) δC 175.0 (CO), 173.8 (CO), 172.4 (CO), 157.1 (CO), 78.4 (C(CH3)3), 
63.7 (αC), 56.6 (αC), 52.1 (αCH), 39.7 (εCH2), 30.9 (βCH2), 28.9 (CH2), 27.5 (CH3), 23.7 (CH3), 
23.5 (CH3), 23.2 (CH3), 23.2 (CH3), 22.6 (CH2). NOTE: could not accurately assign γ/δCH2 due to 
overlap with other signals. 
[α]D (c = 1.0, MeOH) = +29.7 
HRMS (ESI+, MeOH) calc. for C19H33N6O6: 441.2467; observed: 441.2488 (M+H)+ 
IR (neat) νmax/cm-1 = 3312 (OH br), 3298 (NH), 2969 (CH), 2201 (N3), 1734 (CO), 1249 (OtBu) 









Synthesis of 134 – H2N-Aib2-(L)Lys(NHBoc)OMe  
 
H2NAib2(L)Lys(NHBoc)OMe was synthesised following general procedure A on a 1.22 mmol 
scale to give compound 134 as a white solid (504 mg, 1.17 mmol, 96 %). 
Analytical Data 
Rf (SiO2, 2% MeOH in CH2Cl2) = 0.05 
1H NMR (400 MHz, CDCl3) δH 8.09 (1 H, s, NH), 7.34 (1 H, d, J = 7.5 Hz, NH), 5.06 (1 H, t, J = 5.0 
Hz, NH), 4.46 (1 H, td, J = 8.0, 5.0 Hz, αCH), 3.07-2.95 (2 H, m, εCH2), 1.86-1.76 (1 H, m, part of 
AB system βCH2), 1.64-1.52 (1 H, m, part of AB system βCH2), 1.48 (3 H, s, CH3), 1.46 (3 H, s, 
CH3), 1.45-1.37 (2 H, m, CH2), 1.36 (9 H, s, 3 x CH3), 1.30 (3 H, s, CH3), 1.29 (3 H, s, CH3), 1.32-
1.22 (2 H, m, CH2) 
13C NMR (100 MHz, CDCl3) δC 178.0 (CO), 174.2 (CO), 172.8 (CO), 156.1 (CO), 78.7 (C(CH3)3), 
54.8 (αC), 56.7 (αC), 52.2 (OCH3), 51.9 (αCH), 39.9 (εCH2), 31.6 (βCH2), 29.1 (CH2), 28.9 (CH3), 
28.9 (CH3), 28.4 (CH3), 25.5 (CH3), 24.9 (CH3), 22.0 (CH2) 
[α]D (c = 1.0, CH2Cl2) = +31.3 
IR (neat) νmax/cm-1 = 3361 (NH2), 2934 (CH), 1731 (CO), 1674 (CO), 1259 (OtBu/OMe), 1174 
(OtBu/OMe) 
HRMS (ESI+, MeOH) calc. for C20H38N4NaO6: 453.2684; observed: 453.2690 (M+Na)+ 
Mp (EtOAc): 164-167 oC 
 
Synthesis of 135 – N3-[Aib2-(L)Lys(NHBoc)]2OMe  
 
N3[Aib2(L)Lys(NHBoc)]2OMe was synthesised following general procedure D on a 0.57 mmol 
scale. This was purified by column chromatography (SNAP Ultra 10g, 2% MeOH → 10% MeOH 






Rf (SiO2, 5% MeOH in CH2Cl2) = 0.13 
1H NMR (400 MHz, CD3OD) δH 4.59-4.46 (2 H, m, 2 x αCH), 3.73 (3 H, s, OCH3), 3.25-3.10 (4 H, 
m, 2 x εCH2), 1.84-1.70 (4 H, m, 2 x βCH2), 1.57 (6 H, s, 2 x CH3), 1.56 (6 H, s, 2 x CH3), 1.55 (6 
H, s, 2 x CH3), 1.54 (6 H, s, 2 x CH3), 1.53-1.45 (4 H, m, 2 x CH2), 1.43 (9 H, s, 3 x CH3), 1.42 (9 
H, s, 3 x CH3), 1.40-1.27 (4 H, m, 2 x CH2)  
13C NMR (100 MHz, CD3OD) δC 176.2 (CO), 175.9 (CO), 174.7 (CO), 174.6 (CO), 173.2 (CO), 
172.9 (CO), 157.1 (CO), 157.0 (CO), 78.5 (C(CH3)3), 78.4 (C(CH3)3), 64.4 (αC), 57.8 (αC), 57.2 
(αC), 55.4 (αC), 53.7 (αCH), 52.5 (αCH), 52.9 (OCH3), 40.4 (CH2), 39.7 (εCH2), 32.3 (βCH2), 31.1 
(βCH2), 29.7 (δCH2), 28.9 (δCH2), 28.5 (CH3), 27.8 (CH3), 25.2 (CH3), 25.0 (CH3) 24.9 (CH3), 24.8 
(CH3), 24.7 (CH3), 22.0 (CH2), 21.7 (CH2) 
[α]D (c = 1.0, CH2Cl2) =  +43.2 
IR (neat) νmax/cm-1 = 3310 (NH), 2929 (CH), 2934 (CH), 2112 (N3), 1739 (CO), 1657 (CO), 1250 
(OMe/OtBu), 1168 (OMe/OtBu). 
HRMS (ESI+, MeOH) calc. for C39H70N10NaO11: 877.511774; observed: 877.512418 (M+H)+. 
Mp (CH2Cl2): 189-191 oC. 
 
Synthesis of 136 (N3-[Aib2-(L)Lys(NH2∙HCl)]2OMe) and 137 (N3-[Aib2-(L)Lys(NH2)]2OMe) 
 
N3[Aib2(L)Lys(NHBoc)]2OMe (65 mg, 0.76 mmol) was dissolved in dioxane (1 mL) and a 
solution of HCl in dioxane (4 M, 0.23 mL) and left to stir for 3 h. After this time the reaction 
mixture was concentrated to give compound 136. This was then dissolved in a solution of 2 
M NaOH(aq) and left to stir for 30 min. After this the reaction mixture was concentrated, 
dissolved in EtOAc, washed with H2O and brine, dried (Na2SO4), filtered and concentrated to 
give compound 137 (47 mg, 0.072 mmol, 95 %) as a white solid. 
Analytical Data for 137 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.03 
1H NMR (400 MHz, CD3OD) δH 4.45-4.31 (2 H, m, 2 x αCH), 3.70 (3 H, s, OCH3), 3.35-3.17 (4 H, 
m, 2 x εCH2), 1.91-1.80 (4 H, m, 2 x βCH2), 1.57 (6 H, s, 2 x CH3), 1.55 (6 H, s, 2 x CH3), 1.51 (6 





13C NMR (100 MHz, CD3OD) δC 176.6 (CO), 176.1 (CO), 175.4 (CO), 174.6 (CO), 174.2 (CO), 61.7 
(αC), 56.6 (αC), 56.0 (αC), 55.4 (αC), 54.3 (αCH), 51.9 (αCH), 50.7 (OCH3), 43.7 (εCH2), 42.6 
(CH2), 33.0 (βCH2), 32.7 (βCH2), 28.5 (δCH2), 28.4 (δCH2), 27.9 (CH3), 27.6 (CH3), 27.3 (CH3), 
26.1 (CH3), 25.4 (CH3), 24.8 (CH3), 24.5 (CH3), 21.8 (CH2), 21.4 (CH2) 
[α]D (c = 1.0, MeOH) = +42.2 
IR (neat) νmax/cm-1 = 3412 (NH2), 3321 (NH), 2987 (CH), 2097 (N3), 1721 (CO), 1521 (NH), 1250 
(OtBu) 
HRMS (MALDI, MeOH) calc. for C29H54KN10O7: 693.3814; observed: 693.3816 (M+K)+. 
Mp (EtOAc): 231-234 oC 
 
Synthesis of 174 – Cbz(L)Dap(NHBoc)OH  
Previously synthesised and reported 177 
 
H2N(L)Dap(NHBoc)OH (3.1 g, 15.2 mmol, 1 eq.) was dissolved in a mixture of acetone (15 mL) 
and NaOH (aq) (2 M, 15 mL) and the resulting solution was cooled to 0 oC. Once at temperature 
CbzCl (2.5 mL, 17.5 mmol, 1.15 eq.) was added over 30 min. After addition was complete the 
pH was adjusted to >13 with NaOH (aq) and the mixture was warmed to RT and left to  stir for 
4 h. After this time the solution was cooled back down to 0oC and another portion of CbzCl 
(2.5 mL) was added over 30 min. Once addition was complete the pH was adjusted to >13 
with NaOH (aq), the reaction was warmed to RT and stirred for a further 6 h. After this time the 
reaction mixture was concentrated, dissolved in  NaOH (aq) (2 M, 30 mL) and washed with Et2O 
(2 x 20 mL). The aqueous phase was acidified with HCl (conc) to pH = 1 and washed with EtOAc 
(4 x 50 mL). The EtOAc washes were combined, dried  over Na2SO4, filtered and concentrated 
to give Cbz(L)Dap(NHBoc)OH (1.01 g, 3.00 mmol, 20 %) as a pale-yellow oil. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.37-7.29 (5 H, m, 5 x ArH), 5.74 (1 H, br s, NH), 5.40 (1 H, br s, 
NH), 5.09 (2 H, br s, CH2 of Cbz), 4.31 (1 H, m, αCH), 3.64 (2 H, m, βCH2), 1.44 (C(CH3)3).  








Synthesis of H2NAib2OMe 
Synthesis of the intermediate – N3Aib2OMe  
 
N3Aib2OMe was synthesised by following general procedure D on a 20.0 mmol scale. 
N3Aib2OMe was purified by column chromatography (SNAP Ultra 100g, 0.5% → 4% MeOH in 
CH2Cl2) as a white solid (2.01 g, 8.80 mmol, 45 %). 
Analytical Data 
Rf (SiO2 8:2 Petroleum Ether:EtOAc) = 0.35 
1H NMR (400 MHz, CDCl3) δH 6.95 (1 H, br s, NH), 3.73 (3 H, s, OCH3), 1.54 (6 H, s, 2 x CH3), 1.50 
(6 H , s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.6 (CO), 171.5 (CO), 64.2 (αC), 56.4 (αC), 52.6 (OCH3), 24.6 
(CH3), 24.2 (CH3).  
Synthesis of H2NAib2OMe – Previously synthesised and reported 178 
 
H2NAib2OMe was synthesised by following general procedure A on a 4.95 mmol scale. 
H2NAib2OMe was synthesised as a white solid (929 mg, 4.60 mmol, 93 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.77 (1 H, br s, NH), 3.47 (3 H, s, CH3), 1.51 (6 H, s, 2 x CH3), 1.49 
(6 H, s, 2 x CH3) 
13C NMR (100 MHz, CDCl3) δC 176.3 (CO), 173.0 (CO), 57.1 (αC), 56.7 (αC), 51.9 (OCH3), 24.6 
(CH3), 24.2 (CH3).  










Synthesis of 175 – Cbz-(L)Dap(NHBoc)-Aib2OMe  
 
Cbz(L)Dap(NHBoc)Aib2OMe was synthesised by following general procedure D on a 1.29 
mmol scale. Cbz(L)Dap(NHBoc)Aib2OMe was purified by column chromatography (SNAP Ultra 
25 g, 0.5% → 4%) as a pale-yellow solid (236 mg, 0.45 mmol, 35 %). 
Analytical Data 
Rf (SiO2, 2.5 % MeOH in CH2Cl2) = 0.23 
1H NMR (400 MHz, CDCl3) δH 7.32-7.29 (5 H, m, 5 x ArH), 7.19 (1 H, s, NH), 6.85 (1 H, s, NH), 
6.08 (1 H, br s, NH), 5.97 (1 H, br s, NH), 5.09 (1 H, d, J = 12.5 Hz, part of the AB system for the 
Cbz CH2), 5.05 (1 H, d, J = 12.5 Hz, part of AB system for the Cbz CH2), 4.05 (1 H, q, J = 5.5 Hz, 
αCH), 3.64 (3 H, s, OCH3), 3.57-3.45 (2 H, m, the AB system of βCH2), 1.47 (3 H, s, CH3), 1.46 (3 
H, s, CH3), 1.45 (3 H, s, CH3), 1.42 (3 H, s, CH3), 1.42 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 175.2 (CO), 173.2 (CO), 170.1 (CO), 157.8 (CO), 156.2 (CO), 136.2 
(ArC), 128.5 (ArCH), 128.2 (ArC), 128.0 (ArCH), 80.6 (C(CH3), 67.0 (CH2 of Cbz), 58.2 (αC), 57.2 
(OCH3), 56.6 (αC), 52.4 (αCH) ,42.4 (βCH2), 28.2 (CH3), 25.6 (CH3), 24.8 (CH3), 24.7 (CH3), 24.5 
(CH3) 
[α]D (c = 1.0, CH2Cl2) =  +21.3 
HRMS (ESI+, CH2Cl2) calc. for C25H38N4NaO8: 545.2582; observed: 545.2571 (M+Na)+ 
IR (neat) νmax/cm-1: 3336 (NH amide), 3277 (NH amide), 2987 (Ar), 1709 (CO), 1672 (CO), 1510 
(Ar), 1263 (OMe), 1158 (OMe) 
Mp (CH2Cl2): 110-111 oC 
 
Synthesis of 176 – H2N-(L)Dap(NHBoc)-Aib2OMe  
 
H2N(L)Dap(NHBoc)Aib2OMe was synthesised by following general procedure A on a 0.67 







Rf (SiO2, 100% CH2Cl2) = 0.05 
1H NMR (400 MHz, CD3OD) δH 3.67 (3 H, s, OCH3), 3.39-3.31 (2 H, m, αCH and part of the AB 
system βCH2), 3.16 (1 H, dd, J = 13.0, 6.0 Hz, part of the AB system βCH2), 1.46 (3 H, s, CH3), 
1.45 (9 H, s, 3 x CH3), 1.43 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CD3OD) δC 175.3 (CO), 174.6 (CO), 173.4 (CO), 157.1 (CO), 78.9 (C(CH3)3), 
56.2 (αC), 55.9 (OCH3), 55.0 (αC), 51.4 (αCH), 44.2 (βCH2), 27.5 (CH3), 24.0 (CH3), 23.9 (CH3), 
23.8 (CH3) 
[α]D (c = 1.0, CH2Cl2) = +19.2 
HRMS (ESI+, CH2Cl2) calc. for C17H33N4O6: 389.239461; observed: 389.239612 (M+Na)+ 
 IR (neat) νmax/cm-1 = 3334 (NH2), 3286 (NH), 2985 (CH), 2946 (CH), 1735 (CO), 1667 (CO), 1645 
(NH2), 1511 (CH), 1156 (OMe/OtBu) 










6.4.4. Experimental Details for Section 5 
 
Synthesis of 139 – BocAibN(OMe)Me  
Previously reported and synthesised 179 
 
BocHNAibN(OMe)Me was synthesised by following general procedure D on a 2.05 mmol 
scale. Compound 139 was purified by column chromatography (ZIP sphere 25 g, 5% → 40% 
EtOAc in Petroleum Ether) as a pale-yellow oil (270 mg, 1.10 mmol, 54 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 5.24 (1 H, br s, NH), 3.66 (3 H, s, OCH3), 3.18 (3 H, s, NCH3), 1.52 
(6 H, s, 2 x CH3), 1.41 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.7 (CO), 154.4 (CO), 60.6 (CH3), 56.7 (αC), 33.9 (CH3), 28.4 
(CH3), 24.7 (CH3) 
Spectral data consistent with previously reported data 179 
 
Synthesis of 142 – (E)-ethyl 4-((tertbutoxycarbonyl)amino)-4-methylpent-2-enoate  
Previously synthesised and reported 180 
Synthesis of 140 – Boc AibHO 
 
BocAibNMe(OMe) (1.22 g, 4.96 mmol) was dissolved in THF (30 mL) and cooled to 0 oC. A 
solution of LiAlH4 in THF (1 M, 5.46 mL, 5.46 mmol) was added to this over ~10 min and the 
resulting mixture was left to stir at 0oC for 20 min. After this time the reaction mixture was 
acidified to pH = 2 with 1 M HCl and the THF was removed on a rotary evaporator. The 
resulting solution was washed with 3 x EtOAc. These organic washes were combined and 
washed with brine, dried over Na2SO4, filtered and concentrated to give BocAibHO (789 mg, 
4.22 mmol, 85%) which was used immediately with no further purification. 






BocAibHO (920 mg, 4.92 mmol) and (Carbethoxymethylene)triphenylphosphorane (2.05 g, 
5.90 mmol) were dissolved in THF (24 mL). The resulting solution was left to stir for 48 h. After 
this time the reaction was concentrated and then was repeatedly suspended in diethyl ether 
and filtered to remove triphenylphosphine oxide. The crude reaction mixture was then 
purified by column chromatography (SNAP Ultra 25 g 9:1 Petroleum ether:EtOAc → 1:1 
Petroleum Ether:EtOAc) to give compound 142 (1.02 g, 3.95 mmol, 85 %) as a colourless solid. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 6.99 (1 H, d, J = 16.0 Hz, CH), 5.83 (1 H, d, J = 16.0 Hz, CH), 4.62 
(1 H, br s, NH), 4.18 (2 H, q, J = 7.0 Hz, OCH2), 1.42 (9 H, s, 3 x CH3), 1.40 (5 H, s, 2 x CH3), 1.28 
(3 H, t, J = 7.0 Hz, CH3) 
13C NMR (100 MHz, CDCl3) δC 180.6 (CO), 166.7 (CH), 152.1 (CO), 118.5 (CH), 60.4 (OCH2), 52.9 
(γC), 28.4 (CH3), 27.3 (CH3), 14.2 (CH3) 
Analytical Data consistent with previously reported values 180 
 
Synthesis of 143 – BocAicOEt 
Previously synthesised and reported 181 
 
BocAicOEt was synthesised following general procedure A on a 2.95 mmol scale. This gave 
compound 143 (827 mg, 2.80 mmol, 95 %) as a colourless solid. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 5.43 (1 H, s, NH), 4.11 (2 H, q, J = 7.0 Hz, OCH2), 2.30 (2 H, dd, J = 
9.0, 7.0 Hz, CH2), 1.98 (2 H, dd, J = 9.0, 7.0 Hz, CH2), 1.42 (9 H, s, 3 x CH3), 1.26-1.23 (9 H, m, 2 
x CH3 and CH2CH3) 
13C NMR (100 MHz, CDCl3) δC 173.8 (CO), 156.0 (CO), 100.0 (C(CH3)3), 60.4 (OCH2), 52.0 (γC), 
35.1 (CH2), 29.6 (CH2), 28.4 (CH3), 27.1 (CH3), 14.2 (CH3) 








Synthesis of 144 – HCl∙H2NAicOEt  
Previously synthesised and reported 182 
 
BocAicOEt (1.24 g, 4.8 mmol) was dissolved in dioxane (10 mL) and a solution of HCl in dioxane 
(4 M, 4.83 mL, 19.3 mmol), and left to stir for 3 h. The reaction mixture was then 
concentrated, suspended in Et2O and then concentrated again to ensure full removal of HCl. 
This gave compound 144 (867 mg, 4.56 mmol 95%) as an off-white solid. 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 4.07 (2 H, q, J = 7.0 Hz, CH2 of OEt), 2.33 (2 H, t, J = 7.5 Hz, CH2 of 
Aic), 1.97 (2 H, t, J = 7.5 Hz, CH2 of Aic), 1.31 (6 H, s, 2 x CH3), 1.20 (3 H, t, J = 7.0 Hz, CH3 of 
OEt) 
13C NMR (100 MHz, CDCl3) δC 173.4 (CO), 60.9 (OCH2), 54.1 (γC), 35.0 (CH2 of Aic), 29.4 (CH2 of 
Aic), 24.4 (CH3), 14.2 (CH3 of OEt) 
Spectral data consistent with previously reported values 182 
 
Synthesis of 145 – BocHNAibAicOEt  
Previously synthesised and reported 153 
 
BocAibAicOEt was synthesised by following general procedure E on a 13.2 mmol scale to give 
compound 145 (3.65 g, 10.6 mmol, 80%) as a white solid.  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 6.46 (1 H, s, NH), 4.90 (1 H, br s, NH), 2.31 (2 H, t, J = 8.0 Hz, CH2 
of Aic), 2.03 (2 H, t, J = 8.0 Hz, CH2 of Aic), 1.44 (15 H, s, 5 x CH3), 1.31 (6 H, s, 2 x CH3), 1.24 (3 
H, t, J = 8.0 Hz, CH3 of OEt) 
13C NMR (100 MHz, CDCl3) δC 174.0 (CO), 173.9 (CO), 154.7 (CO), 81.3 (C(CH3)3), 60.4 (CH2 of 
OEt), 57.1 (αC), 52.8 (γC), 34.9 (CH2 of Aic), 29.4 (CH2 of Aic), 28.3 (CH3), 26.1 (CH3), 14.2 (CH3 
of OEt) 





Synthesis of 146 – HCl∙H2NAibAicOEt  
 
BocAibAicOEt (988 mg, 2.87 mmol) was dissolved in dioxane (4 mL) and a solution of HCl in 
dioxane (4 M, 2.84 mL) and stirred for 3 h. The reaction mixture was then concentrated, 
suspended in Et2O and concentrated again to ensure full removal of HCl and gave compound 
146 (761 mg, 2.73 mmol, 95 %). 
Analytical Data 
Rf (SiO2 5 % MeOH in CH2Cl2) = 0.10  
1H NMR (400 MHz, CDCl3) δH 7.15 (1 H, s, NH), 4.07 (2 H, q, J = 7.0 Hz, CH2 of OEt), 2.33 (2 H, 
t, J = 7.5 Hz, CH2 of Aic), 1.96 (2 H, t, J = 7.5 Hz, CH2 of Aic), 1.67 (6 H, s, 2 x CH3), 1.31 (6 H, s, 
2 x CH3), 1.20 (3 H, t, J = 7.0 Hz, CH3 of OEt) 
13C NMR (100 MHz, CDCl3) δC 174.9 (CO), 170.7 (CO), 61.1 (CH2 of OEt), 58.3 (αC), 54.1 (γC), 
35.2 (CH2 of Aic), 29.3 (CH2 of Aic), 26.3 (CH3), 24.6 (CH3), 14.4 (CH3 of OEt) 
IR (neat) νmax/cm-1: 3385 (NH2/NH), 2976 (CH), 2940 (CH), 1713 (CO), 1666 (CO), 1543 (NH), 
1195 (OEt) 
Mp (Et2O) 112-114 oC 
 
Synthesis of 147 – BocHNAibAicOH 
Previously synthesised and reported 153  
 
BocAibAicOEt (988 mg, 2.87 mmol) was dissolved in EtOH (7.2 mL) and NaOH (aq) (2 M, 3.6 mL) 
and stirred for 4 h. The reaction mixture was concentrated and acidified to pH = 2 with 1 M 
HCl (aq) which was extracted 3 x with EtOAc. The organic phase was washed with brine, dried 
over Na2SO4, filtered and concentrated to give compound 147 (815 mg, 2.58 mmol, 90 %) as 
a white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 2.26-2.14 (4 H, m, 2 x CH2 of Aic), 1.42 (6 H, s, 2 x CH3), 1.39 (9 





13C NMR (100 MHz, CD3OD) δC 174.7 (CO), 173.4 (CO), 158.1 (CO), 78.8 (C(CH3)3), 56.1 (αC), 
54.8 (γC), 35.9 (CH2 of Aic), 31.7 (CH2 of Aic), 27.4 (CH3), 25.9 (CH3) 
Analytical data consistent with previously reported information 153 
 
Synthesis of 148 – BocHN[AibAic]2OEt  
Previously synthesised and reported 153 
 
BocHN[AibAic]2OEt was synthesised by following general procedure E on a 2.43 mmol scale. 
This was purified by column chromatography (SNAP Ultra 25 g, 2% → 8% MeOH in CH2Cl2) to 
give compound 148 (1.09 g, 2.00 mmol, 82 %) as a colourless solid.  
Analytical data 
1H NMR (400 MHz, CDCl3) δH 7.15 (1 H, s, NH), 6.59 (1 H, s, NH), 6.16 (1 H, s, NH), 5.67 (1 H, s, 
NH), 3.95 (2 H, q, J = 7.0 Hz, OCH2), 2.19 (2 H, t, J = 8.0 Hz, CH2), 2.06-1.91 (6 H, m, 3 x CH2), 
1.32 (6 H, s, 2 x CH3), 1.29 (15 H, s, 5 x CH3), 1.18 (6 H, s, 2 x CH3), 1.11-1.06 (9 H, m, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 174.5 (CO), 174.1 (CO), 175.0 (CO), 173.7 (CO), 154.8 (CO), 80.0 
(C(CH3)3), 60.1 (OCH2), 57.2 (αC Aic), 56.9 (αC Aic), 53.2 (γC), 52.7 (γC), 34.8 (βCH2), 34.6 
(βCH2), 31.1 (αCH2), 29.4 (αCH2), 28.2 (CH3 – Boc), 26.9 (CH3 – Aic), 26.8 (CH3 – Aic), 25.4 (CH3 
– Aib) 25.4 (CH3 – Aib), 14.1 (CH2CH3) 
HRMS (ESI+, CH2Cl2) calc. for C27H51N4O7: 543.375226; observed: 543.375276 (M+H)+ 
Data consistent with previously reported data 153 
 
Synthesis of 149 – BocHN[AibAic]2OH 
Previously synthesised and reported 153 
  
Boc(AibAic)2OEt (217 mg, 0.40 mmol) was dissolved in EtOH (1 mL) and NaOH (aq) (2 M, 0.6 
mL) and stirred for 4 h. The reaction mixture was concentrated and acidified to pH = 2 with 1 





over Na2SO4, filtered and concentrated to give compound 149 (192 mg, 0.37 mmol, 92 %) as 
a white solid. 
Analytical Data 
1H NMR (400 MHz, CD3OD) δH 2.26-2.20 (2 H, m, CH2), 2.10-2.04 (2 H, m, CH2), 2.02-1.97 (2 H, 
m, CH2), 1.97-1.92 (2 H, m, CH2), 1.36 (9 H, s, 3 x CH3), 1.33 (6 H, s, 2 x CH3), 1.29 (6 H, s, 2 x 
CH3), 1.22 (6 H, s, 2 x CH3), 1.16 (6 H, s, 2 x CH3) 
13C NMR (100 MHz, CD3OD) δC 176.3 (CO), 175.7 (CO), 175.0 (CO), 174.6 (CO), 155.3 (CO), 79.3 
(C(CH3)3), 56.8 (αC), 56.4 (αC), 52.9 (γC), 52.7 (γC), 35.1 (CH2), 34.6 (CH2), 30.7 (CH2), 28.8 
(CH2), 27.5 (CH3), 25.8 (CH3), 25.7 (CH3), 24.4 (CH3) 
HRMS (ESI+, MeOH) calc. for C25H46N4NaO7: 537.325871; observed: 537.325843 (M+Na)+ 
Data consistent with previously reported information 153 
 
Synthesis of 150 – Boc-[Aib-Aic]2-(L)AlaOEt  
 
Boc(AibAic)2(L)AlaOEt was synthesised by following general procedure E on a 0.17 mmol 
scale. This was purified by column chromatography (SNAP 10 g, 2% MeOH in CH2Cl2 → 7% 
MeOH in CH2Cl2) to give compound 150 (76 mg, 0.12 mmol, 73 %) as a white solid. 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.23 
1H NMR (500 MHz, CDCl3) δH 7.32-7.28 (1 H, br s, NH of Ala), 7.19 (1 H, s, NH of Aib 2), 6.66 (1 
H, s, NH of Aic 2), 6.15 (1 H, s, NH of Aic 1), 5.22 (1 H, s, NH of Aib 1), 4.47 (1 H, p, J = 7.5 Hz, 
αCH of Ala), 4.12 (2 H, q, J = 7.0 Hz, CH2 of OEt), 2.25-2.21 (2 H, m, αCH2 of Aic 2), 2.18-2.13 
(2 H, m, βCH2 of Aic 1), 2.12-2.06 (2 H, m, αCH2 of Aic 1), 2.05-1.98 (2 H, m, βCH2 of Aic 2), 
1.44 (3 H, s, 1 x CH3 of Aib 2), 1.43 (3 H, s, 1 x CH3 of Aib 2), 1.43-1.41 (12 H, m, 3 x CH3 of Boc 
and 1 x CH3 of Aib 1), 1.40 (3 H, s, 1 x CH3 of Aib 1), 1.34 (3 H, d, J = 7.5 Hz, CH3 of Ala), 1.30 (3 
H, s, 1 x CH3 of Aic 2), 1.27 (3 H, s, 1 x CH3 of Aic 2), 1.22 (3 H, t, J = 7.0 Hz, CH3 of OEt), 1.20 (3 
H, s, 1 x CH3 of Aic 1), 1.19 (3 H, s, 1 x CH3 of Aic 1) 
13C NMR (125 MHz, CDCl3) δC 174.1 (CO not assigned), 174.0 (CO not assigned), 173.9 (CO not 
assigned), 173.8 (CO not assigned), 173.1 (CO of Ala), 154.8 (CO of Boc), 80.5 (C(CH3)3), 61.0 
(CH2 of OEt), 57.3 (αC of Aib 2), 57.0 (αC of Aib 1), 53.3 (γC of Aic 1), 53.2 (γC of Aic 2), 48.0 
(αCH of Ala), 35.7 (βCH2 of Aic 2), 34.5 (βCH2 of Aic 1), 31.3 (αCH2 of Aic 2), 31.3 (αCH2 of Aic 





of Aic not assigned), 25.6 (CH3 of Aib 2), 25.5 (CH3 of Aib 2), 25.3 (CH3 of Aib 1), 25.2 (CH3 of 
Aib 1), 17.8 (CH3 of Ala), 14.1 (CH3 of OEt) 
[α]D (c = 1.0, CH2Cl2) = +35.2 
HRMS (ESI+, MeOH) calc. for C30H55N5NaO8: 636.3943; observed: 636.3926 (M+Na)+ 
IR (neat) νmax/cm-1 = 3317 (NH), 2977 (CH), 2928 (CH), 1647 (CO), 1527 (CH), 1160 (OEt/OtBu) 
Mp (CH2Cl2): 141-143 oC. 
 
Synthesis of 151 – Boc-[Aib-Aic]2-(L)AlaOH  
 
Boc(AibAic)2(L)AlaOEt (24 mg, 0.040 mmol) was dissolved in EtOH (0.5 mL) and NaOH (aq) (2 
M, 0.06 mL) and stirred for 4 h. The reaction mixture was concentrated and acidified to pH = 
2 with 1 M HCl (aq), which was extracted 3 x with EtOAc. The organic phase was washed with 
brine, dried over Na2SO4, filtered and concentrated to give compound 151 (21 mg, 0.036 
mmol, 90 %) as a white solid. 
Analytical Data 
Rf (SiO2 5% MeOH in CH2Cl2) = 0.03 
1H NMR (400 MHz, CD3OD) δH 4.37 (1 H, q, J = 7.0 Hz, αCH), 2.27 (2 H, t, J = 8.0 Hz, CH2), 2.21-
2.16 (2 H, m, CH2), 2.12-1.97 (4 H, m, 2 x CH2), 1.47 (9 H, s, 3 x CH3), 1.44 (6 H, s, 2 x CH3), 1.41-
1.39 (9 H, m, 3 x CH3), 1.34 (3 H, s, CH3), 1.32 (3 H, s, CH3), 1.29-1.28 (6 H, m, 2 x CH3) 
13C NMR (100 MHz, CD3OD) δC 175.8 (CO), 175.1 (CO), 174.8 (CO), 174.6 (CO), 155.3 (CO), 79.2 
(C(CH3)3), 56.8 (αC), 56.7 (αC), 56.4 (γC), 56.3 (γC), 53.0 (αCH), 35.4 (CH2), 35.1 (CH2), 30.8 
(CH2), 30.5 (CH2), 27.9 (CH3), 25.8 (CH3), 25.7 (CH3), 24.4 (CH3), 24.2 (CH3), 16.4 (CH3 of Ala) 
HRMS (ESI+, CH2Cl2) calc. for C28H51N5NaO8: 608.3630; observed: 608.3631 (M+Na)+ 
IR (neat) νmax/cm-1 = 3400 (OH br), 3201 (NH), 2952 (CH), 1703 (CO), 1662 (CO), 1518 (CH) 










Synthesis of 152 – Boc-[Aib-Aic]2-(L)AlaNHtBu  
 
Boc(AibAic)2(L)AlaNHtBu was prepared by following general procedure E on a 0.029 mmol 
scale. This was purified by column chromatography (SNAP 10 g, 2% MeOH in CH2Cl2 → 8% 
MeOH in CH2Cl2) to give compound 152 (15 mg, 0.024 mmol, 82%) as a white solid. 
Analytical Data 
Rf (SiO2 2 % MeOH in CH2Cl2) = 0.19 
1H NMR (500 MHz, CD3OH) δH 8.00 (1 H, d, J = 7.0 Hz, NH), 7.91 (1 H, s, NH), 7.37 (1 H, s, NH), 
6.95 (1 H, s, NH), 6.93 (1 H, s, NH), 6.87 (1 H, s, NH), 4.23 (1 H, p, J = 7.0 Hz, αCH), 2.26-2.22 (2 
H, m, CH2), 2.21-2.17 (2 H, m, CH2), 2.15-2.09 (2 H, m, CH2), 2.08-2.04 (2 H, m, CH2), 1.48 (9 H, 
s, 3 x CH3), 1.44 (6 H, s, 2 x CH3), 1.40 (6 H, s, 2 x CH3), 1.34 (9 H, s, 3 x CH3), 1.31-1.29 (9 H, m, 
3 x CH3), 1.27 (6 H, s, 2 x CH3) 
13C NMR (125 MHz, CD3OH) δC 175.8 (CO), 175.0 (CO), 174.8 (CO), 173.0 (CO), 155.4 (CO), 79.2 
(C(CH3)3), 56.8 (αC), 56.5 (αC), 53.1 (γC), 53.0 (γC), 50.7 (NHC(CH3)3), 49.7 (αCH), 35.2 (CH2), 
35.0 (CH2), 30.8 (CH2), 30.6 (CH2), 27.5 (CH3), 27.4 (CH3), 25.9 (CH3), 25.8 (CH3), 24.3 (CH3), 
16.9 (CH3 of Ala) 
[α]D (c = 1.0, CH2Cl2) = +34.1 
HRMS (ESI+, MeOH) calc. for C32H60N6NaO7: 663.441569; observed: 663.440550 (M+Na)+ 
IR (neat) νmax/cm-1: 3318 (NH), 2977 (CH), 2927 (CH), 2853 (CH), 1650 (CO), 1524 (NH), 1164 
(OtBu)  
Mp (MeOH): 156-158 oC 
 
Synthesis of 153 – HCl∙H2N-[Aib-Aic]2-(L)AlaOEt  
 
Boc(AibAic)2(L)AlaOEt (15 mg, 0.024 mmol) was dissolved in dioxane (0.2 mL) and a solution 
of HCl in dioxane (4 M, 24 μL) and stirred for 3 h. The reaction mixture was then concentrated, 
suspended in Et2O and concentrated again to ensure full removal of HCl and giving compound 






1H NMR (500 MHz, CDCl3) δH 8.77 (2 H, s, 2 x NH), 7.86 (1 H, br s, NH), 7.20 (1 H, br s, NH), 6.58 
(1 H, s, NH), 4.57 (1 H, m, αCH), 3.50 (2 H, q, J = 7.0 Hz, CH2 of OEt), 2.46-2.25 (4 H, m, 2 x CH2), 
2.16-1.98 (4 H, m, 2 x CH3), 1.53 (3 H, s, CH3), 1.51 (3 H, s, CH3), 1.47 (3 H, s, CH3), 1.43 (3 H, s, 
CH3), 1.34 (6 H, s, 2 x CH3), 1.30-1.28 (9 H, m, 2 x CH3 and Ala CH3) 
13C NMR (125 MHz, CDCl3) δC 175.3 (CO), 174.1 (CO), 173.9 (CO), 173.6 (CO), 170.6 (CO), 61.6 
(CH2 of OEt), 58.3 (αC), 57.1 (αC), 54.4 (γC), 53.7 (γC), 48.0 (αCH), 35.7 (CH2), 31.7 (CH2), 31.4 
(CH2), 27.4 (CH3), 27.2 (CH3), 27.0 (CH3), 25.5 (CH3), 25.2 (CH3), 24.7 (CH3), 24.5 (CH3), 18.5 
(CH3 of Ala), 14.2 (CH3 of OEt) 
HRMS (ESI+, CH2Cl2) calc. for C25H47N5NaO6: 536.3419; observed: 536.3402 (M+Na)+. 
IR (neat) νmax/cm-1 = 3328 (NH2/NH), 2941 (CH), 1713 (CO), 1681 (CO), 1583 (CH), 1262 (OEt) 
Mp (EtOAc): 182-185 oC. 
 
Synthesis of Cbz(L)Ser [OtBu]NHtBu  




Cbz(L)Ser [OtBu]NHtBu was prepared from commercial CbzSer(L)[OtBu]OH following general 
procedure E on a 1.69 mmol scale (w.r.t. CbzSer(L)[OtBu]OH) with 3 eq of coupling partner 
H2NtBu used. The product was obtained without need for further purification as a white solid 
(504 mg, 1.44 mmol, 85 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.40-7.32 (5 H, m, 5 x ArH), 6.53 (1 H, s, NH of NHtBu), 5.77 (1 H, 
br s, NH), 5.16 (1 H, d, J = 12.5 Hz, part of the AB system of CH2Ph), 5.11 (1 H, d, J = 12.5 Hz, 
part of the AB system of CH2Ph), 4.13-4.06 (1 H, m, αCH), 3.83-3.76 (1 H, m, part of the AB 
system βCH2), 3.32 (1 H, t, J = 8.5 Hz, part of the AB system βCH2), 1.36 (9 H, s, 3 x CH3), 1.22 
(9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 169.1 (CO), 154.1 (CO), 136.4 (ArC), 128.5 (ArH), 128.1 (ArH), 
128.0 (ArH), 77.2 (C(CH3)3), 74.1 (C(CH3)3), 66.9 (βCH2), 62.0 (αCH), 51.2 (C(CH3)3), 28.7 (CH3), 
27.5 (CH3) 






Synthesis of H2N(L)Ser [OtBu]NHtBu  





H2N(L)Ser[OtBu]NHtBu was prepared by following general procedure A on a 0.51 mmol scale. 
The product was obtained as a white solid (104 mg, 0.48 mmol, 95%). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.18 (1 H, s, NH), 3.57 (1 H, dd, J = 7.5, 4.0 Hz, αCH), 3.41-3.33 (2 
H, m, βCH2), 1.34 (9 H, s, 3 x CH3), 1.18 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 172.3 (CO), 73.4 (C(CH3)3), 64.2 (βCH2), 55.7 (αCH), 50.5 
(C(CH3)3), 28.7 (CH3), 27.5 (CH3) 
Analytical data consistent with previously reported data. 79 
 
Synthesis of 154 – Boc-[Aib-Aic]2-(L)Ser [OtBu]NHtBu  
 
Boc[AibAic]2(L)Ser [OtBu]NHtBu was prepared by following general procedure A on a 0.039 
mmol scale (w.r.t. Boc[AibAic]2OH) with 3 eq of coupling partner H2NSer[OtBu]NtBu used. The 
crude product purified by column chromatography (3% MeOH in CH2Cl2 → 10% MeOH in 
CH2Cl2, ZIP Sphere 5g) and was obtained as a white solid (23 mg, 0.032 mmol, 82%). 
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.21 
1H NMR (500 MHz, CDCl3) δH 7.06 (1 H, s, NH of Aib 2), 6.95 (1 H, d, J = 6.5 Hz, NH of Ser), 6.90 
(1 H, s, NH of Aic 2), 6.63 (1 H, s, NH of tBu amide), 6.30 (1 H, s, NH of Aic 1), 5.06 (1 H, s, NH 
of Aib 1), 4.32 (1 H, ddd, J = 8.5, 6.5, 4.5 Hz, αCH), 3.73 (1 H, dd, J = 8.5, 4.5 Hz, part of the AB 
system βCH2OtBu), 3.31 (1 H, t, J = 8.5 Hz, part of the AB system βCH2OtBu), 2.31 (2 H, td, J = 
7.5, 3.0 Hz, αCH2 of Aic 2), 2.19-2.13 (4 H, m, αCH2 and βCH2 of Aic 1), 2.09-2.04 (2 H, m, βCH2 





(9 H, s, 3 x CH3 of tBu amide), 1.34 (3 H, s, 1 x CH3 of Aic 2), 1.33 (3 H, s, 1 x CH3 of Aic 2), 1.27 
(6 H, br s, 2 x CH3 of Aic 1), 1.21 (9 H, s, 3 x CH3 of OtBu) 
13C NMR (125 MHz, CDCl3) δC 174.1 (CO of Aib 1), 173.9 (CO of Aic 2), 173.8 (CO of Aib 2), 
173.6 (CO of Aic 1), 169.5 (CO of Ser), 154.7 (CO of Boc), 80.4 (C(CH3)3 of Boc), 73.9 (C(CH3)3 
of OtBu), 61.6 (βCH2OtBu), 57.3 (αC of Aib 2), 57.0 (αC of Aib 1), 53.3 (γC of Aic 1), 53.2 (αCH 
of Ser), 53.1 (γC of Aic 2), 51.2 (C(CH3) of NHtBu), 35.7 (βCH2 of Aic 2), 34.9 (βCH2 of Aic 1), 
31.5 (αCH2 of Aib 1), 31.3 (αCH2 of Aib 2), 28.7 (CH3’s of NHtBu), 28.3 (CH3’s of Boc), 27.5 (CH3’s 
of OtBu), 27.0 (CH3’s of Aic 1), 26.8 (CH3’s of Aic 2), 25.5 (1 x CH3 of Aib 1), 24.4 (1 x CH3 of Aib 
1), 25.3 (1 x CH3 of Aib 2), 25.3 (1 x CH3 of Aib 2) 
[α]D (c = 1.0, CH2Cl2) = +38.7 
HRMS (ESI+, CH2Cl2); calc. for C36H68N6NaO8: 735.499084; observed: 735.499589 (M+Na)+ 
IR (neat) νmax/cm-1: 3353 (NH), 2970 (CH), 2922 (CH), 1649 (CO), 1515 (NH), 1163 (OtBu) 
Mp (CH2Cl2): 156-159 oC 
 
Synthesis of Boc(L)ValNHtBu  
Previously synthesised and reported 183 
 
Boc(L)ValNHtBu was prepared from commercial BocVal(L)OH following general procedure E 
on a 2.3 mmol scale (w.r.t. BocVal(L)OH) with 3 eq of coupling partner H2NtBu used. The 
product was obtained without need for further purification as a white solid (544 mg, 2.0 
mmol, 87 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 5.57 (1 H, s, NH), 4.99 (1 H, m, NH), 3.64 (1 H, dd, J = 9.0, 6.5 Hz, 
αCH), 2.06-1.93 (1 H, m, CH(CH3)2), 1.38 (9 H, s, 3 x CH3), 1.28 (9 H, s, 3 x CH3), 0.88 (3 H, d, J 
= 7.0 Hz, part of the AB system of Val iPr), 0.84 (3 H, d, J = 7.0 Hz, part of the AB system of Val 
iPr) 
13C NMR (100 MHz, CDCl3) δC 170.6 (CO), 155.9 (CO), 79.7 (C(CH3)3), 60.6 (αCH), 51.4 (C(CH3)3), 
31.1 (CH(CH3)2), 28.7 (CH3), 28.3 (CH3), 19.3 (CH3 Val iPr), 17.9 (CH3 Val iPr) 







Synthesis of HCl∙NH2(L)ValNHtBu  
Previously synthesised and reported 184 
 
Boc(L)ValNHtBu (350 mg, 1.29 mmol) was dissolved in dioxane (3 mL) and to this a 4 M 
solution of HCl in dioxane (1.29 mL, 5.15 mmol, 4 eq.) was added. The resulting solution was 
left to stir for 3 h. After this time the reaction mixture was concentrated, then suspended in 
Et2O and concentrated again to ensure full removal of HCl. The target compound was 
obtained as a viscous pale-yellow oil (257 mg, 1.23 mmol, 95 %).  
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.58 (1 H, s, NH), 4.19-4.09 (1 H, br s, αCH), 2.44-2.33 (1 H, br s, 
CH(CH3)2), 1.39 (9 H, s, 3 x CH3), 1.15 (3 H, d, J = 6.5 Hz, one CH3 of iPr), 1.10 (3 H, d, J = 6.5 Hz, 
one CH3 of iPr) 
13C NMR (100 MHz, CDCl3) δC 167.3 (CO), 59.1 (αCH), 52.3 (C(CH3)3), 30.4 (CH), 28.7 (CH3), 18.8 
(CH3 of iPr), 18.4 (CH3 of iPr) 
Analytical data consistent with previously reported data. 184 
 
Synthesis of 155 – Boc-[Aib-Aic]2-(L)ValNHtBu  
 
Boc[AibAic]2(L)ValNHtBu was prepared by following general procedure A on a 0.039 mmol 
scale (w.r.t. Boc[AibAic]2OH) with 3 eq of coupling partner HCl∙H2N(L)ValNtBu used. The crude 
product purified by column chromatography (3% MeOH in CH2Cl2 → 10% MeOH in CH2Cl2, ZIP 
Sphere 5g) and was obtained as a white solid (20 mg, 0.031 mmol, 79%) 
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.18 
1H NMR (500 MHz, CDCl3) δH 7.31 (1 H, s, NH of Aib 2), 7.24 (1 H, d, J = 9.0 Hz, NH of Val), 6.63 
(1 H, s, NH of Aic 2), 6.28 (1 H, s, NH of tBu amide), 6.12 (1 H, s, NH of Aic 1), 5.15 (1 H, s, NH 
of Aib 1), 4.14 (1 H, dd, J = 9.0, 6.0 Hz, αCH of Val), 2.31-2.08 (9 H, m, 8 x Aic CH2’s and βCH of 





1.46 (3 H, s, 1 x CH3 of an Aib that could not be assigned), 1.45 (3 H, s, 1 x CH3 of an Aib that 
could not be assigned), 1.35 (9 H, s, 3 x CH3 of tBu amide), 1.32 (3 H, s, 1 x CH3 of Aic 1), 1.31 
(3 H, s, 1 x CH3 of Aic 1), 1.24 (3 H, s, 1 x CH3 of Aic 2), 1.23 (3 H, s, 1 x CH3 of Aic 2), 0.96 (6 H, 
t, J = 7.0 Hz, 2 x CH3 of Val) 
13C NMR (125 MHz, CDCl3) δC 174.9 (CO of Aic 2), 174. 1 (CO of Aib 2), 173.4 (CO not assigned), 
173.8 (CO not assigned), 170.9 (CO of Val), 154.8 (CO of Boc), 80.7 (C(CH3)3), 59.3 (αCH of Val), 
57.1 (αC of an Aib that could not be assigned), 57.0 (αC of an Aib that could not be assigned), 
53.5 (γC of an Aic that could not be assigned), 53.4 (γC of an Aic that could not be assigned), 
51.5 (C(CH3)3), 35.6 (βCH2 of Aic 2), 34.4 (βCH2 of Aic 1), 31.6 (αCH2 of Aic 2), 31.0 (αCH2 of Aic 
1), 29.9 (βCH of Val), 28.7 (CH3’s of NHtBu), 28.3 (CH3’s of Boc), 27.3 (a CH3 of Aic 1), 27.2 (a 
CH3 of Aic 1), 27.2 (a CH3 of Aic 2), 27.1 (a CH3 of Aic 1), 25.6 (a CH3 of an Aib that could not 
be assigned), 25.5 (a CH3 of an Aib that could not be assigned), 25.4 (a CH3 of an Aib that could 
not be assigned), 25.3 (a CH3 of an Aib that could not be assigned), 19.5 (a CH3 of Val), 17.5 (a 
CH3 of Val) 
1H NMR (500 MHz, CD2Cl2) δH 7.42 (1 H, s, NH of Aib 2), 7.21 (1 H, d, J = 8.5 Hz, NH of Val), 
6.58 (1 H, s, NH of Aic 2), 6.31 (1 H, s, NH of NHtBu), 6.12 (1 H, s, NH of Aic 1), 5.24 (1 H, s, NH 
of Aib 1), 4.06 (1 H, dd, J = 8.5, 6.0 Hz, αCH of Val), 2.27-2.20 (5 H, m, βCH2 of Aic 1 and αCH2 
of Aic 2 and βCH of Val), 2.16-2.11 (4 H, m, αCH2 of Aic 1 and βCH2 of Aic 2), 1.49 (9 H, s, 3 x 
CH3’s of Boc), 1.46 (12 H, s, 4 x CH3’s of both Aib’s), 1.36 (9 H, s, 3 x CH3’s of NHtBu), 1.32 (6 H, 
s, 2 x CH3’s of Aic 2), 1.24 (3 H, s, CH3 of Aic 1), 1.23 (3 H, s, CH3 of Aic 1), 0.97 (6 H, t, J = 7.0 
Hz, 2 x CH3 of Val) 
13C NMR (125 MHz, CD2Cl2) δC 174.5 (CO of Aic 2), 173.9 (CO not assigned), 173.8 (CO not 
assigned), 170.9 (CO of Val), 154.9 (CO of Boc), 80.6 (C(CH3)3 of Boc), 59.3 (αCH of Val), 57.0 
(αC of Aib 1), 56.8 (αC of Aib 2), 53.4 (γC of Aic 1), 53.3 (γC of Aic 2), 50.9 (C(CH3) of NHtBu), 
35.5 (βCH2 of Aic 2), 34.3 (βCH2 of Aic 1), 31.4 (αCH2 of Aic 2), 30.8 (αCH2 of Aic 1), 30.2 (βCH 
of Val), 28.4 (CH3’s of NHtBu), 28.0 (CH3’s of Boc), 26.9 (CH3’s of Aic 1), 26.9 (CH3 of Aic 2), 26.8 
(CH3 of Aic 2), 25.3 (CH3 of Aib not assigned), 25.2 (CH3 of Aib not assigned), 25.1 (CH3 of Aib 
not assigned), 19.2 (CH3 of Val), 17.3 (CH3 of Val) 
[α]D (c = 1.0, CH2Cl2) = +36.1 
HRMS (ESI+, MeOH) calc. for C34H64N6NaO7: 669.4909; observed: 669.4920 (M+Na)+ 
IR (neat) νmax/cm-1: 3303 (NH), 2970 (CH), 2930 (CH), 1640 (CO), 1522 (NH), 1163 (OtBu) 










Synthesis of Boc(L)PheNHtBu  
Previously Synthesised and Reported 185 
 
Boc(L)PheNHtBu was prepared from commercial Boc(L)PheOH following general procedure E 
on a 1.89 mmol scale (w.r.t. Boc(L)PheOH) with 3 eq of coupling partner H2NtBu used. The 
product was obtained without need for further purification, as a white solid (483 mg, 1.51 
mmol, 80 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.36-7.22 (5 H, m, 5 x ArH), 5.26 (1 H, s, NH), 5.19 (1 H, br s, NH), 
4.22-4.12 (1 H, m, αCH), 3.13 (1 H, dd, J = 13.5, 6.0 Hz, part of the AB system βCH2), 2.93 (1 H, 
dd, J = 13.5, 8.0 Hz, part of the AB system βCH2), 1.45 (9 H, s, 3 x CH3), 1.22 (9 H, s, 3 x CH3) 
13C NMR (100 MHz, CDCl3) δC 169.9 (CO), 155.3 (CO), 137.1 (ArC), 129.5 (ArH), 128.6 (ArH), 
126.9 (ArH), 80.0 (C(CH3)3),  56.5 (αCH), 51.2 (C(CH3)3), 39.2 (βCH2), 28.5 (CH3), 28.3 (CH3) 
Analytical data consistent with previously reported data. 185 
 
Synthesis of HCl∙H2N(L)PheNHtBu  
Previously synthesised and reported 186 
 
Boc(L)PheNHtBu (600 mg, 1.88 mmol) was dissolved in dioxane (6 mL) and to this a 4 M 
solution of HCl in dioxane (1.88 mL, 7.52 mmol, 4 eq.) was added. The resulting solution was 
left to stir for 3 h. After this time the reaction mixture was concentrated, then suspended in 
Et2O and concentrated again to facilitate full removal of HCl. The target compound was 
obtained as a viscous pale-yellow oil (292 mg, 1.14 mmol, 95 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.34-7.28 (2 H, m, 2 x ArH), 7.24-7.13 (3 H, m, 3 x ArH), 6.51 (1 
H, s, NH), 4.45-4.40 (1 H, m, αCH), 3.50-3.44 (1 H, m, part of the AB system of βCH2), 3.17-





13C NMR (100 MHz, CDCl3) δC 166.9 (CO), 134.8 (ArC), 130.0 (ArH), 128.8 (ArH), 127.4 (ArH), 
55.0 (αCH), 51.9 (C(CH3)3), 37.6 (βCH2), 28.5 (CH3) 
Analytical data consistent with previously reported data. 186 
 
Synthesis of 156 – Boc-[Aib-Aic]2-(L)PheNHtBu  
 
Boc[AibAic]2(L)PheNHtBu was prepared by following general procedure A on a 0.039 mmol 
scale (w.r.t. Boc[AibAic]2OH) with 3 eq of coupling partner HCl.H2N(L)PheNtBu used. The crude 
product purified by column chromatography (3% MeOH in CH2Cl2 → 10% MeOH in CH2Cl2, ZIP 
Sphere 5g) and was obtained as a white solid (16 mg, 0.022 mmol, 56 %).  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.33 
1H NMR (500 MHz, CDCl3) δH 7.44 (1 H, br s, NH of Phe), 7.31-7.29 (4 H, m, 3 x ArH and 1 x NH 
not assigned), 7.25-7.17 (2 H, m, 2 x ArH), 6.66 (1 H, s, NH not assigned), 6.13 (1 H, s, NH not 
assigned), 6.00 (1 H, s, NH of Aic 1), 5.00 (1 H, s, NH of Aib 1), 4.49 (1 H, q, J = 7.5 Hz, αCH of 
Phe), 3.16 (1 H, dd, J = 14.0, 7.5 Hz, part of the AB system of βCH2 of Phe), 2.96 (1 H, dd, J = 
14.0, 7.5 Hz, part of the AB system of βCH2 of Phe), 2.25-2.18 (2 H, m, CH2 not assigned), 2.18-
2.10 (4 H, m, 2 x CH2 not assigned), 2.09-1.98 (2 H, m, CH2 not assigned), 1.50 (3 H, s, CH3 of 
Aib 2), 1.49-1.47 (12 H, m, 3 x CH3 of Boc and CH3 of Aib 2), 1.47 (3 H, s, CH3 of Aib 1), 1.46 (3 
H, s, CH3 of Aib 1), 1.32 (3 H, s, CH3 of Aic 2), 1.30 (3 H, s, CH3 of Aic 2), 1.27 (9 H, s, 3 x CH3 of 
NHtBu), 1.25 (3 H, s, CH3 of Aic 1), 1.25 (3 H, s, CH3 of Aic 1) 
13C NMR (125 MHz, CDCl3) δC 174.4 (CO of Aic B), 174.0 (CO not assigned), 173.9 (CO not 
assigned), 173.8 (CO not assigned), 170.3 (CO of Phe), 154.8 (CO of Boc), 138.0 (ArC), 129.4 
(ArH), 128.4 (ArH), 126.5 (ArH), 80.8 (C(CH3)3 of Boc), 57.2 (γC not assigned), 57.1 (γC not 
assigned), 55.4 (αCH of Phe), 53.4 (αC of Aib not assigned), 53.3 (αC not assigned), 51.1 
(C(CH3)3 of NHtBu), 37.8 (βCH2 of Phe), 35.5 (βCH2 not assigned), 34.4 (βCH2 not assigned), 
31.4 (αCH2 not assigned), 31.2 (αCH2 not assigned), 28.6 (CH3 of NHtBu), 28.3 (CH3 of Boc), 
27.2 (CH3 of Aic), 27.2 (CH3 of Aic), 27.2 (CH3 of Aic), 27.0 (CH3 of Aic), 25.6 (CH3 of Aib), 25.5 
(CH3 of Aib), 25.4 (CH3 of Aib), 25.4 (CH3 of Aib)  
[α]D (c = 1.0, CH2Cl2) = +36.9 
HRMS (ESI+, MeOH) expected for C38H65N6O7: 717.4909; observed: 717.4901 (M+H)+ 





Mp (CH2Cl2): 167-168 oC 
 
Synthesis of Cbz(L)αMvNHtBu 
Previously synthesised and reported 187 
 
Cbz(L)αMvNHtBu was prepared from Cbz(L)αMvOH following general procedure E on a 1.89 
mmol scale (w.r.t. Cbz(L)αMvOH) with 3 eq of coupling partner H2NtBu used. The product was 
purified by column chromatography (100% CH2Cl2 → 2 % MeOH in CH2Cl2, SNAP Ultra 10g) to 
give the title compound as a white solid (60 mg, 0.18 mmol, 10 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.36-7.28 (5 H, m, 5 x ArH), 6.26 (1 H, s, NH), 5.20 (1 H, s, NH), 
5.11 (1 H, d, J = 12.0 Hz, part of the AB system of the Cbz CH2), 5.04 (1 H, d, J = 12.0 Hz, part 
of the AB system of the Cbz CH2), 2.33-2.21 (1 H, m, CH of αMv), 1.41 (3 H, s, CH3), 1.28 (9 H, 
s, 3 x CH3), 0.92-0.88 (6 H, m, 2 x CH3) 
Analytical data consistent with previously reported data. 187 
 
Synthesis of H2N(L)αMvNHtBu  
Previously synthesised and reported 188 
 
H2N(L)αMvNHtBu was prepared from Cbz(L)αMvNHtBu following general procedure A on a 
0.18 mmol scale. The product was obtained as a white solid (30 mg, 0.16 mmol, 90 %). 
Analytical Data 
1H NMR (400 MHz, CDCl3) δH 7.60 (1 H, s, NH), 2.20 (1 H, hept, J = 7.0 Hz, CH), 1.33 (9 H, s, 3 x 
CH3), 1.20 (3 H, s, CH3), 0.85 (3 H, d, J = 7.0 Hz, CH3), 0.78 (3 H, d, J = 7.0 Hz, CH3).  






Synthesis of 157 – Boc-[Aib-Aic]2-(L)αMvNHtBu 
  
Boc[AibAic]2(L)αMvNHtBu was prepared by following general procedure A on a 0.044 mmol 
scale (w.r.t. Boc[AibAic]2OH) with 1.88 eq of coupling partner H2N(L)αMvNtBu used. The crude 
product purified by column chromatography (3% MeOH in CH2Cl2 → 10% MeOH in CH2Cl2, ZIP 
Sphere 5g) and was obtained as a white solid (17 mg, 0.025 mmol, 57 %).  
Analytical Data 
Rf (SiO2, 5% MeOH in CH2Cl2) = 0.36 
1H NMR (500 MHz, CDCl3) δH 7.39 (1 H, s, NH of NHtBu), 7.28 (1 H, s, NH of Aib 2 [in shoulder 
of solvent peak]), 7.02 (1 H, s, NH of αMv), 6.48 (1 H, s, NH of Aic 2), 6.04 (1 H, s, NH of Aic 1), 
5.01 (1 H, s, NH of Aib 1), 2.52 (1 H, hept, J = 7.0 Hz, CH of αMv), 2.37-2.29 (2 H, m, part of the 
AB system of the βCH2 of Aic 2 and part of the AB system of the βCH2 of Aic 1), 2.25-2.20 (2 
H, m, αCH2 of Aic 2), 2.14-2.09 (3 H, m, αCH2 of Aic A and part of the AB system of the βCH2 
of Aic 1), 2.05-1.97 (1 H, m, part of the AB system of the βCH2 of Aic 2), 1.49 (3 H, s, 1 x CH3 of 
Aib 2), 1.47 (9 H, s, 3 x CH3 of Boc), 1.46 (3 H, s, 1 x CH3 of Aib 2), 1.44 (3 H, s, 1 x CH3 of Aib 
1), 1.44 (3 H, s, 1 x CH3 of Aib 1), 1.36-1.33 (15 H, m, 3 x CH3 of NHtBu; 1 x CH3 of αMv; 1 x CH3 
of Aic 2), 1.27 (3 H, s, 1 x CH3 of Aic 2), 1.26 (3 H, s, 1 x CH3 of Aic 1), 1.21 (3 H, s, 1 x CH3 of Aic 
1), 0.96 (3 H, d, J = 7.0 Hz, CH3 of the αMv iPr), 0.90 (3 H, d, J = 7.0 Hz, CH3 of the αMv iPr) 
13C NMR (125 MHz, CDCl3) δC 174.9 (CO of Aic 2), 173.9 (CO not assigned), 173.9 (CO not 
assigned), 173.7 (CO not assigned), 173.2 (CO of αMv), 154.8 (CO of Boc), 80.9 (C(CH3)3 of 
Boc), 64.6 (αC of αMv), 57.1 (αC of Aib 1), 57.0 (αC of Aib 2), 53.5 (γC of Aic 1), 53.4 (γC of Aic 
2), 50.6 (C(CH3)3 of NHtBu), 35.3 (βCH2 of Aic 2), 34.3 (βCH2 of Aic 1), 33.0 (CH of αMv), 32.3 
(αCH2 of Aic 2), 31.0 (αCH2 of Aic 1), 28.7 (CH3’s of NHtBu), 28.3 (CH3’s of Boc), 27.4 (an 
unassigned Aic CH3), 27.3 (unassigned Aic CH3’s), 26.2 (a CH3 of Aib 1), 26.1 (a CH3 of Aib 1), 
24.9 (a CH3 of Aib 2), 24.7 (a CH3 of Aib 2), 17.1 (an iPr CH3 of αMv), 16.9 (an iPr CH3 of αMv), 
16.7 (CH3 of αMv) 
HRMS (ESI+, MeOH) calc. for C35H67N6O7: 683.5066; observed: 683.5079 (M+H)+ 
[α]D (c = 1.0, CH2Cl2) = +42.3 
IR (neat) νmax/cm-1: 3297 (NH), 2951 (CH), 1713 (CO), 1651 (CO), 1552 (NH) 







7.1. Alternate Synthesis of Compounds 37 and 42 
 
Compounds 37 and 42 were also synthesised by an alternate method to those outlined in 
sections 2.3.2. and 2.3.3. respectively. The yields and time taken to synthesise compounds 37 
and 42 were similar for both routes, and this alternate synthetic route has been included for 
the sake of completeness. 
 
The first step was an EDC∙HCl/HOBt coupling between N3Aib4OH and the corresponding 
amine, either N-Boc-ethylenediamine or N-Boc-1,2-diamino-2-methylpropane. This gave 
compounds 158 and 159 in 55% and 48% yield respectively. These compounds were then 
hydrogenated to deprotect the N-terminal azides and give compounds 160 and 161 in 70% 
and 83% yield respectively. These amines were then coupled to MC-(L)-αMv-F to give 









7.2 Concentration Dependence of H.E. for Compound 45 
 
Figure 7.1 shows that the Δδ observed for the Aib* probe does not change as the 
concentration is increased (in CD3OD). This means that the negligible h.e. observed is a result 
of N→N communication or a conformation that brings the probe/αMv close to each other 













Figure 7.1: Portion of the 13C NMR spectrum of compound 45 in CD3OD showing that Δδ 





7.3 Attempted Synthesis of Compounds 63 and 64 
 
The synthesis of compound 63 was attempted (Scheme 7.2). First compound 162 was coupled 
to H2NAib4OtBu to give compound 163 in 71% yield. This was coupled to 2-ethnylaniline by a 
Sonagashira coupling to give compound 164 in 34 % yield. However, when an azlactone 
coupling between this compound and Cbz-(L)αMv-Aib4-OH was attempted, no product was 
obtained. After this point the synthesis was put on hold, though this compound remains an 
interesting synthetic target that future work may revisit. 
 
 
The synthesis of compound 64 (Scheme 7.3) was started from a double SNAr between 
compounds 165 and 166 to give compound 167 in 60% yield. This was treated with conc. 
H2SO4 to deprotect the two tosylate groups to give compound 168 in 70% yield. This was 
treated with NaBH4 to reduce this anthraquinoline to compound 169 in 75%. A few 






Scheme 7.2: The attempted synthesis of compound 63 























7.5 Synthesis of compounds 80, 82, 87 and 89 
 
Compound 80 was prepared from an acid fluoride coupling between H2NAib3OtBu and 
Cbz(L)αMvF, giving the product in 64 % yield (Scheme 7.4) 
 
 
Compound 82 was synthesised starting from N3Aib5OtBu (Scheme 7.5), a series of 
deprotections and reprotections gave compound 172. This was coupled to compound 75 by 
an azlactone coupling, giving compound 82 in 77% yield 
 
 
Compounds 87 and 89 were both synthesised from an azlactone coupling between N3Aib7OH 
and amine 75 or 66 respectively (Scheme 7.6). This gave compounds 87 and 89 in 80% and 









Scheme 7.4: The synthesis of compound 80 
Scheme 7.5: The synthesis of compound 82 





7.6 Attempted Synthesis of a Dap Based Hydrophilic Aib Foldamer 
 
Initially the non-proteinogenic amino acid diaminopropionic acid (Dap) was chosen before 
Lys, as the residue used to construct a positively charged hydrophilic Aib oligomer. The same 
general approach was taken with this synthesis as with those outlined in Section 4.3. The 
starting point was the commercially available H2N(L)Dap(NHBoc)OH. A methyl ester was 
chosen as the C-terminal protecting group to distinguish between the N and C termini during 
deprotections. The N-terminus of the Dap residue was protected with a Cbz group. 
 
The first step in the synthesis (Scheme 7.7) was a Cbz protection to give compound 174, 
however the yield for this reaction was disappointingly low. This compound was then coupled 
with H2Aib2OMe by an EDC∙HCl/K-Oxyma coupling to give compound 175 in 35% yield. 
Hydrogenation of the N-terminus proceeded smoothly to give compound 176 in 90% yield. 
However, no product was obtained when deprotection of the methyl ester was attempted. 
Rather than reattempt this synthesis the Dap-based compound was abandoned, due to these 










7.7 Concentration Dependence Study for Compounds 122 and 136 
 
To gauge whether any aggregation occurs for compounds 122 and 136, a concentration 
dependence NMR study in CD3OH was undertaken. If the molecules aggregate, then the NH’s 
and the signals for the side chains would be expected to move as their environment changes. 
Neither compound 122 or 136 show any signals moving. This is inconclusive as it could mean 
no aggregation occurs in CD3OD or that the aggregates are present but are stable over the 
concentrations studied (Figures 7.3.a and 7.3.b) 
 
   
 
  
Figure 7.3: 1H NMR concentration dependence study in CD3OH for: a) Compound 122; 





7.8 1H VT NMR of Compound 157 
 
The VT 1H NMR spectra of compound 157 shows the same trends as seen in section 5.4, where 
slow exchange is not reached in either CDCl3 or CD2Cl2 and again line broadening renders the 
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